<div class="entities" style="line-height: 2.5; direction: ltr">International Classification of Sleep Disord Third Edition CI S ers D3 American Academy of Sleep Medicine International Classification of Sleep Disord Third Edition CI S ers D3 American Academy of Sleep Medicine </br>Copyright © 2014 American Academy of Sleep Medicine, 2510 North Frontage Road, Darien, IL 60561, U.S.A. Copies of the manual are available from the American Academy of Sleep Medicine in the U.S.A. All rights reserved.</br>Unless authorized in writing by the AASM, no portion of this book may be reproduced or used in a manner inconsistent with the copyright.</br>This applies to unauthorized reproductions in any form, including computer programs. </br>Correspondence regarding copyright permissions should be directed to the Executive Director, American Academy of Sleep Medicine, 2510 North Frontage Road, Darien, IL 60561, U.S.A. Translations to other languages must be authorized by the American Academy of Sleep Medicine, U.S.A. Recommended Citation American Academy of Sleep Medicine.</br>International classification of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 3rd ed.</br>Darien, IL: American Academy of Sleep Medicine, 2014. </br>International classification of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 3rd ed.</br>American Academy of Sleep Medicine.</br>Includes bibliographies and index. </br>1. Sleep Disorders – Classification.</br>2. Sleep Disorders – Diagnosis ISBN: 0991543416 (print) ISBN: 0991543408 (online) </br>In memory of Peter Hauri, PhD mentor, colleague and friend Table of Contents About the Editor ...........................................................................................8 Editor’s Notes ...............................................................................................9 Acknowledgments......................................................................................10 Introduction.................................................................................................13 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
......................................................................................................19 Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ....................................................................................</br>21 Short-Term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
...............................................................................41 Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
........................................................................................46 ISOLATED SYMPTOMS AND NORMAL VARIANTS Excessive Time in Bed...........................................................................................47 Short Sleeper.........................................................................................................47 Sleep Related Breathing Disorders ..........................................................49 OBSTRUCTIVE SLEEP 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    APNEA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 DISORDERS Obstructive Sleep Apnea, Adult ............................................................................. 53 Obstructive Sleep Apnea, Pediatric ....................................................................... 63 CENTRAL SLEEP 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    APNEA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 SYNDROMES Central Sleep Apnea with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Breathing.............................................</br>69 Central Apnea Due to a Medical Disorder without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Breathing .......</br>75 Central Sleep Apnea Due to High Altitude Periodic Breathing...............................79 Central Sleep Apnea Due to a Medication or Substance.......................................85 Primary Central Sleep Apnea.................................................................................</br>89 Primary Central Sleep Apnea of Infancy ................................................................</br>94 Primary Central Sleep Apnea of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 .........................................................</br>98 Treatment-Emergent Central Sleep Apnea..........................................................102 SLEEP RELATED HYPOVENTILATION DISORDERS Obesity 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
......................................................................108 Congenital 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Central Alveolar Hypoventilation Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ......................................</br>113 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Late-Onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypothalamic Dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ...................</br>118 Idiopathic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Central Alveolar Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.......................................................... 121 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance......................</br>124 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder ..................................</br>128 SLEEP RELATED HYPOXEMIA DISORDER Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ...................................................................................</br>134 Table of Contents ISOLATED SYMPTOMS AND NORMAL VARIANTS 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
................................................................................................................. 139 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ..........................................................................................................</br>141 Central Disorders of Hypersomnolence.................................................143 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Type 1 ............................................................................................... 146 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Type 2 ............................................................................................... 155 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Idiopathic Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ....................................................................................... 161 Kleine-Levin Syndrome........................................................................................166 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder .............................................................</br>171 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance................................................. 175 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Associated with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Psychiatric Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ..........................................</br>179 Insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ................................................................................</br>182 ISOLATED SYMPTOMS AND NORMAL VARIANTS Long Sleeper........................................................................................................187 Circadian Rhythm Sleep-Wake Disorders..............................................189 Delayed Sleep-Wake Phase Disorder .................................................................191 Advanced Sleep-Wake Phase Disorder...............................................................198 Irregular Sleep-Wake Rhythm Disorder ...............................................................</br>204 Non-24-Hour Sleep-Wake Rhythm Disorder........................................................209 Shift Work Disorder..............................................................................................215 Jet Lag Disorder...................................................................................................220 Circadian Sleep-Wake Disorder Not Otherwise 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Specified
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (NOS)........................224 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 .............................................................................................225 NREM-RELATED PARASOMNIAS Disorders of Arousal (From NREM Sleep) ........................................................... 228 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Confusional Arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ........................................................................................... 229</br>Sleepwalking ........................................................................................................</br>229 Sleep Terrors........................................................................................................ 230 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Eating Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.............................................................................240 REM-RELATED PARASOMNIAS REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Behavior Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.............................................................................246 Recurrent Isolated Sleep Paralysis......................................................................254 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nightmare Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
..............................................................................................257 OTHER PARASOMNIAS Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Head Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ..................................................................................</br>264 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
...............................................................................267 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.....................................................................................................270 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder ...............................................................</br>276 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance...................................................276 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Unspecified ....................................................................................278 ISOLATED SYMPTOMS AND NORMAL VARIANTS </br>Sleep Talking........................................................................................................279 Sleep Related Movement Disorders .......................................................281 Restless 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Legs Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.....................................................................................282 Periodic Limb Movement Disorder.......................................................................292 Sleep Related Leg Cramps..................................................................................299 Sleep Related Bruxism ........................................................................................</br>303 Sleep Related Rhythmic Movement Disorder......................................................312 Benign 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of Infancy.....................................................................317 Propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at Sleep Onset.............................................................321 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder ...........................</br>325 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance...............326 Sleep Related Movement Disorder, Unspecified .................................................</br>327 ISOLATED SYMPTOMS AND NORMAL VARIANTS Excessive Fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ....................................................................328 Hypnagogic Foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and Alternating Leg Muscle Activation......................... 330 Sleep Starts (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic Jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) .................................................................................</br>335 Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
................................................................................339 Appendix A: Sleep Related Medical and Neurological Disorders..............................341 Fatal Familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
........................................................................................342 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
........................................................................................345 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ................................................................................... 350 Sleep Related Laryngospasm..............................................................................355 Sleep Related Gastroesophageal Reflux.............................................................358 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Myocardial Ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.....................................................................363 Appendix B: ICD-10-CM Coding for Substance-Induced Sleep Disorders................369 Glossary ....................................................................................................</br>371 Index ..........................................................................................................377 Table of Contents About the Editor Michael Sateia, MD, is Professor of Psychiatry at the Geisel School of Medicine at Dartmouth.</br>He has served in a variety of leadership capacities in Sleep Medicine.</br>He is Past-President of the American Academy of Sleep Medicine.</br>Dr. Sateia was Associate Editor for the Journal of Clinical Sleep Medicine and chaired the Scientific Program Committee of the Associated Professional Sleep Societies.</br>He was a member of the Research Advisory Board of the National Center on Sleep Disorders Research and held a five year Academic Award from the National Heart, Lung, and Blood Institute. </br>He served on the Accreditation Council on Graduate Medical Education Advisory Committee for Sleep Medicine and the American Board of Internal Medicine Policy and Test Committee for Sleep Medicine.</br>His editing respon- sibilities have included the International Classification of Sleep Disorders, 2nd Edition; the comprehensive textbook, Sleep Medicine; and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: Diagnosis and Treatment.</br>In 2009 he received the Nathaniel Kleitman Award from the American Academy of Sleep Medicine.</br>He currently serves as task force chair and editor for the International Classification of Sleep Disorders, 3rd Edition, and chair of the task force on the pharmacological management of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>He has authored numerous scientific articles in sleep medi- cine, focused primarily on 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and professional education in sleep.</br> Editor’s Notes Many people contributed to the development of this manual.</br>The members of the Task Force on ICSD-3, who also chaired individual work groups, devoted countless hours and tireless dedication to the work, as did the members of their respective work groups.</br>Numerous reviewers also provided thoughtful recommendations which served to improve the text.</br>These individuals are acknowledged individually on the following pages. </br>A number of staff members of the American Academy of Sleep Medicine contributed to this work.</br>Our field owes a particular debt of gratitude for the diligence, dedication and determination of Ms. Carolyn Winter-Rosenberg, Director of Coding and Compliance at the AASM, who oversaw all facets of this project.</br>Without her, this publication would not have been possible. </br>Special thanks are extended to the Board of Directors of the American Academy of Sleep Medicine.</br>My personal thanks go to Nancy Collop, President of the AASM at the outset of the project.</br>I would also like to thank the following members of the board during the revision process who provided their expertise and time in reviewing multiple drafts:</br>Amy Aronsky, DO; M. Safwan Badr, MD; Kelly Carden, MD; Ronald Chervin, MD, MS; Nancy Collop, MD; Samuel Fleishman, MD; Timothy Morgenthaler, MD; Susan Redline, MD; Ilene Rosen, MD; Steven Shea, PhD; Patrick Strollo, Jr., MD; Nathaniel Watson, MD, MS; Terri Weaver, PhD, RN; and Merrill Wise, MD. </br>The international review effort was coordinated by the World Sleep Federation.</br>Thanks goes to Clete Kushida, MD, PhD, President of the 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    WSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 for his assistance in this facet.</br>Charles Reynolds, MD, chair of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSM-5 sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 work group, served as a valuable liaison in our efforts to maximize concordance between classification systems. </br>I would also like to thank David Neubauer, MD and Ruth Benca, MD, PhD who provided expertise on 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 conditions, as well as Maria Carra, PhD who assisted with the development of the Movement Disorders chapter. </br>Finally, we are grateful to our colleagues and families, whose patience, support and understanding of the long hours required to bring this manual to fruition often go unheralded, but are deeply appreciated. </br>Michael Sateia, MD, Editor Acknowledgments ICSD Revision Task Force Michael Sateia, MD, Chair Geisel School of Medicine at Dartmouth, Lebanon, NH Richard Berry, MD University of Florida Health Science Center, Gainesville, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    FL Michel
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 Cramer Bornemann, MD HealthEast Care Systems of Minnesota, Maplewood, MN Karl Doghramji, MD, Psychiatric Representative Thomas Jefferson University, Philadelphia, PA Jack Edinger, PhD National Jewish Health, Denver, CO Richard Ferber, MD, Pediatric Representative Harvard Medical School, Boston, MA Gerald Rosen, MD, Pediatric Representative Children’s Hospital of Saint Paul, Saint Paul, MN Michael Silber, MB, ChB Mayo Clinic, Rochester, MN Arthur Walters, MD Vanderbilt University Medical Center, Nashville, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TN
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 Phyllis Zee, MD, PhD Northwestern University Medical School, Chicago, IL Acknowledgments ICSD Revision Workgroups INSOMNIA Jack Edinger, PhD, Chair National Jewish Health, Denver, CO Daniel Buysse, MD University of Pittsburg School of Medicine, Pittsburg, PA Kenneth Lichstein, PhD University of Alabama, Tuscaloosa, AL Jodi Mindell, PhD, Pediatric Representative Saint Joseph’s University, Philadelphia, PA Charles Morin, PhD Universite Laval, Quebec, Canada CIRCADIAN RHYTHM SLEEP WAKE DISORDERS Phyllis Zee, MD, PhD, Chair Northwestern University Medical School, Chicago, IL Judith Owens, MD, Pediatric Representative Children’s National Medical Center, Washington, DC Robert Auger, MD Mayo Clinic, Rochester, MN Makoto Uchiyama, MD, PhD Nihon University School of Medicine, Tokyo, Japan Kenneth Wright, PhD University of Colorado, Boulder, CO James Wyatt, PhD Rush University Medical Center, Chicago, IL Steven Lockley, PhD, Advisor Harvard Medical School, Boston, MA SLEEP RELATED BREATHING DISORDERS Richard Berry, MD, Chair University of Florida Health Science Center, Gainesville, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    FL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 Teofilo Lee-Chiong, MD National Jewish Health, Denver, CO Carole Marcus, MBBCh, Pediatric Representative Children’s Hospital of Philadelphia, Philadelphia, PA Stuart Quan, MD Harvard Medical School, Boston, MA PARASOMNIAS Michel Cramer Bornemann, MD, Chair HealthEast Care Systems of Minnesota, Maplewood, MN Carlos Schenck, MD Hennepin County Medical Center, Minneapolis, MN Gerald Rosen, MD, Pediatric Representative Children’s Hospital of Saint Paul, Saint Paul, MN Mark Pressman, PhD Lankenau Medical Center, Wynnewood, PA HYPERSOMNOLENCE Michael Silber, MB, ChB, Chair Mayo Clinic, Rochester, MN Isabelle Arnulf, MD Hopital Pitie Salpetriere, Paris, France Suresh Kotagal, MBBS, Pediatric Representative Mayo Clinic, Rochester, MN Thomas Scammell, MD Beth Israel Deaconess Medical Center, Boston, MA Sebastiaan Overeem, MD, PhD Radboud University Nijmegen Medical Center, Nijmegen, Netherlands MOVEMENT DISORDERS Arthur Walters, MD, Chair Vanderbilt University Medical Center, Nashville, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TN
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 Ronald Chervin, MD, MS University of Michigan Health System, Ann Arbor, MI Stephen Duntley, MD Critical Care Pulmonary and Sleep Associates, Lakewood, CO Giles Lavigne, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, PhD University of Montreal, Montreal, Canada Daniel Picchietti, MD, Pediatric Representative Carle Foundation Hospital, Urbana, IL Denise Sharon, MD, PhD Tulane University School of Medicine, Destrehan, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    LA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 Marco Zucconi, MD San Raffaele Hospital, Milan, Italy APPENDIX A Members of the Movement Disorders Work Group Sean Caples, DO Mayo Clinic, Rochester, MN Susan Harding, MD University of Alabama, Birmingham, AL Acknowledgments International Society Reviewers ASIAN SLEEP RESEARCH SOCIETY Masako Okawa, MD, PhD Makoto Honda, MD, PhD Yuhei Kayukawa, MD Yuichi Inoue, MD, PhD AUSTRALASIAN SLEEP ASSOCIATION Shantha Rajaratnam, PhD Leon Lack, PhD Nick Antic, PhD CANADIAN SLEEP SOCIETY Charles Samuels, MD Atul Khullar, MD James MacFarlane, PhD Manisha Witmans, MD EUROPEAN SLEEP RESEARCH SOCIETY Claudio Bassetti, MD Ludger Grote, MD, PhD Dieter Reimann, PhD FEDERATION OF LATIN AMERICAN SLEEP SOCIETIES Darwin Vizcarra, MD Stuart Franklin Escobar-Córdoba, MD, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MFP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, PhD Dalva Poyares, MD, PhD SLEEP RESEARCH SOCIETY Ronald Szymusiak, PhD Kingman Strohl, MD Phillip Gehrman, PhD Reviewers Alon Avidan, MD Richard Allen, PhD Richard Bootzin, PhD Christopher Drake, PhD Umakanth Khatwa, MD Sanjeev Kothare, MD Lois Krahn, MD Leon Lack, PhD Mark Mahowald, MD Raman Malhotra, MD William Ondo, MD James Parish, MD David Rapoport, MD Eve Rogers, MD Carol Rosen, MD Katherine Sharkey, PhD Arthur Spielman, PhD Michael Thorpy, MD AASM Staff Jerome 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Barrett
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Executive Director Kathleen McCann, Assistant Executive Director Derek Claussen, Graphic Design Manager Jon Wendling, Publications Production Editor Jason Wilbanks, Programmer Carolyn Winter-Rosenberg, Director of Coding and Compliance Steve Van Hout, Director of Information Technology Introduction Classification of disorders plays several key roles in medicine.</br>The most familiar of these is that is serves as a guide to clinicians in the identification of specific disease states.</br>In doing so, classification systems provide clinicians with important informa- tion regarding numerous related factors including pathogenesis, prognosis, course, and heritability.</br>Moreover, therapeutic interventions are largely guided by the nosologi- cal decisions made by clinicians.</br>In turn, information accrued regarding therapeutic response of these disease states is utilized to further refine the nosology.</br>Classification systems also serve to define the domain of a given discipline, a factor of particular importance for fields such as sleep medicine which cut across many related special- ties.</br>Finally, by identifying areas of uncertainty and overlap among related patholo- gies, these systems play a critical role in guiding future research agendas which will enhance our knowledge and understanding of the clinical features, pathophysiology and treatment response specific to each disorder. </br>Since its infancy 35 years ago, the field of sleep medicine has paid particular atten- tion to the issue of classification, beginning with the 1979 American Sleep Disorders Association’s Diagnostic Classification of Sleep and Arousal Disorders.</br>Since that time, as our knowledge and understanding of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has grown, several differ- ent structural approaches have been utilized in revisions of the classification system, culminating in the International Classification of Sleep Disorders, 2nd Edition.</br>The organization of that edition, although not without its limitations, has proven effective and user-friendly and has been maintained in the current revision. </br>Ideally, classification systems are based largely on pathophysiology.</br>However, such an approach is dependent on adequate knowledge concerning the various pathophysiol- ogies of disease or disorder within a given discipline.</br>As is the case with many diag- nostic systems, our current knowledge and understanding of the pathophysiology of many 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is inadequate.</br>As a result, International Classification of Sleep Disorders, 3rd Edition, not unlike its predecessors, employs a hybrid approach which utilizes pathophysiology, where known, but also relies heavily on phenomenology and organ system approaches.</br>Despite these shortcomings, this approach is one that has proven familiar and workable for sleep medicine clinicians. </br>Recognizing the need for currency and relevance in a rapidly evolving field, the American Academy of Sleep Medicine Board of Directors approved a revision of International Classification of Sleep Disorders, 2nd Edition in 2011.</br>Following appoint- ment of a chair/editor, a task force, consisting of individual work group chairs for each Introduction major division of the manual, was selected, along with two pediatric consultants.</br>A focus group of experts was convened in June 2011 to obtain input on major structural and content issues.</br>Based on this feedback, individual work groups then set about to define the list of disorders to be included within their sections as well as proposed cri- teria for each diagnosis.</br>This process included comprehensive literature searches for every potential diagnosis as well as for their major features.</br>The draft diagnostic crite- ria which emanated from this work were then reviewed and modified by the task force (consisting of the work group chairs and pediatric advisors), as well as by the board of the AASM.</br>The edited criteria were then distributed to external peer reviewers with expertise in the respective areas, as well as to international societies and membership sections of the AASM for comment.</br>These reviews were carefully considered and revi- sions made based on this input.</br>Subsequent to this, text revisions were begun and the same review process and modifications were undertaken once text drafts were com- pleted.</br>Further modifications were made based on recommendations from the AASM board before finalization of the edition.</br>At all points in this process, efforts were made to rely as heavily as possible on available and current scientific evidence.</br>However, due to the paucity of available evidence in many areas, decisions regarding the nosol- ogy were often made by consensus of the work groups, task force, and reviewers. </br>Using ICSD-3 As noted above, the general structure of the current edition closely parallels that of the second edition.</br>The major clinical divisions remain unchanged.</br>As with International Classification of Sleep Disorders, 2nd Edition, pediatric diagnoses are fully integrated into the major clinical diagnoses, with the exception of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, pediatric.</br>Where pediatric presentations call for variation in the diagnostic criteria, those variations are noted within the criteria section.</br>In an effort to better identify those clinical features of a disorder which are developmentally-specific, a text heading for Developmental Issues has been added for each diagnosis.</br>Specific ICD codes (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 10-CM) are listed at the beginning of each diagnosis.</br>Because of the complexities and differences between International Classification of Sleep Disorders diagnoses and the ICD system, assign- ment of codes is challenging.</br>These issues are discussed further under Coding below. </br>Although classification systems are, by their nature, intended to define disorders in the most specific terms possible, clinicians must recognize that there is inevitably some degree of variability in presentation which may result in clinically significant conditions which do not meet all specific criteria for a given diagnosis.</br>Therefore, some degree of judgment is necessary in the application of these criteria.</br>Bearing this exception in mind, all listed criteria should generally be met for establishment of a given diagnosis, unless otherwise specified.</br>Clinicians should note that most diagnoses within the International Classification of Sleep Disorders include a criterion, or cri- teria, that connote clinical significance (i.e., disturbing symptoms, significant conse- quences, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    distress
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or impairment in one or more functional realms).</br>These criteria are particularly important because, without them, many phenomena related to sleep-wake do not rise to a level that requires clinical attention and treatment.</br>Users should also pay particular attention to the Notes section (where included), as these notes provide essential definitions and details concerning application of the criteria. </br>Clinicians will note a number of significant content changes from the former edition.</br>The most apparent of these is the collapse of all previous chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnoses into a single chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis.</br>The rationale for this is described in the introductory section of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A separate diagnosis is retained for short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Within the Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 section, the nomenclature for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been changed to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 and type 2.</br>This modification is discussed in the introduction to that section.</br>Users will also find several new diagnoses within the Sleep Related Breathing Disorders.</br>Within the Central Sleep Apnea Syndromes, a diagnosis of treatment-emergent central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 now appears.</br>This term is preferred to the widely used term complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 because it describes a more specific and well-defined disorder in which the central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 arises in the context of positive airway pressure treatment for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and is not attributable to another cause.</br>Central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    identi- fiable etiologies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 breathing or substance-induced central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not classified as treatment-emergent.</br>Assigning a diagnosis of a sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 requires demonstration of elevated PaCO2 (by direct measure of arterial blood gas or, more commonly, by proxy measures such as end-tidal or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trans- cutaneous CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 determination).</br>The new diagnosis of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 disor- der should be employed when there is sustained drop in SaO2 but PaCO2 has not been measured.</br>Within the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 section, a single set of general criteria and a unified text now describe disorders of arousal from non-rapid eye movement sleep, although additional, specific criteria and separate coding are maintained for the diagnoses within this section (i.e., confusional arousal, sleepwalking and sleep terror).</br>Other, somewhat less consequential additions, deletions and reassignment of diagnoses also appear in this edition.</br>International Classification of Sleep Disorders, 2nd Edition contained a separate chapter for Isolated Symptoms and Normal Variants.</br>A small number of these were felt to qualify as formal diagnoses at this time and have been moved to relevant sections.</br>Other symptoms and variants appear at the conclusion of the chapter to which they are most applicable (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to the Sleep Related Breathing Disorders, long sleeper to Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and movement related variants to the Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 section). </br>15 Introduction Introduction A wealth of information regarding each diagnosis is contained within the separate text headings within each diagnostic section.</br>The outline below details some of the spe- cific content to be found within each text heading.</br>These terms are not indexed in the hard copy version of this manual because they appear throughout the document.</br>Users should refer to the relevant text heading within a specific diagnosis for information related to these terms: Alternate Names Diagnostic Criteria Essential Features Associated Features Clinical and Pathophysiological Subtypes Demographics includes: •</br>Prevalence • Gender bias • Racial / ethnic bias • Cultural issues Predisposing and Precipitating Factors includes: • Risk factors Familial Pattern includes: • Genetics • Familial clusters Onset, Course and Complications includes: • Medical • Neurological • Psychiatric / social Developmental Issues includes: • Pediatric • Geriatric Pathology and Pathophysiology Objective Findings includes: • Sleep logs • Actigraphy • Questionnaires • Polysomnography •</br>Multiple sleep latency test • Neurological ◦ Electroencephalogram ◦</br>Cerebrospinal fluid ◦</br>Neuroimaging ◦ Electromyogram ◦</br>Autonomic • Endocrine • Genetic testing • Physical findings • Respiratory ◦</br>Arterial blood gas ◦ Pulmonary function ◦</br>Ventilatory response • Cardiac ◦</br>Electrocardiogram ◦</br>Echocardiogram ◦ Cardiac catheterization • Serum chemistry Relationship to Other Classification Systems Historically, there have been three major classifications systems for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although the International Classification of Sleep Disorders system has, for many years, been the primary nosology for sleep medicine specialists, both the Diagnostic and Statistical Manual of Mental Disorders (DSM) of the American Psychiatric Association and the International Classification of Diseases (ICD) nosology of the World Health Organization have also classified 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Unfortunately, these competing systems have differed significantly in structure and content over the years.</br>Development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSM-5
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was ongoing during the development of this manual and an effort was undertaken to achieve the greatest degree of concordance possible between these two systems, recognizing that the International Classification of Sleep Disorders will inevitably contain a greater level of detail than DSM due to differences in their target users.</br>This goal was largely achieved although some differences will still exist.</br>The major change to the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 section (i.e. establishment of a single chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis) within this new system is paralleled in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSM-5
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnoses are organized somewhat differently in the DSM clas- sification than in this manual and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 criteria differ slightly.</br>Circadian Rhythm Sleep-Wake Disorder diagnoses are identical within the two systems with the exception that DSM does not include a jet lag disorder.</br>Sleep Related Breathing Disorders are significantly more detailed within International Classification of Sleep Disorders than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSM-5
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, although the organizational structures in this section are quite similar.</br>Sleep Related Movement Disorders and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are likewise similar but with fewer overall diagnoses within 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSM-5
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>With the publication of International Classification of Sleep Disorders, 2nd Edition, a major effort to expand and reorganize sleep related diagnoses within ICD-9-CM was undertaken.</br>This effort resulted in the inclusion of many additional sleep related diag- noses in ICD-9-CM (primarily within the Diseases of the Nervous System section).</br>The archaic distinction between “organic” and “non-organic” disorders has histori- cally been a guiding principle of ICD, resulting in dissemination of sleep diagnoses to both the neurological and mental disorder categories.</br>Clinicians familiar with the ICD- 9-CM categories which have been employed since the most recent changes will find general concordance between the assigned diagnostic codes found herein and the most current version of ICD-9-CM.</br>These ICD-9-CM codes for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are essen- tially carried over to ICD-10-CM.</br>However, certain content revisions in International Classification of Sleep Disorders, 3rd Edition (e.g., chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) necessitates a significant departure from the coding approach utilized in ICD-9-CM and International Classification of Sleep Disorders, 2nd Edition.</br>This is discussed further below. </br>17 Introduction Introduction Coding Diagnostic codes for the relevant ICD-9-CM and ICD-10-CM diagnoses can be found at the beginning of each diagnosis section of the book.</br>In the United States, the former codes (ICD-9-CM) should be employed until the implementation date for ICD-10-CM which, at the time of this writing, is to be no sooner than October 1, 2015.</br>Following that date, only the ICD-10-CM codes should be used.</br>As already stated, clinicians should recognize that there is not precise concordance between the assigned codes for International Classification of Sleep Disorders, 3rd Edition diagnoses and the diagno- ses listed within ICD.</br>Changes to the International Classification of Sleep Disorders classification system are not reflected in the ICD system for many years.</br>Moreover, the ICD classification of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has historically been significantly less detailed than ICSD (particularly for international users not employing the Clinical Modification (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) version used in the United States).</br>Hence, clinicians will find many areas in which assigned codes found in this manual do not correspond as closely as one would like to ICD codes.</br>Most notably, with the collapse of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnoses into a single disorder in International Classification of Sleep Disorders, 3rd Edition, the assigned codes for this diagnosis within International Classification of Sleep Disorders, 3rd Edition are 307.42 (ICD-9-CM) – “Nonorganic persistent disorder of initiating or maintaining sleep” and F51.01 (ICD-10-CM) – “Primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.”</br>A variety of other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnoses will continue to appear in the ICD system but, with the classifi- cation and coding changes recommended herein, these become essentially defunct for sleep medicine clinicians.</br>In summary, the assigned codes in this edition represent “best approximations” to the corresponding ICD codes, but some degree of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    discrep-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ancy between the systems will exist in a number of areas. </br>18 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
...........................................................................21 Short-Term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
......................................................................41 Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ..............................................................................46 Isolated Symptoms and Normal Variants Excessive Time in Bed .................................................................................</br>47 Short Sleeper................................................................................................47 </br>This section includes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 chiefly characterized by the complaint of insom- nia.</br>For the purpose of this manual, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is defined as a persistent difficulty with sleep initiation, duration, consolidation, or quality that occurs despite adequate opportunity and circumstances for sleep, and results in some form of daytime impair- ment.</br>These three components of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
—persistent sleep difficulty, adequate sleep opportunity, and associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
—are collectively implied by text references to the term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Among adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep complaints most typically include difficulties initiating or maintaining sleep.</br>Concerns about lengthy periods of nocturnal wakefulness, insufficient amounts of nocturnal sleep, or poor sleep quality often accompany these complaints.</br>Individuals who report these sleep related symptoms in the absence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not regarded as having an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that warrants clinical attention other than education and reassurance.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 among children is often reported by their caretakers and char- acterized by bedtime resistance, frequent nighttime awakenings and/or an inability to sleep independently.</br>Regardless of the exact nature of the nocturnal sleep concerns, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime impairments
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are reported, presumably caused by the nighttime sleep diffi- culties or by some common but unidentified mechanism during sleep and wakeful- ness.</br>Daytime symptoms typically include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    decreased mood
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, general malaise, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cognitive impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Among adults, chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may impair social or vocational functioning and reduce quality of life, whereas in chil- dren it may lead to poor school performance, impaired attention, and behavioral disturbance.</br>In some patients, physical symptoms such as muscle tension, palpita- tions, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also be attributed to the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Others with more severe forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be at increased risk for motor vehicle and work-site acci- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dents
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as well as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often accompa- nies comorbid medical illnesses, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It may also arise in association with the use, abuse, or exposure to certain substances.</br>When 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to these conditions and is persistent and prominent, a 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sep- arate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis is warranted. </br>19 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 nosology presented in this text represents a marked departure from the previous International Classification of Sleep Disorders, 2nd Edition 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 classification system in terms of its conceptual framework and relative simplicity.</br>The previous 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 nosology of the International Classification of Sleep Disorders promoted the concept that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can exist as a primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or arise as a secondary form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to an underlying primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance abuse disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, many symptoms and associated fea- tures of so-called primary and secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are overlapping, thus making differentiation among such subtypes difficult, if not impossible.</br>There is increas- ing recognition that even when 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 arises “secondary” to another condition, it often develops an independent course over time and may remain as a clinically significant condition, even if the so-called primary condition is adequately treated.</br>Evidence suggests that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, if left untreated, may adversely affect the outcome of these comorbid conditions.</br>Moreover, it appears that treatment of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may improve outcome of both the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the comorbid conditions.</br>Given these observations, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 seems best viewed as a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that warrants separate treatment attention. </br>In addition to the primary vs. secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 distinction, prior editions of the International Classification of Sleep Disorders delineated multiple putative “primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
” diagnostic subtypes.</br>Specifically, both the original 1990 version of the International Classification of Sleep Disorders and the International Classification of Sleep Disorders, 2nd Edition described primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtypes such as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psycho-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 physiological 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, inadequate sleep hygiene, and paradox- ical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as discrete diagnostic entities.</br>Experience suggests that, in practice, it is rare to encounter patients who meet the diagnostic criteria for exclusively one of these subtypes.</br>In fact, many of the diagnostic criteria delineated for these subtypes represent generic characteristics (e.g., engaging in sleep-disruptive habits; underesti- mation of sleep time, evidence of conditioned arousal) of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, per se, and do not facilitate discrimination among these subtypes or between these subtypes and those presumed to have “secondary” forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Both clinical experience and a growing body of empirical findings have shown that the diagnostic distinctions advocated by previous versions of the International Classification of Sleep Disorders are difficult to reliably ascertain and are of question- able validity.</br>In view of such considerations, the current manual abandons the previ- ously employed complex and highly specific 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 classification scheme described by the original International Classification of Sleep Disorders and the 2nd Edition in favor of a more global and defensible nosology. </br>20 The manual includes three diagnostic categories for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>These diag- noses apply to patients with and without comorbidities regardless of whether those comorbidities are viewed as potentially sleep disruptive.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by chronic sleep onset and/or sleep maintenance complaints with asso- ciated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and is reserved for individuals whose 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 exceed minimal frequency and duration thresholds shown to be associated with clin- ically significant morbidity outcomes.</br>Short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by sleep/wake difficulties that fail to meet the minimal frequency and duration criteria of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Nonetheless, short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with clinically significant sleep dissatisfaction or waking impairment.</br>Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be assigned to those rare cases that fail to meet criteria for short- term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, yet are thought to have sufficient symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to warrant clinical attention. </br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Disorder ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 307.42 ICD-10-CM code:</br>F51.01 Alternate Names Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, disor- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    der
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of initiating and maintaining sleep, behavioral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of childhood, sleep-onset association disorder, limit-setting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-F must be met A.</br>The patient reports, or the patient’s parent or caregiver observes, one or more of the following:1 .</br>Difficulty initiating sleep. </br>2. Difficulty maintaining sleep. </br>3. Waking up earlier than desired. </br>4.</br>Resistance to going to bed on appropriate schedule. </br>5.</br>Difficulty sleeping without parent or caregiver intervention. </br>B. The patient reports, or the patient’s parent or caregiver observes, one or more of the following related to the nighttime sleep difficulty: . Fatigue/malaise. </br>2. Attention, concentration, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    memory impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>3. Impaired social, family, occupational, or academic performance. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 .</br>Mood disturbance/irritability. </br>5. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>6.</br>Behavioral problems (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    impulsivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aggression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>7. Reduced motivation/energy/initiative. </br>8.</br>Proneness for errors/accidents. </br>9.</br>Concerns about or dissatisfaction with sleep. </br>C. The reported 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep/wake complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cannot be explained purely by inadequate opportunity (i.e., enough time is allotted for sleep) or inadequate circumstances (i.e., the environment is safe, dark, quiet, and comfortable) for sleep. </br>D. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and associated daytime symptoms occur at least three times per week. </br>E. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and associated daytime symptoms have been present for at least three months.2 F. The sleep/wake difficulty is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Notes .</br>Reports of difficulties initiating 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep, difficulties maintaining sleep, or waking up too early can be seen in all age groups.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>Resistance going to bed on an appropriate schedule and difficulty sleeping without parent or caregiver intervention is seen most commonly in children and older adults who require the supervision of a caretaker due to a significant level of functional impairment (e.g., those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>2. Some patients with chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may show recurrent episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep/wake difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lasting several weeks at a time over several years, yet not meet the three-month duration criterion for any single such episode.</br>Nonetheless, these patients should be assigned a diagnosis of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, given the persistence of their intermittent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 over time. </br>3.</br>Some patients who use hypnotic medications regularly may sleep well and not meet the criteria for an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 when they take such medications.</br>However, in the absence of such medications these same patients may meet the above criteria.</br>This diagnosis would apply to those patients particularly if they present clinically and voice concerns about their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inability to sleep without their sleep
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 medications. </br>4.</br>Many comorbid conditions such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic pain disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or gast- roesophageal reflux disease (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GERD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) may cause the sleep/wake complaints delineated here.</br>When such conditions are the sole cause of the sleep difficulty, a separate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis may not apply.</br>However, in many patients such conditions are chronic and are not the sole cause of sleep difficulty.</br>Key determining factors in the decision to invoke a separate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis include: “How much of the time does the sleep difficulty arise as a result of factors directly attributable to the comorbid condition (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GERD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
)?”</br>or “Are there times that the sleep/wake complaints occur in the absence of these factors?”</br>“Have perpetuating 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cognitive or behavioral factors (e.g., negative expectations, conditioned arousal, sleep-disruptive habits
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) arisen, suggesting an autonomous aspect to the ongoing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
?”</br>If there is evidence that the patient’s sleep/ wake complaints are not solely caused by the medical condition, and those sleep/wake complaints seem to merit separate treatment attention, then a diagnosis of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be made. </br>Essential Features The essential feature of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a frequent and persistent difficulty initiating or maintaining sleep that results in general sleep dissatisfaction.</br>The sleep complaint is accompanied by distress about poor sleep and/or impairment in family, social, vocational, academic, or other important areas of functioning.</br>Furthermore, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and associated waking symptoms occur despite having adequate time and circumstances each night to obtain necessary sleep.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dis- order can occur in isolation or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbidly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical condition, or substance use. </br>The sleep complaints that comprise chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may include difficul- ties initiating 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep or difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 maintaining sleep.</br>The latter complaint may include waking up during the night with difficulty returning to sleep or having a final awaken- ing occurring too early, well before the desired rising time.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be characterized solely by sleep onset or sleep maintenance complaints or, more commonly, by both types of complaints occurring together.</br>Individuals’ sleep com- plaints may also change over time such that those with solely sleep onset complaints may subsequently develop sleep maintenance complaints and vice versa.</br>Also, those who present initially with mixed sleep onset and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep maintenance difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may later evidence one or the other of these difficulties but not both.</br>Complaints about poor-quality, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    unrefreshing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or nonrestorative sleep often accompany sleep onset and sleep maintenance complaints, but do not suffice to define 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 when occurring as the sole sleep complaint. </br>The degree of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 required to assign a chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diag-</br>nosis is somewhat arbitrary in that it relies primarily on individuals
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ’ subjective sleep Insomnia Insomnia complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Moreover, the degree of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 required to connote clinical significance varies across age groups.</br>Nonetheless, sleep onset latencies and periods of wakefulness after sleep onset &gt; 20 minutes generally connote clinically significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children and young adults.</br>In middle and older aged adults, onset latencies and periods of wakefulness during sleep &gt; 30 minutes typically connote clin- ical significance.</br>Complaints of early morning awakening are less well defined, but typically entail the termination of sleep at least 30 minutes before the desired rising time and a concomitant reduced total sleep time compared with the usual premorbid sleep pattern.</br>The exact time at which early morning awakenings occur may vary con- siderably as a function of usual bedtimes.</br>For example, a final awakening at 4:00 a.m. is likely to connote clinical significance when the usual bedtime is 11:00 p.m.</br>but not when the usual bedtime occurs at 9:00 p.m. Symptoms during wakefulness accompany the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and result in the impairment of normal functioning.</br>Common waking symptoms include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; reduced motivation; reduced concentration, attention, and memory functioning; and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or reduced mood.</br>Complaints of subjective 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are also common, although, in contrast to patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 conditions, many with this complaint are not able to nap in the daytime and few show unintentional sleep episodes.</br>Reports of reduced performance at work or school or impaired social functioning also are common.</br>Some affected individuals attribute errors or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    accidents
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at work to their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Somatic symptoms such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or gastrointes- tinal dysfunction are occasionally attributed to the ongoing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as well. </br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sufferers is manifest mainly as a lack of energy and desire to reduce or limit activity levels.</br>This symptom should be differentiated from reports of subjective 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as well as from unintended sleep episodes.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sufferers commonly report subjective sleepiness characterized by a sense of reduced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alertness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and enhanced need or desire to sleep.</br>However, they seldom fall asleep spontaneously without intending to do so.</br>Despite a desire to nap, many individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are unable to do so.</br>Frequent, unintentional daytime sleep episodes are more characteristic of other types of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as sleep disordered breathing, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idio- pathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and the like. </br>In young children, difficulty falling asleep, staying asleep, or both are often the result of inappropriate sleep associations or inadequate limit setting.</br>Inappropriate sleep associ-</br>ations result from a child
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ’s dependency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on specific stimulation, objects, or settings for initiating sleep or returning to sleep following an awakening; in the absence of these conditions, sleep onset is significantly delayed.</br>This manifestation usually presents as frequent nighttime awakenings and/or nighttime fears or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 about sleeping alone.</br>The process of falling asleep is associated with a specific form of stimulation (e.g., rocking, watching television), object (e.g., bottle, excessive feedings), or setting (e.g., lighted room, parents remaining in the room, or child taken to parents
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ’
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 bed).</br>When such conditions are absent, children with this disorder experience difficulty falling asleep at bedtime and following normal nighttime 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>If the conditions associ- ated with falling asleep are reestablished, the child usually resumes sleep relatively quickly.</br>Because sleep-onset associations are highly prevalent in young children, the phenomenon is defined as a disorder only if (1) the associations are highly problem- atic or demanding (e.g., extended rocking, car rides); (2) sleep onset is significantly delayed or sleep is otherwise disrupted in the absence of the associated conditions; and (3) caregiver intervention is frequently required to aid the onset or resumption of sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Limit-setting
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 issues are characterized by bedtime stalling or bedtime refusal that is met with and reinforced by inadequate limit setting by a caregiver.</br>Sleep problems occur when caregivers institute no or few limits or when limits are instituted inconsistently or in an unpredictable manner.</br>Limit-setting sleep problems may also result in prolonged 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal awakenings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, depending on caregiver response during the night. </br>It also should be noted that some children’s needs for specific conditions for sleeping or their resistance to go to bed may reflect underlying 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or fears.</br>Fear of sleep- ing alone, being in the dark, or having nightmares may lead some children to demand certain sleep promoting conditions (presence of parent in bedroom) or to repeatedly delay their bedtimes. </br>Although transient and episodic forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur, the clinically significant daytime consequences of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the longer term, more serious morbidity out- comes most typically develop when the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur at least three times per week and persist for at least three months.</br>For this reason, these frequency and dura- tion criteria must be met for the assignment of a chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis.</br>However, it is recognized that more acute and episodic forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may cause significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    distress
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and functional impairment and require clinical attention.</br>Cases that meet all criteria except the frequency or duration criteria for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be assigned a diagnosis of short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Associated Features Individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 typically note feelings of reduced well-being and general malaise during the day.</br>In addition, excessive focus on and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    worry
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 about ongoing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and their associated daytime consequences are common.</br>Thoughts about ongoing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur through the day and may be amplified as bedtime 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 approaches.</br>Frank performance 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 about sleep is common.</br>Although many with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may appear anxious and worry-prone, their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    worry
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are often focused mainly on their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>When 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    worry
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are more pervasive and not solely focused on sleep problems, a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid anxiety disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present.</br>Many with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 show a pattern of conditioned arousal in response to envi- ronmental cues in their bedrooms or conscious efforts to initiate sleep.</br>Such individuals may fall asleep easily in settings outside of their bedrooms when not trying to sleep, but show a pattern of cognitive and physiological arousal when lying down in their beds with the intention to fall asleep.</br>Some patients with this pattern may report sleeping better when away from home than when at home.</br>Unlike noncomplaining normal sleepers, indi- viduals with chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often express conscious intentions and excessive effort to sleep, only to find sleep difficult to initiate under such circumstances. </br>In children, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be accompanied by daytime behavioral prob- lems and limit-setting difficulties during the day.</br>In addition, the nighttime sleep distur- bance often results in poor parental sleep and associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Marital conflicts regarding how to respond to or intervene with the ongoing sleep problem may arise.</br>Parents also may develop negative feelings toward the child who disrupts their sleep and demands their attention during the night. </br>Clinical and Pathophysiological Subtypes Various clinical and pathophysiological subtypes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been described in previous nosologies.</br>Both the American Psychiatric Association’s Diagnostic and Statistical Manual, 4th Edition, Text Revision (DSM-IV-TR) and the International Classification of Sleep Disorders, 2nd Edition describe independently occurring or primary forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Within 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSM-IV-TR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the global term, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, is applied to all forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that are not better explained by a coincident psychi- atric, medical or substance</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    use/abuse disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Within the International Classification of Sleep Disorders, 2nd Edition system, multiple primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtypes are delin- eated.</br>The specific primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtypes listed in the previous International Classification of Sleep Disorders, 2nd Edition include the following: Psychophysiological 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized primarily by heightened arousal and learned sleep-preventing associations that result in a complaint of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients presumed to have this type of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often have sleep difficulty when trying to sleep in their usual sleep setting at home but may fall asleep easily in a novel sleep setting or when not trying to sleep.</br>They also demonstrate excessive focus on and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    worry
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 about sleep and suffer from elevated levels of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cognitive and somatic arousal
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly at bedtime. </br>26 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Idiopathic insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by a longstanding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaint of sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insidious
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 onset occurring during infancy or early childhood.</br>It is presumed to arise in infancy or early childhood without discernible cause and to persist over time without sustained periods of remission.</br>Given its early onset, stability over time, and lifelong course, this disorder is thought to arise from either genetically determined or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congenital aberrations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the sleep-inducing or arousal systems in the brain, or both.</br>No consistent genetic markers or neural pathology have been identified among those presumed to suffer from this condition. </br>Paradoxical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which has previously been called sleep state misperception, is described as a complaint of severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without corroborative objective evidence of the degree of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 claimed.</br>Those presumed to have this form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulty
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have a marked propensity to underestimate the amount of sleep they actually are obtaining.</br>In essence, they are thought to perceive much of the time they actually sleep as wakefulness.</br>Although many such patients routinely obtain norma- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 amounts of sleep, as documented by standard polysomnographic measures, they complain of the common sleep/wake symptoms of other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Some studies using neuroimaging or sleep electroencephalograph (EEG) spectral analysis techniques have suggested that an altered sleep/wake arousal system in such individ- uals may explain the apparent mismatch between their conventional objective sleep measures and subjective sleep reports. </br>Inadequate sleep hygiene is presumed to result from or be sustained by daily living activities that are inconsistent with the maintenance of good-quality sleep and normal daytime alertness.</br>Patients with this form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have ongoing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep/ wake difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a function of practices such as daytime napping, maintaining a highly variable sleep/wake schedule, routinely using sleep-disruptive products (caf- feine, tobacco, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
) too close to bedtime, engaging in mentally or physically acti- vating or emotionally upsetting activities too close to bedtime, routinely using the bed and bedroom for activities other than sleep, or failing to maintain a comfortable environment for sleep. </br>Behavioral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of childhood is presumed to result from improper sleep train- ing or limit setting by parents or caretakers.</br>Within this broader diagnosis, several subtypes have been described.</br>Sleep-onset association type is characterized by the child
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ’s dependency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on specific stimulation, objects, or settings for initiating sleep or returning to sleep following an awakening; in the absence of these conditions, sleep onset is significantly delayed.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Limit-setting
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type is characterized by bedtime stalling or bedtime refusal that is the result of inadequate limit setting by a caregiver.</br>A mixed type 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 characterized by features of sleep-onset association difficulties and bedtime resistance represents a third subtype within this diagnostic category. </br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSM-IV-TR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and International Classification of Sleep Disorders, 2nd Edition also describe several so-called secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, arising from co-occurring primary or causative conditions.</br>Among these are the following: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to (another) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is thought to be caused by or secondary to a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    co-occurring psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 condition.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a common complaint, particularly among patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Likewise, sleep distur- bance is commonly seen in those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychotic spectrum disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and various Axis II (personality) disorders.</br>Among those individuals presumed to have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has historically been regarded as a secondary symptom, caused by the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 itself. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to (a) medical condition is thought to be caused by or secondary to a co-occurring medical condition.</br>Like the mental disorders, many medical condi- tions may have an ongoing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 complaint associated with them.</br>In particular, those conditions that cause some form of ongoing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or discomfort, mobility lim- itation, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 commonly have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 accompanying them.</br>Among those individuals presumed to have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disor- der, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has historically been regarded as a secondary symptom, caused by the medical disorder itself. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to drug or substance is thought to be caused by or secondary to use of or withdrawal from a drug or substance.</br>Many forms of prescription and nonprescrip- tion medications, street drugs, and other commonly used substances may produce 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 either during periods of use or upon withdrawal.</br>Given these effects, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 complaints may arise either during periods when these substances are used or following their discontinuance.</br>Among those individuals presumed to have insom- nia due to drug or substance, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has historically been regarded as a secondary symptom, caused by the drug or substance itself. </br>Despite the heuristic appeal of these various subtypes, it is often difficult to discrim- inate among them in clinical practice.</br>Many of the defining features of the so-called primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtypes such as conditioned arousal, poor sleep hygiene prac- tices, and underestimation of sleep time are ubiquitous among 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sufferers, per se, and are not specific to one subgroup.</br>This is true whether the so-called primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtypes are considered in isolation or if all of the primary and secondary subtypes mentioned are considered.</br>There is substantial symptom overlap both within the group of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary insomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as well as among the primary and secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Furthermore, many individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have mul- tiple medical and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 comorbidities, making it difficult to assign causation to any single factor.</br>As a result, discrimination among these subtypes has proven difficult given their current definitions and available methods for their ascertain- ment.</br>Furthermore, it is not clear that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is always the result of co-occur- ring medical, mental, or substance use disorders.</br>Often 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may precede the onset of such conditions, and even when precipitated by such conditions, the insom- nia may evolve and develop partial or total independence over time.</br>In such cir- cumstances, the term secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 seems inappropriate.</br>Currently there is limited understanding of mechanistic pathways in chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, so it is not possible to draw firm conclusions about the association or direction of causality between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and such co-occurring conditions.</br>Furthermore, other than the differing treatments required for distinctive comorbidities, efficacious treatments for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 generally are similar across the range of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtypes.</br>Finally, research has provided very limited support for the reliability and validity of the various specific subtypes discussed. </br>International Classification of Sleep Disorders, 2nd Edition additionally delineates the separate pediatric diagnosis, behavioral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of childhood, characterized by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 resulting from inappropriate sleep associations or inadequate limit setting by parents or caretakers.</br>Although perhaps more common in young children, inappropriate sleep associations can occur in older age groups.</br>For example, adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may report intolerance for quiet and dark settings and may not be able to fall asleep unless the television is on.</br>Similarly, it is not clear that limit-setting issues are involved in the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of only young children.</br>Such difficulties also can manifest during adolescence as a function of volitionally delaying bedtimes.</br>Similarly, they may occur in older, cognitively impaired adults when their caretak- ers allow liberal daytime napping that in turn results in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disruptive awakenings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and night wandering.</br>It is also clear that many of the features of sleep/wake dysfunc- tion assigned to this childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtype overlap substantially with the global 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Given these considerations, a separate childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagno- sis is of questionable merit. </br>In addition to these various subtypes, a distinctive subtype of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with objectively short sleep duration has been recently described.</br>This group is characterized by insom- nia complaints, along with an objectively documented average sleep time less than six hours per night and elevated morbidity risk.</br>Because evidence in support of this 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Insomnia insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is currently limited, it is premature to delineate a separate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 category for this presentation at this juncture. </br>Given all of these considerations, a more global and defensible approach has been chosen for the diagnosis of those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic insomnia complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Specifically, the single diagnosis of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is provided for all patients who have per- sistent and frequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 whether they occur in the presence or absence of a potentially sleep-disruptive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid psychiatric illness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical disorder, or pattern of substance use. </br>Demographics The full clinical syndrome of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs in about 10% of the population, but the prevalence of transient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms is much higher (30% to 35% of the population).</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is more common in women, those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    medical/psychiatric/substance disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and in people in lower socioeco- nomic strata.</br>It may occur at any age but is more commonly diagnosed in older adults, most likely due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    age-related deterioration
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in sleep continuity and increase in medical comorbidities and medication use that increase 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 risk. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with requirements of parental/caregiver presence at bedtime and/or during the night, along with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    limit-setting difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, are estimated to occur in 10% to 30% of children, depending on the exact definitions used.</br>Certain subgroups of children, such as those suffering from chronic illnesses or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodevelopmental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, have a somewhat higher prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms.</br>Because children are not expected to sleep through the night with reg- ularity until they are three to six months of age, six months is a reasonable age to first consider a diagnosis of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, unless the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleeplessness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is very marked at an earlier age.</br>Furthermore, sleep-onset associations and limit-set- ting problems are strongly associated with caregivers’ behaviors, bedtime interac- tions, and culture.</br>Thus, the interpretation of the nighttime awakenings and demands for parental contact should be considered in the context of the family and culture.</br>Identification of sleep problems in children and adolescents are often based on spe- cific cultural definitions.</br>Studies on adolescents indicate prevalence rates of 3% to 12%, depending on the diagnostic criteria utilized, with higher frequency in girls than boys after puberty. </br>Predisposing and Precipitating Factors Individuals who have difficulty sleeping during stressful times or who report being habitual light sleepers appear to have elevated propensity to develop chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>30 Prior transient episodes of poor sleep elevate the risk for subsequent development of a chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Job-related stress and factors such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of a loved one, divorce, a marked change in work schedule, job loss, and other major life changes are often precipitating circumstances for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Personality factors that produce anxious overconcern about health, general well-being, or daytime func- tioning may serve as predisposing characteristics because individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often display excessive preoccupation with daytime consequences of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and they devote particular effort to what they presume are sleep-promot- ing practices.</br>A psychological style characterized by the repression and internalization of disturbing affect is characteristic of those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and also may represent a predisposing trait.</br>Parents who have unrealistic sleep expectations for their children may predispose them to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by putting them in bed too early or assigning them too much time in bed each night. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Comorbid psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 conditions, particularly mood and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, are asso- ciated with increased risk for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Likewise, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or medical disorders such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GERD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or those conditions that result in chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or immobility also are associated with increased risk for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A pattern of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol dependence/abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as well as the excessive use of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 or other 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stimulants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 may raise risk for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children is often associated with difficult temperament, as well as other comorbid medical and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 conditions.</br>Unstable home situations, safety concerns and domestic abuse are likewise significant risk factors in both children and adults.</br>Caregiver and relationship factors are also important to consider.</br>Furthermore, parents of children with a current or past history of medical problems may have dif- ficulty setting limits, whether because of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    guilt
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a sense that the child is “vulnerable,” or concerns about doing psychological harm.</br>Environmental factors such as the child sharing a room with a parent or with other siblings, the presence of extended family or others in the home, and cramped living accommodations may contribute to negative sleep-onset associations or poor limit setting. </br>Familial Patterns The familial pattern of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not well documented.</br>Nonetheless, the preva- lence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is higher among monozygotic twins relative to dizygotic twins; it is also higher in first-degree relatives than in the general population.</br>The association is stronger with mothers and daughters.</br>The extent to which 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial aggregation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 represents shared genetic predisposition, shared environment, learned behavior (e.g., by observations of parental behavior), or a by-product of psychopathology remains undetermined. </br>31 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Onset, Course, and Complications Onset may be 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insidious
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or acute.</br>In the former case, individuals often report symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in early life or young adulthood.</br>Onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is often associated with major life events (e.g., separation, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of a loved one), minor daily stressors, or changes in sleep schedule. </br>The course of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be situational, recurrent, or persistent.</br>The specific type of sleep complaint may also change over time.</br>Individuals who complain of diffi- culty falling asleep at one time may later complain of difficulty maintaining sleep, and vice versa.</br>Although short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often remits when the precipitating event subsides or the individual adapts to it, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also persist over time even after the initial triggering factor has disappeared.</br>When left untreated, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may persist and gradually lead to a vicious cycle of poor sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime impairments
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, apprehension of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and further sleep disturbances.</br>Among predisposed individ- uals, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can also follow an intermittent course, with recurrent episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with stressful life events.</br>Even in persistent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, there is extensive night-to-night variability, with an occasional good night’s sleep intertwined with several poor night’s sleep.</br>Approximately 70% of individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at a given time continue reporting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 a year later, and 50% still have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 three years later.</br>Complications of persistent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include increased risks for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, work disability, and prolonged use of prescription or over- the-counter sleep aids. </br>Among children, chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may have its onset at any time during late infancy through the childhood years.</br>The course of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in young children varies and depends on the reasons for the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleeplessness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>When limit-setting factors and negative sleep associations resolve, sleep often improves.</br>With age, inde- pendence and privacy become more important, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may decrease.</br>Complications may result from the consequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and decreased attention and school performance.</br>Increased family tensions and caregiver 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also result.</br>Some who develop 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during childhood may con- tinue to suffer from chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 into adulthood. </br>Developmental Issues Developmental issues during childhood, such as separation 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and age/develop- mental milestones, may predispose a child to developing sleep problems.</br>For example, limit-setting issues are often more common after the child is old enough to climb out of the crib or is moved into a bed, has increased verbal skills, and desires greater indepen- dence.</br>Because children are not expected to sleep through the night with regularity until they are three to six months of age, six months is a reasonable age to first consider a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, unless the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleeplessness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is very marked at an earlier age.</br>However, when 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are persistent and pronounced in infants, underlying medical causes should be considered (e.g., sleep disordered breathing, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GERD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>The specific symptoms of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as well as precipitating and per- petuating factors, may vary across the adult age range.</br>These changes may in part reflect developmental changes across adulthood, such as the phase delay of endoge- nous circadian rhythms in adolescence and young adulthood, and the phase advance and increased number of awakenings often seen even among healthy older adults.</br>Epidemiological studies confirm that sleep onset difficulties and nonrestorative sleep are most common among young adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, whereas sleep maintenance 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and early morning awakening are more common in middle-aged and older adults.</br>Objective 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is uncommon in younger adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but more common in older adults.</br>However, older adults may have less sleep dissatisfaction than their younger counterparts, despite objectively worse sleep continuity.</br>Precipitating factors for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also change across the adult age range, with medical and medication factors assuming a larger role in older adults.</br>Likewise, perpetuating factors may vary with the life circumstances of adults of different ages.</br>One common example is the option of older adults to spend large amounts of time in bed after retirement, which may exacerbate the effects of age on sleep continuity.</br>Finally, medical disorders and symptoms (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    impaired mobility
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) and medications often play a larger role in the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of older adults in comparison with younger adults.</br>Hypnotic medications are disproportion- ately prescribed to older adults, often with limited benefit and the potential for rebound and withdrawal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Pathology and Pathophysiology Studies of the pathophysiology of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have focused on one or more dimensions of physiological hyperarousal during sleep and wakefulness.</br>These studies contrast groups of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sufferers, typically those without sig- nificant comorbidities, with healthy controls using a variety of physiological mea- sures.</br>Many of these studies are characterized by small sample sizes and lack of replication.</br>Collectively these studies suggest increased physiological arousal among individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, characterized by measures such as increased heart rate, altered heart rate variability, increased whole-body metabolic rate, elevated corti- sol, adrenocorticotropic hormone, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CRF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 levels (particularly near sleep onset), increased body temperature and increased high-frequency electroencephalographic (EEG) activity during nonrapid eye movement (NREM) sleep.</br>These studies imply 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 heightened activity of the sympathetic nervous system and hypothalamic-pitu- itary-adrenal axis across sleep and wakefulness that is thought to perpetuate sleep/ wake dysfunction.</br>Some evidence also suggests that physiological dysregulation may be more evident in certain subgroups of individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., those with extreme subjective-objective sleep discrepancies or those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and short objective sleep duration).</br>There is also some evidence that these findings may not generalize to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia comorbid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which may have differ- ent pathophysiological findings. </br>No discrete structural brain pathology can be identified in most individuals with insom- nia.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia comorbid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, brain 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multiple sclerosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may have identifiable 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brain lesions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is rarely their sole neurological symptom.</br>Recent studies have provided conflicting evi- dence regarding the finding of reduced hippocampal or anterior cingulate volume, with most studies reporting negative findings. </br>Objective Findings Although polysomnography is not indicated in the routine evaluation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, it may be useful to rule out other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-disordered
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 breathing) among some patients who appear to meet criteria for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In the absence of other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, results of polysomnographic sleep monitoring of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may show increased sleep latency and/or increased wake time after sleep onset coupled with reduced sleep efficiency in com- parison with age-appropriate norms.</br>Sleep onset latency or wake time after sleep onset often exceeds 30 minutes, although one-hour to two-hour periods of wakefulness in bed are not uncommon.</br>A subset of patients shows reduced sleep duration of less than six hours per night.</br>Some patients show altered sleep architecture with an increase in stage N1 sleep and a decrease in slow wave sleep.</br>Patients with a pronounced condi- tioned sleep difficulty in the home environment may show a reverse first-night effect in the sleep laboratory (i.e., better sleep on the first vs. the second recording night).</br>However, some patients show normal sleep times and an absence of sleep onset or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep maintenance difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on standard polysomnographic (PSG) measures.</br>Some 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients have alterations in power density measures of the sleep EEG when compared with individuals without sleep complaints.</br>Specifically, these patients often show relatively greater power in the high frequency (beta and gamma ranges) band- widths.</br>Some reports have shown that elevated high-frequency power is characteris- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with marked 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    subjective-objective discrepancies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in sleep mea- sures, compared to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with more obvious objective 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or individuals without sleep complaints. </br>34 Serial monitoring with PSG or actigraphy typically shows marked night-to-night vari- ability in all sleep measures as well as in recorded bed and rising times.</br>This variability is typically greater than that of comparison groups of good sleepers. </br>Many patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 underestimate the actual sleep time shown by polysom- nography, and some may provide sleep estimates that fall far short of actual PSG- recorded sleep time.</br>This latter group has previously been categorized as having subjective 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep state misperception, or paradoxical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In general, patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tend to underestimate sleep duration and overestimate sleep latency and awakenings, whereas good sleepers tend to overestimate sleep duration and underestimate sleep latency and awakenings relative to PSG.</br>This subjective-ob- jective mismatch may be related to physiological hyperarousal, and may be one of the core features of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Results of the Multiple Sleep Latency Test (MSLT) usually show normal daytime alert- ness.</br>In several studies, patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have longer mean MSLT values than control subjects, suggesting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperalertness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or hyperarousal.</br>A minority of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients, particularly older adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, have reduced mean MSLT values indicating increased sleepiness.</br>Such a finding should prompt consideration of other concurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Young children typically show essentially normal sleep during PSG monitoring when the caregiver is present and appropriate limits are set in the laboratory. </br>Although PSG and MSLT testing usually are not helpful in the establishment of an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis, there are circumstances that may warrant such testing with selected patients.</br>PSG should be considered when there are reported symptoms or bed partner observations of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or periodic limb movements during sleep.</br>Patients who present 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms accompanied by excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may warrant PSG and MSLT testing, particularly if 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is suspected.</br>Patients who show acceptable adherence to trials of well-established insom- nia therapies but fail to show adequate treatment response may benefit by PSG to rule out a comorbid 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Finally, a small number of functional imaging studies have been conducted during sleep and wakefulness in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and control groups.</br>These studies suggest region- ally specific increases of relative 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucose
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 metabolism in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 compared to controls.</br>Specifically, these studies show smaller wake to NREM decreases of relative 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucose
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 metabolism in sleep/wake-regulating regions including thalamus, upper brainstem, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 anterior cingulate, and limbic cortex in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients.</br>Self-reported and objective sleep disruptions are related to increased relative metabolism in these regions.</br>These findings are similar to regional activation patterns during sleep in an animal model of stress-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other studies using nuclear magnetic resonance spectroscopy have identified reduced 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gamma-aminobutyric acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GABA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
) signaling in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-regu-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 lating regions in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that correlate with objective measure of sleep continuity.</br>Studies examining task-related changes in blood flow using blood oxygenation level dependent functional magnetic resonance imaging (BOLD fMRI) paradigms have shown reduced activation relative to baseline levels in individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 when compared to normal sleeping controls.</br>Task-related activation changes in the direction of “normalization” following cognitive behavioral treatment. </br>Differential Diagnosis A chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that presents as difficulty initiating sleep should be differen- tiated from delayed sleep-wake phase disorder.</br>In the latter condition, sleep initiation is consistently later than desired because the individual’s endogenous circadian rhythm is delayed relative to the desired sleep schedule.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep-onset difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 persist, and sleep time is reduced whenever the individual chooses bedtimes and rising times that are too early and out of phase with the endogenous circadian rhythm.</br>However, patients with delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-wake phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are able to fall asleep with less difficulty, and sleep a normal amount of time, when sleeping in phase with their delayed endogenous rhythm by selecting late bed and rising times.</br>By comparison, those with a chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often feel sleepy at the desired bedtime but are unable to sleep regardless of the timing of their bed and rise times.</br>Furthermore, sleep problems tend to be more variable on a night-to-night basis in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Given the prevalence of delayed sleep- wake phase disorder in teenagers and young adults, it is particularly important to con- sider the possibility of this alternate or comorbid diagnosis when evaluating individuals from these age groups presenting with sleep onset 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 complaints. </br>A chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that presents as a difficulty maintaining sleep with pre- mature morning rise times also should be differentiated from advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-wake phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The latter tends to be more common in older adults than it is in younger adults and children.</br>Among those with an advanced sleep phase pattern, sleep initia- tion is consistently earlier than desired because the individual’s endogenous circadian rhythm is advanced relative to the desired sleep schedule.</br>However, total sleep time is adequate when the individual chooses early bed and rise times that coincide with the advanced endogenous circadian rhythm.</br>In contrast, those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dis- order may display 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep maintenance difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and early morning rise time regard- less of the sleep schedule they select. </br>36 There can be some overlap between chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and both delayed and advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-wake phase disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with a delayed sleep pattern may become chronically frustrated or anxious about their inability to initiate sleep at their desired times, and this frustration or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may continue to disrupt sleep and delay sleep onset well beyond the sleep onset time promoted by the endogenous rhythm.</br>Early morning awakenings may similarly have arousing sleep disruptive effects in the setting of an advanced sleep phase.</br>In such circumstances both a circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm sleep-wake disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis and a chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis may apply and should be assigned. </br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should also be discriminated from situational sleep dif- ficulties arising from sleep-disruptive environmental circumstances.</br>A variety of environmental factors including excessive noise or light and extreme temperatures will disrupt the sleep of most individuals.</br>Also, sleeping in an area where there is imminent threat or danger to one’s safety can also be 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disruptive to sleep.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>Bed part- ners who snore loudly, move excessively during sleep, or have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also disrupt one’s sleep.</br>When an individual reports environmental circumstances that would be regarded as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disruptive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to the sleep of most individuals, a chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should not be assigned.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 applies only when the individual reports sleep difficulty in the context of sleep-conducive envi- ronment circumstances or when the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms show some independence from the environmental factors.</br>When environmental circumstances are a primary cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and associated consequences, a diagnosis of other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be considered. </br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should also be differentiated from patterns of chronic voli- tional sleep restriction (insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Some individuals show excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and reduced sleep at night as a result of electing overly demanding daytime schedules or by volitionally delaying sleep in order to engage in desired recreational or social activities.</br>However, when allowing themselves suffi- cient time to sleep, they are able to initiate and maintain sleep easily and for a normal duration.</br>Those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tend to have excessive wake time and reduced sleep time despite routinely allotting sufficient time to sleep.</br>Moreover, chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not typically associated with excessive daytime sleepi- ness and unintentional daytime sleep episodes, which are often observed in those with patterns of volitional sleep restriction. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms may occur 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis would apply 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 only when: (1) the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms show some independence in their onset or variation over time from the other symptoms of the co-occurring 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; or (2) when 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms persist despite adequate treatment reflected by marked symptom improvement in the coincident 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis would not apply when effective treatment of the coincident 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 resolves the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms. </br>Among children, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present when the child has to sleep alone in a separate room, but absent when the child is allowed to sleep with parents or when a parent is present in the child’s bedroom.</br>An absence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 under the latter circumstances does not indicate the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is resolved.</br>Only when the child is able to sleep consistently independently is there no longer an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 problem.</br>In some children, the persistence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the absence of parents may reflect underlying conditions such as separation 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>In young children, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be the result of medical issues, including gas- troesophageal reflux, as well as developmental milestones, such as motoric, language, and cognitive development.</br>Children, adolescents, and adults may develop a chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 comorbid with a medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symp- toms may arise as a result of either another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a medical condition, or a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that has sleep-disruptive effects.</br>A chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis would apply when: (1) the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms show some independence in their onset or variation over time from the other symptoms of the co-occurring sleep, medical ,or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; or (2) when 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms persist despite ade- quate treatment reflected by marked symptom improvement in the coincident sleep, medical, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Because 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms often develop some independence over time, a chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis usually will be war- ranted when those symptoms are persistent in association with a chronic medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis would not apply when effective treatment of the coincident sleep, medical, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 resolves the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms. </br>Unresolved Issues and Further Directions Much remains to be learned about the underlying pathophysiological pathways leading to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and whether 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be classified as a unitary disorder or sub- divided into several subtypes.</br>Clearly, these issues are closely linked.</br>Further studies that clarify the pathophysiological pathways leading to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ultimately will reveal whether those meeting current criteria for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 suffer from a single disease or multiple separate diseases with similar outward presentations. </br>38 A related unresolved issue is whether the current global classification promotes a generic approach to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 therapy that ultimately fails to benefit some 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subgroups.</br>Perhaps this global classification scheme will overlook distinctive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtypes with specific treatment needs that vary from the generic treatments typically provided. </br>Previous editions of the International Classification of Sleep Disorders allowed for the assignment of an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis to patients who present exclusively with com- plaints of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonrestorative
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sleep; that is, patients who complain only of sleep that is poor in quality or unrefreshing, in the absence of sleep-onset or sleep maintenance complaints, could qualify for an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis in previous versions of this nosol- ogy.</br>The current version of this nosology excludes such patients from the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnostic categories.</br>This decision was based on several considerations.</br>Most insom- nia patients present with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of sleep initiation or maintenance difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although a small subset of patients present with isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of nonrestorative sleep
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, this complaint more commonly arises in association with other symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or in conjunction with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or certain chronic medical conditions (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibromyalgia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic fatigue syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Although various epidemiological studies have identified subgroups who are presumed to have an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and present solely with a complaint that their sleep is non- restorative or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    unrefreshing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such studies typically lack polysomnography that would be needed to rule out other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    occult sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a cause.</br>Finally, nonrestorative sleep remains a poorly defined construct that may reflect not only a type of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but also the daytime consequences of poor sleep such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anergia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>This con- struct would benefit from further definitional efforts and research to explore its clinical significance in the context of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Given these considerations, the isolated com- plaint of nonrestorative sleep was not retained as part of the diagnostic definition of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 delineated in this manual. </br>Bibliography Baglioni C, Battagliese G, Feige B, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a predictor of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a meta-analytic evaluation of longitudinal epidemiological studies.</br>J Affect Dis 2011;135;10–9. </br>Bastien CH, St-Jean G, Morin 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Turcotte I, Carrier J. Chronic psychophysiological 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: hyperarousal and/or inhibition deficits?</br>An ERPs investigation.</br>Sleep 2008;31:887–98. </br>Beaulieu-Bonneau S, LeBlanc M, Mérette C, Dauvilliers Y, Morin 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Family history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in a population-based sample.</br>Sleep 2007;30:1739–45. </br>Billows M, Gradisar M, Dohnt H, Johnston A, McCappin S, Hudson J. Family disorganization, sleep hygiene, and adolescent sleep disturbance.</br>J Clin Child Adolesc Psychol 2009;38:745–52. </br>Bonnet MH, Arand DL. 24-hour metabolic rate in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomniacs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and matched normal sleepers.</br>Sleep 1995;18:581–8. </br>39 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Insomnia Bonnet MH
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Arand DL.</br>Heart rate variability in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomniacs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and matched normal sleepers.</br>Psychosom Med 1998;60:610–5. </br>Bonnet MH, Arand DL.</br>Hyperarousal and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: State of the science.</br>Sleep Med Rev 2010;14:9–15. </br>Buysse DJ, Angst J, Gamma A, Ajdacic V, Eich D, Rössler 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    W.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Prevalence, course, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbidity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in young adults.</br>Sleep 2008;31:473–80. </br>Dohnt H, Gradisar M, Short MA.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and its symptoms in adolescents: comparing DSM-IV and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICSD-II
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnostic criteria.</br>J Clin Sleep Med 2012;8:295–9. </br>Edinger JD, Wyatt JK, Stepanski EJ, et al.</br>Testing the reliability and validity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSM-IV-TR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICSD-2 insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnoses: results of a multi-method/multi-trait analysis.</br>Arch Gen Psychiatry 2011;68:992–1002. </br>Krystal AD, Edinger JD, Wohlgemuth WK, Marsh 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Non-REM sleep EEG frequency spectral correlates of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtypes.</br>Sleep 2002;25:630–40. </br>Lack LC, Wright HR.</br>Treating chronobiological components of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Med 2007;8:637–44. </br>Lichstein KL.</br>Secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In: Lichstein KL, Morin 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, eds.</br>Treatment of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    late-life insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Thousand Oaks, CA: Sage, 2000:297–319. Mindell JA, Kuhn B, Lewin DS, Meltzer LJ, Sadeh A. Behavioral treatment of bedtime problems and night wakings in infants and young children.</br>Sleep 2006;29:1263–76. </br>Mindell 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    JA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Sadeh A, Wiegand B, How TH, Goh DY.</br>Cross-cultural differences in infant and toddler sleep.</br>Sleep Med 2010;11:274–80. </br>Morgenthaler TI, Owens J, Alessi C, et al.</br>Practice parameters for behavioral treatment of bedtime problems and night wakings in infants and young children.</br>Sleep 2006;29:1277–81. </br>Morin 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Bélanger L, LeBlanc M, et al.</br>The natural history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a population-based 3-year longitudinal study.</br>Arch Intern Med 2009;169:447–53. </br>Nofzinger EA.</br>Functional neuroimaging evidence for hyperarousal in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am J Psychiatry 2004;161:2126–31. </br>Nofzinger EA, Nissen C, Germain A, et al.</br>Regional cerebral metabolic correlates of WASO during sleep in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Clin Sleep Med 2006;2:316–22. </br>Ohayon MM.</br>Epidemiology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: what we know and what we still need to learn.</br>Sleep Med Rev 2002;6:97–111. </br>Ohayon MM, Caulet M, Lemoine P. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Comorbidity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of mental and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the general population.</br>Compr Psychiatry 1998;39:185–97. </br>Ohayon MM, Roberts RE.</br>Comparability of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnoses using DSM-IV and ICSD classifications with adolescents.</br>Sleep 2001;24:920–5. </br>Perlis ML, Smith MT, Andrew PJ, Orff H, Giles DE.</br>Beta/gamma EEG activity in patients with primary and secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and good sleeper controls.</br>Sleep 2001;24:110–7. </br>Riemann D, Voderholzer U, Spiegelhalder 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, et al.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and MRI-measured hippocampal volumes:</br>A pilot study.</br>Sleep 2007;30:955–8. </br>Riemann D, Spiegelhalder 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Feige B, et al.</br>The hyperarousal model of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: A review of the concept and its evidence.</br>Sleep Med Rev 2010;14:19–31. </br>Roberts RE, Roberts CR, Chan 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    W.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Persistence and change in symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 among adolescents.</br>Sleep 2008;31:177–84. </br>40 Sánchez-Ortuño MM, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Carney CE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Edinger JD, Wyatt JK, Harris A. Moving beyond average values: assessing the night-to-night instability of sleep and arousal in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSM-IV-TR insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtypes.</br>Sleep 2011;34:531–9. </br>Stepanski E, Zorick F, Roehrs T, Young D, Roth T. Daytime alertness in patients with chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 compared with asymptomatic control subjects.</br>Sleep 1988;11:54–60. </br>Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    A. Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with objective short sleep duration is associated with a high risk for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2009;32:491–7. </br>Winkelman JW, Buxton OM, Jensen JE, et al.</br>Reduced brain 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GABA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: preliminary data from 4T proton magnetic resonance spectroscopy (1H-MRS).</br>Sleep 2008;31:1499–506. </br>Winkelman JW, Benson KL, Buxton OM, et al.</br>Lack of hippocampal volume differences in primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and good sleeper controls: an MRI volumetric study at 3 Tesla.</br>Sleep Med 2010;11:576–82. </br>Zhang J, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Li
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 AM, Kong AP, Lai KY, Tang NL, Wing YK.</br>A community-based study of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in Hong Kong Chinese children: Prevalence, risk factors and familial aggregation.</br>Sleep Med 2009;10:1040–6. </br>Short-Term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Disorder ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 307.41 Alternate Names Acute 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, adjustment 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-E must be met ICD-10-CM code:</br>F51.02 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 A. The patient reports, or the patient’s parent or caregiver observes, one or more of the following:1 . Difficulty initiating sleep. </br>2. Difficulty maintaining sleep. </br>3. Waking up earlier than desired. </br>4.</br>Resistance to going to bed on appropriate schedule. </br>5.</br>Difficulty sleeping without parent or caregiver intervention. </br>B. The patient reports, or the patient’s parent or caregiver observes, one or more of the following related to the nighttime sleep difficulty: . Fatigue/malaise. </br>2. Attention, concentration, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    memory impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>3. Impaired social, family, vocational, or academic performance. </br>4. Mood disturbance/irritability. </br>5. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>6.</br>Behavioral problems (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    impulsivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aggression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>7. Reduced motivation/energy/initiative. </br>8.</br>Proneness for errors/accidents. </br>9.</br>Concerns about or dissatisfaction with sleep. </br>41 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 C. The reported 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep/wake complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cannot be explained purely by inadequate opportunity (i.e., enough time is allotted for sleep) or inadequate circumstances (i.e., the environment is safe, dark, quiet, and comfortable) for sleep. </br>D. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and associated daytime symptoms have been present for less than three months. </br>E. The sleep/wake difficulty is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Notes .</br>Reports of difficulties initiating 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep, difficulties maintaining sleep, or waking up too early can be seen in all age groups.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>Resistance going to bed on an appropriate schedule and difficulty sleeping without parent or caregiver intervention is seen most commonly in children and older adults who require the supervision of a caretaker due to a significant level of functional impairment (e.g., those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>2. Patients with short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may complain of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep/ wake difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 fewer than three times per week on average, yet have clinically significant concerns about their symptoms and warrant clinical attention. </br>3.</br>Many conditions such as grief, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    acute pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or other acute stressors are quite often associated with poor sleep.</br>When such conditions are the sole cause of the sleep difficulty, a separate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis may not apply.</br>The primary factor in determining application of a short- term or adjustment 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis is the extent to which the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 becomes a significant focus for the individual and/or warrants independent clinical attention. </br>Essential Features The essential feature of short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a short-term difficulty ini- tiating or maintaining sleep that results in general sleep dissatisfaction.</br>The sleep complaint is accompanied by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime distress
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 about poor sleep or impairment in family, social, occupational, academic, or other important areas of functioning.</br>Furthermore, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and associated daytime symptoms occur despite having adequate time and circumstances each night to obtain necessary sleep.</br>Short- term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur in isolation or comorbid with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical condition, or substance use.</br>In many cases of short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lasting less than three months, there is an identifiable cause that serves as the precipitant.</br>In other cases, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs episodically, often coincident to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime stressors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that account for the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>42 As is the case for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that compose short- term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may include difficulties initiating 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep or difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 main- taining sleep.</br>The latter complaint may include waking up during the night with difficulty returning to sleep or having a final awakening occurring too early, well before the desired rising time.</br>Short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be character- ized solely by sleep onset or sleep maintenance complaints or, more commonly, by both types of complaints occurring together.</br>Individuals’ sleep complaints may vary such that sleep onset difficulties are apparent on some nights, whereas 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep maintenance difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are present on other nights.</br>Complaints about poor-quality, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    unrefreshing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or nonrestorative sleep may accompany sleep onset and sleep mainte- nance complaints, but do not meet the definition of this condition when they occur in isolation. </br>Associated Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is the primary feature of short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but it is com- monly accompanied by waking symptoms similar to those seen in chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Specific symptoms such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, impaired attention and concentration, poor memory, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and distress about poor sleep are common.</br>When the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 arises in reaction to a stressful life event, such as the loss of a loved one, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    major illness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or divorce, the associated features may include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    worry
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, ruminative thoughts, sadness, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in relation to the specific stressor.</br>If the individual uses 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, illicit drugs, or medications for self-treatment, additional symptoms related to these substances may be seen. </br>Clinical and Pathophysiological Subtypes None. Demographics Short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur at any age.</br>However, a short-term form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be difficult to establish in infants because it is often difficult to link stressors to sleep disturbances in this age group.</br>The exact prevalence of short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is unknown.</br>The one-year prevalence of short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dis- order among adults appears to be in the range of 15% to 20%.</br>Like chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is more prevalent in women than in men, and in older age groups. </br>Predisposing and Precipitating Factors Affected individuals may note a lifelong tendency toward light sleep or diffi- culty sleeping during times of stress.</br>A previous history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive Insomnia Insomnia symptoms and disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also may predispose an individual to develop a short- term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In children, having a parent with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or living in a household lacking parental reinforcement of a consistent sleep/wake schedule may be predisposing factors. </br>An acute, identifiable event or stressor usually precipitates this form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Common precipitating events include changes or disputes in interpersonal relation- ships, occupational stress, personal losses, bereavement, diagnosis or onset of a new medical condition, visiting or moving to a new location, or physical changes to the usual sleep environment or schedule.</br>Changes or stresses with a positive emotional tone also may serve as precipitating events.</br>In children or dependent adults, such 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can arise when the caretaker makes abrupt changes in the child’s or adult’s sleep routines or schedule.</br>As is the case for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, environ- mental factors such as the child sharing a room with a parent or with other sib- lings, the presence of extended family or others in the home, and cramped living accommodations may contribute to negative sleep-onset associations or poor limit setting in children. </br>Familial Patterns Familial patterns are less well documented for cases of short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 disor- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    der
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 than they are for individuals meeting criteria for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Nonetheless, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial aggregation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 found for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is expected to also occur among individuals with more transient forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Data support a greater genetic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diathesis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to psychophysiologic arousal among certain individuals in response to stressors.</br>This may, in turn, suggest a constitutional predisposition to short- term or adjustment 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in such individuals. </br>Onset, Course, and Complications Many individuals who develop short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 experience remission of their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms over time.</br>This occurs as distress over the precipitating event diminishes over time or in response to withdrawal of the stressor.</br>However, a portion of those who initially experience short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may develop a more chronic form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and subsequently meet criteria for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dis- order.</br>These individuals will then have the course and complications described for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Developmental Issues As is the case for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 would not be considered until after a child reaches at least six months of age. </br>44 The propensity to experience 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in response to stress may dispose young and older individuals toward acute forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>As is the case for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep onset difficulties are most common among young adults with short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, whereas sleep maintenance complaints and early morning awakening are more common in middle-aged and older adults.</br>Objective 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is uncommon in younger adults with short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but is more common in older adults.</br>Balancing job and family stressors may contribute to intermittent short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 problems in younger and middle-aged adults.</br>In contrast, older, retired adults may have short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    exacerbations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in comorbid chronic medical con- ditions or due to loss of loved ones that commonly occurs with advancing age. </br>Pathology and Pathophysiology Research on the pathology and pathophysiology of short-term variants of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is generally lacking because the majority of studies addressing this issue have focused on samples with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic insomnia disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Differential Diagnosis Short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 shares many features with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The primary difference between the two conditions is that short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 disor- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    der
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 does not meet the duration and frequency criteria required for the chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis.</br>Short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also should be distinguished from circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm sleep-wake disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 resulting from rotating shift work or jet lag.</br>In the latter case, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 arises from a sleep-wake schedule alteration that results in a mismatch between the endogenous circadian rhythm and the sleep-wake schedule chosen—for example, having to sleep in the daytime rather than during the nighttime.</br>In the case of short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, no such mismatch exists; yet, the individual demonstrates sleep onset or maintenance difficulties nonetheless. </br>Bibliography Agnew HW Jr, Webb WB, Williams RL.</br>The first night effect: an EEG study of sleep.</br>Psychophysiology 1966;2:263–6. </br>Angst J, Vollrath M, Koch 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    R, Dobler-Mikola A.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 The Zurich Study.</br>VII.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: symptoms, classification and prevalence.</br>Eur Arch Psychiatry Clin Neurosci 1989;238:285–93. </br>Healey ES, Kales A, Monroe LJ, Bixler EO, Chamberlin 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Soldatos CR.</br>Onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: role of life- stress events.</br>Psychosom Med 1981;43:439–51. </br>Morin 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Rodrigue S, Ivers H. Role of stress, arousal and coping skills in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Psychosom Med 2003;65:259–67. </br>Roehrs T, Zorick F, Roth T. Transient and short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In: Krieger MH, Roth T, Dement WC, eds.</br>Principles and practice of sleep medicine, 3rd ed.</br>Philadelphia: WB Saunders, 2000:624–32. </br>Tachibana H, Izumi T, Honda S, Takemoto TI.</br>The prevalence and pattern of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in Japanese industrial workers: relationship between psychosocial stress and type of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Psychiatry Clin Neurosci 1998;52:397–402. </br>45 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Disorder ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 307.49 ICD-10-CM code: F51.09 This diagnosis is reserved for individuals who complain of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    difficulty
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 initiating and maintaining sleep and yet do not meet the full criteria for either chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dis- order or short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In some cases, this diagnosis may be assigned on a provisional basis when more information is needed to establish a diagnosis of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It is expected that this diag- nosis will be used sparingly, given its nonspecific nature. </br>46 Isolated Symptoms and Normal Variants Excessive Time in Bed </br>Some individuals may present with isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms such as prolonged sleep latencies or long periods of wakefulness during the night, yet not complain of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 nor show 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime impairments
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In children, this pattern may emerge when parents or caregivers have unrealistic expectations for the child’s sleep needs and rou- tinely allot too much time for the child to be in bed each night.</br>In adults, this pattern is perhaps most common in noncomplaining groups who routinely allot significantly more time in bed than needed for sleep.</br>For example, some individuals who are retired from work or not currently employed may routinely spend excessive time in bed each night and are not bothered by the expanded periods of wakefulness they routinely experience.</br>At present, epidemiological and laboratory studies are unable to ascertain whether adverse health outcomes are more strongly associated with perceived 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep difficulties/dissatisfaction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or with particular objective indices of sleep duration, sleep latency, and sleep continuity. </br>Short Sleeper Some individuals routinely obtain less than six hours of sleep per night on average yet have no sleep/wake complaints.</br>Such individuals are considered to be normal short sleepers if they have no 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of sleep difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and show no obvious 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Among these individuals, the observed relatively low average sleep time does not result from chronic volitional sleep restriction, as in the case of insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but rather indicates a constitutional disposition for reduced sleep requirement.</br>The clinical significance of chronic short sleep duration, and the identifi- cation of possible subtypes, remain open questions.</br>Various studies have linked short sleep duration with metabolic, cardiovascular, and other forms of medical morbidity.</br>However, these studies are typically unable to distinguish between individuals who have short sleep in the context of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, those who are voluntarily restricting their sleep, and those who may have naturally short sleep.</br>Short sleep resulting from different causes may have different pathophysiological signifi- cance.</br>At present, those who demonstrate less than six hours of sleep per night should not be assigned an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis unless they also meet the criteria for one of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtypes described herein. </br>47 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Bibliography Fernandez-Mendoza J, Calhoun S, Bixler EO, Pejovic S, Karataraki M, Liao D. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with objective short sleep duration is associated with deficits in neuropsychological performance: a general population study.</br>Sleep 2010;33:459–65. </br>Hartmann E. Sleep requirement: long sleepers, short sleepers, variable sleepers, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomniacs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Psychosomatics 1973;14:95–103. </br>Ohayon MM, Caulet M, Guilleminault C. How a general population perceives its sleep and how this relates to the complaint of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 1997;20:715–23. </br>Roehrs T, Zorick F, Roth T. Transient and short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In: Krieger MH, Roth T, Dement WC, eds.</br>Principles and practice of sleep medicine, 3rd ed.</br>Philadelphia: WB Saunders, 2000:624–32. </br>Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    A. Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with objective short sleep duration is associated with a high risk for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2009;32:491–7. </br>Webb WB, Friel J. Characteristics of “natural” long and short sleepers: a preliminary report.</br>Psychol Rep 1970;27:63–6. </br>48 Sleep Related Breathing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Disorders Obstructive Sleep Apnea Disorders Obstructive Sleep Apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Adult....................................................................53 Obstructive Sleep Apnea, Pediatric..............................................................63 Central Sleep Apnea Syndromes Central Sleep Apnea with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Breathing ...................................69 Central Apnea Due to a Medical Disorder without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Breathing.............................................................................75 Central Sleep Apnea Due to High Altitude Periodic Breathing .....................79 Central Sleep Apnea Due to a Medication or Substance .............................85 Primary Central Sleep Apnea .......................................................................</br>89 Primary Central Sleep Apnea of Infancy.......................................................94 Primary Central Sleep Apnea of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
................................................98 Treatment-Emergent Central Sleep Apnea ................................................</br>102 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation Disorders Obesity Hypoventilation Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ............................................................108 Congenital 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Central Alveolar Hypoventilation Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 .............................</br>113 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Late-Onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with Hypothalamic Dysfunction.......... 118 Idiopathic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Central Alveolar Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ................................................121 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance ............124 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder.........................</br>128 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Disorder Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
..........................................................................134 Isolated Symptoms and Normal Variants 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 .......................................................................................................139 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 .................................................................................................141 The sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are characterized by abnormalities of respi- ration during sleep.</br>In some of these disorders, respiration is also abnormal during wakefulness.</br>The disorders are grouped into obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) disorders, central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, many patients will meet diagnostic criteria for more than one of these groups.</br>In particular, many patients have a combination of obstruc- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although a diagnosis is often based on which disorder Sleep Related Breathing Disorders predominates, this may vary from night to night as well as over time in individual patients.</br>There is also overlap in pathophysiology, as some central apneas are associ- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ated
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 with a closed upper airway and many obstructive apneas begin during a time of falling ventilatory drive. </br>In the sections that follow, individual respiratory events (e.g., apneas, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) are not defined; rather, reference is made to the most recent version of the American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events for these definitions.</br>The AASM Manual for the Scoring of Sleep and Associated Events includes different scoring rules for adult and pediatric individuals, definitions of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and central apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and rules for scoring 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 breathing and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are separated into adult and pediatric categories, as the presenta- tion, diagnostic criteria, course, and complications differ significantly.</br>These disorders are characterized by upper airway narrowing or closure during sleep while respiratory effort continues (at least during some portion of the event).</br>The use of out-of-cen- ter sleep testing (OCST) with limited channels (electroencephalogram [EEG] is not usually recorded) is now included in the diagnostic criteria for adult 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>The central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea syndromes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are characterized by reduction or cessation of airflow due to absent or reduced respiratory effort.</br>Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur in a cyclical or intermittent fashion.</br>Patients with central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of various etiologies may also exhibit 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>In primary central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the cause of the disorder is unknown (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>The arterial partial pressure of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carbon dioxide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (PaCO2) during wake in these patients is normal or low.</br>Patients do not meet diagnostic criteria for other central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dis- orders.</br>In central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 breathing, there is a cyclical pattern of crescendo-decrescendo respiration separated by central apneas or central hypopneas.</br>Most patients with this disorder have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (reduced or preserved ejection fraction), although, less commonly, others exhibit this breathing pattern fol- lowing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or in association with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In high-altitude peri- odic breathing, the disorder is associated with acute ascent to high altitude.</br>Symptoms must be present to establish the diagnosis of high-altitude periodic breathing, as this breathing pattern is an expected finding after ascent to altitude.</br>Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to medical or neurological condition (not 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is usually due to a struc- tural lesion in the central nervous system.</br>These disorders should be excluded before a diagnosis of primary central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is made.</br>In central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to drug or substance, the patient demonstrates central apneas secondary to the effects of potent opioids or other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory depressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on respiratory control centers. </br>Treatment-emergent central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a new addition to the International Classification of Sleep Disorders.</br>In this disorder, the patient exhibits 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    predominantly obstructive events during
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnostic sleep testing (e.g., obstructive or mixed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and obstructive hypopneas), but central apneas or central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 emerge or persist on positive airway pressure treatment without a backup rate and are the predominant residual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing abnormality
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (i.e., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events have resolved).</br>A diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    treatment-emergent central sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is made when the central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 component is not better explained by another diagnosis (i.e., another central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are characterized by an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal increase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the arterial PCO2 (PaCO2) during sleep.</br>Adult and pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are defined by different criteria.</br>For adults, an increase in the arterial PCO2 (or sur- rogate) to greater than 55 mm Hg for at least 10 minutes or an increase ≥ 10 mm</br>Hg above the awake value to a value of 50 mm Hg or greater for at least 10 minutes is required.</br>In pediatric patients, the PaCO2 (or surrogate) must be greater than 50 mm Hg for greater than 25% of total sleep time. </br>In this edition of the International Classification of Sleep Disorders, there are a number of changes in the classification of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is listed as a separate disorder given that it is both prevalent and has distinct clinical characteristics.</br>In contrast to other sleep related hypoventila- tion disorders, a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 requires documenta- tion of awake (daytime) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (PaCO2 &gt; 45 mm Hg).</br>For the other disorders in this category, awake 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may or may not be present. </br>In the previous version of the International Classification of Sleep Disorders, a group of disorders were listed under the category of sleep related hypoventilation/hypoxemia disorders.</br>In the International Classification of Sleep Disorders, 3rd Edition, disorders manifesting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are separated from disorders in which only a finding of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation) during sleep is documented.</br>Demonstrating sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 rather than simply 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has important diagnostic and treatment consequences.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are characterized by sustained periods of significantly reduced oxyhemoglobin saturation during sleep.</br>This diagnostic category is used when sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is either not present or the status is unknown.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, ven- tilation-perfusion mismatch, low partial pressure of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, shunt, or a combination of Sleep Related Breathing Disorders Sleep Related Breathing Disorders these factors.</br>Many diverse etiologies can be associated with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>There are no longer separate diagnostic categories for the various types of medical and neurological pathology that may contribute to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In the International Classification of Sleep Disorders, 2nd Edition, these included lower 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, pulmonary parenchymal and vascular pathology, and neuromus- cular and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In the International Classification of Sleep Disorders, 3rd Edition, the specific pulmonary or neurological disorder should be diagnosed 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sep-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 arately, in association with a diagnosis of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due medical or neurological condition or sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Bibliography Badr MS, Toiber F, Skatrud JB, Dempsey J. Pharyngeal narrowing/occlusion during central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Appl Physiol 1995;78:1806–15. </br>Berry RB, Brooks R, Gamaldo CE, Harding SM, Lloyd RM, Marcus CL and Vaughn BV for the American Academy of Sleep Medicine.</br>The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.0.3. www.aasmnet.org.</br>Darien, IL: American Academy of Sleep Medicine, 2014 Tkacova R, Niroumand M, Lorenzi-Filho G, Bradley TD.</br>Overnight shift from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to central apneas in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: role of PCO2 and circulatory delay.</br>Circulation 2001;103:238–43. </br>Tkacova R, Wang H, Bradley TD.</br>Night-to-night alterations in sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Sleep Res 2006;15:321–8. </br>52 Obstructive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Apnea Disorders Obstructive Sleep Apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Adult ICD-9-CM code: 327.23 ICD-10-CM code: G47.33 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep disor- dered breathing, obstructive sleep apnea hypopnea syndrome. </br>The term upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway resistance syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    UARS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is subsumed under this diagnosis because the pathophysiology does not significantly differ from that of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Use of the term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pickwickian syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is discouraged because not only has it been applied to those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but also indiscriminately used to describe persons who are only obese and those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria (A and B) or C satisfy the criteria A.</br>The presence of one or more of the following: .</br>The patient complains of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, nonrestorative sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms. </br>2. The patient wakes with breath holding, gasping, or choking. </br>3. The bed partner or other observer reports habitual snoring, breathing interruptions, or both during the patient’s sleep. </br>4. The patient has been diagnosed with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cognitive dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrial fibrillation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or type 2 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>B. Polysomnography (PSG) or OCST1 demonstrates: .</br>Five or more predominantly obstructive respiratory events2 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and mixed apneas, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or respiratory effort related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 [RERAs])3 per hour of sleep during a PSG or per hour of monitoring (OCST).1 OR C. PSG or OCST1 demonstrates: .</br>Fifteen or more predominantly obstructive respiratory events (apneas, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or RERAs)3 per hour of sleep during a PSG or per hour of monitoring (OCST).1 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Notes .</br>OCST commonly underestimates the number of obstructive respiratory events per hour as compared to PSG because actual sleep time, as determined primarily by EEG, is often not recorded.</br>The term respiratory event index (REI) may be used to denote event frequency based on monitoring time rather than total sleep time. </br>2. Respiratory events defined according the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events. </br>3. RERAs and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events based on 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from sleep cannot be scored using OCST because 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by EEG criteria cannot be identified. </br>Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by repetitive episodes of complete (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) or partial (hypopnea) upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurring during sleep.</br>These events often result in reduc- tions in blood 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation and are usually terminated by brief 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from sleep.</br>By definition, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events last a minimum of 10 seconds.</br>Most events are 10 to 30 seconds in duration but occasionally persist for one minute or longer.</br>Events can occur in any stage of sleep but more frequently occur in stages N1, N2, and R sleep than in stage N3 sleep.</br>Events are usually longer and associated with more severe decreases in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation when they occur in stage R sleep and when the individual is sleeping supine.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation usually returns to baseline values following resumption of normal breathing but may remain low if the apneic or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events are very frequent and prolonged, or if there is underlying pulmonary pathology.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is typically reported by bed partners, as are wit- nessed episodes of gasping or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    choking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and body movements that disrupt sleep.</br>Most patients awaken in the morning feeling tired and unrefreshed regardless of the duration of their time in bed.</br>Apneas, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be exacerbated following the ingestion of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, use of sedating medications prior to sleep, or following an increase in body weight. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a major presenting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaint
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in many but not all cases.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is most evident during relaxing or inactive situations.</br>With extreme sleepi- ness, sleep may occur while actively conversing, eating, walking, or driving.</br>In women, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a less prominent complaint.</br>Additionally, reports of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, poor sleep quality, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are common, particularly among women.</br>Quality of life generally is adversely affected by unrefreshing sleep, sleepiness, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Bed part- ners may also report sleep disruption and associated consequences.</br>The frequency of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep correlates poorly with daytime symptom severity and impact on quality of life.</br>In some cases, affected individuals will not endorse any symptoms or confirm any bed partner observations. </br>Associated Features Systemic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a common finding in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>There is substan- tial clinical and epidemiologic evidence implicating 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a significant risk factor for development of systemic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 independent of other conditions such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and smoking.</br>Additionally, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is frequently observed in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor- onary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrial fibrillation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and it may be an independent risk factor for these conditions.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is also associated with type 2 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and there are accumulating data to suggest that it is a risk factor for the development of type 2 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with severe disease may be at risk for developing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmo-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 nary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, although this is usually seen only in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to comorbid conditions such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morbid obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    COPD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>When 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 coexists with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dilated cardiomyopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemic heart disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, there may be worsening of the underly- ing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and predisposition to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Gastroesophageal reflux symptoms, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erectile dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are some- times reported in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The disorder can also be associated with the following motor 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: OSA-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from non-rapid eye movement (NREM) sleep mimicking a primary disorder of arousal (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 arousal, sleep- walking, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
); OSA-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from REM sleep mimicking REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; disorders of arousal from NREM associated with slow wave sleep rebound during initiation of nasal continuous positive airway pressure (CPAP) therapy of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; OSA-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 linked with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep related eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; and OSA-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebral anoxic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 attacks with prominent motor activity. </br>Severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as determined by the frequency of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or degree of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation correlates poorly with symptomatic sleepiness.</br>Different measures of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including self-reported severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, commonly used indices such as the Epworth Sleepiness Scale, and objective measures such as the Multiple Sleep Latency Test (MSLT), are not strongly correlated and, thus, assessment of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be difficult and relatively unreliable.</br>In addition, patients may adapt to any level of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 over time and fail to view it as a reportable problem.</br>Bed partner-observed breathing pauses and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disruptive snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may not always be accompa- nied by patient complaints of sleepiness.</br>Finally, it is important to note that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a condition with a number of possible 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    etiologies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and a range of manifestations (see Differential Diagnosis). </br>55 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Clinical and Pathophysiological Subtypes Apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are believed to have similar pathophysiology and consequences.</br>Therefore, from a clinical perspective, there is little importance in distinguishing patients who have predominantly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from those who have predominantly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Occasionally, patients may demonstrate only 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    REM-related apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but there is no consensus to suggest that this is a distinct clinical or pathophysiological subtype. </br>Some patients have relatively few arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturations but a significant number of respiratory events characterized by narrowing of the upper airway result- ing in brief 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from sleep.</br>Depending on the definition of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 employed, these events typically meet criteria for either 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with arousal but no desaturation, or for RERAs.</br>When initially described, this latter group was said to have UARS.</br>Current data suggest that this condition represents simply a variant of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in which 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events result in arousal but minimal arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation.</br>Patients with this condition commonly snore and report 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, there are some reports of patients with frequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the absence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>They tend to be less obese than individuals who have respiratory event-associated arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation.</br>The prevalence of this group of patients is unknown.</br>When advanced technology is used to detect changes in airflow (as described in the AASM Manual for the Scoring of Sleep and Associated Events), most of these patients will be diagnosed as having 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as defined by the criteria listed above. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    COPD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 frequently coexist, but there is no common pathophysiologic rela- tionship.</br>Nevertheless, individuals with both disorders have greater nocturnal 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation and daytime 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for the same degree of bronchial airflow obstruc- tion, and greater risk of developing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and right heart failure.</br>The prevalence rate for having both conditions has been estimated to be 1%. </br>Demographics 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur in any age group.</br>Estimates of prevalence are very dependent on how sleep related respiratory events are defined, as well as their frequency and other criteria used to define disease.</br>Nevertheless, general population-based studies from a number of countries indicate that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs in 3% to 7% of adult men and 2% to 5% of adult women.</br>However, because many individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 do not endorse 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the prevalence of the disease is likely much higher.</br>A major study yielded prevalence rates as high as 24% in men and 9% in women using only an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea-hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 index (AHI) criterion of ≥ 5/hour, although addition of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 criterion reduced these estimates to 4% in males and 2% in females. </br>56 The prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 increases with age, although it appears to plateau in the elderly.</br>The ratio of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in men compared to women is approximately two to one.</br>This dispar- ity may decline in middle to older age as a result of a greater risk for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in women after menopause. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs in all racial and ethnic groups.</br>In younger and elderly groups, but not in middle-aged groups, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been reported to be more prevalent in blacks than whites.</br>The prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in Asian patients is comparable to that of whites, despite having a generally lower body mass index (BMI).</br>Differences in craniofacial features that predispose Asians to developing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are the likely explanation.</br>Data comparing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 prevalence rates among Hispanics and Native Americans to other racial/ethnic groups are sparse, although it is clear that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs commonly in these groups. </br>Predisposing and Precipitating Factors The major predisposing factor for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is excess body weight.</br>It has been estimated that ~60% of moderate to severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is attributable to obesity.</br>The risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 increases as the degree of additional weight increases, with an extremely high preva- lence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in people with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morbid obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with normal or below-nor- mal body weight are more likely to have upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a localized structural abnormality such as a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    maxillomandibular malformation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or adenotonsillar enlargement.</br>Increasing neck circumference predicts higher AHIs; it is not, however, independent of BMI.</br>Instability in ventilatory control appears to increase risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Those patients with an exaggerated ventilatory response to a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have a greater propensity for obstructive events.</br>Menopause is a risk factor for this disorder in women, even after adjustment for age and BMI.</br>However, use of hormone replacement therapy may be protective.</br>There are conflicting data concerning smoking as a risk factor for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Various abnormalities of the bony and soft tissue structures of the head and neck may predispose the individual to having 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>These may be 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hereditary
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., mandibular size, mandibular position, palatal height) or acquired (e.g., enlarged adenoids and tonsils).</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Endocrine disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    acromegaly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and hypothy- roidism are risk factors for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Adults and children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Down syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also have a high prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is common in patients with some 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that affect peripheral muscles, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myotonic dystrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is likely made worse following 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 consumption or use of sedating medications before sleep and by nocturnal nasal restriction or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to abnormal morphology, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhinitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or both. </br>Familial Patterns 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a heritable condition as demonstrated by familial clustering of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients.</br>First-degree relatives of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients are twice as likely to have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in comparison Sleep Related Breathing Disorders Sleep Related Breathing Disorders to those not affected.</br>Clustering of symptoms that are associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and snorting or gasping also occurs.</br>Heritability explains approximately one third of the variation in the AHI, with a substantial proportion of the heritability explained by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other inherited traits that might predispose an indi- vidual to developing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include craniofacial morphology and ventilatory control.</br>Familial environmental factors such as physical activity and eating habits may play a role as well.</br>Nevertheless, genetic studies to date have not identified a unique gene or genes responsible for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 heritability. </br>Onset, Course, and Complications As documented in longitudinal population studies, the severity of untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 mea- sured by the AHI tends to slowly progress over time.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 becomes more severe in patients whose BMI increases, but may improve with weight reduction.</br>However, the effect of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight gain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on increasing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 severity is greater than the impact of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on decreasing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 severity.</br>Moreover, the consequences of weight change are more evident in men than women. </br>Substantial evidence implicates 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a risk factor for incident systemic hyper- tension, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and premature mortality.</br>Data suggest that these effects are more evident in men and middle-aged individuals.</br>In addition, there is accumulating evidence to suggest that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a risk factor for the development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    type 2 diabetes mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 independent of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Various 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are commonly observed in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Evidence suggests that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is particularly related to the onset and recurrence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrial fibrillation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may increase the severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Because of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, func- tional impairment occurs commonly as manifested by poor job performance, loss of employment, impaired family relationships, and reduction in overall quality of life.</br>The risk of motor vehicle 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    accidents
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is significantly increased among those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Developmental Issues 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur in any age group, but in adults, prevalence accelerates between young adulthood and middle age, with a plateau reached after approximately age 65 years.</br>Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs in the elderly, it is commonly observed with few symptoms.</br>In addition, some evidence suggests that risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be less important in the elderly.</br>This has raised the possibility that its presence in this age group represents a distinct clinical variant.</br>Pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is discussed in a separate section (below). </br>58 Pathology and Pathophysiology The pathophysiology underlying upper airway narrowing during sleep is multifactorial.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 commonly have reduced cross-sectional area of the upper airway lumen due to either excessive bulk of soft tissues (tongue, soft 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    palate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and lateral pha- ryngeal walls) or craniofacial anatomy, or both.</br>During inspiration, negative pressure is generated in the lumen of the upper airway, promoting closure.</br>However, pharyngeal dilating muscles act to maintain patency.</br>The activity of these muscles decreases with sleep onset, but is normally adequate to maintain an open airway.</br>In persons with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the activity of the pharyngeal dilating muscles becomes insufficient to prevent narrow- ing and/or closure of the upper airway.</br>This state-dependent change is the major con- tributing factor leading to an obstructed upper airway.</br>There is a further reduction in tone and phasic activity of pharyngeal dilating muscles during REM sleep, particularly in phasic REM, which likely contributes to apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that are longer and more pronounced.</br>Decreased end-expiratory lung volume and falling ventilatory drive associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also predispose to upper airway narrowing or closure.</br>In the breaths leading up to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, end-expiratory upper airway caliber pro-</br>gressively decreases.</br>Smaller end-expiratory lung volume may result in smaller upper airway size due to decreased downward traction (tracheal tug).</br>Some patients have unstable ventilatory control (high 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    loop gain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) with resulting periods of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that may also contribute to upper airway narrowing. </br>The mechanisms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea/hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 termination are controversial.</br>Event termination may occur with or without an associated arousal.</br>Some events may resolve with aug- mentation of upper airway muscle tone from chemical (low PaO2, high PaCO2) and mechanical (upper airway mechanoreceptors) stimuli, whereas others may depend on a change of sleep state (arousal) at either a cortical or subcortical level.</br>Cortical arous- als are associated with changes detectable by EEG, whereas other changes of state may be detectable only by direct or indirect measures of sympathetic tone.</br>Even if 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not required for termination of all 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events, sleep fragmentation from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is nevertheless believed to be a significant cause of excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 typically last considerably longer in REM and, in some patients, are only present in this sleep stage.</br>The explanation for this finding is unknown. </br>As an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 event progresses, the patient gradually becomes more hypox- emic; the degree of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation is dependent not only on the duration of the event, but also on the patient’s baseline 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation and lung volume and the presence of comorbid lung conditions.</br>Slight 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercarbia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also occurs during apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and is worse during REM sleep. </br>59 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Accumulating evidence indicates that persons with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have elevated levels of circu- lating inflammatory mediators related to repetitive episodes of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation and increased sympathetic nervous system activity.</br>Both of these findings may be import- ant in the pathogenesis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Objective Findings Obstructive apneas are documented by a cessation of airflow with ongoing respiratory efforts during PSG or an OCST.</br>When breathing effort is recorded with respiratory inductance plethysmography, it typically shows paradoxical movement of the rib cage and abdomen.</br>If esophageal manometry is used, increasingly large swings between inspiratory and expiratory efforts are observed.</br>Obstructive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are a reduction rather than a cessation of airflow with ongoing respiratory effort.</br>Increasing respira- tory effort with constant or reduced flow is indicative of increased upper airway resis- tance.</br>This state is most accurately identified with a quantitative measurement of flow and esophageal manometry, although it can be inferred when there is obvious inspira- tory airflow limitation (flattening of the inspiratory flow) on a nasal pressure recording.</br>Although patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have predominantly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events, they may also have variable amounts of central apneas.</br>In some patients, these resolve with admin- istration of positive airway pressure, whereas in others frequent central apneas either persist or emerge, at least during the initial night of positive airway pressure treatment. </br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation typically declines for a variable period of time following the onset of an event (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), with the nadir usually occurring after normal breath- ing resumes.</br>The degree of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation may range from as little as 1% to 2%, up to 30% to 40% or greater.</br>If the baseline 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation is normal, there may be no discernible drop in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation despite evidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airflow limitation fol-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lowed by arousal.</br>As a result, some events associated with evidence of increased respi- ratory effort (and/or flattening of inspiratory flow) and an arousal at event termination may not meet diagnostic criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>These events are defined as RERAs.</br>These events are presumed to have the same underlying pathophysiology as obstructive apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) and are considered to be as much of a risk factor for symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    unrefreshing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime somnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as frank 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>The EEG may provide evidence of a brief arousal from sleep, and the submental electro- myogram may demonstrate a burst of activity indicating upper airway dilating muscle activation immediately preceding the resumption of normal breathing.</br>Microphones may record a sudden resumption of loud snoring.</br>Obstructive apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be accompanied by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bradyarrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachyarrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or both; however, the prevalence of this finding in patients varies widely.</br>At the time of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, there is often a surge in both sympathetic nervous system activity and systemic blood pressure. </br>Differential Diagnosis In contrast to patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, those with isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will not exhibit obstruc- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tive apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or RERAs on PSG or OCST and do not have other sleep symp- toms attributable to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, because arousal-based 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and RERAs cannot be identified with OCST, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cannot be excluded if the OCST is negative. </br>Patients with central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have predominantly central rather than obstruc- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tive apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or RERAs as the primary finding on PSG or OCST.</br>If mixed apneas are predominant, a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be made. </br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will demonstrate daytime 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercap-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 nia.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may not be a prominent feature, although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur.</br>Patients with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may show episodes of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation without evidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airflow obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on PSG or OCST.</br>Confirmation of nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will be diagnostic.</br>However, if 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or hypo- pneas are evident, a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be made instead of, or in addition to, the diagnosis of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 must be differentiated from other causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idio- pathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and insufficient sleep.</br>These conditions often can be identified on the basis of history, but PSG and/or MSLT may be required to confirm the diagnosis. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be distinguished from other causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as noc- turnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    panic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 attacks, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    asthma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, paroxysmal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal angina pectoris
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In many cases, absence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will be highly suggestive of etiologies other than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, the absence of obstructive apneas, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or RERAs on PSG will definitively exclude 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as the diagnosis. </br>Unresolved Issues and Further Directions </br>Although substantial evidence implicates 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a risk factor for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, it has not been clearly demonstrated that treatment mitigates this risk.</br>This is especially a concern for patients with mild 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 who are not hypersom- nolent.</br>The pathophysiologic mechanisms linking 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to increased risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 require further investigation.</br>Although there Sleep Related Breathing Disorders Sleep Related Breathing Disorders is a clear association between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and type 2 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, further studies are needed to determine whether 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is an independent risk factor and what mechanisms are involved. </br>Bibliography Berry RB, Brooks R, Gamaldo CE, Harding SM, Lloyd RM, Marcus CL and Vaughn BV for the American Academy of Sleep Medicine.</br>The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.0.3. www.aasmnet.org.</br>Darien, IL: American Academy of Sleep Medicine, 2014 Berry RB.</br>Dreaming about an open upper airway.</br>Sleep 2006;29:429–30. </br>Budhiraja R, Budhiraja P, Quan SF.</br>Sleep-disordered breathing and cardiovascular disorders.</br>Respir Care 2010;55:1322–32. </br>Iber C, Ancoli-Israel S, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chesson
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 AL, Quan SF; for the American Academy of Sleep Medicine.</br>The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications.</br>1st ed.</br>Westchester, IL: American Academy of Sleep Medicine, 2007. </br>Pamidi S, Aronsohn 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Tasali 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    E. Obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: role in the risk and severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Best Pract Res Clin Endocrinol Metab 2010;24:703–15. </br>Patel SR, Larkin EK, Redline S. Shared genetic basis for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and adiposity measures.</br>Int J Obes (Lond) 2008;32:795–800. </br>Pepin JL, Guillot M, Tamisier R, Levy P.</br>The upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway resistance syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Respiration 2012;83:559–66. </br>Peppard PE, Taheri S. Excess weight and sleep-disordered breathing.</br>J Appl Physiol 2005;99:1592–9. </br>Punjabi NM.</br>The epidemiology of adult 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Proc Am Thorac Soc 2008;5:136–43. </br>White DP.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Proc Am Thorac Soc 2006;3:124–8. </br>Younes M. Role of arousal in the pathogenesis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am J Respir Crit Care Med 2004;169:623–33. </br>Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S.</br>The occurrence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 among middle-aged adults.</br>N Engl J Med 1993;328:1230–5. </br>Young T, Peppard PE, Gottlieb DJ.</br>Epidemiology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a population health perspective.</br>Am J Respir Crit Care Med 2002;165:1217–39. </br>62 Obstructive Sleep Apnea, Pediatric ICD-9-CM code: 327.23 ICD-10-CM code: G47.33 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obstructive sleep apnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep hypopnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, obstructive hypoventila- tion, and upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>The term upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway resistance syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    UARS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is subsumed under this diagnosis because the pathophysiology does not significantly differ from that of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Use of the term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pickwickian syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is discouraged, as this term has been used loosely to cover a constellation of conditions including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A and B must be met A.</br>The presence of one or more of the following: .</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>2. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Labored
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, paradoxical, or obstructed breathing during the child’s sleep. </br>3. Sleepiness, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, behavioral problems, or learning problems. </br>B. PSG demonstrates one or both of the following: .</br>One or more obstructive apneas, mixed apneas, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, per hour of sleep.1 OR .</br>A pattern of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, defined as at least 25% of total sleep time with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (PaCO2 &gt;</br>50 mm Hg) in association with one or more of the following: </br>a. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>b. Flattening of the inspiratory nasal pressure waveform.</br>c. Paradoxical thoracoabdominal motion. </br>Notes .</br>Respiratory events defined according to the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events. </br>Essential Features Pediatric criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 apply to patients younger than 18 years.</br>However, for the purpose of PSG scoring, the AASM Manual for the Scoring of Sleep and Associated Events states that adult diagnostic criteria may be used for patients aged 13 to 18 years. </br>Sleep Related Breathing Disorders Sleep Related Breathing Disorders Pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by intermittent complete or partial obstruction (obstruc- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
); prolonged partial upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; or both prolonged and intermittent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that disrupt normal ventilation during sleep, normal sleep patterns, or both.</br>Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may demonstrate several breathing patterns during sleep.</br>Some children have cyclic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    episodes of obstructive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, similar to that of adults with the syndrome.</br>However, some patients, particularly younger children, have a pattern of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which consists of long periods of persistent partial upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desatu- ration, or both.</br>Some children may manifest a pattern of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    UARS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 similar to that seen in adults, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without identifiable 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airflow obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and increasingly negative esophageal pressure swings and cyclic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In children, upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs predominantly during REM sleep.</br>Children often do not have cor- tical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in response to the upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, although they may have movement or autonomic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Perhaps as a result of this higher arousal threshold, sleep architecture is usually normal, with normal amounts of slow wave sleep.</br>Even short obstructive apneas may be associated with severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 because children have a lower functional residual capacity and a higher metabolic rate than adults. </br>Most children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 present with a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and difficulty breathing during sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is usually loud and may be punctuated by pauses and gasps, with associated movements or arousal from sleep.</br>However, some patients, particu- larly infants and those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, may not snore.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often have continuous 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without pauses or arous- als.</br>Children have a very compliant rib cage.</br>As a result, paradoxical breathing is a prominent sign in these patients (note that paradoxical breathing during REM sleep is a normal phenomenon in young children up to at least age three years).</br>A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pectus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 excavatum may be present.</br>Thoracic retractions may be present.</br>Children may sleep in unusual positions, such as seated or with their neck hyperextended.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Diaphoresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be observed.</br>Morning 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also occur.</br>Many parents of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are so concerned about their child’s breathing that they sleep with their child or stimu- late their child to terminate the apneas. </br>Excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present, especially in older children and adoles- cents, but is seen less commonly in children than in adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Developmental, behavioral, and learning issues are frequently present.</br>These may include attention problems, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    moodiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and impaired academic performance. </br>64 Associated Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are often present during sleep and may be severe.</br>A prom- inent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sinus arrhythmia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is often seen, although other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are rare.</br>Secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur.</br>Breathing during wakefulness is normal, although mouth breath- ing secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adenoidal hypertrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present.</br>Other nonspecific daytime symptoms related to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adenotonsillar hypertrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as frequent upper respiratory tract 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphagia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, may occur.</br>Although studies have shown that children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 generally have larger tonsils and adenoidal tissue than do other children, the size of the tonsils and adenoidal tissue does not predict disease in individual patients. </br>Clinical and Pathophysiological Subtypes Clinical presentations include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and recurrent arousal associated with increased respiratory effort (RERAs). </br>Demographics The prevalence in children has been estimated at 1% to 4%, but the prevalence may currently be higher due to the pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 epidemic.</br>The prevalence in infants and adolescents is unknown.</br>In prepubertal children, the disease occurs equally among boys and girls; in adolescents, data suggest the prevalence may be higher in males.</br>There appears to be a higher prevalence in black children than white children; the prev- alence in other ethnic groups is unknown.</br>The disease can occur at any age, from the neonatal period to adolescence, but in otherwise healthy children it is most common in the preschool age (in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adenotonsillar hypertrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) and in adolescents (in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Predisposing and Precipitating Factors 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Adenotonsillar hypertrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are the most common predisposing/precip- itating factors.</br>Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    craniofacial abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    micrognathia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or midfacial hypoplasia, are at risk.</br>Those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Down syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are particularly at risk for having 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often have upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway muscle weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which predisposes to airway collapse.</br>Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebral palsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be predisposed to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 because of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    spasticity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    incoordination
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the upper airway muscles.</br>Infants with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may develop 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other medical conditions such as mucopoly- saccharidosis and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sickle cell disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may predispose to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Pharyngeal flap oper- ations, typically performed to improve speech quality in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cleft palate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, can result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Environmental tobacco 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    smoke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 exposure has been associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>65 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Familial Patterns There is evidence for an increased risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children with affected family members.</br>Potential mechanisms for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial aggregation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include heritability of pre- disposing skeletal, soft tissue, body habitus, or respiratory control characteristics.</br>However, the relative roles of genetic factors versus environmental factors have not been determined. </br>Onset, Course, and Complications The exact course of pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has not been well studied.</br>Symptoms typically begin within the first few years of life, although the disease may not be diagnosed until many years later.</br>The natural course of untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not known.</br>A few short-term studies suggest that some children with mild disease may improve, or conversely, have worsening of the condition; long-term studies are not available.</br>Complications are frequent and may be severe.</br>In early childhood, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can cause growth failure, especially when associated with a comorbid genetic or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    craniofacial disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Cognitive and behavioral complications are common and may include developmental delay, poor school performance, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attention deficit hyperactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dis- order, inattention and impairment in concentration, and aggressive behavior.</br>Rarely, cases of severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    asphyxial brain damage
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been reported.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cardiovascular complications
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and systemic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Developmental Issues Developmental issues are reviewed within individual sections. </br>Pathology and Pathophysiology In children, as in adults, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 results from a combination of abnormal neuromuscular control and anatomical narrowing of the collapsible (supracartilaginous) portion of the upper airway.</br>During wakefulness, the patient with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 compensates by augmenting upper airway muscle tone to dilate the upper airway; thus, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 does not occur.</br>During sleep, there is a decrease in ventilatory drive and in neuromuscular tone, facilitating upper airway collapse.</br>The resultant recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and sleep disruption may lead to neurobehavioral, cardiovascular, and growth abnor- malities.</br>Childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has also been associated with metabolic and inflammatory abnormalities. </br>In most children who are otherwise healthy, upper airway narrowing is primarily due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adenotonsillar hypertrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also occurs in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which is becoming increasingly prevalent.</br>Other causes for upper airway narrowing include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    craniofacial anomalies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly those involving midface 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoplasia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or micrognathia/retrognathia.</br>In addition, children with decreased upper airway muscle tone or abnormal upper airway muscle function, such as children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscular dys-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 trophy or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebral palsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, are at increased risk for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Objective Findings PSG demonstrates obstructive and mixed apneas, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or periods of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In children, obstructive apneas lasting two respiratory cycles or longer are scored.</br>In contrast to adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, EEG 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may or may not be present fol- lowing apneas, especially in young children, although subcortical/autonomic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (as manifested by body movements, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or measurements of pulse transit time or arterial tonometry) may occur.</br>Possibly as a result of the higher arousal threshold, sleep architecture is usually preserved.</br>Apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur primarily during REM sleep, and breathing may be totally normal during NREM sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events are frequently associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Evaluation of the upper airway by endoscopy, radiography, computed tomographic scans, or magnetic resonance imaging studies may show large tonsils and adenoidal tissue and a narrow upper airway, although these tests are not performed routinely.</br>Echocardiography may show evidence of right, left, or biventricular hypertrophy. </br>Differential Diagnosis Pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 must be differentiated from isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but without observed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, labored breathing during sleep, daytime behavioral issues, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or other symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may not require further laboratory investigation.</br>However, children who have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 need evaluation to deter- mine whether they have isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (N.B. this distinction cannot reliably be made clinically but should be based on PSG).</br>Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 do not have apneas, gas exchange abnormalities, or frequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on PSG.</br>Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be differentiated from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by the lack of chest or abdominal wall move- ment associated with the central apneas.</br>Mixed apneas may be seen and are included in the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Children with fixed upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to struc- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tural abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tend to obstruct both awake and asleep, and have stridor rather than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children must be distinguished from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonobstructive alveolar hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Children with lung or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>It may be difficult to separate nonobstructive hypoventila- tion and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, especially because the two conditions may coexist.</br>In general, children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonobstructive hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will not snore and will not have paradoxical inward rib cage motion during inspiration, although the latter may be present in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 must be differentiated from Sleep Related Breathing Disorders Sleep Related Breathing Disorders other causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and insufficient sleep.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may mimic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep and may be indistinguishable from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without the appropriate EEG monitoring, especially in infants who may have only subtle motor components of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Unresolved Issues and Further Directions There is a need for further research in many aspects of pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although studies of prevalence have been performed in the past, the prevalence has probably increased in recent years due to the increasing prevalence of childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Further data regarding the prevalence in infants and adolescents is needed.</br>The natural course of the disease, the optimal techniques for monitoring patients during PSG, the effects of mild 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and the threshold necessitating treatment require further study.</br>The role of genetic, ethnic, and anatomic factors in the pathophysiology of childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also requires further study. </br>Bibliography Arens R, Marcus CL.</br>Pathophysiology of upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a developmental perspective.</br>Sleep 2004;27:997–1019. </br>Arens R, McDonough JM, Costarino AT, et al.</br>Magnetic resonance imaging of the upper airway structure in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am J Respir Crit Care Med 2001;164:698–703. </br>Marcus CL, Brooks LJ, Davidson Ward S, et al.; American Academy of Pediatrics.</br>Diagnosis and management of childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: technical report.</br>American Academy of Pediatrics.</br>Pediatrics 2012;130:e714–55. Marcus CL, Brooks LJ, Draper 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Gozal D, et al.; American Academy of Pediatrics.</br>Diagnosis and management of childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: clinical practice guideline.</br>American Academy of Pediatrics.</br>Pediatrics 2012;130:576–84. </br>Redline S, Tishler PV, Schluchter M, Aylor J, Clark 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
,</br>Graham G. Risk factors for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-disordered
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 breathing in children.</br>Associations with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, race, and respiratory problems.</br>Am J Respir Crit Care Med 1999;159:1527–32. </br>68 Central Sleep Apnea Syndromes Central Sleep Apnea with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Breathing ICD-9-CM code: 786.04 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 respiration. </br>Diagnostic Criteria (A or B) + C + D satisfy the criteria A.</br>The presence of one or more of the following: 1. Sleepiness. </br>ICD-10-CM code: R06.3 Sleep Related Breathing Disorders .</br>Difficulty initiating or maintaining sleep, frequent awakenings, or nonrestorative sleep. </br>3. Awakening short of breath. </br>4.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>5. Witnessed apneas. </br>B. The presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrial fibrillation/flutter
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>C. PSG (during diagnostic or positive airway pressure titration) shows all of the following: </br>1. Five or more central apneas and/or central hypopneas per hour of sleep.1 .</br>The total number of central apneas and/or central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is &gt; 50% of the total number of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and hypopneas.2 .</br>The pattern of ventilation meets criteria for Cheyne-Stokes breathing (CSB).1 D.</br>The disorder is not better explained by another current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use (e.g., opioids), or substance use disorder. </br>Notes .</br>As defined by the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events. </br>2.</br>If criterion C2 is not met, CSB can be listed as a polysomnographic finding. </br>3.</br>A diagnosis of central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (CSA) with CSB does not exclude a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>69 Sleep Related Breathing Disorders Essential Features CSA-CSB is characterized by recurrent central apneas or central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>alternat- ing with a respiratory phase exhibiting a crescendo-decrescendo pattern of flow (or tidal volume).</br>The longer cycle length (&gt; 40 seconds; typically 45 to 60 seconds) distinguishes CSB from other central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 types.</br>The vast majority of patients with CSA-CSB have either systolic or diastolic heart failure.</br>In systolic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 the cycle length is longer (longer respiratory phase) than in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diastolic heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and there is often a delay in the nadir of the associated 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desatu- ration.</br>Patients with CSA-CSB have normal or low daytime arterial PCO2 (PaCO2).</br>Some patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have a mixture of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and central apneas with more central apneas in the later part of the night or when the patient is placed on posi- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 airway pressure (PAP).</br>A diagnosis of CSA-CSB requires that events be predom- inantly central apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with an average frequency of at least 5/hour during a diagnostic PSG or either the diagnostic or therapeutic portion of a split-night study.</br>For patients with a mixture of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and CSA-CSB, the central apneas may appear only after elimination of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on positive airway pressure.</br>In patient with CSA-CSB, arousal from sleep tends to occur at the zenith of respiratory effort between contiguous central apneas or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>This can result in sleep fragmen- tation.</br>However, patients may complain of disturbed nocturnal sleep or nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 rather than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Associated Features Presenting features of CSB pattern during sleep may include excessive daytime sleep- iness, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Because many patients with CSA-CSB have known 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, their complaints of frequent awakenings or disturbed sleep may be falsely assumed to be entirely secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Because studies have shown that approximately 60% of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have some form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a high index of suspicion is indicated.</br>A CSB pattern can also occur during wakefulness and can be observed at bedside or in the clinic.</br>Some studies suggest that the pres- ence of CSA-CSB during wakefulness is associated with a worse prognosis.</br>Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is the major cause of CSA-CSB, recent studies suggest that it can be noted after 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>CSA-CSB can rarely present in an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 form or be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>As in other forms of CSA, apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are associated with absent or reduced ventilatory effort, respectively, due to diminished central respiratory drive.</br>Of inter- est, a longer respiratory phase between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with a longer circulation time and delay in the saturation nadir.</br>The CSB breathing pattern is characteristically observed during stages N1 and N2 and usually resolves or is attenuated during REM sleep.</br>In patients with both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and CSA-CSB, the relative amount of central and obstructive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can vary over time or even within the same night. </br>Clinical and Pathophysiological Subtypes </br>Some patients have combined 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and CSA, and the CSA-CSB may not manifest until the patient is placed on positive airway pressure treatment.</br>These patients are considered to have both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and CSA with CSB.</br>Patients with systolic or diastolic heart failure may have CSB, but the cycle length is longer in those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    systolic dys-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 function.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may have CSB, but the characteristic cycle length is less well described. </br>Demographics CSA with CSB generally is seen in subjects older than 60 years.</br>The prevalence of this 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the setting of chronic congestive heart failure has been reported to be 25% to 40%, depending on how patients are divided into those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    predomi- nant OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and those with CSA.</br>In patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 there is a striking male predominance in the occurrence of CSA-CSB.</br>Of interest, the use of β-blockers and angiotensin-converting enzyme inhibitors for treatment of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has not decreased the prevalence of CSA-CSB.</br>Some form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is reported in 50% to 70% of patients following 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, depending on the AHI cutoff used for diagno- sis.</br>Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 predominates, central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is also common especially in the first few days following 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>CSA-CSB has been reported to occur in 26% to 50% of patients in the acute period following 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Predisposing and Precipitating Factors The most important predisposing factors are the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and possibly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Within the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 population, risk factors for CSB pattern during sleep include male sex, age older than 60 years, the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrial fibrillation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and daytime 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (i.e., awake PaCO2 of 38 mm Hg or less).</br>In general, greater 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary congestion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (higher left ventricular end-diastolic pressure) predicts lower PaCO2.</br>Some studies suggest that CSA-CSB occurs more commonly in the supine position.</br>Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is often listed as a possible cause of CSA- CSB, there is scant literature documenting this association. </br>Familial Patterns Not applicable or known. </br>71 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Onset, Course, and Complications There are no definitive data concerning the onset.</br>However, because it is seen in the setting of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    possibly renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, CSA with CSB most likely has its onset following the development of one of these illnesses.</br>In the setting of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    systolic congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, it is associated with a poor prognosis, as indicated by a greater adjusted relative risk for mortality-cardiac transplantation com- pared to patients without CSB.</br>These data suggest that CSB pattern during sleep par- ticipates in the pathophysiology and progression of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Its clinical signifi- cance in the setting of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 remains less certain.</br>In some patients with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 after 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the pattern can transition to one of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 following 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been found to be associated with a worse prognosis. </br>Developmental Issues Although there are reports of CSB in children, the condition is extremely rare in this age group.</br>Of interest, one study of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 across all age groups found CSB to be absent in children but present in 40% of the adult patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A limitation of the study was that only ten children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 were studied. </br>Pathology and Pathophysiology CSA with CSB generally arises because of instability in the respiratory control system.</br>A high ventilatory drive and delay in chemoreceptor response to changes of PaCO2 and PaO2 (due to increased circulation time) are likely the major factors.</br>This 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tends to occur in individuals with a chronically low PaCO2 when awake and asleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hyperventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs due to an increase in the responsiveness of the periph- eral and central chemoreceptors.</br>The increased responsiveness is believed to be due to both increased sympathetic tone and stimulation of vagal irritant receptors in the lungs by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary congestion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The PaCO2 in individuals with CSB pattern and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is closer to their apneic threshold than in those without CSB pattern (primarily due to a smaller sleep related rise in PaCO2 in those with CSB), so that even modest increases in ventilation can drive PaCO2 below the apneic threshold.</br>The most common trigger factor for central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is an arousal from sleep, which abruptly augments ventilation and drives PaCO2 below the apneic threshold. </br>The crescendo-decrescendo pattern of tidal volume results from prolonged lung-to-che- moreceptor circulatory delay, such that changes in PaCO2 in the lung are 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trans-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 mitted only very slowly to the chemoreceptors, resulting in a gradual buildup and falloff of ventilatory stimulation.</br>The length of the cycle is directly proportional to lung-to-chemoreceptor circulation time and inversely proportional to cardiac output.</br>Accordingly, whereas the length of the ventilatory-apneic cycle in primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is typically shorter than 40 seconds, in CSB pattern it is almost invariably longer than 40 seconds (usually 45-90 seconds).</br>One study of patients with varying degrees of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 found a considerably shorter cycle time in patients with normal ejection frac- tion (e.g., diastolic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>The pathophysiology of CSB pattern in the setting of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has not been examined in any detail.</br>However, apneas in association with these medical disorders are believed to be due to a reduction in PaCO2 below the apneic threshold.</br>In individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary congestion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    volume overload
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) may play a role in stimulating 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Objective Findings The polysomnographic hallmarks of CSB pattern are recurrent central apneas and central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 alternating with ventilatory periods having a prolonged crescen- do-decrescendo pattern of airflow (tidal volume).</br>CSB pattern typically occurs at the transition from wakefulness to NREM sleep and during stages N1 and N2.</br>It tends to dissipate in stages N3 and R.</br>In stage N3 sleep the sleeping PaCO2 is higher (further above the apneic threshold).</br>During REM sleep the hypoxic and hypercapnic ventila- tory responses are lower, thereby reducing the tendency for an overshoot in ventilation which may drive PaCO2 below the apneic threshold. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are frequently seen in association with CSB and are typically noted at or near the zenith in respiratory effort (or airflow), although can occur at or near the onset of the respiratory phase pattern.</br>In contrast, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tend to occur at 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 termination in other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>As noted above, a longer respiratory phase (and cycle length) is associated with lower cardiac output and longer circulation time. </br>Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, rather than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, can occur at the nadir in respiratory effort in patients with CSB and have been included in calculation of the central AHI in a sub- stantial number of investigations.</br>Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are characterized by the absence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, flattening in the nasal pressure or PAP device flow signal, and thoracoab- dominal paradox. </br>Central apneas and central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are usually accompanied by modest oxyhemo- globin 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation seldom falls below 80% to 85%.</br>The combination of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from sleep leads to sleep fragmenta- tion with reduced amounts of stage N3 sleep.</br>Additionally, PaCO2 less than 40</br>mm Hg is typically observed during wakefulness.</br>In patients with both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive and central apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the proportion of central apneas tends to increase over the night, and this is Sleep Related Breathing Disorders Sleep Related Breathing Disorders associated with a fall in the sleeping PaCO2.</br>The lower sleeping PaCO2 is thought to be due to an increase in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary congestion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the night with stimulation of juxta- capillary (J) receptors in the lung interstitium and a subsequent increase in ventilatory drive.</br>As noted above, some patients have more CSA-CSB in the supine position. </br>Differential Diagnosis Primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 can usually be distinguished from CSB pattern by the absence of a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and by the absence of a crescendo-decrescendo breathing pattern between central apneas.</br>The cycle length (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 + ventilatory phase) in primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is typically less than 40 seconds.</br>High-altitude periodic breathing only occurs at high altitude and is not associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to drug or substance have a history of use of this type of medication, and an ataxic breathing pattern may be present.</br>If patients with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 asso- ciated with opioids manifest periodic breathing, the respiratory phase does not have a crescendo-decrescendo pattern and the cycle length is shorter.</br>Patients with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to a medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will have central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that does not have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 morphology, as the name implies.</br>Sleep related hypoven- tilation and hypoxemic syndromes can be readily distinguished from CSA-CSB by documentation of an awake PaCO2 &gt;</br>45 mm</br>Hg and/or sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with CSA-CSB usually have an awake PaCO2 &lt;</br>40 mm Hg.</br>In patients with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, some central apneas may be present, but these events do not have a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 morphology.</br>Additionally, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation in sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes is generally more pronounced during REM sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is distinguished by the presence of respiratory efforts during apneas.</br>A few central apneas or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at sleep onset or during REM sleep are normal, especially in elderly subjects.</br>These cease once sleep becomes stable. </br>Unresolved Issues and Further Directions The pathophysiology and clinical significance of CSB pattern have not yet been eluci- dated in the setting of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Less is also known about the importance of CSB in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with a normal ejection fraction. </br>Bibliography Dowdell WT, Javaheri S, McGinnis 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    W. Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 respiration presenting as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Clinical and polysomnographic features.</br>Am Rev Respir Dis 1990;141:871–9. </br>Hall M, Xie A, Rutherford R, Ando S, Floras J, Bradley T. Cycle length of periodic breathing in patients with and without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am J Respir Crit Care Med 1996;154:376–81. </br>Lanfranchi P, Braghiroli A, Bosimini E, et al.</br>Prognostic value of nocturnal Cheyne-Stokes respiration in chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Circulation 1999;99:1435–40. </br>74 MacDonald M, Fang J, Pittman SD, White DP, Malhotra A.</br>The current prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in congestive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients treated with beta-blockers.</br>J Clin Sleep Med 2008;4:38–42. </br>Naughton M, Benard D, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tam A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Rutherford R, Bradley T.</br>The role of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the pathogenesis of central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am Rev Respir Dis 1993;148:330–8. </br>Peer A, Lorber A, Suraiya S, Malhotra A, Pillar G. The occurrence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 respiration in congestive heart failure: the effect of age.</br>Front Psychiatry 2010;1:133. </br>Pressman MR, Benz RL, Schleifer CR, Peterson DD.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ESRD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: acute beneficial effects of treatment with nasal continuous positive airway pressure.</br>Kidney Int 1993;43:1134–9. </br>Sahlin C, Svanborg E, Stenlund H, Franklin KA.</br>Cheyne-Stokes respiration and supine dependency.</br>Eur Respir J 2005;25:829–33. </br>Sin D, Fitzgerald F, Parker J, Newton G, Floras J, Bradley T. Risk factors for central and obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 450 men and women with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am J Respir Crit Care Med 1999;160:1101–6. </br>Sin DD, Logan AG, Fitzgerald FS, et al.</br>Effects of continuous positive airway pressure on cardiovascular outcomes in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with and without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Respiration.</br>Circulation 2000;102:61–6. </br>Wedewardt J, Bitter T, Prinz C, Faber L, Horstkotte D, Oldenburg O. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 respiration in heart failure: cycle length is dependent on left ventricular ejection fraction.</br>Sleep Med 2010;11:137–42. </br>Xie A, Skatrud J, Puleo D, Rahko P, Dempsey J. Apnea-hypopnea threshold for 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am J Respir Crit Care Med 2002;165:1245–50. </br>Central Apnea Due to a Medical Disorder without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Breathing ICD-9-CM code: 327.27 Alternate Names Not applicable or known. </br>Diagnostic Criteria Criteria A-C must be met A.</br>The presence of one or more of the following1: 1. Sleepiness. </br>ICD-10-CM code: G47.37 Sleep Related Breathing Disorders .</br>Difficulty initiating or maintaining sleep, frequent awakenings, or nonrestorative sleep. </br>3. Awakening short of breath. </br>4.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>5. Witnessed apneas. </br>B. PSG shows all of the following: </br>1. Five or more central apneas and/or central hypopneas per hour of sleep.2 Sleep Related Breathing Disorders .</br>The number of central apneas and/or central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is &gt; 50% of the total number of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>3. Absence of CSB.2 C. The disorder occurs as a consequence of a medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but is not due to medication use or substance use. </br>Notes .</br>In infants and young children, symptoms are supportive but not required. </br>2. As defined by the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events. </br>3.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not required but may be present.</br>If the patient meets criteria for both sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to medical or neurological condition not 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, both diagnoses can be made. </br>4.</br>In some patients other abnormalities of breathing such as ataxic breathing may be prominent. </br>5.</br>A diagnosis of central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder without CSB does not exclude a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Essential Features 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 that is attributed to a medical or neurological condition (and does not have the pattern of CSB) is classified here.</br>The majority of these patients have brainstem lesions of developmental, vascular, neoplastic, degenerative, demyelinating, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    traumatic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 origin. </br>Associated Features Patients generally present with sleep fragmentation, excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other signs and symptoms that are often, but not invariably, present include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, witnessed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and awakening with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    shortness of breath
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The presentation varies with the cause of central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and may include neurological findings. </br>Clinical and Pathophysiological Subtypes None.</br>Some of the common medical and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 causing central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 not associated with CSB are listed in Pathology and Pathophysiology (below). </br>Demographics The prevalence and demographics of this disorder vary with the underlying etiology.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chiari malformation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) can present in infancy or childhood, but the most common age of presentation is 20 to 40 years.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tend to be older. </br>76 Predisposing and Precipitating Factors Because of the heterogeneity of etiologies in this type of CSA, predisposing and pre- cipitating factors are variable.</br>In 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 there is herniation of a portion of the brainstem through the foramen magnum.</br>In 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1, a portion of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebellar tonsils herni-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ate.</br>CSA in these patients is believed to occur due to impaired function of ventilatory control centers in the brainstem. </br>Familial Patterns None known. </br>Onset, Course, and Complications These factors vary as well with the different etiologies.</br>In 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 the presentation is typi- cally age 20 to 40 years of age but can occur in infants and children.</br>With the increased use of magnetic resonance imaging (MRI), cases are often diagnosed before symptoms are severe.</br>The CSA following a cerebrovascular accident (
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CVA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
) is abrupt in onset.</br>In patients exhibiting both central and obstructive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the central apneas tend to resolve with time.</br>Some 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    post-CVA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with central apneas have central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with CSB, whereas in others the CSA does not have a pattern consistent with CSB.</br>The central apneas can lead to sleep fragmentation, yielding either 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or both.</br>There is little evidence that these apneas or their associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lead to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or other adverse car- diovascular consequences. </br>Developmental Issues Not known. </br>Pathology and Pathophysiology 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is caused by failure of the ventilatory control centers to initiate ventilatory effort.</br>The abnormality is due to dysfunction of central ventilatory control centers.</br>The pres- ence of sleep may unmask ventilatory control abnormalities with the loss of the wake- fulness stimulus.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may coexist with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, not CSB, in which case both diagnoses can be made. </br>A number of causes of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
–not Cheyne- Stokes—have been described.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 exhibit 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, central, or a mixture of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and central apneas.</br>Some patient exhibit 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal hypoventi- lation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but rarely 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>CSA and/or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be the initial presenta- tion of the disorder.</br>Symptoms include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (especially with laughter, coughing, Sleep Related Breathing Disorders Sleep Related Breathing Disorders or exertion), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neck pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vertigo
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>An MRI is diagnostic of the condition and should be considered as part of the evaluation of all patients without an obvious cause of central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Brainstem 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neoplasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can present with central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 not of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type.</br>Patients with a recent cerebrovascular accident show a high incidence of sleep disor- dered breathing.</br>Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is more common, central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be noted initially after a cerebrovascular accident.</br>Some patients exhibit a pattern of CSB, whereas in others periodic breathing without the characteristic CSB pattern is present.</br>Patients with multiple system 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also present with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 that does not have a CSB pattern. </br>Objective Findings The polysomnogram of the patient with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to medical or neurological condi- tion—not CSB—demonstrate recurrent (five or more per hour) central apneas and/or central hypopneas.</br>The central apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 meet criteria for these events as defined by the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events.</br>Runs of recurrent central apneas separated by periods of ventilation may occur.</br>The interevent respiratory phase is typically brief with a maximum of five breaths.</br>The central apneas do not have the pattern of CSB. </br>Differential Diagnosis Patients with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
—not CSB—should be dif- ferentiated from primary CSA, in which no known cause is identified.</br>As the name implies, patients with a pattern of CSB should be classified as such.</br>Patients with central nervous system 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may have a central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with or without an increase in daytime PaCO2. </br>Unresolved Issues and Further Directions With the possible exception of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    poststroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the disorders classified here are thought to be relatively rare.</br>The presenting symptoms may not be a sleep related complaint.</br>Except for those associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    poststroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 CSA, the disorders are not well characterized. </br>Bibliography Cormican LJ, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Higgins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 AC, Davidson R, et al.</br>Multi system 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 presenting as central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Eur Respir J 2004;24:323–5. </br>Dauvilliers Y, Stal V, Abril B, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chiari malformation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Neurol Neurosurg Psychiatry 2007;78:1344–8. </br>78 Fernández AA, Guerrero AI, Martínez MI, et al.</br>Malformations of the craniocervical junction (Chiari type I and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    syringomyelia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: classification, diagnosis and treatment).</br>BMC Musculoskelet Disord 2009</br>Dec 17;10 Suppl 1. </br>Parra O, Arboix A, Bechich S, et al.</br>Time course of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-related breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    first-ever stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or transient ischemic attack.</br>Am J Respir Crit Care Med 2000;161:375–80. </br>Siccoli MM, Valko PO, Hermann DM, Bassetti CL.</br>Central periodic breathing during sleep in 74 patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    acute ischemic stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
—neurogenic and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiogenic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 factors.</br>J Neurol 2008;255:1687–92. </br>Central Sleep Apnea Due to High Altitude Periodic ICD-10-CM code: G47.32 Breathing ICD-9-CM code: 327.22 Alternate Names None. </br>Diagnostic Criteria Criteria A-D must be met A. Recent ascent to high altitude.1 B.</br>The presence of one or more of the following:2 Sleep Related Breathing Disorders . Sleepiness. </br>2. Difficulty initiating or maintaining sleep, frequent awakenings, or nonrestorative sleep. </br>3. Awakening with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    shortness of breath
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morning headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>4. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Witnessed apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>C.</br>The symptoms are clinically attributable to high-altitude periodic breathing or PSG, if performed, demonstrates recurrent central apneas or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 primarily during NREM sleep at a frequency of ≥ 5/hour. </br>D.</br>The disorder is not better explained by another current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use (e.g., narcotics), or substance use disorders. </br>Notes .</br>Typically at least 2,500 meters (8,202 feet), although some individuals may exhibit the disorder at altitudes as low as 1,500 meters. </br>2. Periodic breathing is a common response to altitude.</br>Associated symptoms are required to make the diagnosis of a disorder.</br>There is no level of the central AHI separating a normal and abnormal response to high altitude. </br>3.</br>A diagnosis of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to high-altitude period breathing does not exclude a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>79 Sleep Related Breathing Disorders Essential Features High-altitude periodic breathing is characterized by alternating periods of central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperpnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with recent ascent to high altitude.</br>The pattern of periodic breathing is an expected response to ascent to elevation.</br>Only those individuals who manifest related symptoms, as described below, are diagnosed with this disorder.</br>The cycle length of this respiratory pattern is commonly less than 40 seconds and often as short as 12 to 20 seconds.</br>The percentage of individuals exhibiting periodic breathing during sleep increases at higher altitudes.</br>Approximately 25% exhibit periodic breath- ing at 2,500 meters (8,202 feet), and virtually 100% demonstrate periodic breathing at 4,000 m (13,123 feet).</br>Periodic breathing has been described at altitudes as low as 1,500 meters (4,900 feet).</br>Chronic exposure to altitude above 2,500 meters has also been associated with periodic breathing in some studies. </br>Associated Features At altitude, individuals may complain of frequent awakenings, poor-quality sleep, and a sense of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>These symptoms will often improve with time at moderate altitude but may persist at extreme altitude.</br>Alterations in sleep associated with ascent to alti- tude include a reduction in stage N3 sleep and increased arousal frequency.</br>Total sleep time and the amount of REM sleep are either unchanged or decreased.</br>Of note, the degree of both subjective and objective impairment of sleep quality was not correlated with the severity of periodic breathing in a number of studies. </br>Clinical and Pathophysiological Subtypes None known. </br>Demographics The demographics of high-altitude periodic breathing are not known.</br>High-altitude periodic breathing tends to occur in individuals with a high hypoxic and probably hypercapnic ventilatory response.</br>Because men generally have higher chemorespon- siveness than women, high-altitude periodic breathing may be more common in men than in women.</br>As stated above, periodic breathing will occur in virtually anyone ascending to higher than 4,000 meters and in some individuals at lower altitudes.</br>The latter group probably comprises individuals with increased hypoxic chemoresponsive-</br>ness.</br>In one study, individuals both with and without periodic breathing at altitude had alterations in sleep architecture.</br>Those with periodic breathing had a greater arousal index, although their sleep architecture was otherwise not significantly different from individuals who did not develop periodic breathing. </br>80 Predisposing and Precipitating Factors The only known predisposing factor for the development of high-altitude periodic breathing is increased ventilatory chemoresponsiveness, primarily hypoxic ventila- tory responsiveness.</br>A high hypoxic ventilatory response will lead to increased hyper- ventilation on ascent to altitude.</br>This 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 leads to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocapnic alkalosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that, during sleep, inhibits ventilation.</br>Thus, repetitive cycles of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperpnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 develop during NREM sleep.</br>The obvious precipitating factor for the development of this periodic breathing is ascent to altitude.</br>The more rapid the ascent, the more likely periodic breathing is to develop. </br>Familial Patterns Some data suggest that ventilatory chemoresponsiveness is directly inherited.</br>Because elevated hypoxic responsiveness is a predisposing variable in the development of high-altitude periodic breathing, it would seem likely that there would be a familial pattern in the development of this 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory abnormality
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, there are no data addressing this issue. </br>Onset, Course, and Complications This respiratory pattern will generally be evident during sleep immediately after ascent to altitude.</br>This depends to some extent on the rapidity of the ascent, the elevation, and individual predisposition.</br>However, it will be present most often on the first night at altitude.</br>At moderate altitude, the breathing pattern may become more regular over time, although at extreme altitude it is likely to persist.</br>One recent study found that the amount of periodic breathing continued to increase over three days to two weeks of acclimatization.</br>Studies of adaptation to altitude suggest that sleep quality may improve despite further increases in periodic breathing.</br>It has been hypothesized that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 itself may have an important role in disturbing sleep architecture.</br>Thus, sleep and symptoms may improve during acclimatization to altitude even if the amount of periodic breathing actually increases. </br>The complications of high-altitude periodic breathing, which are generally limited to disrupted sleep on the initial nights at altitude, include frequent awakenings, often with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    shortness of breath
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or a sensation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    suffocation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that may lead to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or sleep- iness on the following day.</br>There is no clear association between periodic breathing and other altitude syndromes (high-altitude 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, acute mountain sick-</br>ness, and high-altitude 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebral edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>In fact, periodic breathing is a marker of high hypoxic responsiveness, which generally yields improved oxygenation at altitude and a reduced frequency of the maladaptive syndromes. </br>81 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Developmental Issues Relatively little is known about differences between children and adults concerning periodic breathing at altitude.</br>One study did compare breathing in children and their fathers.</br>The children revealed reduced nocturnal 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation and associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at high altitude similar to the adults, but their breathing pattern was more stable.</br>The investigators hypothesized that children may have a lower 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 threshold for 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 than adults. </br>Pathology and Pathophysiology High-altitude periodic breathing is believed to be a product of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 induced by the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypobaric hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 encountered at altitude.</br>At 2,500 meters the atmo- spheric pressure is approximately 570 mm Hg and the ideal alveolar 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 around 55 mm Hg (depending on the level of PaCO2).</br>Actual arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 values will be lower, especially during sleep.</br>The hypoxic ventilatory response shows a steep increase in ventilation when the arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 level drops below 55 mm Hg.</br>The increases in venti- lation associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocapnic alkalosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Because PaCO2 is the principal stimulus to respiration during NREM sleep, a low PaCO2 can yield a loss or reduction in respiratory drive, resulting in central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The greater the ventilatory response to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the greater the fall in PaCO2.</br>Thus, individuals with brisk hypoxic responses more commonly tend to demonstrate this respiratory pattern.</br>Over the course of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the PaO2 falls and PaCO2 rises, eventually stimulating a resumption of ventilation.</br>However, after several large breaths, the PaCO2 again falls below the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 threshold, initiating another pause in breathing.</br>This cycle is then repeated over the course of the night.</br>Of note, the respiratory pattern is often improved during REM sleep with reduced cycling.</br>This is likely due to the decreased hypoxic and hypercapnic responsiveness characteristic of REM sleep.</br>Of interest, in one study the hypoxic ventilatory response continued to increase up to seven days after ascent to altitude.</br>This resulted in a lower PaCO2 and higher PaO2.</br>The reduction in peri- odic breathing in some individuals with adaptation to altitude despite a greater venti- latory response to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be due to a lowering of the apneic threshold.</br>Other studies have found that the amount of periodic breathing continues to increase over three days to two weeks of acclimatization despite improvements in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation.</br>The increase in both periodic breathing and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation is thought to be due to increased controller gain of the respiratory system. </br>A number of studies have found that the impairment of sleep architecture does not correlate with the degree of periodic breathing.</br>One study found that the amount of periodic breathing was greater on the third night at altitude compared to the first night.</br>However, both the nocturnal 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation and amount of stage N3 also increased on the third night compared to the first night.</br>It has been hypothesized that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 rather than periodic breathing might be the major factor disturbing sleep. </br>Objective Findings The PSG of individuals with high-altitude periodic breathing demonstrates recur- rent central apneas with a cycle time of less than 40 seconds, and typically around 20 seconds.</br>There is some degree of associated arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation.</br>The apneas are short, generally 8 to 10 seconds in duration.</br>In one study, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 duration was around 8 seconds (7 to 9 seconds) in children and approximately 12 seconds (10-14 seconds) in adults. </br>The cycle length is commonly less than 40 seconds.</br>This breathing pattern occurs only during NREM sleep with more rhythmic respiration during REM sleep.</br>Because this breathing pattern is a physiologic adaptation to altitude, there is no specific number of apneas per hour of sleep that is considered normal or abnormal.</br>The apneas and associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperpnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can lead to recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from sleep, which often increase stages N1 and N2 sleep while reducing stage N3 sleep.</br>REM sleep (stage R) duration is generally preserved, as is total sleep time.</br>As noted above, some studies have found a reduction in total sleep time and stage R as well as stage N3.</br>Of interest, the arousal index was only around 25% of the AHI in some investigations. </br>Differential Diagnosis High-altitude periodic breathing should be distinguished from other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRBDs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The major distinguishing factor is, of course, recent ascent to high altitude.</br>An individual with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will likely continue to have this nocturnal respiratory problem at altitude.</br>Altitude might even exacerbate the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic mountain sickness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 demonstrate relative 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at altitude (i.e., breathe less than is encoun- tered in normal individuals at similar altitude) such that they are more hypoxic than normal individuals who have a greater ventilatory response to the same ambient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>During sleep, these individuals often demonstrate further arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation.</br>Some of the individuals will demonstrate apneas or periodic breathing.</br>A diagnosis of chronic mountain sickness does not imply that periodic breathing is present.</br>However, periodic breathing may be more common in these patients than previously appreciated. </br>Unresolved Issues and Further Directions Recent studies suggest that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 rather than the amount of periodic breathing may be the major factor impairing sleep quality.</br>Further studies relating changes in sleep and periodic breathing at altitude are needed. </br>83 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Bibliography Anholm J, Powles A, Downey R, et al.</br>Operation Everest II: arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation and sleep at extreme simulated altitude.</br>Am Rev Respir Dis 1992;145:817–26. </br>Bloch KE, Latshand 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Turk AJ, et al.</br>Nocturnal periodic breathing during acclimatization at very high altitude at Mount Muztach Ata (7,546 m).</br>Am J Respir Crit Care Med 2010;182:562–8. </br>Burgess, K.R., Lucas, S.J., Shepherd, K.L., et al.</br>Worsening of central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at high altitude—a role for cerebrovascular function.</br>J Appl Physiol 2013; 114: 1021–8. </br>Coote JH, Tsang G, Baker A, Stone B. Respiratory changes and structure of sleep in young high-altitude dwellers in the Andes of Peru.</br>Eur J Appl Physiol 1993;66:249–53. </br>Goldberg S, Schoene R, Haynor D, et al.</br>Brain tissue pH and ventilatory acclimatization to high altitude.</br>J Appl Physiol 1992;72:58–63. </br>Johnson P, Edwards N, Burgess KR, Sullivan CE.</br>Sleep architecture changes during a trek from 1400 to 500 m in the Nepal Himalaya.</br>J Sleep Res 2010;19:148–56. </br>Kohler M, Kriemler S, Wilhelm EM, Brunner-LaRocca H, Zehnder M, Bloch KE.</br>Children at high altitude have less nocturnal periodic breathing than adults.</br>Eur Respir J 2008;32:189–97. </br>Lahiri S, Barnard P. Role of arterial chemoreflex in breathing during sleep at high altitude.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prog
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 Clin Biol 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Res
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 1983;136:75–85. </br>Lahiri S, Meret 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Sherpa M. Dependence of high altitude 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on ventilatory sensitivity to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Respir Physiol 1983;52:281–301. </br>Lombardi C, Meriggi P, Agostoni P, et al.</br>Highcare Investigators.</br>High-altitude 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and periodic breathing during sleep: gender-related differences.</br>J Sleep Res 2013; 22:322–30. </br>Nickol AH, Leverment J, Richards P, et al.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Temazepam
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 at high altitude reduces periodic breathing without impairing next-day performance: a randomized cross-over double-blind study.</br>J Sleep Res 2006;15:445–54. </br>Nussbaumer-Ochsner Y, Ursprung J, Siebenmann C, Maggiorini M, Bloch KE.</br>Effect of short-term acclimatization to high altitude on sleep and nocturnal breathing.</br>Sleep 2012;35:419–23. </br>Schoene R. Control of ventilation in climbers to extreme altitude.</br>J Appl Physiol 1982;53:886–90. </br>Waggener 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TB
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Brusil PJ, Kronauer RE, Gabel RA, Inbar GF.</br>Strength and cycle time of high-altitude ventilatory patterns in unacclimatized humans.</br>J Appl Physiol 1984;56:576–81. </br>White D, Gleeson 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Pickett C, Rannels A, Cymerman A, Weil J. Altitude acclimatization: influence on periodic breathing and chemoresponsiveness during sleep.</br>J Appl Physiol 1987;63:401–12. </br>84 Central Sleep Apnea Due to a Medication or ICD-10-CM code: G47.39 Substance ICD-9-CM code: 327.29 Alternate Names Narcotic or opioid induced central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-E must be met Sleep Related Breathing Disorders A.</br>The patient is taking an opioid or other respiratory depressant. </br>B. The presence of one or more of the following: . Sleepiness. </br>2. Difficulty initiating or maintaining sleep, frequent awakenings, or nonrestorative sleep. </br>3. Awakening short of breath. </br>4.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>5. Witnessed apneas. </br>C. PSG (diagnostic or on positive airway pressure) shows all of the following: </br>1. Five or more central apneas and/or central hypopneas1 per hour of sleep (PSG). </br>2. The number of central apneas and/or central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is &gt; 50% of the total number of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>3. Absence of CSB.1 D. The disorder occurs as a consequence of an opioid or other respiratory depressant. </br>E.</br>The disorder is not better explained by another current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Notes .</br>As defined by the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events. </br>2. Ataxic breathing (irregular variations in respiratory cycle time and tidal volume) may be noted. </br>3. Nocturnal and/or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present but are not required.</br>If sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present, a diagnosis of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to medication or substance use can be made as well as a diagnosis of central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance. </br>4.</br>A diagnosis of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to a medicationor substance does not exclude a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. Sleep Related Breathing Disorders Essential Features Users of potent long-acting opioids may have central apneas during sleep.</br>The most common offending drug is 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>However, the condition has also been described in patients taking long-acting forms of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morphine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxycodone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 as well as individu- als being treated with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fentanyl
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 patches or continuous narcotic infusions.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Suboxone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (a combination of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    buprenorphine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    naloxone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
) is often used for treatment of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcotic dependence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and can also cause drug-induced central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The description of this population is complicated by the fact that many of the affected indi- viduals may be using multiple drugs (prescribed or illicit) that affect sleep and breathing. </br>Associated Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Breathing abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with these drugs are not restricted to central apneas and may also include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with prolonged respiratory events.</br>In fact, many patients present with a combination of both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and CSA.</br>Patients who have nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may have normal or increased daytime PaCO2.</br>In most patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the PaCO2 is only mildly increased (46-50 mm Hg).</br>Patients with drug-induced central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 who are being treated for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often report significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Due to the sedating effects of opioid medications, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may not substantially improve even if the central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is treated successfully.</br>However, one study of patients on chronic 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 mainte- nance found the average Epworth Sleepiness Scale score to be within normal range.</br>In these patients, who manifested only mild to moderate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (average AHI about 18/ hour), the degree of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 correlated with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 index.</br>A case series of patients treated with opioids for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 found AHI values above 30/hour (up to 100/hour) and moderate to severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In this group, 50% to 80% of respiratory events were central apneas.</br>Sleepiness that is disproportionately high in comparison to the severity of the AHI (and in some cases, at least partially unresponsive to treatment) is likely due to the direct sedative effects of the narcotic medication itself. </br>Clinical and Pathophysiological Subtypes None known. </br>Demographics There are no known sex, racial, or ethnic differences.</br>The prevalence of this disorder is not known, although limited data suggest that it occurs commonly in those being treated with opioids for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>86 Predisposing and Precipitating Factors Use of a potent long-acting narcotic is the major causative factor.</br>If patients are suc- cessfully withdrawn from the offending medication, the central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may resolve. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications </br>This disorder is typically seen after opioids have been used for at least two months.</br>An increased risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been reported with the use of potent narcotics.</br>There has been a large increase in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    deaths
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to the increasing use of this medication for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Many of these 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    deaths
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur during sleep. </br>Developmental Issues Information regarding the presentation of this disorder in children is limited.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to opioid medications has been described in children being treated for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Pathology and Pathophysiology The presumed pathophysiology for the development of these varied 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing abnor-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 malities during sleep is the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that occurs through action of the drugs on the μ-receptors on the ventral surface of the medulla.</br>Studies have 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    demon-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 strated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the awake hypercapnic ventilatory drive; however, it often improves after five to eight months of continued drug use.</br>In one study the hypoxic ventilatory drive never fully normalized.</br>Another study of patients on chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    meth- adone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 maintenance found that the hypoxic ventilatory drive is increased compared to that of control subjects.</br>In this study the hypercapnic ventilatory response was reduced in comparison with that of controls who were not taking opioids.</br>The difference was not due to a lower tidal volume but rather reduced respiratory rate.</br>Differences in technique or patient population may explain the divergent findings.</br>The cause of the ataxic breathing in patients on opiates is not known.</br>However, one study of patients on chronic opioids found that the incidence of ataxic breathing increased with the total narcotic dose. </br>Objective Findings The drug-induced central apneas may occur as a form of periodic breathing with runs of central apneas separated by a short ventilatory phase (2 to 4 breaths) or intermittent and sporadic central apneas.</br>The underlying breathing pattern may show a slow respi- ratory rate or an ataxic breathing pattern.</br>The term ataxic breathing is sometimes used as a synonym of Biot breathing, although definitions of the latter term vary widely. </br>87 Sleep Related Breathing Disorders Sleep Related Breathing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Disorders Ataxic breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by an irregular breathing rhythm as well as irregular depth of breathing (tidal volume).</br>Obstructive breathing events are also common in patients taking potent opioids and a diagnosis of both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is often appro- priate.</br>Prolonged obstructive apneas with severe arterial desaturation may be noted.</br>The drug-induced central apneas occur mainly during NREM sleep and, in patients without coexistent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the AHI may be much lower during REM than during NREM sleep.</br>Patients also tend to have a low arousal index and increased stage N3 sleep.</br>Unlike other forms of central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, drug-induced central apneas may occur during stage N3 sleep. </br>Differential Diagnosis This condition is best distinguished from other types of central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by the patient’s ongoing use of long-acting opioids.</br>Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRBDs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present and may complicate PSG findings. </br>Unresolved Issues and Further Directions Further study is needed to determine risk factors and pathogenesis for development of these sleep disordered breathing patterns in users of long-acting opioids.</br>It has been hypothesized that these sleep disordered breathing patterns may play a role in the unex- plained increased mortality in this population.</br>This also requires further study. </br>Bibliography Alattar MA, Scharf SM.</br>Opioid-associated central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a case series.</br>Sleep Breath 2009;13:201–6. </br>Centers for Disease Control and Prevention (CDC).</br>Vital signs: risk for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    overdose
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 used for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 relief—United States, 1999-2010.</br>MMWR Morb Mortal Wkly Rep 2012;61:493–7. </br>Farney RJ, Walker JM, Cloward TV, Rhondeau 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S. Sleep-disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with long-term opioid therapy.</br>Chest 2003;123:632–9. </br>Guilleminault C, Cao M, Yue HJ, Chawla 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P. Obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and chronic opioid use.</br>Lung 2010;188:459–68. </br>Ramar K. Reversal of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-disordered
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 breathing with opioid withdrawal.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Pract 2009;9:394–8. </br>Santiago TV, Pugliese AC, Edelman NH.</br>Control of breathing during 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 addiction.</br>Am J Med 1977;62:347–54. </br>Shook JE, Watkins WD, Camporesi EM.</br>Differential roles of opioid receptors in respiration, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and opiate-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am Rev Respir Dis 1990;142:895–909. </br>Teichtahl H, Prodromidis A, Miller B, Cherry G, Kronborg I. Sleep-disordered breathing in stable 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 programme patients: a pilot study.</br>Addiction 2001;96:395–403. </br>Teichtahl H, Wang D, Cunnington D. Ventilatory responses to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in stable 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 treatment patients.</br>Chest 2005;128:1339–47. </br>Walker JM, Farney RJ, Rhondeau SM.</br>Chronic opioid use is a risk factor for the development of central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and ataxic breathing.</br>J Clin Sleep Med 2007; 3:455–61. </br>88 Wang D, Teichtahl H, Goodman C, Drummer O, Grunstein RR, Kronborg I. Subjective 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and daytime function in patients on stable 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 maintenance treatment: possible mechanisms.</br>J Clin Sleep Med 2008;4:557–62. </br>Primary Central Sleep Apnea ICD-9-CM code: 327.21 Alternate Names Idiopathic central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-D must be met A.</br>The presence of at least one of the following1: 1. Sleepiness. </br>ICD-10-CM code: G47.31 Sleep Related Breathing Disorders .</br>Difficulty initiating or maintaining sleep, frequent awakenings, or nonrestorative sleep. </br>3. Awakening short of breath. </br>4.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>5. Witnessed apneas. </br>B. PSG demonstrates all of the following: . Five or more central apneas and/or central hypopneas2 per hour of sleep (PSG). </br>2. The number of central apneas and/or central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is &gt; 50% of the total number of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>3.</br>Absence of CSB.2 C. There is no evidence of daytime or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>D.</br>The disorder is not better explained by another current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use, or substance use disorder. </br>Notes .</br>In children, daytime symptoms may not be evident. </br>2. As defined by the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events. </br>Essential Features Primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is of unknown etiology (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) and is characterized by recurrent central apneas, defined as a cessation of airflow during sleep associated with an absence of respiratory effort.</br>Airflow and respiratory effort cease simultaneously in a repetitive Sleep Related Breathing Disorders fashion over the course of the night.</br>This recurrent cessation and resumption of venti- lation can lead to sleep fragmentation, yielding excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, frequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal awakenings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or both.</br>Thus, patients may present with symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyper- somnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 tend to have low normal arterial PaCO2 during wakefulness (less than 40 mm Hg).</br>Patients with a known medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that is believed to cause central apneas are classified elsewhere. </br>Associated Features Patients generally present with excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep fragmentation, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other signs and symptoms that are often, but not invariably, present include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, witnessed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and awakening with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    shortness of breath
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Clinical and Pathophysiological Subtypes The disorder is rare, precluding identification of any definite subtypes. </br>Demographics Not known.</br>Most studies suggest this disorder is rare, most common in middle-aged to elderly individuals, and more frequent in men than women, although not all studies support this sex bias. </br>Predisposing and Precipitating Factors 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 in these patients occurs because the arterial PCO2 (PaCO2) drops below the hypo- capnic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 threshold (HAT).</br>During wakefulness, drops in PaCO2 do not result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, during sleep, when the PaCO2 drops below the HAT, respiratory effort ceases.</br>For most patients, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HAT
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is within a few mm Hg of the awake PaCO2.</br>Any factors that narrow the gap between the sleeping PaCO2 and the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HAT
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 predispose to central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A high ventilatory response to 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 seems to be a major predisposing factor in the development of primary CSA.</br>This can lead to the instability in venti- latory control that characterizes the disorder.</br>Frequent arousal from sleep can also predispose to the development of central apneas, as ventilatory control is somewhat unstable at sleep-wake transitions.</br>Increased ventilation associated with arousal can result in a PaCO2 below the HAT after the return to sleep.</br>Because ventilatory drive is lower during REM than NREM sleep, hypocapnic central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is much less common during that sleep stage.</br>Two other variables have been discussed as possible predispos- ing factors, although their true role in the development of this syndrome is uncertain.</br>First, frequent arousal or awakening due to low arousal threshold or sleep maintenance 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been reported to lead to an increase in central apneas.</br>Because ventila- tory control can be somewhat unstable in the normal wake-sleep transition with occa- sional central apneas being observed in otherwise normal individuals, any disorder that interrupts sleep may worsen CSA.</br>Some studies have suggested a worsening of primary CSA in the supine position, but this has been more clearly documented in patients with CSB. </br>Familial Patterns Some data suggest that ventilatory chemoresponsiveness is directly inherited.</br>Because elevated 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 responsiveness is a predisposing variable in the development of idio- pathic CSA, it would seem likely that there would be a familial pattern in the develop- ment of this 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory abnormality
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, there are no data addressing this issue. </br>Onset, Course, and Complications Not known.</br>The apneas can lead to sleep fragmentation, yielding either hypersomno- lence or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>There is little evidence that these apneas or their associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lead to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or other adverse car- diovascular consequences. </br>Developmental Issues Criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of infancy and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are detailed elsewhere and it should be noted that central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is defined somewhat differently in infants and chil- dren than in adults.</br>Central apneas that are brief (&lt; 20 seconds in duration) and not associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or arousal are commonly observed in both premature and term infants. </br>In adults, population studies report an increase in the occurrence of central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with increasing age, especially in men. </br>Pathology and Pathophysiology Primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is caused by instability of the respiratory control system in the transition from wakefulness to sleep and less commonly during stable NREM sleep.</br>Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with primary CSA most often occurs during stages N1 and N2 sleep and is rare during stages</br>N3 and R sleep.</br>Central apneas tend to occur in individuals with a high or increased ventilatory responsiveness to 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Arterial PCO2 levels below the hypocapnic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 threshold lead to a cessation in ventilatory effort and, therefore, a central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Individuals with high 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 ventilatory responsiveness tend to have lower PaCO2 levels (both daytime and sleep) and a lower gradient between the sleep- ing PaCO2 and the apneic threshold.</br>Hence, a smaller increase in ventilation is required to reach this 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 threshold and inhibit ventilation.</br>Individuals with high chemore- sponsiveness also 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperventilate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 more in response to small changes in arterial PaCO2.</br>This again often drives the PaCO2 below the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 threshold, yielding a cessation Sleep Related Breathing Disorders Sleep Related Breathing Disorders of ventilation.</br>However, not all factors that cause greater ventilatory drive have the same effect.</br>Studies suggest that although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 increases chemoresponsiveness to PaCO2, the gap between the PaCO2 and the apneic threshold is smaller (predispos- ing to central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Metabolic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    acidosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonhypoxic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 chemoreceptor 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stimulants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 tend to decrease HAT more than they decrease the sleeping PaCO2, resulting in a larger gap between the HAT and the sleeping PaCO2 and lower likelihood of central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Metabolic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alkalosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tends to increase 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HAT
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as well as decrease ventilatory responsive- ness, yielding a smaller gap between the HAT and sleeping PaCO2. </br>Objective Findings The PSG of the patient with primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 demonstrates more than five central apneas and/or central hypopneas per hour of sleep.</br>The central apneas and central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 meet criteria for these respiratory events in adults or children as defined by the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events.</br>Published studies of patients with primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 have required that &gt; 50% to 85% of respiratory events be central apneas.</br>Periodic breathing characterized by episodes of recurrent central apneas separated by periods of ventilation may occur.</br>The inter- event respiratory phase is typically brief with a maximum of five breaths.</br>The venti- latory phase between central apneas does not have the crescendo-decrescendo pattern of CSB breathing.</br>Central apneas commonly lead to mild arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation, although more severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur.</br>Central apneas may also lead to arousal from sleep, causing fragmentation and yielding increased stages N1 and N2 sleep at the expense of stage N3 sleep.</br>As noted above, central apneas in these patients are less common during REM sleep.</br>In summary, respiration, arterial oxygenation, and sleep architecture are affected by this disorder.</br>Additionally, an arterial PaCO2</br>less than 40 mm</br>Hg is typically observed during wakefulness.</br>These patients do not exhibit sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Differential Diagnosis Normal individuals may have a few central apneas in the wake-sleep transition.</br>However, once stable sleep is achieved, these apneas should cease.</br>Normal individuals should not have more than five central apneas per hour of sleep. </br>Primary CSA must be distinguished from other sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Some patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    predominantly OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will have central apneas during diagnostic or positive airway pressure titration studies.</br>These apneas tend to resolve immediately or over time on positive airway pressure treatment.</br>The pattern of central apneas in primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 differs from that of CSA with CSB.</br>Primary CSA lacks the crescendo-decrescendo pattern of respiration between contiguous central apneas noted in patients with CSA with CSB.</br>The cycle length is longer in CSB (greater than 40 seconds and typically 45 to 90 seconds).</br>The longer cycle length in CSB versus primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is due to a longer respiratory phase between central apneas.</br>In primary CSA, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is often terminated abruptly by a large breath, and there are usually no more that 4 to 5 breaths between apneas.</br>Furthermore, most patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 respiration will have a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to substance use, particularly potent long-acting narcotics, may exhibit periodic breathing with central apneas, but the pattern of ventilation between apneas does not have a crescendo-decrescendo pattern and the cycle length is shorter than 40 seconds.</br>In addition, the underlying pattern of breathing is often 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ataxic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (irregular varia- tions in cycle length and tidal volume) and a low respiratory rate may be noted.</br>Unlike primary CSA, central apneas can occur during stage N3 in patients taking opioids.</br>Patients with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to medical or neurological conditions not of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 pattern often have a history of a known 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (recent cerebrovascular accident) but in others a high index of suspicion for an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    underlying disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is indi- cated.</br>For example, patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chiari malformation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may present in adulthood with unexplained central apneas and relatively few other symptoms.</br>Thus, primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is a diagnosis based on careful exclusion of other causes of CSA. </br>In sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and hypoxemic syndromes, patients have normal or increased daytime arterial PCO2 (PaCO2) with the onset or worsening of hypoven- tilation during sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is defined as a PaCO2 &gt; 45 mm</br>Hg.</br>Patient with primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 usually have an awake PaCO2 &lt;</br>40 mm Hg.</br>The causes of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include abnormalities in ventilatory control, neuro- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parenchymal lung disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or restrictive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>PSG in these patients may reveal a few central apneas, but the predominant pattern is one of reduced tidal volume (shallow pattern of breathing), often without a compensatory increase in respiratory rate.</br>There is usually significant 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or ventilation perfusion mismatch.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parenchymal lung disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 typically have abnormal pulmonary function tests and the most severe arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation typically occurs during REM sleep. </br>Unresolved Issues and Further Directions </br>Although primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is believed to be a relatively rare disorder, additional prevalence data are needed.</br>The pathophysiology of this disorder remains unclear.</br>Specifically, the relative roles of instability in sleep state (low arousal threshold, delayed transition from wake to stable sleep) and respiratory control instability (elevated hypercapnic ventila- tory response) require further elucidation. </br>93 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Bibliography Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Rein J, Vela-Bueno A, Kales A. Prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep- disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in women: effects of gender.</br>Am J Respir Crit Care Med 2001;163:608–13. </br>Bradley T, McNicholas W, Rutherford R, Popkin J, Zamel N, Phillipson E. Clinical and physiological heterogeneity of the central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am Rev Respir Dis 1986;134:217–21. </br>Dempsey 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    JA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Smith CA, Przybylowski T, et al.</br>The ventilatory responsiveness to CO(2) below eupnoea as a determinant of ventilatory stability in sleep.</br>J Physiol 2004;560:1–11. </br>Eckert DJ, Jordan AS, Merchia P, Malhotra A. Central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: Pathophysiology and treatment.</br>Chest 2007;131:595–607. </br>Hall MJ, Xie A, Rutherford R, Ando S, Floras JS, Bradley TD.</br>Cycle length of periodic breathing in patients with and without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am J Respir Crit Care Med 1996;154:376–81. </br>White D, Zwillich C, Pickett C, Douglas N, Findley L, Weil J. Central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: improvement with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    acetazolamide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy.</br>Arch Intern Med 1982;142:1816–9. </br>Xie A, Rankin F, Rutherford R, Bradley TD.</br>Effects of inhaled 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and added dead space on 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic central sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Appl Physiol 1997;82:918–26. </br>Xie A, Rutherford R, Rankin F, Wong B, Bradley T. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypocapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and increased ventilatory responsiveness in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic central sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am J Respir Crit Care Med 1995;152:1950–5. </br>Xie A, Wong B, Phillipson E, Slutsky A, Bradley T. Interaction of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and arousal in the pathogenesis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic central sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am J Respir Crit Care Med 1994;150:489–95. </br>Primary Central Sleep Apnea of Infancy ICD-9-CM code: 770.81 ICD-10-CM code:</br>P28.3 Alternate Names Infant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of infancy, primary sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the newborn. </br>Inappropriate terms for primary central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the newborn include near-miss sudden infant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndrome (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SIDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
),</br>near-SIDS, aborted 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SIDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and aborted crib 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; these terms imply a causal relationship between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SIDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that is not supported by extensive research.</br>Likewise, the term “apparent life-threatening event (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ALTE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
)” should not be used.</br>Although some infants with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 present with an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ALTE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, there are many other causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ALTE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and some children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 do not have ALTE. </br>Diagnostic Criteria Criteria A-D must be met A. Apnea or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cyanosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is noted by an observer or an episode of sleep related central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is detected by monitoring. </br>B. The infant has a conceptional age of at least 37 weeks. </br>94 C. PSG or alternative monitoring such as hospital or home 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 monitoring shows either: .</br>Recurrent, prolonged (&gt; 20 seconds duration) central apneas.1 .</br>Periodic breathing2 for ≥ 5% of total sleep time. </br>D.</br>The disorder is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or medication. </br>Notes .</br>Normative data concerning the number of prolonged central apneas per hour are not well established. </br>2. As defined by the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events. </br>3. Short (&lt; 20 seconds) central apneas associated with significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are more likely to be a sign of decreased pulmonary reserve than of central nervous system pathology. </br>4. Definitive determination of the central nature of apneas requires simultaneous monitoring of airflow and respiratory effort.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and mixed apneas may also be present, but central apneas are predominant. </br>Essential Features Primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA of infancy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by prolonged, predominantly central apneas in children of at least 37 weeks conceptional age.</br>These events are typically associated with physiological compromise (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bradycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), or the need for intervention such as stimulation or resuscitation.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or mixed apneas or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also be seen, although central events are the predominant finding.</br>It is a disorder of respira- tory control that can be either a developmental problem associated with immaturity of the brainstem respiratory centers or secondary to other medical conditions that produce 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by mechanisms such as direct 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of central respiratory control.</br>Apnea in the neonate or infant may be exacerbated or precipitated by a variety of medical condi- tions, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, gastroesophageal reflux, substances, or anesthesia, which must be recognized and treated to stabilize the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>If another medical condition appears to be the cause rather than an exacerbating factor for the CSA, then the condition should be classified as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to a medical or neurological condition, or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to a medication or substance. </br>Despite the heterogeneity of infant risk groups and underlying pathophysiology, most studies report a progressive decrease in frequency of apneas and risk of symptomatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 secondary to other medical conditions after the early weeks of life. </br>95 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Associated Features Infants may present with an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ALTE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (defined by a National Institutes of Health Development Conference as “an episode that is frightening to the observer, and that is characterized by some combination of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>[</br>central or occasionally obstructive], color change, marked change in muscle tone, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    choking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or gagging.</br>In some cases, the observer fears that the infant has died”).</br>Many infants with primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA of infancy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will not have an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ALTE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and many 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ALTEs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 of infancy is state dependent, and the frequency of respiratory events increases during active (REM) sleep.</br>Paradoxical chest wall movements are common during active sleep in infants and may cause a fall in arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation because of ventilation or perfusion defects associated with a decrease in functional residual capacity.</br>Underlying comorbidities (for example, chronic lung disease or abnormal neurological status) can predispose the infant to having a more severe or prolonged course for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Note that a small upper airway will exaggerate the obstructive elements of this disorder. </br>Clinical and Pathophysiological Subtypes Not applicable. </br>Demographics Less than 0.5% of full-term newborns experience symptomatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Studies have shown that during the first six months of life, 2% of healthy full-term infants will experience at least one 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 event lasting 30 seconds or longer or an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that lasts at least 20 seconds and is associated with a heart rate less than 60 beats per minute.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Apnea of infancy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs equally in males and females, and in infants of all races and ethnic groups. </br>Predisposing and Precipitating Factors Many factors may precipitate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes, including gastroesophageal reflux, intra- cranial pathology, substances, anesthesia, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, impaired oxygenation, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sepsis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    meningitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, respiratory syncytial virus 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and pertussis).</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with respiratory syncytial virus, in particular, can increase the fre- quency and the duration of apneas. </br>Familial Patterns None known. </br>Onset, Course, and Complications Onset is usually in the first weeks or months of life.</br>Some infants may be diagnosed by nursing observations or routine monitoring soon after birth.</br>Older infants may present with an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ALTE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or may have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    failure to thrive.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>The prognosis is generally good, with res- olution of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 over the first few years of life and no residual sequelae.</br>The presence of persistent severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be an indication of an underlying medical condition and should prompt further evaluation.</br>Patients with persistent severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may develop sequelae related to hypoxic events. </br>Developmental Issues This is a condition of infancy that normally improves over time. </br>Pathology and Pathophysiology Physiological factors contributing to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are related to immaturity of respiratory control.</br>These include developmental alterations in central drive, chemoreceptor or mechanoreceptor responses, and upper airway reflexes.</br>Precipitating factors for wors- ening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, intracranial pathology, substances, anes- thesia, metabolic disturbances, impaired oxygenation, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Objective Findings Apnea is predominantly central, but obstructive and mixed apneas may occur.</br>Apneas are seen most frequently during REM sleep.</br>Other diagnostic tests, such as a full EEG or evaluation for reflux, may be appropriate in individual cases. </br>Differential Diagnosis Primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 of infancy should be distinguished from the normal respiratory pauses that occur during sleep.</br>Normative respiratory data from several large studies show that healthy asymptomatic infants commonly have central respiratory pauses, either as isolated events (particularly during REM sleep) or after sigh breaths or movements. </br>Primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 of infancy should be distinguished from the popular clinical term, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ALTE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which is not a specific diagnosis but an ill-defined constellation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parent-reported apnea symptoms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that range in severity from benign to life threatening. </br>Recurrent, severe infant sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is usually due to other comorbid conditions, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or unrecognized neurological conditions such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brainstem malformation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or neurodegenerative condi- tion; thus an evaluation for these conditions should be performed.</br>Another diagnos- tic consideration is a form of child abuse (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Munchausen syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by proxy) mani- fest as imposed upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or attempted suffocation.</br>Primary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 of infancy should be disassociated from the postmortem diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SIDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although a small percentage of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SIDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 victims experience 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms prior to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Sleep Related Breathing Disorders Sleep Related Breathing Disorders primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the newborn or infant has not been established as an independent risk factor for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SIDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Unresolved Issues and Further Directions Infancy is a developmental period normally characterized by instability of control of breathing; thus, defining what is abnormal is a diagnostic challenge.</br>Further research is needed into the mechanisms of ventilatory control development in the infant and the pathophysiologic factors resulting in infant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Bibliography American Academy of Pediatrics.</br>Apnea, sudden infant death syndrome, and home monitoring.</br>Pediatrics 2003;111:914–7. </br>Hunt CE, Hufford DR, Bourguignon C, Oess MA.</br>Home documented monitoring of cardiorespiratory pattern and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation in healthy infants.</br>Pediatr 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Res
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 1996;39:216–22. </br>National Institutes of Health Consensus Development Conference on Infantile Apnea and Home Monitoring, Sept 29 to Oct 1, 1986.</br>Pediatrics 1987;79:292–9. Ramanathan R, Corwin MJ, Hunt CE, et al.</br>Cardiorespiratory events recorded on home monitors: Comparison of healthy infants with those at increased risk for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SIDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>JAMA 2001;285:2199–207. </br>Southall DP, Plunkett MC, Banks MW, Falkov AF, Samuels 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Covert video recordings of life- threatening child abuse: lessons for child protection.</br>Pediatrics 1997;100:735–60. </br>Primary Central Sleep Apnea of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ICD-9-CM code: 770.82 ICD-10-CM code:</br>P28.4 Alternate Names Apnea of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-D must be met A. Apnea or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cyanosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is noted by an observer, or an episode of sleep related central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bradycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is detected by hospital monitoring in the postnatal period. </br>B. The infant has a conceptional age less than 37 weeks at the time of onset of symptoms. </br>C. PSG or alternative monitoring such as hospital or home 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 monitoring shows either: .</br>Recurrent prolonged (&gt; 20 seconds duration) central apneas.1 2.</br>Periodic breathing2 for ≥ 5% of total sleep time. </br>98 D. The disorder is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or medication. </br>Notes .</br>Normative data concerning the number of prolonged central apneas per hour are not well established. </br>2. As defined by the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events. </br>3. Short (&lt; 20 seconds) central apneas associated with significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are more likely to be a sign of decreased pulmonary reserve than of central nervous system pathology. </br>4. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and mixed apneas may also be present, but central apneas are predominant. </br>Essential Features Apnea is very common in preterm infants, and the prevalence varies inversely with ges- tational age.</br>In the preterm infant, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be anticipated, is primarily related to immaturity, and may require supportive ventilatory and pharmacologic treatment.</br>The condition will improve with maturation unless extenuating conditions, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic lung disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, are present.</br>Apneas are predominantly central, but mixed or obstructive apneas or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be seen.</br>The events are typically associated with physiological compromise (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, bra- dycardia) or the need for intervention such as stimulation or resuscitation. </br>Associated Features Apnea in the preterm infant is commonly associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bradycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Primary CSA of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is state dependent, and the frequency of respiratory events increases during active (REM) sleep.</br>Paradoxical chest wall movements are common during active sleep in neonates and may cause a fall in arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation because of ventilation or perfusion defects associated with a decrease in functional residual capac- ity.</br>Underlying comorbidities (for example, chronic lung disease or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal neuro- logical status)
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can predispose the infant to having a more severe or prolonged course for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Note that a small upper airway will exaggerate the obstructive elements of this disorder. </br>Clinical and Pathophysiological Subtypes None known. </br>99 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Demographics The prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 varies inversely with conceptional age.</br>In studies, approximately 25% percent of infants who weigh less than 2,500 g at birth and 84% of infants under 1,000 g may experience symptomatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the neo- natal period.</br>Ninety-two percent of preterm infants will be symptom free by 37 weeks postconceptional age, and 98% by 40 weeks after conception, with resolution in most infants by 43 weeks postconception.</br>Apnea of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs equally in males and females, and in infants of all races and ethnic groups. </br>Predisposing and Precipitating Factors Developmental delay in respiratory control associated with premature birth is the major predisposing condition.</br>Diverse factors are known to precipitate development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes in predisposed preterm infants.</br>These include thermal instability, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, intracranial pathology, substances, anesthesia, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, impaired oxygenation, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with respiratory syncytial virus can increase the frequency and the duration of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in predisposed infants.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can present as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Persistence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 after 43 weeks conceptional age should raise suspicion of addi- tional etiologic factors. </br>Familial Patterns None known. </br>Onset, Course, and Complications In preterm infants, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is rare on day one of life, and its presence usually signals another illness.</br>More typical onset occurs between the second and seventh days.</br>Apnea of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 usually ceases by 37 weeks conceptional age but may persist for several weeks beyond term, especially in infants born before 28 weeks postconception; 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 beyond 43 weeks postconception is rare.</br>Adverse outcomes for former preterm infants are more closely related to the prenatal or neonatal course, associated comorbidities, and environmental factors than to the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 per se.</br>For most children, long-term outcomes for uncomplicated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are excellent.</br>However, the prognosis for infants with persistent recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea spells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 requiring frequent resuscitation is more guarded and depends on the cause of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and associated comorbidities. </br>Developmental Issues This is a condition related to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that normally improves over time. </br>100 Pathology and Pathophysiology Physiological factors contributing to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are related to immaturity of respiratory control.</br>These include developmental alterations in central drive, chemoreceptor or mechanoreceptor responses, and upper airway reflexes.</br>Precipitating factors for wors- ening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in preterm infants include thermal instability, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, intracranial pathology, substances, anesthesia, metabolic disturbances, impaired oxy- genation, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Objective Findings Most premature neonates are diagnosed with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 based on cardio- respiratory monitoring in the neonatal intensive care unit, rather than by PSG.</br>When PSG is performed, central apneas are often shown to have a mixed component, with mixed apneas accounting for 50% to 75% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in small premature infants; studies suggest that obstructive-type events account for 10% to 20% of events; and pure central events, 10% to 25%.</br>Periodic breathing may be present. </br>Differential Diagnosis Apnea of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be distinguished from normal, physiologic respiratory pauses that occur during sleep in infants.</br>Studies have shown that healthy asymptom- atic infants commonly have brief (&lt; 20 second) central respiratory pauses, either as isolated events (particularly during REM sleep) or after sigh breaths or movements (in which case the apneas may be longer).</br>These infants are typically asymptomatic, with no changes in color or muscle tone. </br>The differential diagnosis is long and includes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 secondary to severe gastroesoph- ageal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, central nervous system malformations or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hemorrhage
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sepsis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and rarely primary cardiac 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Comorbid conditions should be suspected whenever 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are severe or continue beyond 43 weeks gestation. </br>Unresolved Issues and Further Directions The mechanisms underlying physiologic maturation of ventilatory control are not well understood.</br>Further research is required to determine which infants are at greatest risk for severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Bibliography American Academy of Pediatrics.</br>Apnea, sudden infant death syndrome, and home monitoring.</br>Pediatrics 2003;111:914–7. </br>Hunt CE, Hufford DR, Bourguignon C, Oess MA.</br>Home documented monitoring of cardiorespiratory pattern and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation in healthy infants.</br>Pediatr 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Res
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 1996;39:216–22. </br>101 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Kahn A, Rebuffat E, Sottiaux M, Blum D. Management of an infant with an apparent life-threatening event.</br>Pediatrician 1988;15:204–11. </br>National Institutes of Health Consensus Development Conference on Infantile Apnea and Home Monitoring, Sept 29 to Oct 1, 1986.</br>Pediatrics 1987;79:292–9. Ramanathan R, Corwin MJ, Hunt CE, et al.</br>Cardiorespiratory events recorded on home monitors: Comparison of healthy infants with those at increased risk for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SIDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>JAMA 2001;285:2199–207. </br>Rigatto H. Breathing and sleep in preterm infants.</br>In: Loughlin G, Carroll J, Marcus C, eds.</br>Sleep and breathing in children.</br>New York: Marcel Dekker, 2000:495–515. </br>Schmidt B, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Roberts RS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Davis P, et al.</br>Long-term effects of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>N Engl J Med 2007;357:1893–902. </br>Southall DP, Plunkett MC, Banks MW, Falkov AF, Samuels 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Covert video recordings of life- threatening child abuse: lessons for child protection [see comments].</br>Pediatrics 1997;100:735–60. Treatment-Emergent Central Sleep Apnea ICD-9-CM code: 327.29 ICD-10-CM code: G47.39 Alternate names Complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-C must be met A. Diagnostic PSG shows five or more predominantly obstructive respiratory events1 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or mixed apneas, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or RERAs) per hour of sleep B. PSG during use of positive airway pressure without a backup rate shows significant resolution of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive events and emergence or persistence of central apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with all of the following: </br>1. Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
—central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 index [CAHI] ≥ 5/hour. </br>2. Number of central apneas and central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is ≥ 50% of total number of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>C. The central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., CSA with CSB or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to a medication or substance). </br>Notes .</br>Respiratory events defined according the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events. </br>2. A diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    treatment-emergent central sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 does not exclude a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>That is, a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be made based on the diagnostic sleep study. </br>102 Essential Features A diagnosis of treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is characterized by predominantly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive events (
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>

<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or mixed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) during a diagnostic sleep study with persistence or emergence of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 during administration of positive airway pressure without a backup rate, despite significant resolution of obstructive respiratory events.</br>If the central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, patients are given a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 rather than treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (e.g., a patient with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 exhibits mainly obstructive events during diagnostic PSG but then exhibits predominantly central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with CSB on positive airway pressure). </br>Associated Features Patients with treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 have several characteristics when placed on positive airway pressure without a backup rate.</br>A high number of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 persist on PAP treatment, and the AHI is often higher during NREM than REM sleep.</br>This is due to the fact that treatment-emergent central apneas almost invariably occur during NREM sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pressures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that are effective in controlling obstructive events during REM sleep prove ineffective during NREM sleep due to emergence of central apneas.</br>If patients can attain stage N3, central apneas often decrease until interrupted by an arousal or transition to a lighter stage of sleep that precipitates another run of central apneas or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 can have persistent sleep fragmentation on CPAP treatment and may report little benefit from therapy. </br>Clinical and Pathophysiological Subtypes None known. </br>Demographics The percentage of patients with persistent or emergent central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on the initial poly- somnographic positive airway pressure titration varies from 2% to 20% depending on the characteristics of the group studied (community or referral sleep center) and the methodology.</br>If patients who are taking opioids or have underling central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with CSB are included, the percentage is at the higher end of the range.</br>The percentage of patients with central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that persists on chronic CPAP treatment (approxi- mately 2%) is considerably lower than the percentage identified on the first or second night of CPAP treatment. </br>Predisposing and Precipitating Factors A number of factors have been hypothesized to cause treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, but definitive data are not available.</br>The patients presumably have characteristics that would predispose them to instability in ventilatory control or sleep maintenance. </br>103 Sleep Related Breathing Disorders Sleep Related Breathing Disorders These include a low arousal threshold and high ventilatory controller gain.</br>Studies have found that often a small increase in end-tidal PCO2 can stabilize breathing in patients with treatment-emergent central apneas.</br>Therefore, any events that predis- pose a patient to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can trigger treatment-emergent central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In some, but not all studies, the overall AHI on the diagnostic PSG (or diagnostic portion of a split-night PSG) was higher in the treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 group compared to the patients without this diagnosis.</br>In other studies, patients with treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 had more central apneas during the diagnostic PSG and were more likely to be male.</br>However, identified risk factors for treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 vary considerably from study to study. </br>Of note, the emergence of central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 after treatment of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with tra- cheostomy, maxillomandibular advancement, and oral appliance treatment for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been reported.</br>A case report of the development of central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 following nasal surgery in a patient with known 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has also recently been published. </br>Familial Patterns None known. </br>Onset, Course, and Complications The recognition of treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 follows PAP titration.</br>An accurate esti- mate of the percentage of patients with treatment-emergent central apneas whose central events persist on long-term PAP treatment does not exist, as most published reports are retrospective and had a significant number of patients lost to follow-up.</br>Of interest, one study comparing the results of an initial CPAP titration study with one per- formed after six months of therapy found patients who did not meet criteria for treat- ment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 on the initial study but met the criteria on the second study.</br>Those patients with treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 that do not experience resolution of central apneas on chronic PAP treatment are found to have a high number of residual events on PAP machine interrogation in clinic follow-up.</br>Nocturnal oximetry at home on PAP treatment may show persistent arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation.</br>Sleep fragmentation and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may persist if a significant number of central apneas remain.</br>There is the potential for poor adherence and acceptance of PAP treatment as a result of this. </br>Developmental Issues Treatment-emergent sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has not been described in children but this may be due to the relatively small number of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 who are treated with PAP. </br>104 Pathology and Pathophysiology Due to variation in definitions of treatment-emergent CSA, the pathophysiology is not clearly defined.</br>A low arousal threshold and difficulty reaching stage N3 sleep may pre- dispose to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep instability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 destabilize breathing.</br>A high ventilatory response to PaCO2 and a small difference between the sleeping PaCO2 and the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 threshold may also predispose patients to treatment-emergent central apneas.</br>Treatment with excessive positive airway pressure may trigger treatment-emergent central apneas in susceptible individuals. </br>Objective Findings PSG during a full night diagnostic study (or diagnostic portion of a split-night PSG) shows 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    predominantly obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or mixed apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of five or more per hour of sleep.</br>PSG with PAP (either a full night titration study or PAP treatment portion of a split night study) without a backup rate shows significant resolution of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive events and emergence or persistence of central apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or central hypopneas.</br>The CAHI is five or greater per hour, and more than 50% of the respiratory events are central in nature.</br>A diagnosis of treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 excludes patients who manifest central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on PAP treatment when the 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is better explained by another CSA dis- order or by over-titration. </br>PSG with administration of PAP often reveals adequate treatment during REM sleep and stage N3 sleep but repetitive episodes of central events during stages N1 and N2.</br>In some patients, progressive increases in pressure with a goal of preventing airflow limitation reach a “break point” at which central apneas appear. </br>Differential Diagnosis Many patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have a few central events while on PAP.</br>However, in the majority of cases, the central AHI is not ≥ 5/hour and central events are not ≥ 50% of the total number of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, while on PAP, exhibit predominantly central events that are believed to be secondary to a CSA disor- der classified elsewhere.</br>In this case, a diagnosis of both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is appropriate, rather than a diagnosis of treatment-emergent CSA.</br>For example, a patient taking 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 has predominantly obstructive events during the diagnostic portion of a split-night PSG.</br>Once obstructive events are eliminated on PAP, CSA with ataxic breathing is noted.</br>A diagnosis of both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to a medication or substance should be made if criteria for that disorder are met. </br>105 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Unresolved Issues and Further Directions The true incidence of treatment-emergent sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as well as the percentage of patients who have persistent central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on chronic PAP treatment remains to be defined.</br>Further prospective studies with clearly defined inclusion and exclusion crite- ria are needed to better define the exact percentage of patients with treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 who have persistent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 after chronic PAP treatment.</br>There may be night-to- night variability in the amount of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 displayed by a given patient.</br>It is unknown, for example, whether treatment-emergent central apneas that resolve on chronic PAP treatment will re-emerge if the patient discontinues PAP treatment for a period of time and then restarts treatment.</br>A number of factors have been hypothesized to increase the likelihood of treatment-emergent central apneas including overtitration (excessive pressure), undertitration (respiratory effort 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 followed by central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), the use of bilevel PAP rather than CPAP, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from mask leak, and use of a split night study.</br>Further study is needed to verify that these factors do indeed predispose a patient to develop treatment-emergent central apneas.</br>The evolution of treatment-emergent central apneas on chronic PAP treatment also remains to be determined; that is, to what extent do central events resolve over time and what is the time course of this resolu- tion?</br>In light of the increasing utilization of auto-titrating PAP, further investigation of the incidence of treatment-emergent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 with this modality is indicated. </br>Bibliography Allam JS, Olson EJ, Gay PC, Morgenthaler TI.</br>Efficacy of adaptive servoventilation in treatment of complex and central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes.</br>Chest 2007;132:1839–46. </br>Dernaika T, Tawk M, Nazir S, Younis W, Kinasewitz GT.</br>The significance and outcome of continuous positive airway pressure-related central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during split-night sleep studies.</br>Chest 2007;132:81–7. </br>Gay PC.</br>Complex sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: it really is a disease.</br>J Clin Sleep Med 2008;4:403–5. </br>Gilmartin GS, Daly RW, Thomas RJ.</br>Recognition and management of complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-disordered
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 breathing.</br>Curr Opin Pulm Med 2005;11:485–93. </br>Javaheri S, Smith J, Chung E.</br>The prevalence and natural history of complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Clin Sleep Med 2009;5:205–11. </br>Lehman S, Antic 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Thompson C, Catcheside 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Mercer J, McEvoy RD.</br>Central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on commencement of continuous positive airway pressure in patients with a primary diagnosis of obstructive sleep apnea-hypopnea.</br>J Clin Sleep Med 2007;3:462–6. </br>Malhotra A, Bertisch S, Wellman A. Complex sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: it isn’t really a disease.</br>J Clin Sleep Med 2008;4:406–8. </br>Morgenthaler TI, Kagramanov V, Hanak V, et al.</br>Complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: is it a unique clinical syndrome?</br>Sleep 2006;29:1203–9. </br>Thomas RJ, Daly RW, Weiss JW.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Low-concentration carbon dioxide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is an effective adjunct to positive airway pressure in the treatment of refractory mixed central and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep-disordered
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 breathing.</br>Sleep 2005;28:69–77. </br>106 Thomas RJ, Mietus JE, Peng CK, et al.</br>Differentiating obstructive from central and complex sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 using an automated electrocardiogram-based method.</br>Sleep 2007;30:1756–69. </br>Thomas RJ, Terzano MG, Parrino L, Weiss JW.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obstructive sleep-disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with a dominant cyclic alternating pattern--a recognizable polysomnographic variant with practical clinical implications.</br>Sleep 2004;27:229–34. </br>Westhoff M, Arzt M, Litterst P. Prevalence and treatment of central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 emerging after initiation of continuous positive airway pressure in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without evidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Breath 2012;16:71–8. </br>107 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Disorders The primary feature of these disorders is insufficient sleep related ventilation, result- ing in abnormally elevated arterial partial pressure of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carbon dioxide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (PaCO2) during sleep.</br>In addition, demonstration of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is required for a diagno- sis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (OHS).</br>Awake 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is defined as an arterial partial pressure of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carbon dioxide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (PaCO2) greater than 45 mm Hg.</br>In the sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 other than OHS, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may or may not be present.</br>If 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present during wakefulness, it worsens during sleep in all of these disorders. </br>General Criteria Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Criterion A must be met A. Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as defined by the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events, is present.1,2 Notes .</br>Monitoring of arterial PCO2 during sleep is not practical.</br>Acceptable surrogates include end-tidal PCO2 or transcutaneous PCO2. </br>2. Arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation is often present but is not required for the diagnosis. </br>Obesity 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation Syndrome ICD-9-CM code: 278.03 ICD-10-CM code: E66.2 Alternate Names Hypercapnic sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Use of the term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pickwickian syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is discouraged because not only has it been applied to those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but also indiscriminately used to describe persons who are only obese and those with OHS. </br>Diagnostic Criteria Criteria A-C must be met A. Presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during wakefulness (PaCO2 &gt; 45 mm Hg) as measured by arterial PCO2, end-tidal PCO2, or transcutaneous PCO2. </br>B. Presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (BMI &gt; 30 kg/m2; &gt; 95th percentile for age and sex for children).</br> </br>108 C. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not primarily due to lung parenchymal or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, pulmonary vascular pathology, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (other than mass loading from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), medication use, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or a known congenital or idiopathic central alveolar hypoventilation syndrome. </br>Notes .</br>PSG shows worsening of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep if PaCO2 or noninvasive estimate of the PaCO2 is measured. </br>2. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is often present and, in such cases, a diagnosis of both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and OHS should be made. </br>3.</br>Arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation is usually present but is not required for the diagnosis. </br>Essential Features OHS is characterized by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and daytime 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (arterial PaCO2 &gt; 45 mm Hg) that cannot be fully attributed to an underlying cardiopulmonary or neurologic disease.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 worsens during sleep and is often associated with severe arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is often worse during REM than during NREM sleep.</br>The majority of OHS patients have comorbid 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (80% to 90%).</br>In these patients, daytime 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 may improve or even normalize with adequate PAP treatment and sustained adherence to treatment.</br>Those OHS patients without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 exhibit sustained or intermittent episodes of shallow breathing during sleep associated with worsening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with OHS may have few, if any, sleep com- plaints, or may present with considerable 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 including reduced sleep efficiency and frequent awakenings.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may remain 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    unno-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 ticed for quite some time until sudden deterioration with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiopulmonary arrest
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    decompensation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (acute or chronic hypercapnic respiratory failure) develops. </br>Associated Features Patients with OHS commonly complain of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The severity of hyper- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    somnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may not correlate closely with degree of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other symptoms include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morning headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    impairments of memory
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or concentration.</br>Physical examination may reveal features suggestive of cor pul- monale or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    circulatory congestion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as plethora, scleral injection, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Laboratory testing commonly shows 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and elevated serum 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 on electrolyte testing (≈ serum 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
), reduced forced vital capacity during 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmo-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 nary function testing, right heart strain, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    right ventricular hypertrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and right atrial enlargement on electrocardiography and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventricular dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on echocardiography. </br>109 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Consequences of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include pulmonary artery hyper- tension, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurocognitive dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Clinical and Pathophysiological Subtypes Not applicable or known. </br>Demographics OHS may be underdiagnosed if 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 analysis (≈ serum 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
) is not performed in obese patients presenting with complaints suggestive of OHS.</br>The prevalence of OHS in populations of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 varies across studies but is often in the range of 10% to 15% of obese patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although the prevalence of OHS is higher in men than women the difference is not as prominent as in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Predisposing and Precipitating Factors 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is believed to be the primary pathophysiologic factor responsible for hypoven- tilation and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Greater degrees of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are often associated with worse sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but individual variations in the severity of hypercap- nia at similar weights may be seen.</br>The use of central nervous system depressants, such as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, anxiolytics, and hypnotics, may further worsen respiratory impair- ment.</br>Patients who are hypercapnic and hypoxemic during wakefulness will invari- ably become even more so during sleep, in particular REM sleep, but the relationship between wake SaO2/PaCO2 and sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not sufficiently strong to have substantial predictive value in individual patients. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications Persons who are eventually diagnosed with OHS either present initially for evalu- ation of suspected 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or are identified following one or more episodes of severe hypercapnic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The course can be variable but is generally slowly pro- gressive.</br>Many affected individuals with severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 develop 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurocognitive dys-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 function.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is common in those with chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although the risk of increased morbidity and mortality appears to increase with worsening sleep related hypoventilation/hypoxemia, the specific relationship between sleep related hypoventi- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lation/hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and morbidity and mortality is not well defined.</br>Obesity, itself, can lead to other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    shortness of breath
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on exer- tion and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orthopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, even in the absence of demonstrable elevation of daytime PaCO2. </br>110 However, in one study of inpatients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 had an 18-month mortality of 23% compared with 9% in the group with equivalent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but no 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Many patients with OHS respond to CPAP or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bilevel
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 PAP with improvement in daytime PaCO2.</br>However, normalization of daytime PaCO2 occurs in only a minority of patients.</br>In one study, 34% of OHS patients using PAP more than 4.5 hours per night had normalization of the PaCO2.</br>In contrast 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may worsen with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy alone for the associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Developmental Issues Not known. </br>Pathology and Pathophysiology The etiology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not completely understood.</br>Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is common, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not entirely a function of upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The importance of various factors leading to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 likely varies among patients.</br>It has been postulated that sustained nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 results from the development of short (due to apnea-hypopnea) or longer (secondary to hypoven- tilation) periods of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 accompanied by inadequate compensation (i.e., 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 unloading) during periods of ventilation between obstructive events.</br>Abnormal venti- latory control (blunted hypercapnic ventilatory response) allows 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to persist into wakefulness after the cause of acute 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is no longer present.</br>A chronic hypercapnic state would produce an elevation of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Although this blunts the degree of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    acidosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to an elevated PaCO2, it reduces the compensatory CO2 ventilatory response.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Impaired renal bicarbonate excretion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 rate, as seen in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or diuretic-related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chloride deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, may contribute to the persistence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 itself is also associated with several factors that predispose to 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 retention.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 itself increases 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 production.</br>There is an increased work of breathing due to mass loading from the additional weight on the respiratory pump as well as resistive loading due to intermittent upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>Numerous factors impair 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 elimination including altered lung volumes and mechan- ics, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventilation-perfusion abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atelectasis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or pulmonary conges- tion, reduced chemosensitivity and load responsiveness, and suppression of respiratory drive due to obesity-related humoral factors, such as resistance to the elevated leptin levels that occur in patients with the OHS (leptin is a respiratory stimulant).</br>The impor- tance of these factors likely varies from patient to patient. </br>Objective Findings Arterial blood gas testing during wakefulness shows 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and often 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in untreated patients.</br>Even with effective treatment most OHS patients continue to Sleep Related Breathing Disorders Sleep Related Breathing Disorders exhibit some degree of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The characteristic polysomnographic finding is sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation during sleep with or without obstructive apneas and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Worsening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep can be documented by an arterial blood gas measurement of PaCO2 during sleep (rarely performed) or transcutaneous or end-tidal PCO2 measurements.</br>Periods of decreased tidal volume lasting up to several minutes with sustained arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation are usually present.</br>Intermittent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be observed.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present in the majority of OHS patients, during at least a portion of the night.</br>The transient ven- tilation between obstructive events (even if associated with arousal from the preceding obstructive event) is not sufficient to prevent worsening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>Severe arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation is usually associated with the obstructive events.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Electrocardiography, chest radi- ography, and echocardiography may demonstrate evidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>The serum 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 level is usually elevated due to renal compensation for chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory acidosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>In one study, a serum 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 level threshold &gt; 27 mEq/L had a sensitivity of 92% and a specificity of 50% of identifying OHS in obese patients suspected of having 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>This suggests that the serum 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 level may be useful to screen patients for possible OHS.</br>However, an arterial blood gas is required for diagnosis of OHS, as the serum 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 level may be elevated due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic alkalosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Differential Diagnosis The differential diagnosis includes any disorder that can give rise to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during wakefulness and sleep.</br>This includes pulmonary airway and parenchymal dis- orders, pulmonary vascular pathology, neuromuscular and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, severe untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothyroidism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, use of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory suppressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and congenital or idio- pathic central alveolar hypoventilation syndromes.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 syndromes can be distinguished from sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by the periodic alterations in airflow and accompanying periodic fluctuations in SaO2.</br>In contrast, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation due to sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is generally more sustained, usually several minutes or longer in duration.</br>When more than one disorder is believed to be responsible for the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventilatory insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep, all pertinent diagnoses should be coded. </br>Unresolved Issues and Further Directions Future research into the pathogenesis of this disorder, including renal 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 homeostasis, is needed.</br>Because it is clinically impractical to routinely obtain arterial blood samples during sleep in most persons suspected of this disorder, other techniques of measuring 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels must be investigated.</br>The degree and duration of hypercapnia/ 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 necessary to produce adverse consequences, such as pulmonary hyperten- sion, in individual patients is not well defined.</br>Little information is available regarding the effect of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy or noninvasive ventilation on the course of the underlying disease.</br>Studies are needed to determine the optimal time to initiate these interventions and the specific subpopulations of patients who will benefit most from these therapies. </br>Bibliography Berger KI, Goldring RM, Rapoport DM.</br>Obesity 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Semin Respir Crit Care Med 2009;30:253. </br>Budweiser S, Riedl SG, Jörres RA, et al.</br>Mortality and prognostic factors in patients with obesity- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 undergoing noninvasive ventilation.</br>J Intern Med 2007;261:375–83. </br>Littleton SW, Mokhlesi B. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pickwickian syndrome-obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Clin Chest Med 2009;30:467–78, vii-viii. </br>Mokhlesi B; Tulaimat A; Evans AT et al.</br>Impact of adherence with positive airway pressure therapy on 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Clin Sleep Med 2006;2:57–62. </br>Mokhlesi B. Obesity 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a state-of-the-art review.</br>Respir Care 2010;55:1347–62. </br>Nowbar S, Burkart KM, Gonzales R, et al.</br>Obesity-hypoventilation in hospitalized patients: prevalence, effects, and outcome.</br>Am J Med 2004;116:1–7. </br>Piper AJ, Grunstein RR.</br>Obesity 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: mechanisms and management.</br>Am J Respir Crit Care Med 2011;183:292–8. </br>Piper AJ.</br>Obesity 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
--the big and the breathless.</br>Sleep Med Rev 2011;15:79–89. </br>Congenital Central Alveolar 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation Syndrome ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.25 ICD-10-CM code: G47.35 Alternate Names Congenital central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>The term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Ondine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
’s curse is no longer recommended due to its negative connotations. </br>Diagnostic Criteria Criteria A and B must be met A. Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present. </br>B. Mutation of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PHOX2B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 gene is present. </br>Notes .</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be associated with either 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (PaCO2 &gt; 45 mm Hg) or normal daytime PaCO2 levels. </br>Sleep Related Breathing Disorders Sleep Related Breathing Disorders In either case, the PaCO2 is higher during sleep and meets criteria for sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>2. PSG monitoring demonstrates severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation.</br>Some central apneas may occur but the predominant pattern is reduced flow/tidal volume. </br>3.</br>Although the condition is termed congenital, some patients with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PHOX2B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 genotype may present phenotypically later in life (and even in adulthood), especially in the presence of a stressor such as general anesthesia or a severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory illness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Essential Features Congenital central alveolar hypoventilation syndrome (CCHS) is a syndrome of auto- nomic dysfunction, primarily the failure of automatic central control of breathing, due to a mutation of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PHOX2B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 gene.</br>CCHS is characterized by the onset of hypoven- tilation, usually at birth.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is worse during sleep than wakefulness and is unexplained by primary pulmonary, neurological, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>CCHS typically presents in an otherwise normal-appearing infant who is noted to have cyano- sis, feeding difficulties, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypotonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or, less commonly, central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Some children are diagnosed following cardiovascular collapse.</br>The infant requires intubation and then cannot be weaned from mechanically assisted ventilation, despite appearing vigorous and having a normal chest radiograph.</br>Some infants may appear to breathe adequately on clinical examination but experience episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (not necessarily 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) characterized by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with CCHS may occa- sionally present later in life with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cyanosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, an apparent life-threatening event, cor pul- monale, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxic neurological damage
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>CCHS has been diagnosed in adults who present with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 following anesthesia or in association with a minor 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory illness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; these patients usually have a mild mutation, and may have evidence of longstanding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cognitive deficits
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Most patients with CCHS have sufficiently severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep that they require mechanically assisted ventilation, although this state-dependent difference may not be apparent during early infancy.</br>Some patients (~15%) hypoventilate during wakefulness as well as during sleep and require continuous ventilatory support.</br>However, most patients with CCHS do not require ventilatory support during wakefulness but may have subtle abnormali- ties in gas exchange when physically inactive or during vigorous exercise. </br>Associated Features Associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autonomic abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hirschsprung disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in approximately 16% of patients with CCHS, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autonomic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., decreased heart rate variabil- ity or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypotension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), neural 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ganglioneuromas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or ganglioneuroblastomas), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    swallowing dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the early years, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ocular abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., stra- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bismus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
).</br>Most patients are cognitively normal, although developmental delay may be present, especially in patients in whom the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has not been well controlled. </br>Clinical and Pathophysiological Subtypes Research suggests that severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    illness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is related to the type of mutation present.</br>Most patients have a polyalanine expansion mutation; those with more polyalanine repeats are more likely to have severe disease including waking 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with a point mutation or frame shift mutations are at greater risk for neural 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Demographics The prevalence of CCHS is not known, but the disease is rare.</br>The condition occurs equally among both sexes and all ethnic/racial groups. </br>Predisposing and Precipitating Factors This is a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congenital genetic syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Familial Patterns CCHS usually occurs as a de novo mutation, but siblings with the condition have been reported.</br>As the gene is dominant, patients are at risk of having children with CCHS. </br>Onset, Course, and Complications </br>The condition is genetic and is therefore present from birth, but some patients may present later in life.</br>The physiological abnormalities of CCHS persist for life and are not ameliorated over time.</br>However, the clinical consequences of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be prevented by providing adequate ventilatory support.</br>If untreated, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 usually results from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or complications of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with poorly controlled CCHS may develop 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental retardation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, growth failure, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>When treated, infants with CCHS may improve over the first six to 12 months.</br>Some patients who initially require ventilatory support 24 hours a day may progress to adequate ventilation during wakefulness.</br>However, patients continue to require ventilatory support during sleep.</br>Conversely, some patients may develop the need for continuous ventilatory support.</br>It is unclear whether these patients had condi- tions that worsened, were not adequately evaluated and treated initially, or were asso- ciated with changing ventilatory demands.</br>Even with treatment, patients with CCHS require close monitoring, particularly during infancy.</br>Minor medical illnesses, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    upper respiratory tract illnesses
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diarrhea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, may precipitate bouts of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lethargy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are often early signs of impending 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The clinical signs of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in these patients may be subtle, as the Sleep Related Breathing Disorders Sleep Related Breathing Disorders children do not show signs of distress or increased work of breathing, such as retrac- tions and nasal flaring.</br>As a result, gas exchange abnormalities may progress for some time without notice until the child appears to deteriorate suddenly with cardiopulmo- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nary arrest
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or severe decompensation. </br>Developmental Issues Not applicable. </br>Pathology and Pathophysiology The exact pathophysiology of CCHS is unknown.</br>Radiologic and postmortem studies have not shown gross central nervous system abnormalities.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PHOX2B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 gene plays a role in the development of the autonomic system.</br>Functional MRI and physiologic studies have shown widespread 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebral abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in response to stimuli such as exogenous 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Objective Findings 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are present on PSG during sleep.</br>Central apneas may be present, but 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with decreased tidal volume and respiratory rate is more common.</br>In contrast to most types of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children, abnormalities may be more severe during NREM than during REM sleep.</br>Patients may not arouse from sleep despite severe gas exchange abnormalities.</br>Paradoxical breath- ing and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 do not typically occur. </br>Patients with CCHS have flat rebreathing hypoxic and hypercapnic responses, although they may respond to transient ventilatory challenges of the peripheral chemorecep- tors.</br>Arterial blood gases may be normal during wakefulness but will be abnormal if obtained from an arterial line during sleep.</br>In patients with chronically untreated or poorly controlled CCHS, a compensated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory acidosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present.</br>In these patients, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present and the serum 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 level may be elevated.</br>Computed tomography and MRI scans of the head are normal.</br>Electrocardiography, echocardiography, or cardiac catheterization may reveal evidence of pulmonary hyper- tension.</br>Pulmonary function tests may be normal or show evidence of mild 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive or restrictive lung disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 resulting from associated conditions such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tracheitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Differential Diagnosis CCHS must be distinguished from other forms of central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chiari malformation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, other causes of central nervous system disturbance such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, metabolic conditions such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Leigh disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>CCHS must also be distinguished from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to conditions such as diaphrag- matic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscular dystrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Infants presenting with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or an apparent life-threatening event due to causes such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be thought to have CCHS.</br>However, these infants typically have intermittent episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 rather than sustained 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and the episodes typically resolve once the primary cause has been treated.</br>CCHS patients presenting with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be misdiagnosed as having 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congenital heart disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Unresolved Issues and Further Directions </br>There are many unresolved issues regarding CCHS, including prevalence data, precise genotype-phenotype correlations, effect of aging on patients with CCHS, long-term outcome of children with CCHS born to parents with CCHS, and the exact nature of the gene-encoded deficit. </br>Bibliography Amiel J, Laudier B, Attie-Bitach T, et al.</br>Polyalanine expansion and frameshift mutations of the paired-like homeobox gene 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PHOX2B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in congenital central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Nat Genet 2003;33:459–61. </br>Gozal D, Marcus CL, Shoseyov D, Keens TG.</br>Peripheral chemoreceptor function in children with the congenital central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Appl Physiol 1993;74:379–87. </br>Macey PM, Woo MA, Macey KE, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 reveals posterior thalamic, cerebellar, midbrain, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    limbic deficits
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in congenital central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Appl Physiol 2005;98:958–69. </br>Marcus CL, Jansen MT, Poulsen 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Keens 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Nield TA, Lipsker LE et</br>al.</br>Medical and psychosocial outcome of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congenital central hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Pediatr 1991;119:888–95. </br>Paton JY, Swaminathan S, Sargent CW, Hawksworth A, Keens TG.</br>Ventilatory response to exercise in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congenital central hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am Rev Respir Dis 1993;147:1185–91. </br>Paton JY, Swaminathan S, Sargent CW, Keens TG.</br>Hypoxic and hypercapnic ventilatory responses in awake children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congenital central hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am Rev Respir Dis 1989;140:368–72. </br>Weese-Mayer DE, Berry-Kravis EM, Ceccherini I, Keens TG, Loghmanee DA, Trang H. An official ATS clinical policy statement: Congenital central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: genetic basis, diagnosis, and management.</br>Am J Respir Crit Care Med 2010;181:626–44. </br>Weese-Mayer DE, Berry-Kravis EM, Marazita ML.</br>In pursuit (and discovery) of a genetic basis for congenital central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Respir Physiol Neurobiol 2005;149:73–82. </br>117 Sleep Related Breathing Disorders Sleep Related Breathing Disorders 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Late-Onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypothalamic Dysfunction ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.26 ICD-10-CM code: G47.36 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Late-onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; rapid-onset 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothalamic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and autonomic dysregulation (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ROHHAD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Diagnostic Criteria Criteria A-E must be met A. Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present. </br>B. Symptoms are absent during the first few years of life. </br>C. The patient has at least two of the following: . Obesity. </br>2. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Endocrine abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of hypothalamic origin.</br>3.</br>Severe emotional or behavioral disturbances. </br>4. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tumor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of neural origin. </br>D. Mutation of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PHOX2B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 gene is not present. </br>E.</br>The disorder is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use, or substance use disorder. </br>Notes .</br>Central apneas may occur but the predominant pattern is reduced flow/tidal volume associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation. </br>Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Late-onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothalamic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a disorder of central control of ventilation.</br>Patients are usually healthy until early childhood (often 2-3 years of age) when they develop 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperphagia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, followed by central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which often presents as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be precipitated by a mild 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory illness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or anesthesia.</br>Patients require ventilatory support during sleep; most patients breathe adequately during wakefulness but some need ventilatory support during both wakefulness and sleep.</br>The hypoventila- tion persists even if the patients lose weight, differentiating the condition from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients often develop hypothalamic endocrine dysfunc- tion characterized by increased or decreased hormone levels, which may include one or more of the following: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes insipidus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inappropriate antidiuretic hormone hyperse- cretion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, precocious puberty, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypogonadism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperprolactinemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothyroidism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and decreased growth hormone secretion.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Mood and behavior abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sometimes severe, have frequently been reported.</br>Developmental delay or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present, but many patients are cognitively normal.</br>Other symptoms of hypothalamic dysfunc- tion, such as temperature dysregulation, have been reported. </br>Associated Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of neural origin such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ganglioneuroma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur. </br>Clinical and Pathophysiological Subtypes None known. </br>Demographics There are no prevalence data.</br>The disorder seems to occur equally among males and females. </br>Predisposing and Precipitating Factors Unknown.</br>Patients do not have the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PHOX2B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 genetic mutation of congenital central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Familial Patterns Familial cases have not been reported. </br>Onset, Course, and Complications Patients are typically normal at birth.</br>Obesity often begins in early childhood, perhaps because the child is old enough to walk around and obtain his/her own food.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 typically presents several years after the onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and requires ventila- tory support via face mask or tracheostomy.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 does not improve over time.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been reported from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or hyper- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    natremia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes insipidus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; case series have reported a high mortality. </br>Developmental Issues Not applicable. </br>Pathology and Pathophysiology The cause of the disorder is not known.</br>The brain typically appears normal on imaging or at autopsy, or may show secondary signs of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Objective Findings 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are present on PSG during sleep.</br>Central apneas may be present, but 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with decreased tidal volume and respiratory rate is more common.</br>Obstructive apneas may occur but are not the primary abnormality. </br>119 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Patients have flat hypoxic and hypercapnic responses.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carbon dioxide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 determinations may be normal during wakefulness but will demonstrate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>In patients with chronically untreated or poorly con- trolled 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a compensated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory acidosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present, with ele- vated serum 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels.</br>In these patients, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present.</br>Serum tests may show evidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endocrine abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypernatremia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is common.</br>Computed tomography and MRI scans of the head are normal.</br>Electrocardiography, echocardiography, or cardiac catheterization may reveal evidence of pulmonary hyper- tension.</br>Pulmonary function tests may be normal or show evidence of mild 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive or restrictive lung disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 resulting from associated conditions such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tracheitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Differential Diagnosis The disorder can be distinguished from late presentation of congenital central hypoven- tilation syndrome by testing for the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PHOX2B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 gene.</br>Genetic testing may also be useful in distinguishing the disorder from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prader-Willi syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which is characterized by a known genetic abnormality.</br>Most children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prader-Willi syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypotonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at birth and more severe developmental delay.</br>The disorder can be distinguished from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endocrine abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothalamic abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and by the persistence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 despite 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In addition, the patients typically have a totally flat hypercapnic ventilatory response rather than the blunted response seen in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The disorder should be distinguished from isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopituitarism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothalamic disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and from obesity-related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Unresolved Issues and Further Directions The etiology of the disorder is not known.</br>Although the disorder shares some fea- tures of congenital central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including the presence of neural 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, it does not share the same gene.</br>Little information is available on prevalence or long-term prognosis. </br>Bibliography Ize-Ludlow D, Gray 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    JA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Sperling MA, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Rapid-onset obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothalamic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and autonomic dysregulation presenting in childhood.</br>Pediatrics 2007;120:e179–88. </br>Katz ES, McGrath S, Marcus CL.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Late-onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothalamic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a distinct clinical syndrome.</br>Pediatr Pulmonol 2000;29:62–8. </br>120 Idiopathic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Central Alveolar Hypoventilation ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.24 ICD-10-CM code: G47.34 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alveolar hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, central alveolar 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic central alveolar hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonapneic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 alveolar 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary alveolar hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A and B must be met A. Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present. </br>B. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not primarily due to lung parenchymal or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, pulmonary vascular pathology, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congenital hypoventilation syndromes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Notes .</br>The predominant respiratory pattern is one of reduced tidal volume or ataxic breathing with associated arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation.</br>Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present, it is not believed to be the major cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>When criteria are met, a diagnosis of both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and idiopathic central alveolar 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be made. </br>2. Arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation is often present but is not required for the diagnosis. </br>Essential Features Idiopathic central alveolar 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is defined as the presence of decreased alve- olar ventilation resulting in sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in individuals with presumed normal mechanical properties of the lung and respiratory pump.</br>Thus, chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep exists without any readily identifiable impairments of res- piration, such as pulmonary airway or parenchymal conditions, neurologic, neuromus- cular or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, other sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or use of respiratory depressant medications or substances.</br>Diurnal as well as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is believed to be due primarily to blunted chemoresponsiveness to 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and O2.</br>However, reported cases are few and not studied in enough detail to conclu- sively establish a well-defined etiology.</br>Alternatively, these cases may represent a mixed group of patients with varied underlying conditions erroneously deemed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a result of incomplete diagnostic work-up.</br>Patient may complain of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morning headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurocognitive decline and sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or may be entirely asymptomatic.</br>Frequent episodes of shallow breathing may be noted to occur during sleep. </br>Sleep Related Breathing Disorders Sleep Related Breathing Disorders Associated Features Consequences of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include pulmonary artery hyper- tension, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurocognitive dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with other comorbid sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are likely to experience greater severity and dura- tion of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 than are patients with isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic central hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Clinical and Pathophysiological Subtypes Not applicable or known. </br>Demographics Not known.</br>It is likely that some patients with this diagnosis may have an underlying anatomic or functional defect affecting respiratory mechanics and ventilatory drive which remains undiagnosed. </br>Predisposing and Precipitating Factors The use of central nervous system depressants, such as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, anxiolytics, and hyp- notics, may further worsen hypercapnia/hypoxemia.</br>Patients who are hypercapnic and hypoxemic during wakefulness will generally become even more so during sleep, in particular REM sleep, but the relationship between wake SaO2/PaCO2 and sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not sufficiently strong to have substantial predictive value in individual patients. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications The onset of the condition is variable, often presenting in adolescence or early adulthood.</br>The disorder is generally slowly progressive.</br>Many affected individuals with severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 develop 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurocognitive dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is common in those with chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although the risk of increased morbidity and mortality appears to increase with worsening sleep related hypoventilation/hypoxemia, the specific relationship between sleep related 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation/hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and mor- bidity and mortality is not well defined. </br>Developmental Issues Not known. </br>122 Pathology and Pathophysiology The etiology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in these patients is not understood.</br>Chronic hyper- capnia and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic central alveolar hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is believed to be due to defective 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    O2 homeostasis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, with impaired 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 unloading, reduced chemoresponsiveness to 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    O2,
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and suppression of respiratory drive.</br>Imaging of the central nervous system does not document a structural defect.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 worsens during sleep compared to waking levels due to a further reduction in che- mosensitivity and decreased activity of the ventilatory muscles.</br>Additionally, daytime 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, if sufficiently severe, may place the patient near or on the steep portion of the oxyhemoglobin dissociation curve where even relatively small decrements in arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 tension result in large decrements in oxyhemoglobin saturation.</br>Thus, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in these patients may have a relatively great impact on oxyhemoglobin saturation. </br>Objective Findings The characteristic polysomnographic finding is demonstration of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (determination of PaCO2 by arterial blood gas or by a surrogate measure [end-tidal 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 or transcutaneous 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
]).</br>Periods of decreased tidal volume lasting up to several minutes, with sustained arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation, are usually present.</br>Intermittent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be observed.</br>Daytime arterial blood gases may be normal or show 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Electrocardiography, chest radiography, and echocardiography may demonstrate evidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Central nervous system imaging is generally unremarkable. </br>Differential Diagnosis The differential diagnosis includes any disorder that can cause 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>This includes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, pulmonary airway and paren- chymal disorders, pulmonary vascular pathology, neuromuscular and chest wall dis- orders, severe untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothyroidism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and use of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory suppressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>CCHS is associated with an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal PHOX2B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 gene.</br>Unlike patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    late-onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothalamic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic central hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 do not have evidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothalamic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It is essential to excluded medical and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that are associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 before a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic central hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be made.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 syndromes can be distinguished from sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by the periodic alterations in airflow and accompanying periodic fluctuations in SaO2.</br>In contrast, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation due to sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is generally more sustained, usually several minutes or longer in duration.</br>When more than one disorder is believed Sleep Related Breathing Disorders Sleep Related Breathing Disorders to be responsible for the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventilatory insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep, all pertinent diagnoses should be coded. </br>Unresolved Issues and Further Directions A better understanding of the etiology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic central alveolar hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is essential to guide preventive and treatment measures.</br>Because it is clinically imprac- tical to routinely obtain arterial blood samples during sleep in most persons suspected of this disorder, other techniques of measuring 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels must be investigated.</br>The degree and duration of hypercapnia/hypoxemia necessary to produce adverse conse- quences, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, in individual patients is not well defined.</br>Little information is available regarding the effect of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy or noninvasive ventilation on the course of the underlying disease.</br>Studies are needed to determine the optimal time to initiate these interventions and the specific subpopulations of patients who will benefit most from these therapies. </br>Bibliography Brown LK.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes.</br>Clin Chest Med 2010;31:249–70. </br>Casey KR, Cantillo KO, Brown LK.</br>Sleep-related hypoventilation/hypoxemic syndromes.</br>Chest 2007;131:1936–48. </br>Chebbo A, Tfaili A, Jones SF.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes.</br>Med Clin North Am 2011;95:1189–202. </br>Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance ICD-9-CM code: 327.26 ICD-10-CM code: G47.36 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alveolar hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonapneic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 alveolar hypoventila- tion, secondary alveolar 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-C must be met A. Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present. </br>B. A medication or substance known to inhibit respiration and/or ventilatory drive is believed to be the primary cause of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>C. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not primarily due to lung parenchymal or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, pulmonary vascular pathology, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or a known congenital central alveolar hypoventilation syndrome. Notes . </br>2. 3. </br>Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 may be present, they are not believed to be the major cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The predominant respiratory pattern is one of reduced tidal volume or ataxic breathing and associated arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation.</br>When criteria are met, a diagnosis of both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to medication or substance as well as sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance may be made. </br>Arterial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is often present but is not required for the diagnosis. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present during wakefulness but is not required for the diagnosis. </br>Essential Features This disorder is characterized primarily by chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to prolonged use of medications or substances known to depress ventilatory drive and/or impair respiratory muscle mechanics.</br>These agents include long-acting nar- cotics, anesthetics, sedative compounds, and muscle relaxants.</br>The risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is increased with the concomitant use of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 or with polypharmacy.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Respiratory depressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can precipitate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with limited pul- monary reserves or exacerbate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in those with baseline 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is commonly present and can show either a sustained reduction or episodic fluctuations.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also be present during wakefulness in some patients.</br>Patients can either be asymptomatic or present with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest tightness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Neurocognitive dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may arise following use of narcotics. </br>Associated Features Medications and substances that reduce respiratory drive may also alter the mechanics of the upper airway.</br>By decreasing upper airway muscle tone, these agents may pre- cipitate or exacerbate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and CSA.</br>It is not currently known whether chronic use of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory depressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will eventually give rise to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary artery hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but this seems unlikely. </br>Clinical and Pathophysiological Subtypes Not applicable or known. </br>Demographics The demographics of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to use of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory suppressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not known.</br>It is clear that baseline 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 prior to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    initiation of respiratory Sleep Related Breathing Disorders Sleep Related Breathing Disorders depressant medication will worsen following
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 initiation of the medication.</br>Thus, preva- lence may be higher in patients with greater perturbations of pulmonary function or neuro- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscular weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Individuals with chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during wakefulness will expe- rience even greater decrements of alveolar ventilation during sleep.</br>Studies of patients on 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 maintenance have generally found no or mild 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>There is scant literature about daytime or nocturnal PaCO2 in patients on potent opioids for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Predisposing and Precipitating Factors The use of medications or substances that impair respiration mechanics or drive is the primary pathophysiologic factor responsible for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>There are significant inter-individual differences in sensitivity and tolerance to respira- tory depressants.</br>Obesity or the presence of medical and neurologic diseases that may produce 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may further worsen hypercapnia/hypoxemia.</br>Patients who are hypercapnic and hypoxemic during wakefulness will generally become even more so during sleep, in particular REM sleep, but the relationship between wake SaO2/ PaCO2 and sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not sufficiently strong to have substantial pre- dictive value in individual patients. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications Onset and course of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 parallel the use and dosing of medications or substances that can impair respiration, as well as the development of tolerance to these substances.</br>There may be variability in susceptibility to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in dif- ferent individuals.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Comorbid pulmonary or neurologic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may accentuate the severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients may present for evaluation of suspected 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or may be identified following one or more episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It is not known if chronic use of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory depressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can lead to the development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmo-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 nary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Neurocognitive dysfunc- tion may develop either as a direct result of medication usage or as a consequence of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Pathology and Pathophysiology 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a direct result of impaired respiratory drive and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    O2 chemo-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 sensitivity.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 worsens during sleep, especially in REM sleep, compared to waking levels, due to a further reduction in chemosensitivity and decreased activity of the ventilatory muscles.</br>In addition, use of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory suppressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may give rise to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and CSA that may contribute to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>126 Objective Findings The characteristic PSG finding is demonstration of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by monitoring of PaCO2 or acceptable surrogate during sleep.</br>Sustained 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desat- uration during sleep that is unexplained by discrete 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events is common.</br>However, this finding alone is not sufficient to make a diagnosis of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Medication use can also produce 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or central apneas.</br>Intermittent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be observed.</br>An ataxic breathing pattern may be present. </br>Differential Diagnosis The differential diagnosis encompasses essentially all disorders that can lead to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>This includes OHS, pulmonary airway and parenchy- mal disorders, pulmonary vascular pathology, neuromuscular and chest wall disor- ders, severe untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothyroidism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and congenital or idiopathic central alveo- lar 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 syndromes can be distinguished from sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by the periodic alterations in airflow and accompanying periodic fluctuations in SaO2.</br>In contrast, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation due to sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is generally more sustained, usually several minutes or longer in dura- tion.</br>When more than one disorder is believed to be responsible for the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventilatory insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep, all pertinent diagnoses should be coded. </br>Unresolved Issues and Further Directions Studies of the factors influencing individual susceptibility and tolerance to hypoven- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tilation/hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to medications or substances are needed.</br>The long-term con- sequences of chronic use of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory depressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are poorly understood.</br>The value of routinely measuring PaCO2 during sleep in patients taking respiratory depressants is not clear.</br>Additionally, because it is clinically impractical to routinely obtain arterial blood samples during sleep in most persons suspected of this disorder, other techniques of measuring 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels must be investigated.</br>Little information is available regarding the effect of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy or noninvasive ventilation on the course of the underlying disease.</br>Studies are needed to determine the optimal time to initiate these interventions and the specific subpopulations of patients who will benefit most from these therapies. </br>Bibliography Brown LK.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes.</br>Clin Chest Med 2010;31:249–70. </br>Casey KR, Cantillo KO, Brown LK.</br>Sleep-related hypoventilation/hypoxemic syndromes.</br>Chest 2007;131:1936–48. </br>Chebbo A, Tfaili A, Jones SF.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes.</br>Med Clin North Am 2011;95:1189–202. </br>Macintyre PE, Loadsman 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    JA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Scott 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Opioids, ventilation and acute 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 management.</br>Anaesth Intensive Care 2011;39:545–58. </br>127 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Tassinari D, Sartori S, Tamburini E, et al.</br>Adverse effects of transdermal opiates treating moderate-severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in comparison to long-acting 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morphine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
: a meta-analysis and systematic review of the literature.</br>J Palliat Med 2008;11:492–501. </br>Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder ICD-9-CM code: 327.26 ICD-10-CM code: G47.36 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alveolar hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonapneic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 alveolar 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, secondary alveolar 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-C must be met A. Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present. </br>B. A lung parenchymal or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, pulmonary vascular pathology, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is believed to be the primary cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>C. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not primarily due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use, or a known congenital central alveolar hypoventilation syndrome. </br>Notes .</br>Arterial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is often present but is not required for the diagnosis. </br>2.</br>Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 may be present, they are not believed to be the major cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The predominant respiratory pattern is one of reduced tidal volume or ataxic breathing and associated arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation.</br>When criteria are met, a diagnosis of both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to medical or neurological condition as well as sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder may be made. </br>3. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present during wakefulness but is not required for the diagnosis. </br>Essential Features Lung airway or parenchymal disease, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic and neuromuscular disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, if sufficiently severe, can result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventilatory impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Acute exacerbations of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can accentuate the severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present and is usually most severe during REM sleep.</br>In some patients, hypercap- nia may also be present during wakefulness.</br>Patients can either be asymptomatic or present with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest tightness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is often noted with severe chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Specific 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are associated with abnormal findings on pulmonary function testing, radiographic imaging, echo- cardiography, and pulmonary artery catheter measurements.</br>Suspected 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic or neuromuscular
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be investigated using central nervous system imaging or measures of peripheral nerve or muscular function. </br>Associated Features Consequences of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 arising as a result of medical and neurologic disorders include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary artery hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and neu- rocognitive dysfunction.</br>Some of these disorders are prevalent diseases and commonly overlap.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multiple disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are likely to experience greater severity and duration of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 than are patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    either disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 alone. </br>Clinical and Pathophysiological Subtypes The clinical presentation varies with the underlying disorder responsible for the sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chronic obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by generally fixed and not fully reversible lower 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airways obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and includes chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bronchitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    emphysema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, cystic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bronchiectasis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Chronic bron- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a clinical entity defined by the presence of chronic productive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cough
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for at least three months of the year, for at least two consecutive years, in the absence of other identifiable etiologies.</br>Emphysema is characterized by destruction of lung tissue and the dilation of peripheral airspaces without evident 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Emphysema and chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bronchitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often coexist.</br>Alpha-1 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antitrypsin deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a genetic cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bronchiectasis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and cystic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are characterized by lower 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway inflammation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and destruction of airways and lung parenchyma.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic lower airways obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are increasingly predis- posed to developing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as the severity of the underlying lower 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airways obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 increases. </br>Parenchymal lung disease associated with restrictive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventilatory dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    interstitial lung disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) can also be associated with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Neurologic, neuromuscular, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can produce 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to an abnormal ventilatory pump (secondary to reduced muscle strength or anatomic distortion of the chest wall structures) that is unable to meet the ventilatory require- ments for maintaining PaCO2 at or below 45 mm Hg.</br>In addition, some of these patients have reduced central neural chemoresponsiveness.</br>Last, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be worsened Sleep Related Breathing Disorders Sleep Related Breathing Disorders by the development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atelectasis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or aspiration due to defective swallowing associated with some neurologic and neuromuscular conditions. </br>Demographics The demographics of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder are a function of the prevalence, clinical characteristics, and degree of severity of the under- lying conditions.</br>Thus, prevalence may be higher in patients with greater perturbations of pulmonary function or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Individuals with chronic hyper- capnia during wakefulness will experience even greater decrements of alveolar venti- lation during sleep. </br>Predisposing and Precipitating Factors </br>Greater impairments of respiratory function are associated with greater risk for sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, there is no recognized threshold of pulmonary parenchymal or vascular disease severity that adequately predicts the risk of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in individual patients.</br>Reduced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chemosensitivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present in some 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The use of central nervous system depressants, such as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, anxiolytics, and hypnotics, may further worsen respira- tory impairment.</br>Patients who are hypercapnic and hypoxemic during wakefulness will generally become even more so during sleep, in particular REM sleep, but the rela- tionship between wake SaO2/PaCO2 and sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not sufficiently strong to have substantial predictive value in individual patients. </br>Familial Patterns Genetic patterns for many of the disorders are not known.</br>Alpha-1 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antitrypsin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 defi- ciency is a genetic disorder characterized by defective production of the enzyme inhib- itor; severe forms of deficiency can lead to emphysema.</br>Genetic causes of bronchi- ectasis include primary ciliary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyskinesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and cystic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Muscular dystrophies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are genetically inherited.</br>The familial patterns of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to these disorders reflect those of the underlying inherited conditions. </br>Onset, Course, and Complications Onset and course of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 parallels the presence and severity of the underlying medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that impair respiration although substan- tial variability in course is observed even within the same underlying condition.</br>Many affected individuals with severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 develop 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and neurocog- nitive dysfunction.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is common in those with chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although the risk of increased morbidity and mortality appears to increase with worsening sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the specific relationship between sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and morbidity and mortality is not well defined.</br>Many patients respond to assisted ven- tilation, whereas 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may worsen with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy alone. </br>Pathology and Pathophysiology Pulmonary parenchymal diseases are characterized by altered lung volumes (e.g., reduced functional residual capacity) and abnormal ventilation/perfusion relationships, which can result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during wakefulness.</br>Decreased lung volume is associated with reduced 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 reserves that increase the risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In addition, sleep may be associated with an altered pattern of ventilatory-muscle acti- vation, particularly during REM sleep when, due to reduced activation of the intercos- tal and accessory muscles, there is a disproportionate ventilatory burden placed on the diaphragm.</br>This may lead to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or in those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In the latter, lung hyperinfla- tion creates a mechanical disadvantage to the diaphragm.</br>Many neurologic and neu- romuscular disorders are associated with impaired respiratory mechanics and reduced 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 chemosensitivity.</br>Finally, daytime 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, if sufficiently severe, may place the patient near or on the steep portion of the oxyhemoglobin dissociation curve, where even relatively small decrements in arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 tension result in large decrements in oxyhemoglobin saturation.</br>Thus, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in these patients may have a relatively great impact on oxyhemoglobin saturation. </br>Objective Findings The characteristic polysomnographic finding is demonstration of sleep related hypoven- tilation (by arterial PaCO2, transcutaneous PCO2, or end-tidal PCO2).</br>Sustained 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation during sleep that is unexplained by discrete 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events is common but is not sufficient to establish a diagnosis of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Intermittent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be observed.</br>Many medical and neurologic disorders are associated with significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and changes in sleep architecture, including prolonged sleep onset latency, reduced sleep efficiency, and decreased sleep stages N3 and REM, may be present.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and central apneas, when present, will further disturb sleep and accentuate sleep related oxyhe- moglobin desaturation.</br>Daytime arterial blood gases may be normal or show 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (especially when present during the day as well as at night) can be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Electrocardiography, chest radiography, and echocardiography may demonstrate evidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>In patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or restrictive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 spirometry shows a restrictive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventilatory dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with the forced vital capacity (FVC) often Sleep Related Breathing Disorders Sleep Related Breathing Disorders less than 50% of predicted.</br>However, significant nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur with FVC values greater than 50% of predicted. </br>Differential Diagnosis The differential diagnosis includes all disorders which can give rise to hypoventila- tion during sleep.</br>This includes OHS, use of medications or substances that can sup- press respiratory drive, and congenital or idiopathic central alveolar hypoventilation syndromes.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 can be distinguished from sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by the periodic alterations in airflow and accompanying periodic fluctuations in SaO2.</br>In contrast, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation due to sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is generally more sustained, usually several minutes or longer in duration.</br>When more than one disorder is believed to be responsible for the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventilatory insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep, all pertinent diagnoses should be coded. </br>Unresolved Issues and Further Directions Thresholds of impairments of ventilation and respiratory drive producing hypercapnia/ 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 need to be identified.</br>The degree and duration of hypercapnia/hypoxemia necessary to produce adverse consequences, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, in indi- vidual patients is not well defined.</br>The value of routinely measuring PaCO2 during sleep in these patients is not clear.</br>Additionally, because it is clinically impractical to routinely obtain arterial blood samples during sleep in most persons suspected of this disorder, other techniques of measuring 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels must be investigated.</br>Little infor- mation is available regarding the effect of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy or noninvasive ventilation on the course of the underlying disease.</br>Studies are needed to determine the optimal time to initiate these interventions and the specific subpopulations of patients who will benefit most from these therapies. </br>Bibliography Ambrosino N, Carpenè 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    N, Gherardi M.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 Chronic respiratory care for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in adults.</br>Eur Respir J 2009;34:444–51. </br>Beuther 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    asthma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Semin Respir Crit Care Med 2009;30:321–9. Biering-Sørensen F, Jennum P, Laub M. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 following spinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cord injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Respir Physiol Neurobiol 2009;169:165–70. </br>Castriotta RJ, Murthy JN.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 after spinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cord injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Semin Respir Crit Care Med 2009;30:330–8. </br>Dhand UK, Dhand R. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in neuromuscular diseases.</br>Curr Opin Pulm Med 2006;12:402–8. </br>Donath J, Miller 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    A. Restrictive chest wall disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Semin Respir Crit Care Med 2009;30:275–92. </br>Fathi M, Lundberg IE, Tornling G. Pulmonary complications of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polymyositis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dermatomyositis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Semin Respir Crit Care Med 2007;28:451–8. </br>132 Glass GA, Josephs KA, Ahlskog JE.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Respiratory insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as the primary presenting symptom of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multiple-system atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Arch Neurol 2006;63:978–81. </br>Kennedy JD, Martin AJ.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure and neuromuscular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Pediatr Clin North Am 2009;56:261–73, xii. </br>Taylor-Cousar JL.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in cystic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Semin Respir Crit Care Med 2009;30:293–302. </br>Toussaint M, Chatwin M, Soudon P. Mechanical ventilation in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Duchenne
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic respiratory insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: clinical implications of 20 years published experience.</br>Chron Respir Dis 2007;4:167–77. </br>Vazquez-Sandoval A, Huang EJ, Jones SF.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Semin Respir Crit Care Med 2009;30:348–58. </br>Wider C, Wszolek ZK.</br>Rapidly progressive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial parkinsonism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (Perry syndrome)--a literature review.</br>Parkinsonism Relat Disord 2008;14:1–7. </br>133 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Disorder Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ICD-9-CM code: 327.26 ICD-10-CM code: G47.36 Alternate Names Nocturnal 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (or oxyhemoglobin) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, low nocturnal 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation. </br>Diagnostic Criteria Criteria A and B must be met A. PSG, OCST or nocturnal oximetry shows the arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation (SpO2) during sleep of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 88% in adults or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 90% in children for ≥ 5 minutes. </br>B. Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not documented.1 Notes .</br>If sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is documented (as measured by arterial blood gas, transcutaneous PCO2, or end-tidal 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 sensors), the disorder is classified as sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>2. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 may be present, but these are not believed to be the major cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>3. Physiological causes, if known, should be indicated (e.g., shunt, ventilation-perfusion [V/Q] mismatch, low mixed venous 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and/ or high altitude). </br>Essential Features Significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep is present and is believed to be secondary to a medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not better explained by another sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Although some amount of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present, these disorders are not thought to be pri- marily responsible for the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>Some patients with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also exhibit 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during wakefulness.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has not been documented (if so, a diagnosis of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is made).</br>The presentation of patients with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 varies with the underly- ing medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can arise from airway or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parenchymal pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic and neuromuscular disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Acute exacerbations of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can accentuate the severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to underlying lower 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway obstructive disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary parenchymal disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, vascular pathology, and other causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is generally sustained (several minutes or longer), whereas sawtooth fluctuations of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation (typically less than one minute) characterize 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or CSA.</br>Patients can either be asymptomatic or present with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of nocturnal dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, impaired sleep quality, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest tightness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is often noted with severe chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Associated Features Consequences of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include pulmonary artery hyper- tension, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurocognitive dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Some of the disorders causing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are prevalent diseases and not uncommonly overlap.</br>Patients with multi- ple 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are likely to experience greater severity and duration of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 than are patients with a single disorder. </br>Clinical and Pathologic Subtypes Specific variations in the sleep related findings have not been described for the various etiologies. </br>Demographics The demographics of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are a function of the prevalence, clinical characteristics and degree of severity of the underlying conditions.</br>Thus, prevalence may be higher in patients with greater perturbations of pulmonary function or neu- romuscular weakness.</br>Individuals with chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during wakefulness will experience even greater decrements of oxygenation during sleep. </br>Predisposing and Precipitating Factors </br>Greater impairments of respiratory function are associated with greater risk for sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, there is no recognized threshold of pulmonary paren- chymal or vascular disease severity or extent of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that ade-</br>quately predicts the risk of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in individual patients.</br>Patients who are hypoxemic during wakefulness will generally become even more so during sleep, especially REM sleep.</br>Among the best predictors of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are reduced baseline wake SaO2 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with wake 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be suspected of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, the relationship between wake SaO2/PaCO2 and sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not sufficiently strong to have substantial predictive value in individual patients. </br>135 Sleep Related Breathing Disorders Sleep Related Breathing Disorders Familial Patterns Genetic patterns for many of the disorders are not known.</br>Alpha-1 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antitrypsin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 defi- ciency is a genetic disorder characterized by defective production of the enzyme inhib- itor; severe forms of deficiency can lead to emphysema.</br>Genetic causes of bronchiec- tasis include primary ciliary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyskinesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and cystic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Muscular dystrophies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are genetically inherited.</br>The familial patterns of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to these disorders reflect those of the underlying inherited conditions. </br>Onset, Course, and Complications Onset and course of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 parallel the presence and severity of the underlying medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that impair respiration, although sub- stantial variability in course is observed even within the same underlying condition.</br>Many affected individuals with severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 develop 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and neuro- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cognitive dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is common in those with chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Higher rates of painful crises accompany 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sickle cell disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although the risk of increased morbidity and mortality appears to increase with wors- ening sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the specific relationship between sleep related hypox- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    emia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and morbidity and mortality is not well defined.</br>Many patients respond to 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy; in some, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may worsen with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy alone for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Pathology and Pathophysiology 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may arise from a shunt physiology, ventilation-perfusion [
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    V/Q
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
] 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mismatch-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 ing, low mixed venous 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and/or high altitude.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also gives rise to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; however, when 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been documented, a diagnosis of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be assigned, rather than sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Pulmonary parenchymal diseases are characterized by altered lung volumes (e.g., reduced functional residual capacity) and abnormal ventilation/perfusion relationships, which can result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during wakefulness.</br>Decreased lung volume is associated with reduced 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 reserves that increase the risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In addition, sleep may be associated with an altered pattern of ventilatory muscle acti- vation, particularly during REM sleep when, due to reduced activation of the intercos- tal and accessory muscles, there is a disproportionate ventilatory burden placed on the diaphragm.</br>This may lead to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In the latter, lung hyperinflation creates a mechanical disadvantage to the diaphragm.</br>In 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sickle cell anemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, decreased oxyhemo- globin affinity may partly contribute to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Many neurologic and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscu- lar disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are associated with impaired respiratory mechanics and reduced 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 che- mosensitivity.</br>Finally, daytime 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, if sufficiently severe, may place the patient near or on the steep portion of the oxyhemoglobin dissociation curve where even rela- tively small decrements in arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 tension result in large decrements in oxyhe- moglobin saturation.</br>Thus, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in these patients might have a relatively great impact on oxyhemoglobin saturation. </br>Objective Findings Various patterns of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation (sustained, intermittent, or episodic) may be observed during sleep.</br>The diagnosis is generally made on the basis of overnight oxim- etry (alone or as a component of PSG or OCST); less commonly, arterial blood gas mea- surements are indicated, especially if concomitant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is suspected.</br>PSG may demonstrate normal sleep architecture or frequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, increased wakeful- ness after sleep onset and reduced sleep efficiency; however, the contribution of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to the altered sleep architecture, if present, is uncertain.</br>Daytime arterial blood gases may be normal or show 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Nocturnal oxim- etry usually shows sustained periods of reduced arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 but clusters of more severe drops in the arterial 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation can occur every one to two hours due to worsening of breathing during REM sleep.</br>A sawtooth pattern of briefer 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (typically less than one minute) suggests the presence of discrete events (apneas or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Some sawtooth changes may be superimposed on low baseline 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 saturation but are not the predominant pattern.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polycythemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Electrocardiography, chest radiography, and echocardiography may demonstrate evidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Differential Diagnosis The differential diagnosis encompasses all disorders which can give to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>This includes pulmonary airway and parenchymal disorders, pulmonary vascular pathology, neuromuscular and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, OHS, use of medications or substances that can suppress respiratory drive, and congenital or idiopathic central alveolar hypoventilation syndromes.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 syndromes can be distinguished from sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by the periodic alterations in airflow and accompanying periodic fluctuations in SaO2.</br>In contrast, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation associated with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is generally more sustained, usually several minutes or longer in duration.</br>In cases when more than one disorder is believed to be responsible for the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventilatory insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep, all pertinent diagnoses should be coded. </br>Unresolved Issues and Further Directions The degree and duration of hypercapnia/hypoxemia necessary to produce adverse consequences, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, in individual patients is not well defined.</br>The value of routinely measuring arterial blood gases or SaO2 during sleep Sleep Related Breathing Disorders Sleep Related Breathing Disorders is not clear.</br>With the exception of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    COPD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, little information is available regarding the effect of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy on the course of the underlying disease.</br>Even less is under- stood regarding the consequences of isolated sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the need for 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 supplementation in patients with normal daytime wake 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels.</br>Studies are needed to determine the optimal time to initiate 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 therapy and the specific subpopulations of patients who will benefit most from this intervention. </br>Bibliography Berry RB, Sriram P. Evaluation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Semin Respir Crit Care Med 2009;30:303–14. </br>Brown LK.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes.</br>Clin Chest Med 2010;31:249–70. </br>Casey KR, Cantillo KO, Brown LK.</br>Sleep-related hypoventilation/hypoxemic syndromes.</br>Chest 2007;131:1936–48. </br>Chebbo A, Tfaili A, Jones SF.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes.</br>Med Clin North Am 2011;95:1189–202. </br>Mogri M, Desai H, Webster L, Grant BJ, Mador MJ.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients on chronic opiate therapy with and without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Breath 2009;13:49–57. </br>138 Isolated Symptoms and Normal Variants 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ICD-9-CM code: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    786.09
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ICD-10-CM code: R06.83 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a respiratory sound generated in the upper airway during sleep that typically occurs during inspiration but may also occur in expiration; the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 described here occurs without episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, RERAs or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The intensity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may vary and often will disturb the bed partner’s sleep and even awaken the patient.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in this context does not cause symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the patient.</br>This type of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has variously been referred to as habitual, primary or simple snoring. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a cardinal symptom of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A designation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    habitual snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cannot be made in those who exhibit symptoms (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness/fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or other related symptoms) or report possible breathing pauses, without objective mea- surement of breathing during sleep.</br>In addition, those individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (especially pulmonary or systemic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, cor- onary artery disease, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrial fibrillation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) are at increased risk for the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 even in the absence of complaints of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Therefore, PSG or OCST is required in order to effectively rule out 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in such populations.</br>It should also be noted that patients who initially have isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be at risk for developing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with aging or weight gain. </br>Occasional 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is almost universal.</br>Estimates on 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 vary widely depending on its definition.</br>The incidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children is reported to be 10% to 12%.</br>The Wisconsin cohort study reports 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    habitual snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in about 24% of adult women and 40% of adult men.</br>Prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 increases with age in both sexes, except that the prevalence of reported 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 starts to decrease again in men after 70 years of age.</br>Some have hypothesized that his may be due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    decreased hearing acuity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in older individuals. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is most common in adult men and is also linked to obesity.</br>Nasal obstruc- tion increases the risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Ingestion of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, muscle relaxants, narcotics, or other substances that decrease upper airway muscle tone predisposes an individual to snoring.</br>Smoking, particularly in males, has also been shown to be a risk factor.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has also been shown to increase during pregnancy.</br>In children, an association has been reported between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and adenotonsillar hypertrophy.</br>During 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Sleep Related Breathing Disorders Sleep Related Breathing Disorders there is vibration of the uvula and soft 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    palate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, although it may also involve the faucial pillars, pharyngeal walls, and lower structures.</br>Snorers have been shown to have mor- phologic derangements of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    palate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 consistent with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurogenic lesions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>These are thought to be due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from vibration.</br>If PSG is performed, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tends to be loudest during stage N3 sleep or REM sleep. </br>Epidemiologic studies are difficult to interpret if sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was not excluded by PSG.</br>Based on the current literature, habitual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children may be associated with worse school performance, but conclusive evidence for this is lacking.</br>Some studies have suggested that adult 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snorers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may have a higher prevalence of cardiovas- cular disease, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and ischemic heart disease.</br>However, a large observational study in which all subjects underwent PSG found no increased risk of cardiovascular morbidity or mortality with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    habitual snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Of interest, one study found that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atherosclerosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the carotid artery, but this has not been confirmed by other studies.</br>As 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tends to increase during pregnancy, the impact of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on maternal health is of great interest.</br>A study found that preg- nancy-onset habitual snoring (but not chronic [pre-conceptual] snoring) was associated with increased risk of gestational 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    preeclampsia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Further studies are needed in this area. </br>Bibliography Cho JG, Witting PK, Verma M, et al.</br>Tissue vibration induces carotid 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    artery endothelial dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a mechanism linking 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carotid atherosclerosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
?</br>Sleep 2011;34:751–7. </br>Kezirian EJ, Chang JL.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and health consequences: the jury is still out.</br>Sleep 2013;36:613. </br>Lee SA, Amis TC, Byth 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, et al.</br>Heavy 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carotid artery atherosclerosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2008;31:1207–13. </br>Marin JM, Carrizo SJ, Vicente E, Agusti AG.</br>Long-term cardiovascular outcomes in men with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnoea-hypopnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with or without treatment with continuous positive airway pressure: an observational study.</br>Lancet 2005;365:1046–53. </br>Mason RH, Mehta Z, Fonseca AC, Stradling JR, Rothwell PM.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and severity of symptomatic and asymptomatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carotid stenosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a population-based study.</br>Sleep 2012;35:1147–51. </br>O’Brien LM, Bullough AS, Owusu JT, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pregnancy-onset habitual snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, gestational 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    preeclampsia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: prospective cohort study.</br>Am J Obstet Gynecol 2012;207:487.e1–9. </br>Rich J, Raviv A, Raviv N, Brietzke 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>An epidemiologic study of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and all-cause mortality.</br>Otolaryngol Head Neck Surg 2011;145:341–46. </br>140 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Catathrenia Catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, also known as sleep related groaning, is included in the SRBD section because it appears to be associated with prolonged expiration, usually during REM sleep.</br>However, some studies have documented 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during NREM sleep.</br>Typically, a deep inspiration is followed by prolonged expiration and a monotonous vocalization resembling groaning.</br>The pattern is sometimes called 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bradypnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (low respiratory rate).</br>The affected individual is usually unaware of the problem, but clini- cal evaluation is sought due to complaints of the bed partner or family members.</br>The recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bradypneic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes may resemble central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 except that central apneas are not typically associated with vocalization.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is thought to be rare and more common in men.</br>Several episodes may occur nightly and often in clusters.</br>The long-term consequences of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are unknown, but the disorder is primarily a social problem for the affected individual.</br>The episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not associ- ated with sleep talking or body movement.</br>No association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been demonstrated.</br>The onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has recently been reported in patients taking 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sodium oxybate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The clinical significance of this finding is unclear. </br>Bibliography Abbasi 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Morgenthaler TI, Slocumb NL, et al.</br>Nocturnal moaning and groaning-catathrenia or nocturnal vocalizations.</br>Sleep Breath 2012;16:367–73. </br>Pevernagie DA, Boon PA, Mariman ANN, Verhaeghen DB, Pauwels RA.</br>Vocalization during episodes of prolonged expiration: a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to REM sleep.</br>Sleep Med 2001;2:19–30. </br>Poli F, Ricotta L, Vandi S, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 under 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sodium oxybate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Breath 2012;16:427–34. </br>Vetrugno R, Lugaresi E, Plazzi G, Provini F, D’Angelo R, Montagna P. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal groaning
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
): an abnormal respiratory pattern during sleep.</br>Eur J Neurol 2007;14:1236–43. </br>Vetrugno R, Provini F, Plazzi G, Vignatelli L, Lugaresi E, Montagna P. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal groaning
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
): a new type of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Neurology 2001;56:681–3. Sleep Related Breathing Disorders Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence Narcolepsy Type 1......................................................................................146 Narcolepsy Type 2......................................................................................155 Idiopathic Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
..............................................................................161 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ..............................................................................166 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder....................................................171 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance .......................................175 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Associated with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Psychiatric Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.................................179 Insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.......................................................................182 Isolated Symptoms and Normal Variants Long Sleeper ..............................................................................................187 Adequate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alertness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is necessary for well-being and performance in modern society.</br>Sleepiness predisposes an individual to developing serious performance decrements in multiple areas of function, as well as to potentially life-threatening domestic, occu- pational, and vehicular accidents.</br>This section includes a group of disorders in which the primary complaint is 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 not caused by disturbed nocturnal sleep or misaligned circadian rhythms.</br>Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present, but they must be adequately treated before a diagnosis in this category can be established.</br>In this nosology, the term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is used to describe the symptom of exces- sive sleepiness, whereas 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 refers to specific disorders, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is defined as the inability to stay awake and alert during the major waking episodes of the day, resulting in periods of irrepressible need for sleep or unin- tended lapses into 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drowsiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or sleep.</br>Sleepiness may vary in severity and is more likely to occur in sedentary, boring, and monotonous situations that require little active participation.</br>Some patients are aware of increasing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 before falling asleep, whereas others can fall asleep with little or no prodromal symptoms (“sleep attacks”).</br>This group of patients sometimes can present following motor vehicle accidents attrib- utable to sleepiness.</br>In some forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with large increases in total daily amount of sleep without any genuine feeling of resto- ration.</br>In others, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be alleviated temporarily by naps but reoccurs shortly thereafter.</br>In young children, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may express itself as excessively long night sleep or with the recurrence of previously discontinued daytime napping.</br>Children may Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 paradoxically present with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inattentiveness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, emotional lability, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperactive behavior
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or decreased performance in school.</br>In most cases, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a chronic symptom.</br>It must occur for at least three months prior to diagnosis. </br>The severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be quantified subjectively using severity scales such as the Epworth Sleepiness Scale and objectively using the Multiple Sleep Latency Test (MSLT).</br>These measures do not always correlate with each other and must be used with appropriate clinical judgment.</br>When applied in clinical settings, the MSLT is sensitive to sleep deprivation and circadian effects.</br>It has not been validated as a diagnostic test in people who are habitually awake throughout the night and sleep during the day.</br>Normal and abnormal ranges of sleep latencies have not been estab- lished when this test is administered at times other than the hours between 8:00 a.m. and</br>6:00 p.m. Normative data are not available for children younger than six years. </br>The MSLT measures the physiological tendency to fall asleep in quiet situations.</br>In the context of diagnosing central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders of hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the MSLT should be con- ducted according to standardized procedures, as defined in the American Academy of Sleep Medicine (AASM) practice parameters.</br>In particular, patients should be encour- aged to sleep as much as possible during the week and, especially, during the night prior to the MSLT.</br>Delaying wake-up time and subsequent MSLT start time may be appropriate in some patients with delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It is strongly rec- ommended that adequate sleep be documented by sleep log and, whenever possible, actigraphy for a period of one to two weeks prior to the MSLT.</br>MSLT mean sleep latencies should be considered a continuum with values below five minutes generally considered as indicative of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and those over 10 minutes generally consid- ered indicative of normal alertness.</br>In this section, a mean MSLT sleep latency of less than eight minutes is used to define sleepiness for diagnostic purposes.</br>This value has been shown to be the best cutoff in the context of diagnosing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, with approximately 90% of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 having a latency below this level.</br>The presence of multiple sleep onset rapid eye movement periods (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) during the MSLT is a more specific finding in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 than is a mean sleep latency less than or equal to eight minutes, although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can also be seen in the presence of insuffi- cient sleep, circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (including delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or shift work), sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or, occasionally, normal subjects.</br>The results of an MSLT should be carefully interpreted in the context of the patient’s history and the complaint of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>144 The maintenance of wakefulness test is a measure of the ability to remain awake during the daytime in a darkened, quiet environment and is usually administered to assess response to treatment.</br>It should not be used for diagnostic purposes. </br>A 24-hour continuous sleep recording or an actigraphic recording of at least one week is useful in the diagnosis of some patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In all cases in which a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is to be made, a review of other sleep, medical, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as well as substance and medication use, should be performed. </br>In this edition of International Classification of Sleep Disorders the preferred names of certain central disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been changed.</br>In particular, nar- colepsy has been divided into 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 rather than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with and without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>This change is predicated on the concept that absence of hypocretin (orexin) is a fundamental marker of the most precisely defined category of the disorder.</br>Because some patients without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will also have low cerebrospinal fluid (CSF) hypocretin-1 levels, the use of the term “
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
” or “narcolepsy-cataplexy” is inappropriate.</br>The change is not intended to imply that the presence or absence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is unimportant clinically nor that mea- suring CSF hypocretin-1 levels is obligatory.</br>The motivation behind the decision to eliminate the subcategories of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is discussed in the appropriate section.</br>The decision to use 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as the preferred name in place of recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is based on data suggesting that the condition is fairly homo- geneous, as well as the lack of definite evidence for other major subcategories of the disorder. </br>Bibliography Arand D, Bonnet M, Hurwitz T, Mitler M, Rosa R, Sangal RB.</br>A Review by the MSLT and MWT Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine.</br>The clinical use of the MSLT and MWT.</br>Sleep 2005;28:123–44. </br>Aurora RN, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lamm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 CI, Zak 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, et al.</br>Practice parameters for the non-respiratory indications for polysomnography and multiple sleep latency testing for children.</br>Sleep 2012;35:1467–73. </br>Littner MR, Kushida C, Wise M, et al.; Standards of Practice Committee of the American Academy of Sleep Medicine.</br>Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test.</br>Sleep 2005;28:113–21. </br>Mignot E, Lin L, Finn L, et al.</br>Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults.</br>Brain 2006;129:1609–23. </br>145 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence Narcolepsy Type 1 ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 347.01 ICD-10-CM code: G47.411 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypocretin deficiency syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy-cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A and B must be met A.</br>The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months.1 B.</br>The presence of one or both of the following: . 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (as defined under Essential Features) and a mean sleep latency of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 8 minutes and two or more sleep onset REM periods (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) on an MSLT performed according to standard techniques.</br>A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (within 15 minutes of sleep onset) on the preceding nocturnal polysomnogram may replace one of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on the MSLT.2 . CSF hypocretin-1 concentration, measured by immunoreactivity, is either 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 110 pg/mL or &lt;1/3 of mean values obtained in normal subjects with the same standardized assay. </br>Notes .</br>In young children, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may sometimes present as excessively long night sleep or as resumption of previously discontinued daytime napping. </br>2.</br>If 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type I is strongly suspected clinically but the MSLT criteria of B1 are not met, a possible strategy is to repeat the MSLT. </br>Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 is a disorder primarily characterized by excessive daytime sleepi- ness and signs of REM-sleep dissociation, the most specific of which is 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It has now been firmly established that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 is caused by a deficiency of hypothalamic hypocretin (orexin) signaling.</br>Patients with low or undetectable concen- trations of hypocretin-1 in the CSF compose a specific disease population with a single etiology and relatively homogenous clinical and polysomnographic features.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and low or absent CSF hypocretin-1</br>levels are classified as having nar- colepsy type 1, even if they do not manifest 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>146 Excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is the cardinal symptom, and often the most disabling.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 experience repeated daily episodes of an irrepressible need to sleep or lapses into sleep.</br>Most patients awaken refreshed after a sleep episode but begin to feel sleepy again after variable times.</br>Sleepiness is most likely to occur in monotonous situations that require no active participation; for example, watching television or riding in a car.</br>Physical activity may temporarily suppress the urge to sleep.</br>In some cases 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 manifests as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sudden irresistible sleep
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 “attacks” that may occur in unusual situations such as eating or walking.</br>Often, such sleep attacks occur on a background of overall sleepiness.</br>Even when seemingly awake, many nar- colepsy patients have lapses in vigilance, sometimes in combination with automatic behavior, such as writing gibberish or interrupting a conversation with a completely different topic.</br>Sleepiness generally has a serious impact on the ability of the patient to function in educational, social, and occupational situations. </br>Because patients are rarely examined during an attack of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, its presence needs to be established based on the clinical interview alone.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is defined as more than one episode of generally brief (&lt; 2 minutes), usually bilaterally symmetrical sudden loss of muscle tone with retained consciousness.</br>The episodes are precipitated by strong emotions, usually positive, with almost all patients reporting some episodes precipitated by emotions associated with laughter.</br>The finding of transient reversible loss of deep tendon reflexes during an attack, if observed, is a strong diagnostic finding.</br>In children (and rarely adults), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may present close to disease onset as facial (or generalized) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypotonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with droopy eyelids, mouth opening, and protruded tongue, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gait unsteadiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which clearly are not related to emotion.</br>Facial and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    masticatory movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur.</br>In children, anticipation of a reward is a common precipitant.</br>It is important to use child-appropriate contexts and language when trying to elicit a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children. </br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 phenotype differs widely between patients, ranging from sporadic partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 triggered by laughter, to frequent complete attacks of collapse brought about by a variety of emotions.</br>In the vast majority of attacks, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is bilateral, although patients sometimes report one side of the body to be more affected than the other.</br>Partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be very subtle and sometimes only recognized by experi- enced observers such as the patient’s partner.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Neck weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, producing head drop, is a common complaint, whereas facial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may lead to sagging of the jaw and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysarthria
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Respiratory muscles are not involved although patients sometimes describe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    shortness of breath
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 when symptomatic.</br>Attacks start abruptly and usually build up over several seconds, especially in attacks producing complete 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and collapse.</br>Positive motor phenomena are not uncommon, with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle twitching Central Disorders of Hypersomnolence Central Disorders of Hypersomnolence or small jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly of the face.</br>Although many emotions can potentially lead to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, those associated with mirth are usually the most potent.</br>Laughing out loud, telling a joke, and making a witty remark are typical examples.</br>The frequency of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is variable, ranging from less than one attack per month to more than 20 attacks per day.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is generally short-lived, lasting a matter of seconds, with the vast majority of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lasting less than two minutes.</br>However, if a particular trigger continues, consecutive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may merge together to form what seems to be one long episode.</br>Sudden withdrawal of anticataplectic medication, especially anti- depressants, can result in “
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    status cataplecticus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
” in which long-lasting attacks happen virtually continuously. </br>Associated Features In addition to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 often report several other symptoms, none of which are specific for the disorder.</br>Many patients report disruption of nocturnal sleep, which can sometimes be of major concern.</br>Although sleep onset is rarely a problem, an inability to maintain continuous sleep is very common.</br>33% to 80% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are defined as vivid dreamlike expe- riences occurring at the transition from wake to sleep.</br>Typically, hypnagogic halluci- nations have a multimodal or “holistic” character, often combining visual, auditory, and tactile phenomena.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnopompic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are similar but occur at sleep to wake transitions.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 describes the disturbing temporary inability to move voluntary muscles at sleep-wake transitions.</br>Despite being awake and conscious of the sleeping environment, it is impossible for subjects to move their limbs or even open their eyes.</br>The experience may last for several minutes and can be very distressing.</br>Other symptoms may include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ptosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blurred vision
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diplopia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, presumably as a result of sleepiness. </br>Epidemiological studies have shown that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a common symptom of narco- lepsy.</br>Around disease onset, an unexplained increase in body weight is often observed.</br>Obesity (defined as a body mass index ≥ 30 kg/m2) occurs more than twice as often in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcoleptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 populations as in control groups.</br>An increased frequency of several other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been described in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including sleep talking, periodic limb movements of sleep, sleep disordered breathing, and REM sleep behavior disor- der.</br>There is an increased prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive symptoms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, although there are con- flicting reports on how often these symptoms qualify as a clinical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Recent studies point to a high level of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    panic attacks or social phobias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in about 20%.</br>More than half of patients report severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which can be distinct from sleepiness. </br>148 Clinical and Pathophysiological Subtypes Narcolepsy type 1 due to a medical condition:</br>This condition is primarily associated with central nervous system (CNS) disorders, including autoimmune or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paraneoplastic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anti-Ma2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or antiaquaporin4 antibodies, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or other lesions of the hypothalamus.</br>In addition, undetectable hypocretin-1 levels have been reported in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 after severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The condition must fulfill criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 and be attributable to another medical disorder. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with low CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 should be diagnosed, even in the absence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, if diagnostic criteria A and B2 are fulfilled. </br>Demographics 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs in 0.02% to 0.18% of the United States and western European populations.</br>A lower prevalence has been reported in Israel, whereas narco- lepsy with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be slightly more common in Japan (0.16% to 0.18%).</br>Both sexes are affected, with a slight preponderance of males. </br>Predisposing and Precipitating Factors Several unproven precipitating factors have been suggested in case reports, including head 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sustained sleep deprivation, unspecified 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    viral illness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and sudden changes in sleep-wake patterns.</br>Several studies have pointed to seasonal patterns in the onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which may point to a specific environmental trigger.</br>Recent studies have shown an increase in antibodies against 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    beta-hemolytic streptococcus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which were strongest around onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and decreased with disease duration, suggesting that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    streptococcal infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may constitute an environmental trigger.</br>There have been reports of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 occurring after vaccination against 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    H1N1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated influ- enza, but a definite causal association has not yet been established.</br>Tribbles homolog 2 antibodies, found in some patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autoimmune uveitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, have been described in 14% to 26% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients, but the significance is uncertain. </br>Familial Patterns At the genetic level, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is closely associated with the human leukocyte antigen (HLA) subtypes DR2/DRB1*1501 and DQB1*0602.</br>These two subtypes are always found together in whites and Asians, but in blacks, DQB1*0602 is more specifically associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Almost all patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are positive for DQB1*0602, compared with 12% to 38% of the general population who have this HLA subtype.</br>Other subtypes also have less striking associations.</br>For example, DQB1*0301 is associated with increased susceptibility to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 whereas subtypes such as DQB1*0501 and DQB1*0601, are protective in the presence of DQB1*0602.</br>Genomewide studies have found associations between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and polymorphisms in T cell receptor alpha, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 necrosis factor (TNF)-alpha 2, and TNF receptor 2 as well as the purinergic receptor P2Y11 genes. </br>There is a low prevalence of familial cases; the risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 in first-de- gree relatives of affected individuals is approximately 1% to 2%.</br>When compared to the population prevalence, this indicates a tenfold to fortyfold increase in risk.</br>This increased risk cannot be explained solely by HLA gene effects, suggesting the exis- tence of other genetic factors.</br>Multiplex families with more than two affected members are uncommon.</br>In most cases, normal CSF hypocretin levels have been found in these families, and the association with HLA DQB1*0602 is much weaker compared to spo- radic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>So far, only a single case of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 has been described in association with a preprohypocretin mutation. </br>Onset, Course, and Complications Onset usually occurs after five years of age and most typically between ages 10 and 25 years.</br>However, a bimodal distribution in the age at onset has been described in some populations with a first peak occurring at adolescence (age 15 years) and a second at the age of 35 years.</br>Recent studies highlight the fact that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and especially 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, in young children may present somewhat differently, resulting in delayed diagnosis and erroneously high estimates of age of onset. </br>Sleepiness is usually the first symptom to manifest.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 most often occurs within one year of onset but in rare cases, may precede the onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or commence up to 40 years later.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and disturbed noctur- nal sleep often manifest later in the course of the disease. </br>When left untreated, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 is often socially disabling and isolating.</br>Patients have a tendency to fail in school and are often dismissed from their jobs.</br>Driving may be avoided for fear of a motor vehicle accident.</br>The inability to sleep at night may further contribute to a loss of control these patients have over their schedule.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight gain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also are common. </br>In most cases, symptoms gradually develop over several years.</br>When the clinical picture has fully developed, there are usually only minor fluctuations in severity.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may lessen with age, or occasionally increase in frequency and severity. </br>150 Developmental Issues In recent years, increasing attention has been given to the clinical presentation of nar- colepsy in childhood.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is infrequent prior to the age of four years.</br>In addition, the clinical presentation in children may be different from that of adults.</br>In young children, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be difficult to assess, and may express itself as excessively long night sleep, or the recurrence of previously discontinued daytime napping.</br>Moreover, children may paradoxically present with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperactive behavior
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, behavioral problems or decreased performance in school.</br>Inattentiveness, lack of energy, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bizarre hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or a combination thereof can lead to a psy- chiatric misdiagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    schizophrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In this population, the presence of ancillary symptoms such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also be difficult to confirm, depending on the child’s verbal ability.</br>Precocious puberty and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also develop around the time of symptom onset.</br>REM sleep behavior dis- order or REM sleep without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also be manifest at the time of symptom onset. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be very severe around disease onset and appear phenotypically differ- ent from typical episodes seen in adulthood.</br>In addition to typical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 triggered by positive emotions, children can also present with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 involving the face, eyelids, and mouth not clearly associated with emotion.</br>Together with tongue protrusion, this characteristic pattern has been termed a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplectic facies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also display positive motor phenomena, ranging from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    perioral dyskinetic or dys-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tonic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to frank stereotypies.</br>In children, anticipation of reward may also be a precipitant. </br>The diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 in children may be complicated because of diffi- culties performing the MSLT, and lack of normative values in children younger than six years.</br>If the MSLT shows equivocal results, repeating it after a time interval may be helpful.</br>Given these difficulties, CSF hypocretin-1 measurements are of particular value, as hypocretin-1 levels are low or undetectable very shortly after disease onset in children as well. </br>Pathology and Pathophysiology It is now firmly established that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 is caused by deficiencies in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypo- cretin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 signaling, most likely due to a selective loss of hypothalamic hypocretin pro- ducing neurons.</br>Several animal models lacking hypocretin neurotransmission 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    demon-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 strate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, indicating a causal relationship.</br>The vast majority of patients (90% to 95%) with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have undetectable or low (&lt; 110 pg/mL) levels of hypocretin-1 in the CSF.</br>Patients without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be hypocretin deficient as well, although at a much lower frequency, and are thus also classified as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1.</br>The strong HLA association in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has led to the hypothesis that auto- immunity is a likely etiological mechanism, potentially explaining the selectivity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuronal destruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the hypothalamus.</br>However, definitive proof for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autoimmunity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has not been obtained. </br>Objective Findings 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 is essentially defined as a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocretin deficiency syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which is reflected in the need for objective measurements in the clinical criteria.</br>This require- ment is further driven by the fact that many patients require lifelong treatment with potentially addictive medications, underscoring the importance of objective confirma- tion of the diagnosis. </br>It is strongly recommended that the MSLT be preceded by at least one week of acti- graphic recording with a sleep log to establish whether the results could be biased by insufficient sleep, shift work, or another circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1, the MSLT demonstrates a mean sleep latency of less than eight minutes and typically less than five minutes.</br>Meta-analysis shows mean sleep latencies in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcoleptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 3.1 ± 2.9 minutes.</br>In addition, two or more 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 must be present.</br>Recent data suggest that a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 within 15 minutes of onset of nocturnal sleep is a highly specific finding in the absence of another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but with low sensitivity.</br>Therefore, the criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 allow the “replacement” of one 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the MSLT with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on the preceding poly- somnogram.</br>For the correct interpretation of MSLT findings, the recordings should be performed with the following conditions: (1) the patient must be free of drugs that influence sleep for at least 14 days (or at least five times the half-life of the drug and longer-acting metabolite), confirmed by a urine drug screen; (2) the sleep-wake sched- ule must have been standardized and, if necessary, extended to a minimum of seven hours in bed each night (longer for children) for at least seven days before polysom-</br>nography (preferably documented by sleep log and, whenever possible, actigraphy); and (3) nocturnal polysomnography should be performed on the night immediately preceding the MSLT to rule out other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that could mimic the diagnostic features of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1.</br>Sleep time during polysomnography should be curtailed as little as possible with the goal of at least seven hours asleep.</br>The overnight poly- somnogram may demonstrate an increase in the amount of stage N1 sleep, and there may be a disruption of the normal sleep pattern, with frequent awakenings.</br>REM sleep without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present. </br>Measuring CSF levels of hypocretin-1 is a highly specific and sensitive test for the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1. Hypocretin-1 can be measured in crude CSF, using a commercially available radioimmunoassay.</br>When using the Stanford reference sample, values less than 110 pg/mL are highly specific.</br>Alternatively, a laboratory may elect to obtain control data themselves, in which case a level of less than 33% of mean control values is considered abnormal.</br>Issues concerning the standardization of CSF hypocre- tin measurements remain, but extensive protocols are available.</br>Low CSF hypocre- tin values are occasionally observed in seriously 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ill
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with other disorders and should be interpreted within the clinical context. </br>HLA typing of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcoleptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 almost always shows the presence of HLA DQB1*0602 (and DR2 or DRB1*1501 in whites and Asians), but this is not diagnostic for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Approximately 25% of the normal Caucasian population, 12% of the Japanese population, and 38% of the black population are positive for DQB1*0602.</br>HLA typing could be considered when a spinal tap is contemplated to assess hypocretin-1 values: if the patient is HLA-negative, hypocretin-1 levels are most likely normal. </br>Differential Diagnosis In the absence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 can be diagnosed based on the pres- ence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and low CSF hypocretin-1 levels.</br>When 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is absent and CSF hypocretin-1 levels are normal or unknown, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 should be diagnosed. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 must be differentiated from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy-like
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes that are occasionally observed in normal individuals.</br>For example, feelings of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are some- times reported when healthy subjects laugh out loud.</br>In genuine 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, episodes most often occur with a significant frequency, and are associated with loss of muscle tone.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be differentiated from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypotension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, transient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemic attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, drop attacks, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    akinetic seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vestibular disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psycho-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 logical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Clear improvement with antide- pressant medications may favor a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in difficult cases. </br>Sleepiness may be secondary to obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, shift work, the effects of substances or medications, or other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Many of these conditions can result in early onset REM sleep as well.</br>When 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present, these disorders do not preclude a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1.</br>When there is a questionable history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in such cases, either comorbid conditions should be adequately treated before performing an MSLT or CSF hypocretin-1 should be measured. </br>153 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence Idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is differentiated from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 by the absence of cat- aplexy and the lack of two or more 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on the MSLT.</br>In contrast with patients who have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 generally have high sleep efficiency, sleep drunkenness, and long, unrefreshing naps. </br>In insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, there is no 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and normalizing sleep time elim-</br>inates the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may mimic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but do not show the typical MSLT findings.</br>Malingering and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance abuse disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be considered in patients who try to mislead the clinician in order to obtain stimulant medications. </br>Unresolved Issues and Further Directions Ten percent of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have normal hypocretin-1 levels in the CSF, which suggests that CSF levels either do not perfectly reflect brain hypocretin neurotransmission or that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be caused by factors other than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocretin deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The cause of the hypocretin cell destruction remains unknown, although an autoimmune-mediated mechanism is suspected.</br>Levels of hypocretin-1 have been reported in the blood of some subjects.</br>The development of serum tests to determine 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocretin deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 would provide a less invasive diagnos- tic approach. </br>Bibliography Andlauer O, Moore H, Jouhier L, et al.</br>Nocturnal REM sleep latency for identifying patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy/hypocretin deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>JAMA Neurol 2013;6:1–12. </br>Aran A, Einen M, Lin L, Palazzi G, Nishino S, Mignot E. Clinical and therapeutic aspects of childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy-cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a retrospective study of 51 children.</br>Sleep 2010;33:1457–64. </br>Arii J, Kanbayashi T, Tanabe Y,</br>et al. CSF hypocretin-1 (orexin-A) levels in childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and neurologic disorders.</br>Neurology 2004;63:2440–2. </br>Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders.</br>Lancet Neurol 2008;7:649–62. </br>Dauvilliers Y, Gosselin A, Paquet J, Touchon J, Billiard M, Montplaisir J. Effect of age on MSLT results in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy-cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Neurology 2004;62:46–50. </br>Dauvilliers Y, Arnulf I, Mignot E. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Lancet 2007;369:499–511. </br>Kotagal S, Krahn LE, Slocumb N. A putative link between childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Med 2004;5:147–50. </br>Mignot E, Lammers GJ, Ripley B, et al.</br>The role of cerebrospinal fluid hypocretin measurement in the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Arch Neurol 2002;59:1553–62. </br>Mignot E, Lin L, Finn L, et al.</br>Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults.</br>Brain 2006;129:1609–23. </br>154 Nevsimalova S, Prihodova I, Kemlink D, Lin L, Mignot E. REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) can be one of the first symptoms of childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Med 2007;8:784–6. </br>Overeem S, van Nues SJ, van der Zande WL, Donjacour CE, van Mierlo P, Lammers GJ.</br>The clinical features of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a questionnaire study in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with and without hypocretin-1 deficiency.</br>Sleep Med 2011;12:12–8. </br>Pizza F, Franceschini C, Peltola H, et al.</br>Clinical and polysomnographic course of childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Brain 2013 Oct 18.</br>[Epub ahead of print] Plazzi G, Parmeggiani A, Mignot E, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy-cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with precocious puberty.</br>Neurology 2006;66:1577–9. </br>Serra L, Montagna P, Mignot E, Lugaresi E, Plazzi G. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 features in childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Mov Disord 2008;23:858–65. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Type 2 ICD-9-CM code: 347.00 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-E must be met ICD-10-CM code: G47.419 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 A.</br>The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months. </br>B. A mean sleep latency of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 8 minutes and two or more sleep onset REM periods (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) are found on a MSLT performed according to standard techniques.</br>A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (within 15 minutes of sleep onset) on the preceding nocturnal polysomnogram may replace one of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on the MSLT. </br>C. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is absent.1 D. Either CSF hypocretin-1 concentration has not been measured or CSF hypocretin-1 concentration measured by immunoreactivity is either &gt; 110 pg/mL or &gt; 1/3 of mean values obtained in normal subjects with the same standardized assay.2 E.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or MSLT findings are not better explained by other causes such as insufficient sleep, obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or the effect of medication or substances or their withdrawal. </br>Notes .</br>If 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 develops later, then the disorder should be reclassified as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1. Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 .</br>If the CSF Hcrt-1 concentration is tested at a later stage and found to be either 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 110 pg/mL or &lt; 1/3 of mean values obtained in normal subjects with the same assay, then the disorder should be reclassified as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1. </br>Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 is characterized by excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and abnormal man- ifestations of REM sleep on polysomnography/MSLT.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is absent, although some 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atypical sensations of weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 triggered by unusual emotions such as stress and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anger
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be reported.</br>Refreshing daytime naps are characteristic. </br>An essential feature of the diagnosis is the presence of a mean sleep latency less than or equal to eight minutes and two or more 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on an MSLT (or one 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on an MSLT and one on the preceding nocturnal polysomnogram).</br>The presence of CSF hypocretin-1 concentrations 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 110 pg/mL or less than one third of mean values obtained in normal subjects with the same assay excludes the diagnosis, but most patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 will not have undergone CSF examination. </br>Associated Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or automatic behavior may be present.</br>Memory lapses, automatic behavior, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ptosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blurred vision
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diplopia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and nonrapid eye movement (NREM) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur.</br>Nocturnal sleep disruption with frequent awaken- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 may be present. </br>Clinical and Pathophysiological Subtypes Narcolepsy type 2 due to a medical condition: This condition fulfills criteria for nar- colepsy type 2 and is attributable to another medical disorder.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Neurologic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sarcoidosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the hypothalamus, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autoimmune
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paraneoplastic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with anti-Ma-2 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anti-aquaporin-4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 antibodies, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multiple sclerosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myotonic dystrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prader-Willi syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and head 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In disorders associated with both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and narco- lepsy type 2, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myotonic dystrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prader-Willi syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 should only be made if abnormal MSLT findings persist after the sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is adequately treated.</br>In all cases, especially with complex problems such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, clinical judgment should be used to determine if the development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was a mere coincidence or was triggered by the event or disorder. </br>156 Demographics The exact prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 is uncertain.</br>Cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without cat- aplexy represent 15% to 25% of the clinic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcoleptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 population.</br>A population-based study suggested a higher percentage (36%), corresponding to a point prevalence of 20.5/100,000.</br>Population-based studies have shown that approximately 4% to 9.5% of adults may have multiple 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 during random 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MSLTs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but shift workers and subjects with sleep deprivation or sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 were included in the studies.</br>Although both sexes can be affected, the prevalence may be slightly higher in men.</br>The age of onset mirrors that of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1. Predisposing and Precipitating Factors As discussed below, about 24% of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but no 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will have low CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels and almost all of these will be positive for the HLA DQB1*0602 antigen.</br>These patients probably share a common pathogenesis with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and should be classified as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1.</br>Underlying genetic and envi- ronmental factors associated with other patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 are unknown.</br>Environmental precipitating factors are suspected from case reports but have never been proven to trigger 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Among the most commonly reported triggers are head 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and unspecified viral illnesses. </br>Familial Patterns The detailed genetic pattern of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 is unknown.</br>Relatives of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 may be more likely to experience partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms compatible with the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2. Onset, Course, and Complications Onset typically occurs during adolescence.</br>In about 10% of patients, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will develop later in the course of the disease, necessitating a change in diagnosis to narco- lepsy type 1.</br>Most of these patients will, if tested, have absent or intermediate levels of CSF Hcrt-1.</br>In a cohort of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in whom CSF Hcrt-1 status was known, 33% of those with low levels later developed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, compared with 18% with intermediate levels and only 1% with normal levels.</br>When left untreated, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 is socially disabling and isolating.</br>Patients have a ten- dency to fail in school and are often dismissed from their jobs.</br>Driving may be avoided for fear of a motor vehicle accident.</br>The inability to sleep at night may further contrib- ute to a loss of control these patients have over their schedule.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight gain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also are common. </br>157 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Developmental Issues Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy type 2 will typically
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 present with a reappearance of regular daytime napping after naps had been discontinued.</br>In all pediatric cases, one should consider the possibility of an evolving disorder with the development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 over time.</br>Once the patient develops clear 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the diagnosis should be changed to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1.</br>Limited information is available on 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 prior to adolescence.</br>Descriptions of the experience of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or hypnagogic halluci- nations are very difficult to evoke in young patients, and normative data are not avail- able for the MSLT in children younger than six years of age.</br>In peripubertal children and adolescents, the diagnosis is often challenging.</br>The most common causes of short sleep latencies, often with multiple 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 on the MSLT, are chronic sleep depri- vation and delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Behavioral problems may be associated with the onset of the disorder, and symptoms may be hidden by the patient.</br>Inattentiveness, lack of energy, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bizarre hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or a combination thereof can lead to a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 misdiagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    schizophrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>If the MSLT shows equivocal results, repeating it after a time interval may be helpful, as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often emerge later in children. </br>Pathology and Pathophysiology Narcolepsy type 2 is most likely a heterogeneous disorder.</br>Approximately 24% of nar-</br>coleptic patients without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have a low CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 concentration, and another 8% have intermediate levels (&gt; 110 pg/mL but 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 200 pg/mL).</br>The CSF Hcrt-1 status of most patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 is unknown (those patients who are known to have absent CSF Hcrt-1 levels are classified as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1).</br>Therefore, there will be a subgroup of about one fourth to one third of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 patients who will have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocretin deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, presumably from loss of the hypocretin-producing neurons.</br>This group of patients cannot be accurately separated clinically or by labora- tory tests (other than CSF Hcrt-1 level) from the majority of patients without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 who have normal CSF Hcrt-1 levels.</br>Although those with low CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels have a younger age of onset and their MSLT shows shorter mean sleep latency with more 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in comparison with those with normal levels, there is too much overlap between the groups for these differences to be helpful diagnostically in individual patients.</br>One hundred percent of patients with low CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels are positive for HLA DQB1*0602.</br>About 26% of patients with normal levels are also HLA posi- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a percentage not higher than that seen in the normal population.</br>The underlying pathophysiology of the remainder of patients who have normal CSF Hcrt-1 levels is unknown.</br>It is possible some may have partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocretin deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 severe enough to cause 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but not severe enough to result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or low CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels.</br>However, support for this hypothesis is lacking in that there are no major differences in clinical or polysomnographic findings in those positive or negative for HLA DQB1*0602.</br>In the only postmortem study of a case of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without cata- plexy (CSF Hcrt-1 status unknown), the number of hypocretin cells was decreased but not as much as in cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Objective Findings It is strongly rcommended that the MSLT be preceded by at least one week of acti- graphic recording with a sleep log to establish whether the results could be biased by insufficient sleep, shift work, or another circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The MSLT 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    demon-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 strates a mean latency of less than eight minutes, typically less than five minutes, with two or more 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or one 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 together with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on the preceding polysomnogram.</br>Meta-analysis shows mean sleep latencies in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcoleptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 3.1 ± 2.9 minutes.</br>Recent data suggest that a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 within 15 minutes of onset of nocturnal sleep is a highly specific finding in the absence of another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but with low sensitivity.</br>Therefore, the criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 allow the “replacement” of one 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the MSLT with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on the preceding poly- somnogram.</br>For the correct interpretation of MSLT findings, the recordings should be performed with the following conditions: (1) the patient must be free of drugs that influence sleep for at least 14 days (or at least five times the half-life of the drug and longer-acting metabolite), confirmed by a urine drug screen; (2) the sleep-wake sched- ule must have been standardized and, if necessary, extended to a minimum of seven hours in bed each night (longer for children) for at least seven days before polysom-</br>nography (preferably documented by sleep log and, whenever possible, actigraphy); and (3) nocturnal polysomnography should be performed on the night immediately preceding the MSLT to rule out other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that could mimic the diagnostic features of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2.</br>Sleep time during polysomnography should be curtailed as little as possible, with the goal of at least seven hours asleep.</br>The overnight poly- somnogram may demonstrate an increase in the amount of stage N1 sleep, and there may be a disruption of the normal sleep pattern, with frequent awakenings.</br>REM sleep without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present. </br>About 45% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 cases have been reported to be HLA DQB1*0602 positive, compared with 12% to 38% of controls.</br>Whereas essentially all patients who have low CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels will be positive, about 25% of those with normal levels will also be positive.</br>Assuming that 24% of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but no 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will have low CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels, the probability that an HLA- positive patient will have low 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels is only 0.56.</br>Therefore the HLA status of a patient cannot be used to diagnose 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 nor to predict with high probability the patient’s CSF Hcrt-1 levels.</br>However, if lumbar puncture is contemplated to measure CSF Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Hcrt-1 levels, HLA typing should be performed first; if the patient is HLA negative, CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels will almost certainly be normal and the lumbar puncture will be unnecessary. </br>Approximately 24% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcoleptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have a low CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 concentration and another 8% have intermediate levels (&gt; 110 pg/mL but 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 200 pg/ mL).</br>If the CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels of such patients are known to be low, they are classified as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1, but the CSF Hcrt-1 status will not be known for most of these patients.</br>Possible indications for considering measuring CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hcrt-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels as a diag- nostic procedure would be the presence of disorders such as obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or the use of psychotropic medications that may complicate interpretation of an MSLT. </br>Differential Diagnosis Narcolepsy type 1 is diagnosed if 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present or the CSF hypocretin levels are known to be low even in the absence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hyper- somnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may have mean sleep latencies on MSLT similar to those of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2, but have fewer than two 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on MSLT and the preceding polysomnogram combined.</br>In contrast to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 generally have high sleep efficiency, sleep drunkenness, and long, unrefreshing naps.</br>Sleepiness may be secondary to obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, shift work, the effects of substances or medications, or other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Many of these conditions can result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    early-onset REM sleep
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, so their clinical and polysomnographic exclusion is essential before a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 is made.</br>However, the presence of other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 does not preclude a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 if 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    REM abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 persist after adequate treatment of the initial disorder.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may mimic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but do not show the typical MSLT findings.</br>Malingering and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance abuse disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be considered in patients who try to mislead the clinician in order to obtain stimulant medications. </br>Unresolved Issues and Further Directions Excluding the minority of patients with definite 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocretin deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the underlying biology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is unknown.</br>It is not estab- lished whether 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 is a homogeneous or heterogeneous condition.</br>It is uncertain whether or not some patients have partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocretin deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 not iden- tifiable from CSF measurements.</br>Further advances in classification will depend on answers to these unknowns.</br>Further studies on the natural history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 are needed to determine the cause of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the risk of development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 over time. </br>160 Bibliography Andlauer O, Moore IV H, Hong SC, et al.</br>Predictors of hypocretin (orexin) deficiency in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2012;35:1247–55. Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders.</br>Lancet Neurol 2008;7:649–62. </br>Mignot E, Lin L, Finn L, et al.</br>Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults.</br>Brain 2006;129:1609–23. </br>Oka Y, Inoue Y, Kanbayashi T, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: 2 subtypes based on CSF hypocretin-1/ orexin-A findings.</br>Sleep 2006;29:1439–43. </br>Sasai T, Inoue Y, Komada Y, Sugiura T, Matsushima E. Comparison of clinical characteristics among 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with and without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without long sleep time, focusing on HLA-DRB1(*)1501/DQB1(*)0602 finding.</br>Sleep Med 2009;10:961–6. </br>Silber MH, Krahn LE, Olson EJ, Pankratz VS.</br>The epidemiology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in Olmsted County, Minnesota: a population-based study.</br>Sleep 2002;25:197–202. </br>Takei Y, Komada Y, Namba 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, et al.</br>Differences in findings of nocturnal polysomnography and multiple sleep latency test between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Clin Neurophysiol 2012;123:137–41. </br>Thannickal TC, Nienhuis R, Siegel JM.</br>Localized loss of hypocretin (orexin) cells in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2009;32:993–8. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Idiopathic Hypersomnia ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.11 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Idiopathic CNS hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-F must be met ICD-10-CM code: G47.11 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 A.</br>The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months.1 B. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is absent. </br>C. An MSLT performed according to standard techniques shows fewer than two sleep onset REM periods or no sleep onset REM periods if the REM latency on the preceding polysomnogram was less than or equal to 15 minutes.2 D.</br>The presence of at least one of the following: .</br>The MSLT shows a mean sleep latency of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 8 minutes. </br>2. Total 24-hour sleep time is ≥ 660 minutes (typically 12–14 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hours)3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on 24-hour polysomnographic monitoring (performed after correction of chronic sleep deprivation), or by wrist actigraphy in Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 association with a sleep log (averaged over at least seven days with unrestricted sleep).4 E. Insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is ruled out (if deemed necessary, by lack of improvement of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 after an adequate trial of increased nocturnal time in bed, preferably confirmed by at least a week of wrist actigraphy). </br>F. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or MSLT findings are not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, other medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or use of drugs or medications. </br>Notes .</br>Severe and prolonged sleep inertia, known as sleep drunkenness (defined as prolonged difficulty waking up with repeated returns to sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, automatic behavior, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) and/or long (&gt; 1 hour), unrefreshing naps are additional supportive clinical features. </br>2. A high sleep efficiency (≥ 90%) on the preceding polysomnogram is a supportive finding (as long as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is ruled out). </br>3. The total 24-hour sleep time required for diagnosis may need to be adapted to account for normal changes in sleep time associated with stages of development in children and adolescents as well as for variability across cultures in all age groups. </br>4. Occasionally, patients fulfilling other criteria may have an MSLT mean sleep latency longer than 8 minutes and total 24-hour sleep time shorter than 660 minutes.</br>Clinical judgment should be used in deciding if these patients should be considered to have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (IH).</br>Great caution should be exercised to exclude other conditions that might mimic the disorder.</br>A repeat MSLT at a later date is advisable if the clinical suspicion for IH remains high. </br>Essential Features IH is characterized by excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that occurs in the absence of cat- aplexy, is accompanied by no more than one 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on MSLT and preceding poly- somnogram combined, and is not adequately explained by another disorder.</br>Other dis- orders causing sleepiness must be carefully considered and excluded, especially insuf- ficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Objective evidence of hypersomnolence must be demonstrated by an MSLT showing a mean sleep latency of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 8 minutes or by polysomnography or wrist actigraphy showing a total 24-hour sleep time of ≥ 660 minutes.</br>A prolonged and severe form of sleep inertia, historically known as sleep drunkenness, consists of prolonged difficulty waking up with repeated returns to sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, automatic behavior, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It is reported in 36% to 66% of patients with IH in differ- ent series.</br>Subjects typically do not easily awaken to alarm clocks and frequently use special devices or procedures to wake up.</br>Naps are generally long, often more than 60 minutes, and described as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    unrefreshing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by 46% to 78% of patients.</br>Sleep efficiency on polysomnogram is usually high (mean 90% to 94%).</br>Self-reported total sleep time is longer than in controls and is ≥ 10 hours in at least 30% of patients. </br>Associated Features Associated symptoms which suggest a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysfunction of the autonomic nervous system
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present.</br>These symptoms include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orthostatic disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, perception of temperature dysregulation, and peripheral vascular complaints (Raynaud-type phe- nomena with cold hands and feet).</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also be reported, but the frequency is uncertain (4% to 40% in different series). </br>Clinical and Pathologic Subtypes The 2005 2nd edition of the International Classification of Sleep Disorders divided IH into two disorders: IH with long sleep time, and IH without long sleep time.</br>IH is likely a heterogeneous condition, the pathophysiology of which is currently unknown.</br>However, recent studies suggest that a division of the disorder based on the length of nocturnal sleep lacks validity.</br>Comparison of patients with ≥ 10 hours of sleep to those with &lt; 10 hours show no differences in Epworth Sleepiness Scale scores, MSLT mean sleep latencies, or percentage with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep drunkenness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    unrefreshing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 naps, hypnago- gic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The only reported differences are that the group with long sleep is somewhat younger and thinner, with lower Horne-Ostberg scores and marginally higher sleep efficiency.</br>If MSLT mean sleep latencies are not used as a diagnostic criterion, the distribution of latencies is unimodal, suggesting no sepa- rate subtypes.</br>In addition, an actigraphy study has shown that patients with IH tend to overestimate their sleep time by a mean of 0.99 hours, thus making the fundamental criterion for distinguishing between patients with long and shorter sleep inaccurate.</br>Clinicians may wish to continue to note sleep duration as an important clinical feature, but the caveats discussed above should be clearly considered.</br>Any future separation of IH into distinct conditions must await advances in understanding the underlying biology. </br>Demographics Prevalence and incidence of IH are not known.</br>Some studies have suggested a higher prevalence in women. </br>163 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Predisposing and Precipitating Factors In contrast to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the disorder is not known to be HLA associated, and no con- sistent precipitating factor has been identified. </br>Familial Patterns A familial predisposition to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been reported but rigorous studies have not been performed. </br>Onset, Course, and Complications The mean age of onset of IH in different series is 16.6–21.2 years.</br>Once established, the disorder is generally stable in severity and long lasting, although a spontaneous remission rate of 14% has been reported in one series.</br>Complications are mostly social and professional, and include poor work or school performance, reduced earnings, and loss of employment. </br>Developmental Issues IH frequently develops in adolescence.</br>Exclusion of other causes of hypersomno- lence in that age group, including delayed sleep-wake phase disorder, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and use of recreational drugs, is essential.</br>Early in the development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may not be present on MSLT; therefore, some patients may need to be reclassified later as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2.</br>If the 24-hour total sleep time is used to confirm the diagnosis of IH in a child or adolescent, normal values may need to be adapted to account for changes in sleep time associated with stages of development. </br>Pathology and Pathophysiology The pathophysiology of IH is unknown.</br>Neurochemical studies measuring monoamine metabolites in the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been inconclusive.</br>CSF hypocretin-1 concentrations in patients with IH are normal.</br>CSF 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    histamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels have been reported to be low in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and IH, but a recent study did not confirm these findings. </br>Objective Findings Polysomnographic monitoring generally demonstrates NREM and REM sleep in expected proportions with normal REM latency.</br>Total sleep time is often prolonged.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be either absent or adequately treated before diagnosing this disor- der, with special attention paid to excluding significant respiratory effort related arous- als.</br>The MSLT should not show more than one 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (or none if a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was observed on the preceding night’s polysomnogram (PSG)).</br>The mean sleep latency on the MSLT is usually shorter than in controls but longer than in most patients with nar- colepsy, averaging 8.3 and 7.8 minutes in two large studies. </br>In patients with MSLT mean latencies &gt; 8 minutes, prolonged sleep monitoring should be performed by polysomnography (24 hours) or wrist actigraphy (7 days with unre- stricted sleep) after correction of sleep deprivation, exclusion of other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and discontinuation of sedating medication as required for an MSLT (see Narcolepsy– Objective Findings).</br>Total 24-hour sleep time in adults (major sleep episode plus naps) must be ≥ 660 minutes (note that the use of 24-hour PSG monitoring for the diagnosis of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IH
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 has been validated against controls, but the use of seven days of actigraphic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mon-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 itoring still awaits validation). </br>Differential Diagnosis IH may be confused with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, especially when respiratory-related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (rather than apneas or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) are present.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 is distinguished from IH by the presence of two or more sleep onset REM periods on the MSLT or preceding PSG.</br>Insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 must be carefully excluded by extending the patient’s sleep before testing.</br>Historical information, physical examination, and, if indicated, laboratory testing including brain imaging should help rule out 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder.</br>In particular, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, residual hyper- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    somnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 following adequate treatment of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and sleep fragmentation due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may mimic IH.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance must be considered and ruled out by discontinuation of possible causative agents, if clinically appropriate.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be consid- ered in patients with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 condition, most typically 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The complaint of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and prolonged sleep may be rather similar to that of patients with IH, except that it may vary from day to day and is often associated with poor sleep at night.</br>The MSLT in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 does not demonstrate a short mean sleep latency.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is character- ized by persistent or relapsing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that does not resolve with sleep or rest.</br>Patients clearly complain of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 rather than excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and the mean MSLT sleep latency is normal.</br>Long sleepers feel fully refreshed and do not experience 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 if they are allowed to sleep as long as they need, in contrast with patients with IH who continue to feel sleepy regardless of prior sleep duration. </br>Unresolved Issues and Future Directions There is a paucity of knowledge regarding the neurobiology of IH.</br>Further research in this area, as well as more precise characterization of clinical characteristics and treat- ment response, is required. </br>165 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Bibliography Ali M, Auger RR, Slocumb NL, Morgenthaler TI.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: clinical features and response to treatment.</br>J Clin Sleep Med 2009;5:562–8. </br>Anderson KN, Pilsworth S, Sharples RD, Smith IE, Shneerson JM.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a study of 77 cases.</br>Sleep 2007;30:1274–81. </br>Bassetti C, Aldrich MS.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a series of 42 patients.</br>Brain 1997;120:1423–35. </br>Dauvilliers Y, Delallee N, Jaussent I, et al.</br>Normal cerebrospinal fluid 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    histamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tele-methylhistamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 conditions.</br>Sleep 2012;35:1359–66. </br>Kanbayashi T, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kodama T
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Kondo H, et al.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSH histamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 contents in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2009;32:181–7. </br>Vernet C, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Arnulf I. Idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with and without long sleep time: a controlled series of 75 patients.</br>Sleep 2009;32:753–9. </br>Vernet C, Leu-Semenescu S, Buzare MA, Arnulf I. Subjective 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: beyond 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Sleep Res 2010;19:525–34. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin Syndrome ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.13 Alternate Names Recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, periodic hypersomnolence. </br>Diagnostic Criteria Criteria A-E must be met ICD-10-CM code:</br>G47.13 A.</br>The patient experiences at least two recurrent episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep duration, each persisting for two days to five weeks. </br>B. Episodes recur usually more than once a year and at least once every 18 months. </br>C. The patient has normal alertness, cognitive function, behavior, and mood between episodes. </br>D.</br>The patient must demonstrate at least one of the following during episodes: </br>1. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cognitive dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>2. Altered perception. </br>3.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anorexia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperphagia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>4. Disinhibited behavior (such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersexuality
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>E.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and related symptoms are not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, other medical, neurologic, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (especially 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bipolar disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), or use of drugs or medications. </br>166 Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by relapsing-remitting episodes of severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cognitive, psychiatric, and behavioral distur- bances.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>A typical episode lasts a median 10 days (range, 2.5–80 days), with rare epi- sodes lasting several weeks to months.</br>The first episode is often triggered by an infec- tion or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 intake, with further episodes recurring every 1–12 months (median three months) for years.</br>During episodes, patients may sleep as long as 16 to 20 hours per day, waking or getting up only to eat and void (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    incontinence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not observed).</br>They remain rousable, but are 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritable
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 if prevented from sleeping.</br>When they are awake during episodes, most patients are exhausted, apathetic, confused, and slow in speaking and answering.</br>Anterograde 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amnesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is typical.</br>Almost all report a dreamlike, altered perception of the environment (derealization).</br>Less commonly, patients eat ravenously (66%, although one third eat less), are 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersexual
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (53%, principally men), childish, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressed
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (53%, predominantly women), and anxious at being left alone and seeing strangers, and experience 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    delusions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (30%).</br>Patients are remark- ably normal between episodes with regard to sleep, cognition, mood, and eating.</br>The disease typically resolves after a median of 14 years, except in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adult-onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cases, when the course may be more prolonged.</br>The simultaneous occurrence of all these symp- toms is the exception rather than the rule, with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 being more char- acteristic at the disease onset and during the first part of the episodes, and disinhib- ited behaviors being evident during only a few episodes.</br>In occasional cases, isolated recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be the only symptom.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Amnesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, transient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphoria
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    elation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may signal the termination of an episode. </br>Associated Features Physical examination is unremarkable, except for general psychomotor slowing.</br>Social and occupational impairment during 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is often severe, with teenagers bedridden for days, but can be variable depending on the frequency, severity, and duration of episodes. </br>Clinical and Pathophysiological 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Subtypes Menstrual-related Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (alternate name: menstrual-related hyper- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    somnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
):</br>This descriptor is used when episodes are exclusively associated with men- struation (occurring just before or during menses), a condition reported in only 18 women worldwide.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes in these cases have been associated with compulsive eating in 65%, sexual disinhibition in 29%, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive mood
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 35%.</br>Episodes last 3 to 15 days and recur less than three times a year.</br>One boy with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is reported to have a sister affected by menstrual-related hypersomnolence.</br>Menstrual-related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be a variant of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, although response to contraceptive doses of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    estrogen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    progesterone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, reported in some cases, suggests a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reproductive endocrine disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Demographics 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is rare, with a prevalence estimated around 1 to 2 cases per million.</br>Roughly 500 cases have been reported to date in the literature, from all countries in which the disease has been investigated.</br>The disease starts during the second decade in 81% of patients, with a male/female ratio of 2:1.</br>Adults and younger children may also be affected. </br>Predisposing and Precipitating Factors Birth and developmental problems, as well as Jewish heritage, are risk factors for devel- oping the syndrome.</br>The frequency of the HLA DQB1*02 was increased compared with controls in a retrospective, multicenter series of 30 patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but not in another larger prospective series (n = 108).</br>A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    flu-like illness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the upper airway (and more rarely 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroenteritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is often reported imme- diately prior to the onset of the first episode, and more rarely before relapses.</br>Other less frequently reported triggering events include 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 consumption, head 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, travel, or exposure to anesthesia. </br>Familial Patterns Familial cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are found in 5% of patients, including twins, parent-child, siblings, and uncle-nephew associations.</br>There is no increased history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in family members of patients. </br>Onset, Course, and Complications Early adolescence (second decade) is the usual age of onset.</br>The course of Kleine-</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by recurrent episodes of severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, lasting up to several weeks, with normal functioning between episodes.</br>Several long-term studies suggest an often-benign course, with episodes lessening in duration, severity, and fre- quency over a median course of 14 years.</br>Male sex, age at onset younger than 12 years or older than 20 years, as well as the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersexuality
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during episodes, predict longer disease duration.</br>Complications are mainly social and occupational.</br>In rare cases, subjects have been reported to choke while eating voraciously, to have suicidal thoughts, or to be involved in a car accident.</br>A reduced long-term working memory capacity following episodes was reported in eight patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Developmental Issues Adolescents are affected in most cases.</br>However, the onset of the condition has been reported in children as young as four years. </br>168 Pathology and Pathophysiology Postmortem examination of the central nervous system has been performed in only four cases, with inconsistent findings.</br>One subject showed significant perivascular lymphocytic infiltrations in the hypothalamus, amygdala, and the grey matter of the temporal lobes; a second demonstrated similar infiltrations in the thalamus; and a third in the diencephalon and the midbrain with a suggestion of mild localized encephali- tis.</br>In the fourth case, a smaller locus coeruleus and decreased pigmentation in the substantia nigra were reported.</br>Magnetic resonance imaging was unremarkable.</br>In contrast, functional brain imaging studies during episodes are frequently abnormal, showing hypometabolism in the thalamus, hypothalamus, mesial temporal lobe, and frontal lobe.</br>Some of these abnormalities persist during asymptomatic periods in half of the patients.</br>An autoimmune basis for the disorder is suggested clinically (onset occurs during adolescence, often in conjunction with an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) and by the occa- sional association with HLA DQB1*02. </br>Objective Findings Routine electroencephalograms obtained during episodes have shown general slowing of background electroencephalographic activity and often paroxysmal—0.5-2.0-sec- ond—bursts of bisynchronous, generalized, moderate- to high-voltage 5- to 7-Hz waves.</br>Polysomnography studies are often difficult to interpret, and results are depen- dent on the duration of recording (overnight vs. 24-hour monitoring) as well as the timing (at the beginning versus the end of episodes or at onset of the disease or later in its course).</br>Twenty-four-hour polysomnography demonstrates prolonged total sleep time (a mean 11–12 hours), and 18 hours or more in some reports.</br>During nocturnal polysomnography in 17 children, nighttime slow wave sleep percentage was decreased during the first half of the episodes, and REM sleep decreased during the second half.</br>Results of the MSLT are highly dependent on the subjects
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ’
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 willingness to comply with the procedure, and may either be normal or abnormal, showing short latencies or mul- tiple 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>CSF cytology and protein are normal.</br>CSF levels of hypocretin-1 were within normal range in 16 patients, although intraepisodic levels are lower than interepisodic levels.</br>Computed tomography scans and magnetic resonance imaging are normal.</br>Brain functional imaging is abnormal in most cases, with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoperfusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the left or right temporal and frontal lobes as well as the diencephalon.</br>These abnor- malities are present during the episode of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sometimes between episodes.</br>Hormone levels are normal, as are 24-hour secretory patterns. </br>Differential Diagnosis Recurrent waxing and waning episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be secondary to struc- tural insults of the central nervous system.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 within the third ventricle (such as Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence colloid cysts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pedunculated astrocytomas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or, in some cases, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    craniopharyngiomas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) may produce intermittent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructions of ventricular flow
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, leading to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vomiting
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, vague sensorial disturbances, and a paroxysmal impairment of alertness.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Encephalitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperammonemic encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multiple sclerosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    porphyria
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lyme disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    basilar migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and complex partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    status epilepticus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 less frequently mimic symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Recurrent episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also are reported in the context of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bipolar disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seasonal affective disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    somatoform disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, the onset and offset of symptoms are less abrupt than in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and persist to some extent between episodes.</br>Other differential diagnoses include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, IH, and insufficient sleep.</br>In these disor- ders, however, the complaint of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs daily and is usually not recurrent or periodic.</br>There is no evidence that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs as a result of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 disorder. </br>Unresolved Issues and Future Directions The pathophysiology of this disorder is not known.</br>Evidence to date suggests that a localized but multifocal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs during episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syn- drome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as functional imaging and electroencephalography (EEG) slowing indicate tha- lamic, temporal, and frontal lobe involvement.</br>The cause of these episodic abnormali- ties may be genetic, autoimmune, inflammatory, or metabolic. </br>Bibliography Arnulf I, Lin L, Gadoth N, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a systematic study of 108 patients.</br>Ann Neurol 2008;63:482–93. </br>Arnulf I, Zeitzer JM, File J, Farber N, Mignot E. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a systematic review of 186 cases in the literature.</br>Brain 2005;128:2763–76. </br>Billiard M, Jaussent I, Dauvilliers Y, Besset A. Recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a review of 339 cases.</br>Sleep Med Rev 2011;15:247–57. </br>Dauvilliers Y, Mayer G, Lecendreux M, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>An autoimmune hypothesis based on clinical and genetic analyses.</br>Neurology 2002;59:1739–45. </br>Engström M, Vigren P, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Karlsson T
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Landtblom A. Working memory in 8 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients: An fMRI study.</br>Sleep 2009;32:681–8. </br>Gadoth N, Kesler A, Vainstein G, Peled R, Lavie P. Clinical and polysomnographic characteristics of 34 patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Sleep Res 2001;10:337–41. </br>Huang Y, Lin Y, Guilleminault C. Polysomnography in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Neurology 2008;70:795–801. </br>Huang Y, Guilleminault C, Lin 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Hwang F, Liu F, Kung Y. Relationship between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in Taiwan.</br>Sleep 2012;35:123–9. </br>170 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder ICD-9-CM code: 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    327.14
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 ICD-10-CM code: G47.14 Alternate Names Not applicable. </br>Diagnostic Criteria Criteria A-D must be met A.</br>The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months. </br>B. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs as a consequence of a significant underlying medical or neurological condition. </br>C.</br>If an MSLT is performed, the mean sleep latency is 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ≤
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 8 minutes, and fewer than two sleep onset REM periods (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) are observed.1 D.</br>The symptoms are not better explained by another untreated sleep disorder,2 a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or the effects of medications or drugs. </br>Notes .</br>In the subtype of residual hypersomnolence after treatment of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the MSLT mean latency may be &gt; 8 minutes. </br>2. Should criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 be fulfilled, a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 or type 2 due to a medical condition should be used rather than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical condition. </br>3.</br>In patients with severe neurological or medical disorders in whom it is not possible or desirable to perform sleep studies, the diagnosis can be made by clinical criteria. </br>Essential Features Patients with this disorder have excessive nocturnal sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    napping
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that is attributable to a coexisting medical or neurological disor- der.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be of variable severity and may resemble that of narco- lepsy (i.e., refreshing naps) or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (i.e., long periods of unrefresh- ing sleep).</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or automatic behavior may be present, but if the patient has 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the MSLT shows two or more 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or CSF Hcrt-1 levels are low, then 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (type 1 or type 2) due to a medical condi- tion should be diagnosed.</br>In patients with both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep related breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder, the latter diagnosis should be made only if the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 persists after adequate treatment of the sleep disordered breathing.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder is only diagnosed if the medical condition is Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 judged to be directly causing the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been described in association with a large range of conditions, including metabolic enceph- alopathy, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brain tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    encephalitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, systemic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inflammation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rheumatologic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), genetic disorders, and neurode- generative diseases. </br>Associated Features Not applicable or known. </br>Clinical and Pathophysiological Subtypes Many medical conditions can cause hypersomnolence. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: Significant hypersomnolence docu- mented by MSLT has been reported in some cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be due to insufficient control of nocturnal symptoms, result- ing in insufficient sleep and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>If so, the diagnosis should be 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that are due to the side effects of dopaminergic agents should be coded as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance.</br>In other cases, however, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is likely of central origin and should be classified in this section.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with an MSLT profile consistent with narco- lepsy should be coded as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical condition. </br>Posttraumatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 appears to be common after 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trau-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 matic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brain injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TBI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), with one meta-analysis suggesting a frequency of 28% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TBI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients.</br>In some cases this may be caused by injury to the hypocretin/orexin neurons or other wake-promoting neural systems.</br>However, the prevalence of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (SRBD) in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is high (frequency 23% to 25%).</br>The nature of the relationship between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TBI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 remains undefined.</br>Therefore, control of other potential 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is necessary prior to making a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Genetic disorders associated with primary central nervous system 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    somnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: Genetic disorders such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Niemann Pick type C disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Norrie disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime somnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prader-Willi syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myotonic dystrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Moebius syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fragile X syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are other examples of centrally mediated sleepiness.</br>A number of genetic disorders have been reported to be associated with both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myotonic dystrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prader-Willi syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>In these cases, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder should be diagnosed only if the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is still present after adequate treatment of the SRBD.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Smith-Magenis syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodevelopmental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 characterized by dysmorphic facial features, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    behavioral disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with onset in early childhood, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime somnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and night awakenings in association with reversal in the timing of the 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 secretion pattern (i.e., the serum levels of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 are high during the daytime and low at night). </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brain tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or other central nervous system lesions: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Strokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sarcoidosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or neurodegenerative lesions of the brain, especially in the hypothalamus or rostral midbrain, may produce daytime sleepi- ness.</br>In patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brain tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be due to the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 itself or the effects of treatment. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endocrine disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypothyroidism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is the most recog- nized example of this condition. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 secondary to metabolic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hepatic encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic renal insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, adrenal or pancreatic insufficiency, exposure to toxins, and certain inherited 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in childhood may result in hypersomnolence. </br>Residual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with adequately treated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: Some patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRBDs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 report persistent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 despite apparently adequate amounts of sleep and optimal treatment of their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other known 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>They may have moderately elevated Epworth Sleepiness Scale scores, but most have mean sleep laten- cies &gt; 8 minutes on MSLT.</br>They also report more 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It is essential that sleep disordered breathing be fully treated for at least three months, and that control of the SRBD be confirmed by: (1) a download of positive airway pressure (PAP) machine compliance data demonstrating optimal usage (preferably at least 7 hours a night); and (2) a polysomnogram demonstrating elimination of essentially all sleep disordered breathing.</br>Other causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as insufficient sleep syn- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to medications or drugs must be eliminated.</br>Animal studies have suggested this residual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 could be caused by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxic injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to monoamine systems.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 itself may also contribute, and more research is needed to understand the underlying mechanism. </br>Demographics Demographics reflect those of the underlying condition. </br>Predisposing and Precipitating Factors Predisposing and precipitating factors reflect those of the underlying condition. </br>173 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Familial Patterns Familial patterns reflect those of the underlying condition. </br>Onset, Course, and Complications Onset, course, and complications reflect those of the underlying condition. </br>Developmental Issues Daytime naps are normal in children younger than 3-4 years; thus, it is difficult to dif- ferentiate physiologic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    napping
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children younger than this age.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Inattentiveness, mood swings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    learning difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often accompany child- hood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Reference values for the MSLT in children differ from those of adults, and this issue should be considered during the evaluation process.</br>Special attention should be paid to genetic disorders in children. </br>Pathology and Pathophysiology Pathology and pathophysiology reflect those of the underlying condition. </br>Objective Findings Nocturnal polysomnography may show normal or moderately disturbed sleep.</br>In patients with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, EEG abnormalities may be present, such as an increase in the amount of slow wave sleep.</br>MSLT must show fewer than 2 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and usually will show a mean sleep latency less than eight minutes.</br>If clin- ically significant sleep disordered breathing or periodic limb movements are present, they should be treated prior to diagnosing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder. </br>Differential Diagnosis See the differential diagnosis in previous hypersomnolence sections.</br>The major chal- lenge in establishing a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder is deter- mining whether the associated medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is truly causing the hypersomnolence. </br>Unresolved Issues and Future Directions </br>This area is understudied.</br>Multiple complex neurological, metabolic, endocrine, and medication-related interactions may be present.</br>Further studies are needed to define the reciprocal relationships between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other diseases. </br>Bibliography Bruin VM, Bittencourt LR, Tufik 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S. Sleep-wake disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson’s disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: current evidence regarding diagnostic and therapeutic decisions.</br>Eur Neurol 2012;67:257–67. </br>174 Castriotti RJ, Wilde MC, Lai JM, Atanasov S, Masel 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Kuna ST.</br>Prevalence and consequences of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    traumatic brain injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Clin Sleep Med 2007;3:349–56. </br>Guilleminault C, Yuen KM, Gulevich MG, Karadeniz D, Leger D, Philip D. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 after 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head-neck trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a medico-legal dilemma.</br>Neurology 2000;54:653–9. </br>Kempf J, Werth E, Kaiser PR, et al.</br>Sleep-wake disturbances 3 years after 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    traumatic brain injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Neurol Neurosurg Psychiatry 2010;81:1402–5. </br>Martinez-Rodriguez JE, Lin L, Iranzo A, et al.</br>Decreased hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myotonic dystrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2003;26:287–90. </br>Mathias JL, Alvaro PK.</br>Prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, disorders, and problems following 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    traumatic brain injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a meta-analysis.</br>Sleep Med 2012;13:898–905. </br>Panossian L, Veasey S. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: mechanisms beyond obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
--a review.</br>Sleep 2012;35:605–15. </br>Vernet C, Redolfi S, Attali, V, et al.</br>Residual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: phenotype and related symptoms.</br>Eur Respir J 2011;38:98–105. </br>Wienecke M, Werth E, Poryazova R, et al.</br>Progressive 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dopamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocretin deficiencies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson’s disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: is there an impact on sleep and wakefulness?</br>J Sleep Res 2012;21:710–7. </br>Zhu Y, Fenik P, Zhan G, et al.</br>Selective loss of catecholaminergic wake active neurons in a murine sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 model.</br>J Neurosci 2007;27:10060–71. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance ICD-9-CM code: 292.85 (drug-induced); 291.82 (alcohol-induced) ICD-10-CM code: F11-F19 (see table in Appendix B for detailed coding instructions) </br>Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to stimulant withdrawal, hyper- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    somnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 due to sedative abuse, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    toxic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    toxic encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-C must be met A.</br>The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep. </br>B. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs as a consequence of current medication or substance use or withdrawal from a wake-promoting medication or substance. </br>C. The symptoms are not better explained by another untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Essential Features Patients with this disorder have excessive nocturnal sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    napping
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that is attributable to sedating medications, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, or drugs of abuse.</br>This diagnosis also includes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with withdrawal from 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amphetamines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and other drugs.</br>If 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 existed prior to stimulant abuse, the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance should not be used. </br>Associated Features Associated features reflect those of the medications or substances responsible. </br>Clinical and Pathological Subtypes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to sedating medications: Sedation is a common side effect of many prescription medications including 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzodiazepines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonbenzodiazepine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 hypnot- ics, opioids, barbiturates, anticonvulsants, antipsychotics, anticholinergics, and some 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antihistamines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Sleepiness also can occur with some 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dopamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 agonists such as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pramipexole
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ropinirole
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and with many 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antiseizure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 medications.</br>Though less common, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can also occur with nonsteroidal anti-inflammatory drugs, some antibiotics, antispasmodics, antiarryhthmics, and beta-blockers.</br>Over-the- counter medications, such as valerian and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, can produce sedation.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is especially common when these drugs are used in elderly patients or those with multiple medical conditions, or in combination.</br>Some tolerance to the sedative effects can occur with time. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur with abuse of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzodiazepines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, barbiturates, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gamma hydroxybutyrate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, opiates, and marijuana. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to stimulant withdrawal: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is common with abrupt discontinuation of stimulants.</br>In chronically heavy 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amphetamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 users, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is most severe in the first week of withdrawal and can persist for up to three weeks; indi- viduals may have an increase in total sleep and daytime napping, but sleep may seem fragmented and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonrestorative
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often accompanies the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyper- somnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Infrequently, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be a residual complaint in those who have used 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stimulants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 in the past but have been abstinent for many years.</br>In people who regularly consume coffee or other sources of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, discontinuation can produce 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inattentiveness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for two to nine days. </br>176 Demographics Patients of any age can experience 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from sedating medications.</br>Stimulant abuse and the consequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during withdrawal are most common in adoles- cents and young adults. </br>Predisposing and Precipitating Factors Sleepiness from sedating medications may be more common in older patients and in those with multiple medical problems. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications Onset, course, and complications reflect those of the medications or substances responsible. </br>Pathology and Pathophysiology Not applicable or known. </br>Objective Findings Polysomnography is generally unnecessary unless a concomitant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is sus- pected.</br>Polysomnography and MSLT results vary depending on the specific substance in question and the timing of the most recent intake.</br>With stimulant withdrawal, noc- turnal polysomnography may show normal sleep, whereas the MSLT typically 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    demon-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 strates a short mean sleep latency with or without multiple 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>A urine tox- icology screen may be positive for the suspected substance.</br>The diagnosis is often confirmed if symptoms resolve after the causal agent is removed. </br>Differential Diagnosis Major 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that are associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, especially 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRBDs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, periodic limb 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, IH, and insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be ruled out.</br>A urine drug screen should routinely accompany an MSLT as the use of or withdrawal from some medications or substances may affect MSLT test results. </br>Although many psychotropic medications may result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, it is import- ant for clinicians to recognize that many 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also are associated with increased prevalence of other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, SRBD, circadian disor- ders, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Although sedative effects of the psychotropic agents Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may contribute to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, clinicians must maintain a high index of suspicion for other sleep related etiologies.</br>When other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are identified, multiple diag- noses may be appropriate. </br>Unresolved Issues and Future Directions Sedatives can worsen sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and more research is needed to understand and manage this interaction. </br>Bibliography Ancoli-Israel S. Sleep and its disorders in aging populations.</br>Sleep Med 2009;10 Suppl 1:S7–11. </br>España RA, Scammell TE.</br>Sleep neurobiology from a clinical perspective.</br>Sleep 2011;34:845–58. </br>Gillin JC, Smith TL, Irwin M, Butters N, Demodena A, Schuckit M. Increased pressure for rapid eye movement sleep at time of hospital admission predicts relapse in nondepressed patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary alcoholism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at 3-month follow-up.</br>Arch Gen Psychiatry 1994;51:189–97. </br>Guilleminault C, Brooks SN.</br>Excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a challenge for the practicing neurologist.</br>Brain 2001;124:1482–91. Juliano LM, Griffiths RR.</br>A critical review of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features.</br>Psychopharmacology (Berl) 2004; 176:1–29. </br>McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM.</br>The nature, time course and severity of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methamphetamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 withdrawal.</br>Addiction 2005;100:1320–9. </br>Mogri M, Desai H, Webster L, Grant BJ, Mador MJ.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients on chronic opiate therapy with and without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Breath 2009;13:49–57. </br>Punjabi NM.</br>The epidemiology of adult 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Proc Am Thorac Soc 2008;5:136–43. </br>Qureshi A, Lee-Chiong T. Medications and their effects on sleep.</br>Med Clin North Am 2004;88:751–66. </br>Roehrs T, Roth T. Sleep, sleepiness, and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 use.</br>Alcohol Res Health 2001;25:101–9. </br>Roehrs T, Bonahoom A, Pedrosi B, Zorick F, Roth T. Nighttime versus daytime hypnotic self- administration.</br>Psychopharmacology 2002;161:137–42. </br>Schweitzer P. Drugs that disturb sleep and wakefulness.</br>In: Kryger MH, Roth T, Dement WC, eds.</br>Principles and practice of sleep medicine, 5th ed.</br>St Louis: Elsevier Saunders, 2011:542–60. William Ishak W, Ugochukwu C, Bagot 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Khalili D, Zaky C. Energy drinks: psychological effects and impact on well-being and quality of life-a literature review.</br>Innov Clin Neurosci 2012;9:25–34. </br>178 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Associated with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Psychiatric Disorder ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.15 ICD-10-CM code: F51.13 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 not due to substance or known physiological condition, nonorganic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, pseudohypersomnia, or pseudonarcolepsy. </br>Diagnostic Criteria Criteria A-C must be met A.</br>The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months. </br>B. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs in association with a concurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>C. The symptoms are not better explained by another untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or the effects of medications or drugs. </br>Essential Features Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may report excessive nocturnal sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or excessive napping.</br>In addition, they often feel their sleep is of poor quality and nonrestorative.</br>Patients are often intensely focused on their hypersomnolence, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms may become apparent only after prolonged interviews or psychometric testing.</br>Associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 conditions include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, conversion or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    undifferentiated somatoform disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and less frequently other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    schizoaffective disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, adjustment disor- der, or personality disorders. </br>Associated Features Poor work attendance, spending full days in bed several times a week, or abruptly leaving work because of a perceived need to sleep are common symptoms.</br>Patients may also have social withdrawal, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and feelings of low energy. </br>Clinical and Pathological Subtypes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
:</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the context of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a frequent feature of atypical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bipolar II disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (recur- rent major 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive episodes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypomanic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes).</br>In seasonal affective disor- der, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, loss of concentration, increased appetite for carbohydrates, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight gain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are reported.</br>MSLT results are usually normal, but long hours spent in bed are reported. </br>Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with a conversion disorder or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    somatic symptom disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: Pseudohypersomnia or pseudonarcolepsy, sometimes with pseudocataplexy, has been described. </br>Demographics 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 accounts for 5% to 7% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyper- somnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cases.</br>Women are more susceptible than men, and the typical age range is between 20 and 50 years.</br>In patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    major depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the prevalence of hypersom- nolence ranges from 5% to over 50% depending on how 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is defined.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 affects over 50% of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seasonal affective disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Predisposing and Precipitating Factors Not applicable or known. </br>Familial Patterns Not known, except for the familial patterns of certain psychiatric disorders (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bipolar II disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Onset, Course, and Complications The mean age of onset is usually in the third decade in both sexes.</br>With major depres- sion, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may persist even after the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episode improves, and persistent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with increased risk of recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Complications are mostly social and occupational. </br>Developmental Issues 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs in 10% to 20% of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    major depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, some- times in combination with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but sleep quality appears normal.</br>Although sleep problems may develop at any stage of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, they are most pronounced during the acute phase.</br>Children and adolescents with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 who manifest either 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 generally manifest more pronounced symptoms, such as anhedo- nia and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Pathology and Pathophysiology The underlying cause is unknown.</br>Although patients with this disorder report sleep- iness, sleep studies reveal little or no evidence of increased propensity to sleep.</br>In some patients, fragmented nighttime sleep may contribute to their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Because of uncertainty about the nature of the relationship, the term “
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
” is preferred to “
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a psychi- atric disorder.” </br>180 Objective Findings Nocturnal polysomnography typically shows a prolonged total time in bed with frag- mented sleep.</br>Sleep latency is prolonged, wake time after sleep onset is increased, awakenings may be frequent and prolonged, and sleep efficiency is low.</br>REM sleep latency may be shortened in the case of untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep latencies on the MSLT are often within normal limits, a result contrasting with the subjective complaint of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and an elevated score on the Epworth Sleepiness Scale.</br>24-hour continuous sleep-recording studies typically show considerable time spent in bed during day and night, a behavior sometime referred to as clinophilia.</br>Psychiatric inter- views and evaluations are essential to diagnose the underlying 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 condition. </br>Differential Diagnosis As there are no definitive tests for diagnosing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with a psy- chiatric disorder, it is essential to rule out other common causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as insufficient sleep, sedation from medications or substances, SRBD, periodic limb 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and IH.</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by persistent or relapsing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that does not resolve with sleep or rest, but the main complaint is usually 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 rather than sleepiness.</br>Insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, impaired concentration, and lowered energy level, but a detailed history of the subject’s current sleep schedule reveals chronic sleep deprivation. </br>Unresolved Issues and Future Directions The lack of concordance between subjective and objective findings raises multiple issues.</br>It is unclear to what extent these patients are objectively sleepy or, instead, suffer from decreased energy and lack of interest that confines them to bed.</br>More research is needed to create an effective definition of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in this population and to develop tools for measuring it.</br>Finally, future efforts should define the mechanism through which some patients express their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Bibliography Guilleminault C, Brooks SN.</br>Excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a challenge for the practicing neurologist.</br>Brain 2001;124:1282–91. </br>Kaplan KA, Harvey AG.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 across 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a review and synthesis.</br>Sleep Med Rev 2009;13:275–85. </br>Kotagal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S. Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children: interface with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Child Adolesc Psychiatr Clin N Am 2009;18:967–77. </br>Liu X, Buysse DJ, Gentzler AL, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive phenomenology
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbidity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2007;30:83–90. </br>Nofzinger EA, Thase ME, Reynolds CF 3rd, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bipolar depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a comparison with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 using the Multiple Sleep Latency Test.</br>Am J Psychiatry 1991;148:1177–81. Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Partonen T, Lönnqvist J. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Seasonal affective disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Lancet 1998;352:1369–74. </br>van den Berg JF, Luijendijk HJ, Tulen JH, Hofman A, Neven AK, Tiemeier H. Sleep in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a population-based study of elderly persons.</br>J Clin Psychiatry 2009;70:1105–13. </br>Vgontzas AN, Bixler EO, Kales A, Criley C, Vela-Bueno A. Differences in nocturnal and daytime sleep between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary and psychiatric hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: diagnosis and treatment implications.</br>Psychosom Med 2000;62:220–6. </br>Insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Syndrome ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 307.44 ICD-10-CM code: F51.12 Alternate Names Behaviorally induced insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, insufficient nocturnal sleep, chronic sleep deprivation, sleep restriction. </br>Diagnostic Criteria Criteria A-F must be met A.</br>The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep or, in the case of prepubertal children, there is a complaint of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    behavioral abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 attributable to sleepiness. </br>B. The patient’s sleep time, established by personal or collateral history, sleep logs, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    actigraphy1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is usually shorter than expected for age.2 C. The curtailed sleep pattern is present most days for at least three months. </br>D.</br>The patient curtails sleep time by such measures as an alarm clock or being awakened by another person and generally sleeps longer when such measures are not used, such as on weekends or vacations. </br>E. Extension of total sleep time results in resolution of the symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>F. The symptoms are not better explained by another untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the effects of medications or drugs, or other medical, neurologic, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Notes .</br>If there is doubt about the accuracy of personal history or sleep logs, then actigraphy should be performed, preferably for at least two weeks. </br>2. In the case of long sleepers, reported habitual sleep periods may be normal based on age.</br>However, these sleep periods may be insufficient for these patients. </br>182 Essential Features Insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs when an individual persistently fails to obtain the amount of sleep required to maintain normal levels of alertness and wakefulness.</br>The individual is chronically sleep deprived as a result of failure to achieve necessary sleep time due to reduced time in bed.</br>There is a U-shaped relationship between age and average sleep time, with the minimum in middle-aged individuals.</br>Examination reveals unimpaired or above-average ability to initiate and maintain sleep, with little or no psychopathology.</br>Physical examination reveals no medical explanation for the patient
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ’s sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A detailed history of the sleep pattern reveals a substantial dis- parity between the need for sleep and the amount actually obtained.</br>The significance of this disparity often goes unappreciated by the patient.</br>Sleep time that is markedly extended on weekend nights or during holidays compared to weekday nights is also suggestive of this disorder.</br>A therapeutic trial of a longer major sleep episode can reverse the symptoms.</br>In individuals with physiologic sleep requirements significantly in excess of seven to eight hours, reported “average” amounts of sleep (e.g., seven hours/night) may, in fact, be insufficient.</br>Additional symptoms such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur. </br>Associated Features Depending upon chronicity and extent of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, individuals with this condition may show 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, concentration and attention deficits, reduced vigilance, distract- ibility, reduced motivation, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anergia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphoria
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, restlessness, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    uncoordination
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and malaise.</br>Secondary symptoms may become the main focus of the patient, serving to obscure the primary cause of the difficulties.</br>Psychologically and somatically normal individuals who chronically obtain less sleep than they physiologically require typi- cally experience 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Situational factors such as demands of the family and work schedule may, on occasion, make it very difficult to obtain adequate sleep. </br>Clinical and Pathophysiologic Subtypes Not applicable or known. </br>Demographics Insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 affects all ages and both sexes.</br>It may be more frequent in adolescence, when sleep need is high, but social pressure and tendency to delay sleep often lead to chronic restricted sleep.</br>Cultural factors may also influence sleep dura- tion, with students from different countries reporting sleep time varying between six and eight hours per night. </br>183 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Predisposing and Precipitating Factors Social and psychological factors may impact nocturnal sleep length and daytime sleep- iness.</br>Cultural habits such as the siesta may enhance evening alertness at the expense of reducing nocturnal sleep efficiency.</br>Also, the evening preference chronotype predis- poses to complaints of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and insufficient sleep.</br>The association of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eveningness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with insufficient sleep persists after controlling for variables such as sex, age, and sleep duration. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications This condition results in increased 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, concentration problems, lowered energy level, and malaise.</br>If unchecked, insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may predispose to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other psychological difficulties, as well as poor work performance and withdrawal from family and social activities.</br>Abuse of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stimulants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 may also occur.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Traffic accidents
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or injury at work may result. </br>Developmental Issues Insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a common problem in adolescents.</br>It should be differ- entiated from delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the effects of recreational drug use, and school avoidance behavior.</br>Increased predisposition to substance use and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    accidents
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in teens may be consequent to insufficient sleep. </br>Pathology and Pathophysiology Symptoms are due to normal physiological and psychological responses to sleep depri- vation.</br>Sleep restriction studies in normal volunteers have shown that even mild sleep restriction (for example, six hours of nocturnal sleep per night) results in a correspond- ing decrease in performance and increased sleepiness.</br>Sleep restriction to four hours per night (i.e., extension of wakefulness to 20 hours per day) will likely lead to greater buildup of homeostatic sleep drive during the waking hours and greater likelihood of impaired performance on a psychomotor vigilance task.</br>The effects of sleep depriva- tion on neurobehavioral performance measures may vary with the nature of the task being considered. </br>In some long sleepers, it is important to be aware that extending sleep to nine or more hours often results in improved performance.</br>The diagnosis of insufficient sleep syn- drome may be especially difficult to make in subjects who have a physiologic need for unusually large amounts of sleep. </br>184 Objective Findings Actigraphy combined with sleep diaries maintained for a 2- to 3-week period may be helpful by documenting total time in bed, sleep latency, total sleep time, and sleep efficiency.</br>Polysomnography and MSLT are not required to establish a diagnosis of insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Rather, sleep time is extended first, and the patient is reevaluated.</br>If a therapeutic trial with a longer sleep episode eliminates the symptoms, insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is diagnosed. </br>Polysomnography, when performed, reveals reduced sleep onset latency, and high (greater than 90%) sleep efficiency.</br>When extended sleep is permitted, prolonged sleep time with slow wave rebound may be seen.</br>Noting a disparity between reported sleep at home and observed total sleep time in the sleep laboratory can be helpful.</br>The MSLT reveals 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, with stage N1 sleep occurring in most naps, with short sleep latency.</br>Stage N2 sleep occurs in more than 80% of MSLT naps.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur. </br>Differential Diagnosis Insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be confused with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or other hypersom- nolence disorders because an abnormal MSLT (even with two 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMPs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) can be observed as the result of acute or chronic sleep deprivation.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be most frequently encountered in adolescents or young adults.</br>The differential diagno- sis of insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 includes numerous other conditions that may result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or shortening of nocturnal sleep duration.</br>These include other central disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, long sleeper or short sleeper, SRBD, circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    affective disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and periodic limb move- ment disorder. </br>Unresolved Issues and Future Directions </br>The correlation between subjectively reported 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, performance-test 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    decre-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 ments, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MSLT-measured sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 after sleep deprivation is poor.</br>Short sleepers often have a higher NREM sleep pressure, as measured by EEG delta power, than long sleepers, even if they do not complain of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>There is interindividual susceptibility to sleep deprivation, with some people being consistently more tired and experiencing greater performance decrement after even a mild degree of sleep deprivation. </br>Bibliography Carskadon MA, Dement WC.</br>Effects of total 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on sleep tendency.</br>Percept Mot Skills 1979;48:495–506. Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Habeck C, Rakitin BC, Moeller J, et al.</br>An event related fMRI study of the neurobehavioral impact of sleep deprivation on performance of a delayed match to sample task.</br>Cogn Brain 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Res
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 2004;18:306–21. </br>Merikanto I,Kronholm E, Peltonen M, Laatikainen T, Lahti T, Partonen T. Relation of chronotype to sleep complaints in the general Finnish population.</br>Chronobiol Int 2012;29:311–7. </br>Mont TH, Buysse DJ, Carrier J, Bart BD, Rose LR.</br>Effects of afternoon “siesta” naps on sleep, alertness, performance, and circadian rhythms in the elderly.</br>Sleep 2001;24:680–7. </br>Mu Q, Mishory A, Johnson KA, et al.</br>Decreased brain activation during a working memory task at rested wakefulness is associated with vulnerability to sleep deprivation.</br>Sleep 2005;28:433–46. </br>Roehrs T, Zorick F, Sicklesteel J, Wittig R, Roth T. Excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with insufficient sleep.</br>Sleep 1983;6:319–25. </br>Taylor DJ, Bramoweth AD.</br>Patterns and consequences of inadequate sleep among college students: substance use and motor vehicle accidents.</br>J Adolesc Health 2010;46:610–2. </br>Tucker AM, Whitney P, Belenky G, Hinson JM, Van Dongen HPA.</br>Effects of sleep deprivation on dissociated components of executive functioning.</br>Sleep 2010;33:47–57. </br>Van Dongen HP, Maislin G, Mullington JM, Dinges DF.</br>The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation.</br>Sleep 2003;26:117–26. </br>186 Isolated Symptoms and Normal Variants Long Sleeper A long sleeper is an individual who consistently sleeps substantially more in 24 hours than does the typical person of his or her age group.</br>For adults, the usually accepted figure is 10 hours or more, but many epidemiologic studies have used sleep times of 8–10 hours.</br>For children and adolescents, the entity should be considered if sleep time is more than two hours longer than age-specific norms.</br>Sleep, although long, is basi- cally normal in architecture and physiology.</br>Sleep efficiency and timing are normal.</br>A consistent daily pattern, documented by a carefully kept sleep log (preferably con- firmed by actigraphy), showing 10 or more hours of sleep per night over a minimum of seven days is desirable for the identification of the long sleeper.</br>In general, long sleepers seek medical help when they develop 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a result of being forced to curtail their sleep time to less than their required amounts.</br>Usually, the long sleep pattern began in childhood, is well established by early adolescence, and persists throughout life.</br>Many long sleepers, because of occupational or educational demands, function with reasonable success on nine hours of sleep per night during the work or school week, with increases to 12 or more hours on weekends and holidays. </br>About 2% of men and 1.5% of women report sleeping at least 10 hours per night.</br>Epidemiologic studies have consistently found an increased mortality (and sometimes increased body mass index, lower 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucose
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 tolerance, higher prevalence of type 2 dia- betes and coronary heart disease) associated with long sleep, compared to average-du- ration sleep, but it is not clear whether most of the subjects were naturally long sleep- ers or had disorders resulting in excessive duration of sleep.</br>In subjects older than 60 years, sleep duration longer than 9.5 hours is associated with male sex, low education, no physical exercise, and more physical diseases.</br>Long (&gt; nine hours) sleep duration has a high heritability (44%) and concordance between monozygotic twins, which is higher if they live together.</br>Genomewide studies favor a polygenic origin of sleep duration, with influence of clock and other genes (DEC2, K+ channel regulatory pro- teins genes).</br>Long sleepers presumably represent the extreme high end of the normal sleep duration continuum. </br>Long sleepers, like short sleepers, have normal absolute amounts of stage N3 sleep, unless there is chronic sleep restriction preceding polysomnography, in which case the absolute amount of N3 stage is increased.</br>Amounts of stages N2 and REM sleep are somewhat higher than normal.</br>The individual has no problem with time distortion or ability to be accurate about the quantity or quality of sleep.</br>Assuming that individuals Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Central Disorders of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have obtained their usual sleep amounts for several nights before the procedure, no 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is evident on the MSLT.</br>It is important to differentiate the long sleeper from patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or medical causes of hypersomnolence.</br>Many pathologic causes of increased sleep have an acute or subacute onset, may not be present since childhood, and rarely show the stable course of the long sleeper.</br>Nevertheless, differentiation from pathologic con- ditions of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be difficult in the child or adolescent because the normal continuum of sleep duration is somewhat higher in these age groups than in adults.</br>The correct determination is often made by exclusion of specific diagnostic features associated with other conditions and by the absence of complaints concerning the quality of the individual’s awake-state functioning when adequate sleep is obtained (e.g., during prolonged holidays).</br>In particular, the differentiation of a genuine long sleeper from a patient with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be difficult.</br>In the genuine long sleeper, sleeping long hours is refreshing, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 disappears when long hours of nocturnal sleep are enforced. </br>Bibliography Aeschbach D, Cajochen C, Landolt H, Borbély AA.</br>Homeostatic sleep regulation in habitual short sleepers and long sleepers.</br>Am J Physiol 1996;270:R41–53. </br>Hartmann E, Baekeland F, Zwilling 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Psychological differences between long and short sleepers.</br>Arch Gen Psychiatry 1972;26:463–8. </br>Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR.</br>Mortality associated with sleep duration and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Arch Gen Psychiatry 2002;59:131–6. </br>Kripke DF, Simons RN, Garfinkel L, Hammond EC.</br>Short and long sleep and sleeping pills.</br>Is increased mortality associated?</br>Arch Gen Psychiatry 1979;36:103–16. </br>Webb WB.</br>Are short and long sleepers different?</br>Psychol Rep 1979;44:259–64. </br>188 Circadian Rhythm Sleep-Wake Disorders Delayed Sleep-Wake Phase Disorder ........................................................191 Advanced Sleep-Wake Phase Disorder .....................................................198 Irregular Sleep-Wake Rhythm Disorder......................................................204 Non-24-Hour Sleep-Wake Rhythm Disorder ..............................................209 Shift Work Disorder ....................................................................................</br>215 Jet Lag Disorder .........................................................................................220 Circadian Sleep-Wake Disorder Not Otherwise 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Specified
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (NOS) ..............224 Circadian rhythms are endogenous, near-24-hour biological rhythms that exist in all living organisms.</br>The internal near-24-hour circadian clock is entrained or synchro- nized to the 24-hour light-dark cycle.</br>In humans, the endogenous period of the circa- dian oscillation is genetically determined and typically is slightly longer than 24 hours.</br>In order to maintain entrainment, the endogenous rhythm must be reset each day to the 24-hour clock time.</br>For optimal sleep, the actual sleep time should match the timing of the circadian rhythm of sleep and wake propensity.</br>Therefore, a recurrent or chronic pattern of sleep and wake disturbance may result from disruption of the internal circa- dian timing system or a misalignment between the timing of the individual’s circadian sleep-wake propensity and the 24-hour social and physical environments (e.g., sleep episodes scheduled entirely or in part during a phase of circadian alertness promotion).</br>As used herein, a circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm sleep-wake disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (CRSWD) is defined by the following criterion: The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is caused by alterations of the circadian time-keeping system, its entrainment mechanisms, or a misalignment of the endogenous circadian rhythm and the external environment. </br>Most CRSWDs arise when a substantial misalignment exists between the internal rhythm and the required timing of the patient’s school, work, or social activities.</br>Therefore, measurement of endogenous circadian timing is important for the accu- rate diagnosis of CRSWDs.</br>In addition to the history, multiple tools are available to assess sleep-wake patterns.</br>Sleep log and actigraphy are essential instruments in the evaluation of CRSWDs and should be conducted for at least seven days, preferably for 14 days, to capture work and non-work days.</br>Circadian chronotype (Morningness- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Eveningness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Questionnaires) and physiological measures of endogenous circadian timing (salivary or plasma dim light 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 onset</br>and urinary 6-sulfatoxymelatonin) also can provide important diagnostic information.</br>Circadian chronotype is a reflec- tion of an individual’s optimal timing of sleep and wake propensity, as well as other Circadian Rhythm Sleep-Wake Disorders physiological and mental functions.</br>Several questionnaires can be used to assess chro- notype of “
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eveningness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
” or “morningness” (e.g., Munich Chronotype Questionnaire, or Morningness-Eveningness Questionnaire). </br>The most common presenting symptoms of CRSWDs are difficulty initiating and maintaining sleep, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but their impact extends to adverse health outcomes, impairments in social, occupational and educational performance, and safety concerns.</br>Important advances have been made in the identification of clin- ical CRSWD subtypes, particularly in the area of pediatrics.</br>However, the challenge remains to develop more precise and clinically practical tools to improve diagnostic accuracy for CRSWDs. </br>General Criteria for Circadian Rhythm Sleep-Wake Disorder </br>Criteria</br>A-C must be met A. A chronic or recurrent pattern of sleep-wake rhythm disruption primarily due to alteration of the endogenous circadian timing system or misalignment between the endogenous circadian rhythm and the sleep-wake schedule desired or required by an individual’s physical environment or social/work schedules. </br>B. The circadian rhythm disruption leads to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or both. </br>C.</br>The sleep and wake disturbances cause clinically significant distress or impairment in mental, physical, social, occupational, educational, or other important areas of functioning. </br>All disorders described in the ensuing section imply a sleep difficulty that meets each of the above criteria.</br>The specific features that characterize each type of CRSWD are included within the individual diagnostic criteria. </br>190 Delayed Sleep-Wake Phase Disorder ICD-9-CM code: 327.31 ICD-10-CM code: G47.21 Alternate Names Delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, delayed sleep phase pattern, motivated delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-E must be met A.</br>There is a significant delay in the phase of the major sleep episode in relation to the desired or required sleep time and wake-up time, as evidenced by a chronic or recurrent complaint by the patient or a caregiver of inability to fall asleep and difficulty awakening at a desired or required clock time. </br>B. The symptoms are present for at least three months. </br>C. When patients are allowed to choose their ad libitum schedule, they will exhibit improved sleep quality and duration for age and maintain a delayed phase of the 24-hour sleep-wake pattern. </br>D. Sleep log and, whenever possible, actigraphy monitoring for at least seven days (preferably 14 days) demonstrate a delay in the timing of the habitual sleep period.</br>Both work/school days and free days must be included within this monitoring. </br>E.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not better explained by another current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use, or substance use disorder. </br>Notes .</br>Standardized chronotype questionnaires are useful tools to assess the chronotype of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eveningness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and morningness.</br>Individuals with this disorder typically score as evening types.</br>This tool can also be useful in determining whether an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eveningness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 circadian preference contributes to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep initiation difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 among those who do not meet full criteria for the disorder. </br>2. Demonstration of a delay in the timing of other circadian rhythms, such as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (measured by dim light 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 onset or urinary 6-sulfatoxymelatonin sampled across a 24-hour period), is desirable to confirm the delayed circadian phase. </br>Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders Essential Features Delayed sleep-wake phase disorder (DSWPD) is characterized by habitual sleep- wake timing that is delayed, usually more than two hours, relative to conventional or socially acceptable timing.</br>Affected individuals complain of difficulty falling asleep at a socially acceptable time, as required to obtain sufficient sleep duration on a school or work night.</br>Once sleep onset occurs, it is reportedly of normal duration.</br>These individ- uals also experience difficulty arising at a socially acceptable wake time, as required to prepare for school or work.</br>When allowed to follow his or her preferred schedule, the patient’s timing of sleep is delayed. </br>Associated Features Individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSWPD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may demonstrate excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep inertia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (extreme difficulty awakening and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) in the morning as a result of curtailed sleep time and awak- ening during a circadian phase of high sleep propensity.</br>Individuals with this disor- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    der
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as well as normal sleepers with evening chronotypes may have increased rates of mental disturbances, such as Diagnostic and Statistical Manual of Mental Disorders (DSM)</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Axis I disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or symptoms (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive symptoms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>In some individuals with DSWPD, there may be an overlap with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    non-24-hour sleep- wake disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or an alternation between symptoms of the two disorders.</br>Attempts to cope with the inability to fall asleep earlier may result in the development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Individuals may use 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, sedatives, hypnotics, or stimulant substances to alleviate symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, thereby perpetuating their underlying 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Clinical and Pathophysiological Subtypes Motivated delayed sleep-wake phase disorder is a subtype typically composed of ado- lescents who have little intrinsic motivation to successfully complete treatment and thereby resume a normal lifestyle (regular school attendance, developmentally appro- priate peer interactions, etc).</br>A history of mood or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (especially school phobia and separation and social 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) or other factors (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    learning disabilities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attention deficit hyperactivity disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) are often present and may motivate the patient (sometimes unconsciously) to avoid a return to normal adolescent activities, espe- cially regular school attendance.</br>It is not uncommon that ill-defined medical issues (e.g., chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mononucleosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes) trigger the onset or complicate the course of the disorder.</br>Important clues, in addition to the exis- tence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    premorbid mental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, include exaggerated presenting symptoms (e.g., “can’t wake up even if I throw cold water on him”) and failure to comply with basic straightforward treatment recommendations (e.g., refusal or inability to stop napping during the day). </br>192 Although social, psychological, and environmental factors may play a significant role in the development of delayed sleep-wake phase, International Classification of Sleep Disorders, 3rd Edition has chosen to list only a single delayed sleep-wake phase diag- nosis, with the recognition that most cases reflect variable chronobiologic and behav- ioral contributions. </br>Demographics The exact prevalence of DSWPD in the general population is unknown.</br>The condition is more common among adolescents and young adults, with a reported prevalence of 7% to 16%.</br>It is estimated that DSWPD is seen in approximately 10% of patients pre- senting in sleep clinics with recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 complaints.</br>There have been no studies assessing racial/ethnic differences in DSWPD. </br>Predisposing and Precipitating Factors Most individuals with DSWPD are evening chronotypes.</br>Many adolescents experi- ence a biological endogenous shift towards later bedtimes beginning around puberty.</br>Genetic factors such as polymorphism in the circadian clock gene hPer3 are associated with DSWPD.</br>Environmental factors, including decreased exposure to light during the phase advance region of the phase response curve (PRC) (i.e., in the morning on days with early wake times) or increased exposure to bright light during the phase delay portion of the PRC (i.e., late in the evening) may exacerbate the delayed circa- dian phase.</br>Individuals may have increased sensitivity in the phase delay region or decreased sensitivity in the phase advance region of the phase response curve to light.</br>Maladjustment to changes in work and social schedules, travel across time zones, and shift work can precipitate this disorder.</br>Individuals may consume excessive 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and other 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stimulants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, which may further delay sleep onset and thus exacerbate the delayed sleep time. </br>Social and behavioral factors play an important role in the development and mainte- nance of the delayed sleep patterns for many affected individuals.</br>Personal, social, and occupational activities that continue into the late evening may perpetuate and exacerbate the sleep phase delay.</br>In adolescents, the role of school avoidance, social maladjustment, and family dysfunction should be considered as contributing factors.</br>Individuals with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    major depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bipolar disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obsessive-compulsive disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attention deficit hyperactivity disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodevelopmental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may have a delayed sleep phase. </br>193 Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders Familial Patterns A positive family history has been reported in approximately 40% of individuals with DSWPD.</br>In one pedigree, DSWPD was suggested to segregate as an autosomal domi- nant trait.</br>Polymorphisms in hPer3, arylalkylamine N-acetyltransferase, human leuko- cyte antigen, and Clock have been suggested to be associated with DSWPD. </br>Onset, Course, and Complications A delayed sleep pattern typically begins during adolescence.</br>Onset in early childhood is also described, especially in familial cases; the onset may follow psychological, medical, or environmental stressors.</br>Without treatment, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSWPD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a chronic condition that may last into late life.</br>However, with increasing age across adulthood, the timing of the sleep-wake cycle may advance, thereby decreasing the propensity to delayed sleep phase.</br>Phototherapy, as well as behavioral and pharmacologic treatments, can advance the timing of sleep hours, but there is usually a continual tendency and prefer- ence for delayed sleep hours, and recurrence is high.</br>Use of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, sedatives, hypnot- ics, or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stimulants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 to treat symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during normal waking hours may lead to substance abuse. </br>Developmental Issues DSWPD may be encountered in any age group but is especially prevalent among ado- lescents and young adults.</br>In addition to the clinical features described elsewhere, DSWPD may present in older children and adolescents with chief 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of truancy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, repeated school absences, chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tardiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or school failure, rather than sleep complaints per se.</br>In severe cases, school attendance is completely curtailed and the patient may have failed to attend school regularly for many months.</br>Extreme diffi- culty in morning awakening, requiring intensive parental involvement, may also be the presenting concern.</br>An increased risk of motor vehicle 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    accidents
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been associated with delayed sleep onset and resultant insufficient sleep in adolescents; thus, the occur- rence of a car crash or “near-miss” incident should alert the clinician to probe for addi- tional evidence of circadian pathology.</br>Adolescents may also present primarily with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    suicidal ideation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is commonly asso- ciated with and may be the chief presenting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaint
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in adolescents with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSWPD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a result of repeated attempts and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    failures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to achieve sleep onset at their desired bedtime. </br>In younger children, the condition may be associated with delays in other markers of circadian phase, including the typical presleep surge in alertness referred to as the “for- bidden zone” or “second wind phenomenon.”</br>Thus, especially in younger children, DSWPD may present primarily as bedtime resistance, as caregivers attempt to establish bedtimes that directly conflict with the child’s circadian-mediated readiness for sleep. </br>194 Several pediatric populations appear to have an increased vulnerability to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DSWPD and sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, likely of multifactorial etiology.</br>These include children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attention deficit hyperactivity disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ADHD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism spectrum disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (ASD).</br>Several studies have examined 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 onset in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ADHD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and reported significant delays in comparison with typically developing children, as well as suc- cessful treatment with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ASD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have a high prevalence (up to 80%) of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including delayed sleep onset, night and early morning awakenings, and irregular sleep patterns, at least some of which appear associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    circadian abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>These children reportedly have a number of alterations in mel-</br>atonin synthesis, levels, amplitude, and patterns of secretion. </br>Little is known about the natural history of the clinical entity of DSWPD in the pediat- ric population, including the impact of various treatment modalities, the likelihood of spontaneous resolution of symptoms, or long-term consequences. </br>There is increasing evidence to suggest that the evening chronotype is associated in both children and adolescents with a number of adverse consequences, including decreased health-related quality of life, higher rates of behavioral/emotional problems including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    suicidality
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, decreased sleep duration and increased 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, more 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, impairments in academic functioning, and increased likelihood of substance use.</br>Thus, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eveningness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may confer an increased risk for physical and mental health problems. </br>Pathology and Pathophysiology The exact mechanisms responsible for DSWPD are unknown.</br>An abnormal interac- tion between the endogenous circadian rhythm and the sleep homeostatic process that regulates sleep and wakefulness may play an essential role in the pathophysiology of DSWPD.</br>Early studies reported an altered phase relationship between the sleep-wake cycle and circadian phase, whereas more recent studies have failed to support this finding.</br>In these patients, sleep onset, sleep offset, and phase of circadian markers such as core body temperature and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 are delayed relative to clock time when com- pared with controls.</br>Although this condition may be predominantly due to a misalign- ment between circadian timing and the external environment, alterations in the length of the circadian period or an altered homeostatic process (indicated by decreased sleep propensity in response to sleep deprivation) also may be contributing factors.</br>In chil- dren and adults, voluntary behaviors such as staying awake late at night and waking up late in the morning or afternoon may result in an abnormal relationship between the endogenous circadian rhythm and the sleep homeostatic process that regulates sleep and wakefulness.</br>Delayed bedtimes and wake times may increase exposure to bright Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders light in the late evening (a delay signal for the circadian clock) and decrease expo- sure to light in the early morning (an advance signal for the circadian clock), thereby promoting and perpetuating the delay in the circadian sleep phase.</br>Given a sufficient discrepancy between early and late wake times, early wake times may be associated with bright light exposure during the maximal phase delay region, perpetuating the cir- cadian phase delay and the disorder.</br>Individuals may have alterations in sensitivity to the phase shifting effects of light.</br>For example, partial sleep deprivation encountered with this disorder can also attenuate the ability to phase-advance the circadian system, further perpetuating the delayed circadian phase. </br>Objective Findings Recordings of sleep logs and actigraphy over an interval of at least seven (and pref- erably fourteen) consecutive days demonstrate delayed sleep onset and sleep offset (typically greater than two hours) relative to socially acceptable times.</br>Though clock times may be culture dependent, for many affected individuals sleep onset is typi- cally delayed until 1:00 a.m. to 6:00 a.m., (though may be earlier based on age and developmental status), and wake time occurs in the late morning or afternoon.</br>Daily demands and schedules may result in an earlier than desired wake-up time during work or school days, but a delay in bedtime and wake-up time is almost always seen during free days and vacation.</br>Polysomnography (though not routinely indicated nor required for the diagnosis), when performed at preferred (delayed) sleep times, is essentially normal for age.</br>If a conventional bedtime and wake-up time are enforced, however, polysomnographic recording may show prolonged sleep latency and decreased total sleep time.</br>Laboratory measures of circadian timing generally show the expected phase delay in the timing of the nadir of the core body temperature rhythm and dim- light 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 onset (DLMO).</br>Several questionnaires are useful in assessing the chro- notype, the degree of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eveningness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morningness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., “Morningness-Eveningness Questionnaire,” “Munich Chronotype Questionnaire”).</br>Individuals with DSWPD, typ- ically score high as evening types, though normal sleepers can also score high on eve- ningness.</br>Elevations are expected in self-report of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as on the Epworth Sleepiness Scale. </br>The results of polysomnography and other diagnostic tools in younger age groups are similar to those seen in adults.</br>Actigraphy and/or sleep logs are useful in the diagnosis of DSWPD in the pediatric population.</br>Several validated instruments are available for assessing phase preference in the pediatric and adolescent pop- ulations.</br>These include the Children’s Chronotype Questionnaire (CCTQ) (par- ent-report), the Morningness-Eveningness Scale for Children (self-report), and the Morningness-Eveningness Questionnaire for Children and Adolescents.</br>These surveys have been used to assess chronotype in the pediatric population and may be useful in clinical settings. </br>Differential Diagnosis Delayed sleep-wake phase disorder must be distinguished from “normal” sleep pat- terns, particularly in adolescents and young adults who maintain delayed schedules regularly or intermittently, without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    distress
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or impaired functioning.</br>DSWPD must be distinguished from other causes of difficulty initiating sleep, including chronic insom- nia disorder.</br>In DSWPD, sleep initiation and maintenance are improved when the patient is allowed to sleep on the preferred schedule.</br>When individuals with DSWPD must arise before the desired wake time, excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep inertia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be evident.</br>Other forms of excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, from which this must be distinguished, do not generally exhibit the pronounced circadian pattern and do not abate with alterations in the sleep-wake schedule.</br>The development of DSWPD may be influenced by alterations in circadian physiology as well as behavioral factors. </br>Inadequate sleep hygiene and insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 must also be considered in the differential. </br>Unresolved Issues and Further Directions There is limited knowledge of the underlying pathophysiology of DSWPD.</br>Recent evidence suggests that alteration in the homeostatic regulation of sleep and alertness may play an important role.</br>The intrinsic circadian period may be abnormally long.</br>Recent advances in the understanding of the molecular basis for the generation and entrainment of circadian rhythms, together with the identification of a familial form of DSWPD, will lead to improved understanding of the mechanisms responsible for this condition, as well as targeted, evidence-based therapies. </br>Bibliography Ancoli-Israel S, Schnierow B, Kelsoe J, Fink R. A pedigree of one family with delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Chronobiol Int 2001;18:831–41. </br>Archer SN, Carpen JD, Gibson M, et al.</br>Polymorphism in the PER3 promoter associates with diurnal preference and delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2010;33:695–701. </br>Bijlenga D, Van Someren EJW, Gruber R, et al.</br>Body temperature, activity, and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 profiles in adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attention-deficit/hyperactivity disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and delayed sleep: a case-control study.</br>J Sleep Res 2013; 22:607–16. </br>Dagan Y, Stein D, Steinbock M, Yovel I, Hallis D. Frequency of delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 among hospitalized 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adolescent psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients.</br>Psychosom 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Res
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 1998;45:15–20. </br>Gruber R, Sheshko D. Circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children and adolescents.</br>In Ivanenko A. (ed), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep and psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children and adolescents.</br>USA: Informa Healthcare, 2008; 61-78. Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders Gruber R, Fontil L, Bergmame L, et al.</br>Contributions of circadian tendencies and behavioural problems to sleep onset problems of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ADHD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>BMC Psychiat 2012;12:212. </br>Kripke DF, Rex KM, Ancoli-Israel S, Nievergelt 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Klimecki W, Kelsoe JR.</br>Delayed sleep phase cases and controls.</br>J Circadian Rhythms 2008;6:6. </br>Marchetti LM, Biello SM, Broomfield NM, Macmahon KM, Espie CA.</br>Who is pre-occupied with sleep?</br>A comparison of attention bias in people with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychophysiological insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and good sleepers using the induced change 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blindness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 paradigm.</br>J Sleep Res 2006;15:212–21. </br>Rahman SA, Kayumov L, Tchmoutina EA, Shapiro 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Clinical efficacy of dim light 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 onset testing in diagnosing delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Med 2009;10:549–55. </br>Reid KJ, Jaksa AA, Eisengart JB, et al.</br>Systematic evaluation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Axis-I
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 DSM diagnoses in delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and evening-type circadian preference.</br>Sleep Med 2012;13:1171–7. </br>Shibui 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Uchiyama M, Okawa M. 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 rhythms in delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Biol Rhythms 1999;14:72–6. </br>Uchiyama M, Okawa M, Shibui 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, et al.</br>Poor compensatory function for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a pathogenic factor in patients with delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2000;23:553–8. </br>Weitzman E, Czeisler C, Coleman R, Spielman, et al.</br>Delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronobiological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with sleep onset 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Arch Gen Psychiatry 1981;38:737–46. </br>Wyatt JK, Stepanski EJ, Kirkby J. Circadian phase in delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: predictors and temporal stability across multiple assessments.</br>Sleep 2006;29:1075–80. </br>Advanced Sleep-Wake Phase Disorder ICD-9-CM code: 327.32 ICD-10-CM code: G47.22 Alternate Names Advanced sleep phase type, advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-E must be met A.</br>There is an advance (early timing) in the phase of the major sleep episode in relation to the desired or required sleep time and wake-up time, as evidenced by a chronic or recurrent complaint of difficulty staying awake until the required or desired conventional bedtime, together with an inability to remain asleep until the required or desired time for awakening. </br>B. Symptoms are present for at least three months. </br>C. When patients are allowed to sleep in accordance with their internal biological clock, sleep quality and duration are improved with a consistent but advanced timing of the major sleep episode. </br>198 D. Sleep log and, whenever possible, actigraphy monitoring for at least seven days (preferably 14 days) demonstrate a stable advance in the timing of the habitual sleep period.</br>Both work/school days and free days must be included within this monitoring. </br>E.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not better explained by another current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use, or substance use disorder. </br>Notes .</br>Standardized chronotype questionnaires are useful tools to assess the chronotype of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eveningness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and morningness.</br>Individuals with advanced sleep phase score as morning types. </br>2. Demonstration of an advance (typically greater than two hours) in the timing of other circadian rhythms such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DLMO
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or urinary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    6-sulfatoxymelatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is desirable to confirm the advanced circadian phase. </br>Essential Features Advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-wake phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (ASWPD) is characterized by a stable advance (earlier timing) of the major sleep episode, such that habitual sleep onset and offset occur typically two or more hours prior to required or desired times.</br>Affected individ- uals complain of early morning or maintenance 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and excessive evening sleep- iness.</br>When affected individuals are allowed to maintain an advanced schedule, sleep quality and quantity are improved. </br>Associated Features Individuals with ASWPD may experience chronic partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to early morning and maintenance 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly if sleep is resisted during early evening. </br>Clinical and Pathophysiological Subtypes Familial patterns are discussed below. </br>Demographics The prevalence of ASWPD in the general population is unknown.</br>In one large survey study involving middle-aged adults (40-64 years), the population prevalence was esti- mated at 1%, although it is unclear what proportion of these subjects would deem their schedule to be significantly troublesome so as to warrant clinical attention.</br>Until the identification of familial cohorts (see below), only four cases were described in the lit- erature.</br>There is no known sex difference. </br>199 Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders Predisposing and</br>Precipitating Factors Advanced age appears to be a risk factor.</br>Among a cohort aged 20 to 59 years, older age was associated with increased 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morningness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which was determined to be a sig- nificant mediator of numerous age-sleep relationships.</br>A patient’s ability to sleep at an abnormal circadian phase (phase tolerance) also impacts the degree to which adverse symptoms are experienced, and this adaptability varies among individuals.</br>Conflicting results have been obtained with respect to the relationship between age and phase tolerance, with some suggesting that age decreases phase tolerance, and others suggesting that age may actually be protective.</br>Methodological differences preclude direct comparisons of the investigations, as do wide variations in the age groups studied.</br>Genetic factors also can influence the development of the condition, as has been definitively demonstrated among select familial cohorts (see Pathology and Pathophysiology section).</br>Environmental influences may precipitate, maintain, or exacerbate the advanced circadian phase, but this has not been proven.</br>ASWPD has been reported in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodevelopmental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In particular, studies in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism spectrum disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Smith-Magenis syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have shown profound alterations in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 secretion profiles, which may manifest as a phase advance with very early morning waking. </br>Familial Patterns Various groups have described kindreds with familial ASWPD.</br>These cases may be characterized by an earlier age of onset.</br>It is not clear whether the familial or non- familial variety of the condition is more common. </br>Onset, Course, and Complications Repetitive attempts to resume sleep with awakenings may result in the development of a comorbid chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Individuals may use 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, other sedatives, and/or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stimulants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 to alleviate symptoms, potentially exacerbating the underlying sleep/ wake disorder.</br>The impact on caregivers of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodevelopmental disor- ders and ASWPD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be particularly profound. </br>Developmental Issues ASWPD is most frequently encountered among older age groups.</br>An early age of onset of ASWPD should prompt further probing for a familial pattern.</br>Caregivers may report that a child wakes “too early” in the morning, which is disruptive to the house- hold routine and may curtail parental sleep.</br>This is particularly true for younger chil- dren, who may require adult supervision once they are awake.</br>However, this complaint regarding the waking pattern is often more related to unrealistic caregiver expecta- tions regarding an “appropriate” wake time for a young child and/or a developmentally inappropriate early bedtime resulting in prolonged time in bed, rather than to a true advance in sleep onset and offset.</br>In some cases, children are motivated to wake up earlier than desired because they are reinforced for this behavior by parental attention or the opportunity to watch television or utilize other media upon waking.</br>The com- plaint that a child “falls asleep too early” in the evening, especially in adolescence, is rare and should raise concerns regarding the possibility of chronically insufficient sleep and/or a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 resulting in increased sleep needs.</br>The rarity of observa- tions of advanced sleep onset and offset times among young children may also be due in part to societal expectations of earlier bed and wake times for this age group; thus, a misalignment with circadian preference is less likely. </br>Pathology and Pathophysiology Possible etiologies include: (1) an alteration in the ability of the circadian clock to phase delay; (2) a dominant phase advance region of the light phase response curve to entraining agents; (3) altered strength of entraining agents, such as light exposure at the appropriate circadian time (voluntarily or involuntarily induced); or (4) a shortened endogenous circadian period of the pacemaker.</br>Among these proposed mechanisms, only the latter has been definitively demonstrated among select familial ASWPD sub- jects.</br>Genetic analyses revealed a missense mutation in a casein kinase (CK1ε) binding region of a Period gene (hPer2), culminating in hypophosphorylation by CK1ε in vitro.</br>Hypophosphorylation of the Period protein results in promotion of its transcription and, ultimately, a decrease in the period length of the clock.</br>However, genetic het- erogeneity is apparent within familial ASWPD, as demonstrated by the fact that other cohorts from this same study and another study did not reveal mutations in hPer2.</br>A separate report of a Japanese familial ASWPD cohort described a missense mutation in a different casein kinase gene (CKIδ), which also resulted in decreased enzymatic activity in vitro.</br>Yet another group described associations between hPer1 and hPer2 polymorphisms and extreme morningness circadian preferences (questionnaire-based), in the absence of discrete ASWPD. </br>Objective Findings Among patients with familial ASWPD, laboratory measures to determine the phase of circadian rhythms reliably show the expected phase advance in the timing of the nadir of the temperature rhythm and the dim light 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 onset, in comparison with unaf- fected controls.</br>Among those with nonfamilial ASWPD, a wider range of timing of circadian markers is found, with some values approaching those of unaffected controls. </br>Polysomnography (though not routinely indicated nor required for the diagnosis), when performed at preferred (advanced) sleep times, is essentially normal for age.</br>If Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders a conventional bedtime and wake-up time is enforced, however, polysomnographic recording may show short sleep latency and early awakening with curtailment of total sleep time. </br>Differential Diagnosis ASWPD must be distinguished from “normal” sleep patterns, particularly among the elderly or very young, who often maintain advanced schedules without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    distress
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or impaired functioning.</br>ASWPD must also be distinguished from other causes of early awakening, including chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Poor sleep hygiene practices, partic- ularly evening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    napping
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 among the elderly, and irregularity of the sleep-wake schedule should also be considered.</br>The possibility of a “free-running” (nonentrained) circadian rhythm also merits consideration, but patients with this condition are most commonly blind and report only periodic complaints of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 depending on the relative rela- tionship between the internal rhythm and that of the light/dark cycle.</br>Major 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a common cause of early awakening that must be considered.</br>These patients do not typically manifest the early evening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that is characteristic of ASWPD.</br>As with any sleep disturbances that persists over time, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can develop second- arily.</br>The Horne-Östberg questionnaire (or other chronotype questionnaire) may assist in determining the contribution of a morningness circadian preference to the presenting sleep/wake complaint.</br>The presence of more than one contributing variable seems to be the norm, and each entity needs to be treated accordingly. </br>Unresolved Issues and Further Directions The existing literature suggests that clinicians are unlikely to encounter patients with stringently defined ASWPD.</br>Until the identification of familial cohorts, only four cases were described.</br>Various treatment trials also support this contention with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    demon-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 stration of objectively conventional sleep and wake times despite study entry based on subjective reports of advanced sleep phase.</br>Select studies of patients with sole complaints of maintenance insomnia/early-morning 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    awakenings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have demonstrated marked advances (earlier timing) of physiologically measured circadian rhythms.</br>The absence of the early evening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness complaint
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be due to the fact that the timing of sleep onset can be more readily modified than wake time, and is likely to be more actively resisted due to its propensity to conflict with social or family obligations.</br>Alternatively, evening sleep that occurs prior to entering the bed/bedroom may not be reported as such.</br>If it is definitively demonstrated that the evening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness complaint
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not present or is not prominent, the term advance-related sleep complaints may be used in lieu of ASWPD.</br>If this broader term is used, the condition is observed more commonly (~7% of respondents in a study of individuals aged 40-64 years).</br>There is limited knowledge of the pathophysiology of ASWPD (or advance-related sleep complaints) beyond those associated with select cases of familial ASWPD.</br>Increased use of physiologic circadian assessments will require the development of normative values to guide practitioners.</br>Knowledge gaps are even more prominent within pediat- ric and adolescent populations. </br>Bibliography Ando 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Kripke DF, Ancoli-Israel 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Delayed and advanced sleep phase symptoms.</br>Isr J Psychiatry Relat Sci 2002;39:11–8. </br>Auger R. Advance-related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Med Clin 2009;4:219–27. </br>Campbell SS, Dawson D, Anderson MW.</br>Alleviation of sleep maintenance 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with timed exposure to bright light.</br>J Am Geriatr Soc 1993;41:829–36. </br>Carpen JD, Archer SN, Skene DJ, Smits M,</br>von Schantz M. A single-nucleotide polymorphism in the 5’-untranslated region of the hPER2 gene is associated with diurnal preference.</br>J Sleep Res 2005;14:293–7. </br>Carpen JD, von Schantz M, Smits M, Skene DJ, Archer SN.</br>A silent polymorphism in the PER1 gene associates with extreme diurnal preference in humans.</br>J Hum Genet 2006;51:1122–5. </br>Carrier J, Monk TH, Buysse DJ, Kupfer DJ.</br>Sleep and morningness-eveningness in the ‘middle’ years of life (20-59 y).</br>J Sleep Res 1997;6:230–7. </br>Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms.</br>Int J Chronobiol 1976;4:97–110. </br>Jones C, Campbell SS, Zone 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, et al.</br>Familial advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
:</br>A short-period circadian rhythm variant in humans.</br>Nature Med 1999;5:1062–5. </br>Kamei R, Hughes L, Miles L, et al.</br>Advanced-sleep phase syndrome studied in a time isolation facility.</br>Chronobiologia 1979;6:115. </br>Moldofsky H, Musisi S, Phillipson EA.</br>Treatment of a case of advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by phase advance chronotherapy.</br>Sleep 1986;9:61–5. </br>Palmer CR, Kripke DF, Savage HC Jr, Cindrich 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    LA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Loving RT, Elliott JA.</br>Efficacy of enhanced evening light for advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Behav Sleep Med 2003;1:213–26. </br>Sack RL, Auckley D, Auger RR, et al., Circadian rhythm sleep disorders: part II, advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    free-running disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and irregular sleep-wake rhythm.</br>An American Academy of Sleep Medicine review.</br>Sleep 2007;30:1484–501. </br>Satoh 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Mishima 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Inoue Y, Ebisawa T, Shimizu T. Two pedigrees of familial advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in Japan.</br>Sleep 2003;26:416–7. </br>Singer 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Lewy AJ.</br>Case report: use of the dim light 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 onset in the treatment of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ASPS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with bright light</br>[abstract].</br>Sleep 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Res
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 1989;18:445. </br>Toh K, Jones CR, He Y, et al.</br>An hPer2 phosphorylation site mutation in familial advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Science 2001;291:1040–3. </br>Xu Y, Padiath QS, Shapiro RE, et al.</br>Functional consequences of a CKIdelta mutation causing familial advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Nature 2005;434:640–4. </br>Yoon IY, Kripke DF, Elliott 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    JA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Youngstedt SD, Rex KM, Hauger RL.</br>Age-related changes of circadian rhythms and sleep-wake cycles.</br>J Am Geriatr Soc 2003;51:1085–91. </br>203 Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders Irregular Sleep-Wake Rhythm Disorder ICD-9-CM code: 327.33 ICD-10-CM code: G47.23 Alternate Names Irregular sleep-wake cycle disorder, irregular sleep-wake rhythm type. </br>Diagnostic Criteria Criteria A-D must be met A.</br>The patient or caregiver reports a chronic or recurrent pattern of irregular sleep and wake episodes throughout the 24-hour period, characterized by symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the scheduled sleep period (usually at night), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (napping) during the day, or both. </br>B. Symptoms are present for at least three months. </br>C. Sleep log and, whenever possible, actigraphy monitoring for at least seven days, preferably 14 days, demonstrate no major sleep period and multiple irregular sleep bouts (at least three) during a 24-hour period. </br>D.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not better explained by another current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use, or substance use disorder. </br>Essential Features Irregular sleep-wake rhythm disorder (ISWRD) is characterized by lack of a clearly defined circadian rhythm of sleep and wake.</br>The chronic or recurring sleep-wake pattern is temporally disorganized so that sleep and wake episodes are variable throughout the 24-hour cycle.</br>Individuals have symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, depending on the time of day and their particular sleep-wake pattern. </br>Associated Features ISWRD is more commonly observed in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodegenerative disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as demen- tia, and in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    developmental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Individuals typically present with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, depending on the time of day.</br>Sleep and wake epi- sodes across the 24-hour cycle are fragmented, with the longest sleep bout being typi- cally less than four hours.</br>Individuals or caregivers report frequent naps throughout the daytime.</br>Total sleep time across the 24 hours may be normal for age. </br>Clinical and Pathophysiological Subtypes Older adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 who experience sundowning may represent a clin- ical subtype with more severe sleep fragmentation and lower circadian rhythm ampli- tude than those who do not experience sundowning. </br>204 Demographics Demographic patterns generally parallel those of associated risk factors such as neuro- developmental and neurodegenerative disorders. </br>Predisposing and Precipitating 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Factors Neurodegenerative disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Huntington disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 increase the risk for ISWRD.</br>Children with developmental disor- ders also are at increased risk for ISWRD. </br>Poor sleep hygiene and lack of exposure to external synchronizing agents such as light, activity, and social schedules may be predisposing as well as precipitating factors involved in the development of ISWRD, particularly in the institutionalized elderly. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications Onset of the condition may occur at any age.</br>Little is known regarding the course and complications of ISWRD in adults.</br>Due to the multiple awakenings and, in the elderly, nocturnal wandering, falls can be an indirect complication.</br>In addition to the patient’s 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-wake dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the caregiver’s sleep is often disrupted.</br>The sleep and wake disruption associated with ISWRD is a common cause of institutionalization. </br>Developmental Issues Caregivers may report that a child with ISWRD has difficulty falling asleep at the desired bedtime or “falls asleep too early” in the evening, wakes “too early” or has dif- ficulty waking in the morning, and/or exhibits developmentally 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inappropriate napping behavior
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the day.</br>Parents may complain that their child sleeps too much or too little or at inappropriate times.</br>Attempts to keep the child awake during the day, especially during sedentary activities, are often unsuccessful.</br>The key characteristics that distinguish ISWRD from other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or circadian sleep wake disor- ders are the lack of prolonged consolidated sleep periods, the often seemingly random distribution in sleep periods across the 24-hour day, and the marked day-to-day and week-to-week variability with little in the way of a clearly predictable major sleep- wake pattern.</br>The impact on caregivers’ sleep and daytime functioning is likely to be particularly profound. </br>There may be phenotypes of ISWRD in children, with differences regarding symptom presentation and severity and chronicity that are related to the underlying condition. </br>205 Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders For example, it is possible that children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic neurologic conditions such as
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or chromosomal syndromes characterized by developmental delays may have a more intractable and treatment resistant pattern compared with children with more self-limited conditions (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    postconcussion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Although ISWRD appears to be rare in typically developing children, it may be envi- ronmentally or behaviorally induced.</br>This may be seen in children with irregular or fragmented sleep and wake schedules because of a chaotic household.</br>Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    developmental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are at increased risk for ISWRD.</br>For example, children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Asperger syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pervasive developmental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 not otherwise spec- ified often have highly irregular sleep patterns.</br>In addition, these children often have circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 which are both more severe and chronic and they are at increased risk for relapse. </br>Both ISWRD and non-24-hour sleep-wake rhythm disorder are also common in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Angelman syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodevelopmental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with an abnormality of chromosome 15q11-q13, and have been reported in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Williams syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodevelopmental genetic disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 characterized by physical abnormalities and a dis- tinctive cognitive profile with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intellectual disabilities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and learning difficulties.</br>Studies in children and adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism spectrum disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Smith-Magenis syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have shown profound alterations in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 secretion profiles.</br>Smith-</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Magenis syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    developmental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 caused by an abnormality in the short (p) arm of chromosome 17.</br>It is characterized by mild to moderate intellectual disabil- ity, distinctive facial features, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and behavioral problems.</br>Decreased concentrations of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and its metabolites and daytime elevation and abnormal rhythm/decreased amplitude of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 secretion have been reported in these popu- lations.</br>These findings may be due to polymorphisms in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 enzymes synthesis or variants in genes coding for 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 receptors.</br>Other postulated mechanisms for circadian rhythm disturbances, particularly ISWRD, in these populations include clock gene polymorphisms and decreased levels of entrainment by social/environmental cues. </br>There may also be medical conditions that predispose typically developing children and adolescents to ISWRD.</br>These include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    traumatic brain injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Brain 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 survivors, especially patients who have experienced disrup- tion in the hypothalamic-pituitary axis, may have an increased prevalence of circadian rhythm disorders, including ISWRD. </br>There is very little literature on ISWRD in the pediatric population; prevalence, sex, and racial/ethnic differences are unknown.</br>Little is known about the natural history of the clinical entity of ISWRD in the pediatric population, including the impact of various treatment modalities, the likelihood of spontaneous resolution of symptoms, or long-term consequences.</br>The impact on caregivers of children with neurodevelopmen- tal disorders and ISWRD may be particularly profound. </br>The prevalence of ISWRD increases with advancing age, but it is likely that age-re- lated increase in neurodegenerative disorders, rather than aging per se, explains this relationship. </br>Pathology and Pathophysiology The etiology of ISWRD is likely multifactorial.</br>Anatomic or functional abnormal- ities of the circadian clock can result in an arrhythmic pattern of rest and activity.</br>Decreased exposure to environmental-entraining agents, such as light and structured physical and social activities (common in institutionalized elderly, and children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    developmental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), also can contribute to the development of an irregular sleep-wake cycle. </br>Objective Findings In addition to a careful sleep history, sleep log and actigraphy monitoring show the expected lack of a clearly defined circadian rhythm of the sleep-wake cycle, which, instead, is characterized by multiple irregular sleep and wake bouts throughout the 24-hour period.</br>The use of sleep log and actigraphy is indicated for the identification of irregular sleep wake rhythm.</br>The irregular sleep-wake pattern is defined as having multiple sleep bouts (typically 2–4 hours) during a 24-hour period.</br>The pattern may vary from day to day, thus monitoring for at least seven days and preferably 14 days may be needed to differentiate the irregular pattern from other circadian rhythm sleep- wake disorders. </br>Polysomnography is not required to establish the diagnosis.</br>Polysomnography may be useful for the diagnosis of other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Monitoring of other circa- dian rhythms, such as core body temperature and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 for at least 24 hours, may also show a loss of clear circadian rhythmicity or a low amplitude rhythm. </br>Differential Diagnosis Poor sleep hygiene and voluntary maintenance of irregular sleep schedules should be distinguished from irregular sleep-wake pattern.</br>Individuals with irregular sleep-wake rhythms may present with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Careful analysis of sleep logs or actigraphy will demonstrate multiple irregular periods of sleep throughout the 24-hour cycle.</br>In both adults and children, other causes of sleep fragmentation and daytime Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders napping, including comorbid medical and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or medication should be identified and treated. </br>Unresolved Issues and Further Directions There is limited knowledge of the pathophysiology and natural history, response to treatment, and complications of the disorder in adults and children.</br>Further research into the relative contribution of alterations in environmental synchronizing agents, such as light and activity, versus a dysfunction of the endogenous circadian clock in the development of irregular sleep and wake patterns will lead to improved understanding of this condition. </br>Bibliography Hopkins R, Rindlisbacher P. Fragmentation of activity periods in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer’s disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Int J Geriatr Psychiatry 1992;7:805–12. </br>McCurry SM, Ancoli-Israel S. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer’s disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Curr Treat Options Neurol 2003;5:261–72. </br>Okawa M, Mishima 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Hishikawa Y, Hozumi S, Hori H, Takahashi K. Circadian rhythm disorders in sleep-waking and body temperature in elderly patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and their treatment.</br>Sleep 1991;14:478–85. </br>Pillar G, Shahar E, Peled N, Ravid S, Lavie P, Etzioni A. 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 improves sleep-wake patterns in psychomotor retarded children.</br>Pediatr Neurol 2000;23:225–8. </br>Pollack C, Stokes P. Circadian rest-activity rhythms in demented and non-demented older community residents and their caregivers.</br>J Am Geriatr Soc 1997;45:446-52. </br>Shochat T, Martin J, Marler M, Ancoli-Israel S. Illumination levels in nursing home patients: Effects on sleep and activity rhythms.</br>J Sleep Res 2000;9:373–9. </br>Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A. Sundowning and circadian rhythms in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer’s disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am J Psychiatry 2001;158:704–11. </br>Witting W, Kwa I, Eikelenboom P, Mirmiran M, Swaab D. Alterations in the circadian rest-activity rhythm in aging and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer’s disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Biol Psychiatry 1990;27:563–72. </br>Zee PC, Vitiello MV.</br>Circadian rhythm sleep disorder: irregular sleep wake rhythm type.</br>Sleep Med Clin 2009;4:213–8. </br>208 Non-24-Hour Sleep-Wake Rhythm Disorder ICD-9-CM code: 327.34 ICD-10-CM code: G47.24 Alternate Names Free-running disorder, nonentrained disorder, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypernychthemeral syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-D must be met A.</br>There is a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or both, which alternate with asymptomatic episodes, due to misalignment between the 24-hour light-dark cycle and the non-entrained endogenous circadian rhythm of sleep-wake propensity. </br>B. Symptoms persist over the course of at least three months. </br>C. Daily sleep logs and actigraphy for at least 14 days, preferably longer for blind persons, demonstrate a pattern of sleep and wake times that typically delay each day, with a circadian period that is usually longer than 24 hours. </br>D.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not better explained by another current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use, or substance use disorder. </br>Notes .</br>Patients may present with a progressively delaying sleep-wake pattern and intermittent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Individual symptoms will depend on when an individual tries to sleep in relation to the circadian rhythm of sleep-wake propensity.</br>The magnitude of the daily delay will depend on the endogenous circadian period, and may range from less than 30 minutes (when the period is close to 24 hours) to more than an hour (when the period is longer than 25 hours). </br>2. The symptomatic episode will typically begin with a gradual increase in sleep latency and delayed sleep onset.</br>As the sleep propensity rhythm shifts into the daytime, patients will have difficulty falling asleep at night and staying awake during the day.</br>As the sleep-wake propensity rhythm drifts further, patients will eventually complain of late afternoon and evening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and naps as well as an early sleep onset time and short sleep latency. </br>3. Other circadian rhythms, such as the DLMO or urinary 6-sulfatoxy- melatonin rhythm obtained at two time points 2-4 weeks apart (i.e., to allow sufficient time for the drift to be apparent) is desirable to confirm the nonentrained rhythm. </br>Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Non-24-hour sleep-wake disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (N24SWD) is characterized by symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that occur because the intrinsic circadian pace- maker is not entrained to a 24-hour light/dark cycle.</br>The non-24-hour period can be shorter or, more typically, longer than 24 hours.</br>Because the endogenous circadian rhythm is not aligned to the external 24-hour environment, symptoms will depend on when an individual tries to sleep in relation to the circadian rhythm of sleep and wake propensity.</br>Individuals typically present with episodes of difficulty falling asleep or staying asleep, excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or both, alternating with short asymp- tomatic periods.</br>The severity of individual sleep-wake symptoms can be variable.</br>Starting with the asymptomatic period when the individual’s endogenous rhythm is aligned to the external environment and required sleep-wake times, sleep latency will gradually increase and the individual will complain of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-onset insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>As the sleep phase continues to drift so that maximal endogenous sleep propensity is now in the daytime, individuals will have trouble staying awake during the day (exhibiting multiple daytime naps) and complain of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Associated Features Most individuals with nonentrained circadian rhythms are totally blind, and the failure to entrain circadian rhythms is related to the lack of photic input to the cir- cadian pacemaker.</br>A small proportion of totally blind people may retain functional circadian photoreception and entrained rhythms if their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blindness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is due exclusively to an outer 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retina disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (rod and cone layer) with retention of functional, intrin- sically photosensitive retinal ganglion cells and the retinohypothalamic pathway.</br>Some blind people may also be able to entrain to nonphotic cues (e.g., the timing of physical activity), producing entrainment at an adverse phase in some cases.</br>In sighted people, social and behavioral factors also play an important role in the development and maintenance of the disorder, as there is an increased incidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Occasionally, the disorder is associated with developmental 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intellectual disability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In sighted individuals, there is often a history of delayed sleep phase, and decreased exposure to light and structured social and phys- ical activity.</br>Some sighted individuals with N24SWD also demonstrate increased sleep duration. </br>Demographics It is thought that over half of totally blind individuals have non-24-hour circa- dian rhythms; 50% to 80% of blind individuals complain of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The prevalence, sex, and racial/ethnic differences of N24SWD in adults and children are unknown. </br>210 Predisposing and Precipitating Factors Total 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blindness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is the most common predisposing condition.</br>In sighted people, the dis- order can be induced by certain environmental conditions, such as decreased or inap- propriately timed exposure to circadian entraining agents, particularly light.</br>Delayed sleep-wake phase disorder may predispose to N24SWD in sighted persons.</br>The con- dition has developed after chronotherapy for DSWPD.</br>This disorder has also been reported in adults following 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    traumatic brain injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Familial Patterns Not applicable or known. </br>Developmental Issues Caregivers may report that a child has difficulty falling asleep at the desired bedtime or “falls asleep too early” in the evening, wakes “too early” or has difficulty waking in the morning and staying awake during the day.</br>Parents may complain that their child sleeps too much or too little or at inappropriate times.</br>The key characteristics that distinguish N24SWD from other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep complaints
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or circadian sleep wake dis- orders are twofold: (1) the predictable pattern of misalignment between the child’s sleep patterns and the light-dark 24-hour cycle (progressive delay in sleep onset-offset across days to weeks); and (2) periods of apparent “symptom remission” during those transient intervals when the child’s circadian sleep-wake propensity coincides with the desired bed and wake times.</br>The impact on caregivers’ sleep and daytime functioning is often profound. </br>Although N24SWD is extremely rare in typically developing or sighted children, it has been reported with some frequency in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intellectual disabilities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blindness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>For example, children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    optic nerve hypoplasia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a variety of under- lying causes, especially those children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoplastic corpus callosum and comor- bid severe intellectual and visual impairments
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, have been reported to have features of N24SWD. N24SWD has also been described in pediatric patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Rett syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (a genetic disorder occurring almost exclusively in girls, characterized by severe developmental regression, language delays, and limited social interactions), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism spectrum disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Angelman syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodevelopmental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 asso- ciated with an abnormality of chromosome 15q11-q13.</br>The common mechanism in all of these disorders is postulated to be lack of entrainment to the 24-hour day that results from the failure to perceive and/or attend to social/environmental zeitgebers (time cues).</br>There have also been several case reports which describe the emergence of N24SWD in intellectually normal sighted children or adolescents who have limited or inappropriate exposure to environmental and other entraining cues (e.g., decreased Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders light during the day and/or excessive light exposure in the evening).</br>These individuals are likely to have significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric impairments
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that predispose them to avoid- ance of social interactions (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) or medical conditions that involve enforced prolonged periods of inactivity (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    traumatic brain injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Little is known about the natural history of the clinical entity of N24SWD in the pedi- atric population, including the impact of various treatment modalities, the likelihood of spontaneous resolution of symptoms, or long-term consequences. </br>There may be varying phenotypes of N24SWD in children, with differences in regard to symptom presentation, severity, and chronicity that are related to the underlying condition.</br>For example, it is likely that children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic neurologic conditions such as
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blindness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodevelopmental disabilities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have a more intractable and treat- ment resistant pattern compared to children with more self-limited conditions (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    traumatic brain injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Onset, Course, and Complications Onset may occur at any age in blind individuals, coincident with loss of light percep- tion, and, in congenitally blind children, onset can occur from birth or during infancy.</br>If untreated, the course is chronic.</br>Attempts to regulate sleep and wake times may involve the use of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sedatives-hypnotics
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and stimulants, which in turn can exac- erbate the underlying 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Depressive symptoms and mood disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be comorbid conditions, particularly in sighted patients.</br>The adverse effects on school or work performance, as well as other psychosocial complications, due to a lack of pre- dictable sleep and wake times and excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, are key motivations for seeking treatment. </br>Pathology and Pathophysiology The intrinsic period of the human circadian pacemaker is usually longer than 24 hours and requires daily input from the environment to maintain synchrony to the 24-hour day.</br>The light-dark cycle is the most important environmental time cue (zeitgeber) in humans (as in other species), although nonphotic time cues also play a role in normal entrainment.</br>A lack of photic input to the circadian pacemaker is clearly the cause of nonentrained rhythms in totally blind people.</br>It has been suggested that, in sighted individuals, a systematic delay due to inadequate exposure to light may contribute to the development of N24SWD.</br>In addition, the disorder may be caused by an extremely prolonged endogenous circadian period that is outside of the range for entrainment to the 24-hour cycle or by an alteration in the response of the circadian clock to the entraining effects of light. </br>212 Objective Findings Sleep studies yield different results depending on the degree of synchrony between sleep times and the circadian pacemaker at the time when the sleep study is performed.</br>Recording of sleep log and actigraphy over prolonged periods (at least 14 days, but ideally longer in blind individuals) demonstrate the lack of a stable relationship between the timing of the sleep-wake cycle and the 24-hour day.</br>When sleep sched- ules follow the endogenous circadian propensity for sleep and wake, sleep onset and wake times are typically delayed each day.</br>Serial measurements of circadian rhythms, such as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, usually show a progressive daily delay of the phase of the rhythm consistent with a period that is longer than 24 hours. </br>Clinical and Pathophysiologic Subtypes Totally blind patients with N24SWD are clinically different than sighted patients.</br>In sighted patients with N24SWD, the circadian period is often 25 hours or longer, whereas in totally blind patients with the disorder, the circadian period follows an average period length which is often closer to 24 hours and rarely may be shorter than 24 hours. </br>Differential Diagnosis Some individuals with severe DSWPD may demonstrate progressive delay of their sleep period by 30 minutes or more for several days, and their symptoms may be con- fused with N24SWD. </br>Behavioral factors and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as well as medical and neurological dis- orders (especially 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blindness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but also 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental retardation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), may play a role in the development of N24SWD.</br>In many of these cases, however, multiple physio- logic, behavioral, and environmental factors contribute to the condition.</br>In the major- ity of these cases, the disorder should be coded as N24SWD.</br>This includes non-24- hour sleep-wake patterns that are associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blindness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Unresolved Issues and Further Directions </br>There is only limited knowledge of the underlying pathophysiology of sighted persons with N24SWD.</br>The primary risk factor in sighted persons appears to be a long circa- dian period that is beyond the range of entrainment to a 24-hour cycle or a progressive delay due to inappropriate exposure to light.</br>This risk may explain the overlap between DSWPD and N24SWD.</br>Future studies are needed to understand the role of genetic predisposition, environmental or social cues and traumatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brain injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the develop- ment of N24SWD, and to delineate other health consequences of the condition.</br>There are substantial knowledge gaps regarding the prevalence, pathophysiology, clinical Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders presentation, natural history, effective treatment strategies, and prognosis of N24SWD in children and adolescents compared with adults. </br>Bibliography Ayalon L, Borodkin 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Dishon L, Kanety H, Dagan Y. Circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 following mild 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    traumatic brain injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Neurology 2007;68:1136–40. Boivin DB, James FO, Santo JB, Caliyurt O, Chalk C. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Non-24-hour sleep-wake syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 following a car accident.</br>Neurology 2003;60:1841–3. </br>Czeisler CA, Shanahan TL, Klerman 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EB
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, et al.</br>Suppression of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 secretion in some blind patients by exposure to bright light.</br>N Engl J Med 1995;332:6–11. </br>Hayakawa T, Uchiyama M, Kamei Y, et al.</br>Clinical analyses of sighted patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    non-24-hour sleep- wake syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: A study of 57 consecutively diagnosed cases.</br>Sleep 2005;28:945–52. </br>Lewy AJ, Newsome 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Different types of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 circadian secretory rhythms in some blind subjects.</br>J Clin Endocrinol Metab 1983;56:1103–7. </br>Lockley SW, Arendt J, Skene DJ.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Visual impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and circadian rhythm disorders.</br>Dialogues Clin Neurosci 2007;9:301–14. </br>Lockley SW, Dijk DJ, Kosti O, Skene DJ, Arendt J. Alertness, mood and performance rhythm disturbances associated with circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the blind.</br>J Sleep Res 2008;17:207–16. </br>Lockley SW, Skene DJ, Butler LJ, Arendt J. Sleep and activity rhythms are related to circadian phase in the blind.</br>Sleep 1999;22:616–23. </br>McArthur A, Lewy A, Sack R. Non-24 hour 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-wake syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in a sighted man: circadian rhythm studies and efficacy of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 treatment.</br>Sleep 1996;19:544–53. </br>Morgenthaler TI, Lee-Chiong T, Alessi C, et al.</br>Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders: An American Academy of Sleep Medicine report.</br>Sleep 2007;30:1445–59. </br>Sack RL, Lewy AJ, Blood ML, Keith LD, Nakagawa H. Circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in totally blind people: incidence and clinical significance.</br>J Clin Endocrinol Metab 1992;75:127–34. </br>Uchiyama M, Lockley SW.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Non-24-hour sleep-wake syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in sighted and blind patients.</br>Sleep Med Clin 2009;4:195–211. </br>Uchiyama M, Okawa M, Shibui 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, et al.</br>Altered phase relation between sleep timing and core body temperature rhythm in delayed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep phase syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    non-24-hour sleep-wake syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in humans.</br>Neurosci Lett 2000;294:101–4. </br>Uchiyama M, Shibui 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Hayakawa T, et al.</br>Larger phase angle between sleep propensity and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 rhythms in sighted humans with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    non-24-hour sleep-wake syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2002;25:83–8. </br>Zaidi FH, Hull JT, Peirson SN, et al.</br>Short-wavelength light sensitivity of circadian, pupillary, and visual awareness in humans lacking an outer retina.</br>Curr Biol 2007;17:2122–8. </br>214 Shift Work Disorder ICD-9-CM code: 327.36 Alternate Names Shift work 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-D must be met ICD-10-CM code: G47.26 Circadian Rhythm Sleep-Wake Disorders A. There is a report of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, accompanied by a reduction of total sleep time, which is associated with a recurring work schedule that overlaps the usual time for sleep. </br>B. The symptoms have been present and associated with the shift work schedule for at least three months. </br>C. Sleep log and actigraphy monitoring (whenever possible and preferably with concurrent light exposure measurement) for at least 14 days (work and free days) demonstrate a disturbed sleep and wake pattern. </br>D.</br>The sleep and/or wake disturbance are not better explained by another current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use, poor sleep hygiene, or substance use disorder. </br>Essential Features Shift work disorder is characterized by complaints of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or excessive sleepi- ness that occur in association with work hours that occur, at least in part, during the usual sleep episode.</br>There are several types of shift-work schedules, including evening shifts, night shifts, early morning shifts, rotating shifts, split shifts, on-call overnight duty, and long duration work shifts that include work hours at night.</br>The sleep distur- bance is most commonly reported in association with night shifts, early morning shifts, and rotating shifts.</br>Total sleep time is typically curtailed by one to four hours, and sleep quality is perceived as unsatisfactory in night, early morning, and rotating shift workers as well as in those who work long-duration shifts.</br>In addition to impairment of performance at work, reduced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alertness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also be associated with consequences for safety during the work schedule and on the commute to and from work.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs despite attempts to optimize environmental conditions for sleep.</br>The condition usually persists only for the duration of the shift work schedule.</br>However, in some individuals, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may persist beyond the duration of shift work. </br>Associated Features Early morning work shifts starting between 4:00 a.m. and 7:00 a.m. can also be asso- ciated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of difficulty in sleep initiation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as well as difficulty awakening. </br>215 Circadian Rhythm Sleep-Wake Disorders Permanent evening shifts may be primarily associated with sleep maintenance dif- ficulty.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 usually occurs during work shifts (mainly night, early morning, and rotating shifts), often accompanied by the need to nap and by impaired mental ability due to the reduced alertness.</br>Reduced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alertness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and increased 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 throughout the waking period may be associated with reduced performance capacity, and with consequences for safety.</br>Also, major portions of free time may have to be used for recovery of sleep, resulting in adverse social consequences.</br>When compared with shift workers without shift work disorder, patients with shift work disorder report greater mood problems, such as impatience, avoidance of interaction with coworkers, a higher risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    impaired social functioning, and lower coping skills.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>Patients with shift work disorder also have a higher risk of subjective health complaints, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ulcers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Risk for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness-related errors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    accidents
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are highest at night, especially in the early morning hours.</br>Drowsy driving accident risk is highest in the morning hours when night shift workers commute home and early morning workers commute to work. </br>Clinical and Pathophysiological Subtypes There are substantial individual differences in the ability to adjust to shift work.</br>However, mechanisms underlying these individual differences are not known. </br>Requirement of extended work hours, such as on-call overnight duty and long-duration work shifts that include work hours at night, represents a specific clinical subtype.</br>In addition to the circadian misalignment (having to work during the night), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with prolonged continuous work may increase the severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and performance impairments. </br>Demographics The prevalence of shift work disorder depends on the prevalence of shift work in the population.</br>It has been estimated that approximately 20% of the workforce in indus- trialized countries is employed in a job that requires shift work.</br>Although the actual prevalence of clinically significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to work schedules is unknown, the total number of night-shift workers suggests that an estimated prevalence of 2% to 5% of the general population is reasonable.</br>The prevalence of shift work disorder among rotating- and night-shift workers has been estimated to be between ~10% and 38%.</br>These figures do not, however, include individuals with early morning or split shift work, which may be other at-risk groups.</br>There is no known sex or racial difference in vulnerability. </br>216 Predisposing and Precipitating Factors Depending on the type of shift, circadian preference may influence the ability to adjust to or tolerate shift work.</br>For example, individuals described as morning types obtain shorter daytime sleep after a night shift.</br>Persons with comorbid medical, psychiat- ric, and other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and individuals with a strong need for stable hours of sleep may be at particular risk.</br>Social pressures before and after a work shift also contribute to short sleep durations in shift workers (e.g., social inter- actions with family and friends, domestic obligations, a second job, and leisure activ- ities).</br>Social pressures also diminish the desire or willingness to maintain a consis- tent daytime sleep schedule on days off, thereby reducing the likelihood of circadian adjustment. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications </br>The condition is closely linked to work schedules and typically remits when the major sleep episode is scheduled at a conventional time.</br>Because there are so many different work schedules, ranging from an occasional overnight shift to regular night work, the course is quite variable.</br>Because shift work is often combined with extended hours of duty, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be a complicating factor.</br>Circadian adaptation is often counteracted by exposure to light at the wrong time of the day and the tendency of most workers to resume full daytime activities and nighttime sleep during weekends and vacations.</br>It has been hypothesized that in some individuals, the condition may lead to chronic sleep disturbances.</br>Complications may include exacerbation of gastrointestinal, met- abolic, reproductive, neoplastic, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Disruptions of social and family life are frequent.</br>Drug and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol dependency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may result from attempts to improve the sleep and wakefulness disturbances produced by shift work.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to the combination of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and circadian misalignment pose important safety concerns.</br>The level of alertness required of the worker, in addi- tion to the intensity of symptoms, needs to be taken into account when evaluating the disorder.</br>For example, the threshold for intervention may be lower for workers whose performance is critical for personal or public safety (for example, health care workers or nuclear power plant or public transport operators). </br>Developmental Issues Not applicable or known. </br>217 Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders Pathology and Pathophysiology The condition is thought to be directly related to circadian misalignment and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is generated by a circadian alerting process that corre- sponds with the time that the worker needs to sleep.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the night and early morning appears to be partly related to cumulative 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and partly due to a decreased circadian alerting signal that corresponds with the work time and the commute to and from work.</br>Tolerance to night work varies considerably and may involve differences in the degree of circadian adaptation (“clock resetting”) to a night-work, day-sleep schedule.</br>Alternatively, tolerance may be related to individual differences in response to circadian and homeostatic influences on sleep and wakeful- ness regulation.</br>Environmental and social factors may exacerbate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with shift work schedules. </br>Objective Findings The condition can usually be diagnosed by history.</br>Sleep logs and actigraphy are rec- ommended to demonstrate a disrupted sleep-wake pattern consistent with shift work disorder.</br>Polysomnographic recordings, while not required for the diagnosis, are useful if the etiology of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is in question (for example to rule out 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Polysomnography during a typical daytime sleep episode after a work shift also can be useful to determine the severity of the sleep disruption, although this is undertaken almost exclusively for research studies of shift work disor- der.</br>Polysomnography may demonstrate impaired sleep quality, with prolonged sleep latency, sleep maintenance difficulty, or shortened total sleep time, depending on the timing of the sleep episode in relation to the underlying phase of the circadian timing system.</br>The sleep episode may be fragmented, with frequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and awaken- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>The Multiple Sleep Latency Test (MSLT) may demonstrate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the time of the work shift.</br>If available, measures of the unmasked 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 rhythm are useful to indicate the degree of circadian misalignment. </br>Differential Diagnosis The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be differentiated from that caused by other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Insufficient sleep related to conflicting daytime activities (for example, child care) or from environmental interference with sleep (for example, daytime noise) often contributes to sleepiness.</br>Sometimes patients with DSWPD may adopt a night-work schedule that is more con- gruent with their sleep preferences.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also suggest other persistent circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm sleep-wake disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, historical informa- tion on the relation between the occurrence of disturbed sleep and work-hour distribu- tion should provide sufficient information to indicate the correct diagnosis.</br>Increasing frustration, negative expectations, and poor sleep hygiene may predispose the person to the development of coexisting chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that could persist beyond the shift work schedule (i.e., shift work may represent a precipitating event that leads to chronic problems with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Drug and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or dependency may result from efforts to treat the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Unresolved Issues and Further Directions </br>Although there is sufficient information regarding the prevalence of shift work in indus- trialized populations, less information is available regarding the actual prevalence of shift work disorder and its impact on health and safety.</br>Further research is needed to improve the definition of what constitutes shift work disorder, to develop diagnostic tools for shift work disorder, to determine the prevalence of shift work disorder using diagnostic criteria, to elucidate the burden of shift work disorder over and above that which may be due to shift work in general, to investigate mechanisms underlying the health and safety consequences of shift work disorder, and to determine which shift workers are at greatest risk of shift work disorder.</br>Furthermore, there is limited information on the role of age, sex, and circadian chronotype on the vulnerability to shift work disorder. </br>Bibliography Akerstedt T. Shift work and disturbed sleep/wakefulness.</br>Occup Med 2003;53:89–94. </br>Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak C.</br>The role of actigraphy in the study of sleep and circadian rhythms.</br>Sleep 2003;26:342–92. </br>Boggild H, Knutsson A. Shift work, risk factors and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Scand J Work Environ Health 1999;25:85–99. </br>Costa G. Shift work and occupational medicine: an overview.</br>Occup Med 2003;53:83–8. </br>Drake CL, Roehrs T, Richardson G, Walsh JK, Roth T. Shift work 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: prevalence and consequences beyond that of symptomatic day workers.</br>Sleep 2004;27:1453–62. </br>Drake CL, Wright KP Jr. Shift work, shift work disorder, and jet lag.</br>In: Kryger MH, Roth T, Dement WC, eds.</br>Principles and practice of sleep medicine, 5th ed.</br>Philadelphia: Elsevier Saunders, 2011:784–98. </br>Flo E, Pallesen S, Magerøy N, et al.</br>Shift work disorder in nurses--assessment, prevalence and related health problems.</br>PLoS One 2012;7:e33981. Folkard S, Tucker P. Shift work, safety and productivity.</br>Occup Med 2003;53:95–101. </br>Horne J, Reyner L. Vehicle accidents related to sleep: a review.</br>Occup Environ Med 1999;56:289–94.</br>Knutsson A. Health disorders of shift workers.</br>Occup Environ Med 2003;53:103–8. </br>Swanson LM, Arnedt JT, Rosekind MR, Belenky G, Balkin TJ, Drake C. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and work performance: findings from the 2008 National Sleep Foundation Sleep in America poll.</br>J Sleep Res 2011;20:487–94. </br>Waage S, Moen 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Pallesen S, et al.</br>Shift work disorder among oil rig workers in the North Sea.</br>Sleep 2009;32:558–65. </br>Wright KP Jr, Bogan RK, Wyatt JK.</br>Shift work and the assessment and management of shift work disorder (SWD).</br>Sleep Med Rev 2013;17:41–54. </br>219 Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders Jet Lag Disorder Jet lag, time zone change syndrome, jet lag syndrome, jet lag type. </br>ICD-9-CM code: 327.35 ICD-10-CM code:</br>G47.25 Alternate Names Diagnostic Criteria Criteria</br>A-C must be met A.</br>There is a complaint of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, accompanied by a reduction of total sleep time, associated with transmeridian jet travel across at least two time zones. </br>B. There is associated impairment of daytime function, general malaise, or somatic symptoms (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastrointestinal disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) within one to two days after travel. </br>C. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not better explained by another current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use, or substance use disorder. </br>Essential Features Jet lag disorder is characterized by a temporary mismatch between the timing of the sleep and wake cycle generated by the endogenous circadian clock and that of the sleep and wake pattern required by a change in time zone.</br>Individuals complain of disturbed sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and impaired daytime function.</br>The severity and duration of symptoms is dependent on the number of time zones traveled, the ability to sleep while traveling, exposure to appropriate circadian times cues in the new environment, tolerance to circadian misalignment when awake during the bio- logical night, and the direction of the travel.</br>Eastward travel (requiring advancing circadian rhythms and sleep-wake hours) is usually more difficult to adjust to than westward travel. </br>Associated Features In addition to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and decreased daytime alertness, associated features may include general malaise and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastrointestinal symptoms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Numerous other variables related to travel, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    decreased mobility
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and/or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 intake, contribute to the overall 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can lead to memory diffi- culties, problems concentrating, driving and flying, and to impaired decision-making.</br>Sleepiness, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and circadian misalignment associated with jet lag may also impair athletic performance.</br>Effects of jet lag not only affect travelers, but also can have significant consequences for airline pilots and flight attendants. </br>220 Clinical and Pathophysiological Subtypes There are individual differences in the ability to adjust to rapid shifts in time zones; however, specific clinical subtypes have not been identified. </br>Demographics Jet lag affects all age, sex, and racial groups.</br>Limited available data suggest that older individuals may experience fewer jet lag symptoms compared with younger individu- als.</br>However, the data have limitations and further research is needed to better define the relationship between age and the development of jet lag disorder. </br>There are no studies on the prevalence of jet lag disorder. </br>Predisposing and Precipitating Factors Disturbed sleep and/or shortened sleep duration before and during travel contribute to jet lag symptoms.</br>Prolonged uncomfortable sitting positions, air quality and pressure, stress, and excessive 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 consumption may increase the severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and impaired alertness and function associated with transmeridian travel. </br>Eastward travel often leads to difficulties with sleep onset as attempts to sleep are made at an earlier internal circadian time when the travelers’ biological clock is pro- moting alertness (i.e., biological day).</br>Difficulty awakening and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur because wake time also occurs at an earlier biological time when the circadian clock is still promoting sleep (i.e., during the travelers’ biological night). </br>Westward jet travel often leads to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the evening hours of the new time zone as the internal circadian clock of the traveler is promoting sleep (i.e., biological night).</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the new time zone is typically manifest as a sleep maintenance issue with early 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morning awakenings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and difficulty returning to sleep because the internal circadian clock of the traveler is promoting wakefulness during the sleep episode (i.e., biological day). </br>Basic circadian science principles suggest that inappropriately timed exposure to light and darkness during and immediately after jet travel can shift the circadian clock in the wrong direction, thereby increasing the duration of jet lag symptoms.</br>Time at destina- tion upon arrival may also influence jet lag symptoms with fewer symptoms reported following midday arrivals after eastward travel. </br>An individual’s innate circadian preference may also confer a greater or lesser ability to adjust to a particular time shift, but this finding has not been systematically assessed. Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders Jet lag is often reported to be worse after eastward than westward travel.</br>Westward travel may generally be easier because the genetically determined period of the cir- cadian clock in humans is on average longer than 24 hours.</br>A circadian period longer than 24 hours is associated with a circadian drive or physiological tendency for bed and wake times to be later, thus making it easier to shift the circadian clock during west- ward travel to more delayed sleep and wake times.</br>However, 20% to 25% of humans have circadian periods that are near to, or shorter than, 24 hours, and these individuals may find it easier to adapt to eastward travel. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications Jet lag is usually a temporary condition.</br>Symptoms begin approximately one to two days after air travel across at least two time zones and are self-limited.</br>The severity and duration of symptoms are usually in proportion to the number of time zones trav- eled and the direction of travel.</br>It is estimated that it takes one day per time zone for circadian rhythms to adjust to the local time.</br>However, if traveling more than six time zones, circadian rhythms may shift in the opposite direction, resulting in a prolonged period of adjustment that may last up to several weeks and increased severity of jet-lag symptoms.</br>Exposure to light at inappropriate times may prolong the time of adjust- ment by shifting the circadian rhythms in the opposite direction.</br>Menstrual and repro- ductive problems have been associated with frequent transmeridian travel in female airline personnel.</br>Poor sleep hygiene practices may perpetuate sleep/wake complaints, and repetitive failed attempts to initiate or maintain sleep at desired times may predis- pose to the development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Developmental Issues The effect of age on the development or severity of jet lag disorder symptoms is unknown. </br>Pathology and Pathophysiology The symptoms of jet lag disorder are due to both desynchronization of endogenous circadian rhythms with local time and sleep disturbance.</br>The severity of symptoms can be influenced by the environment and behaviors of the traveler.</br>Factors inherent to jet travel, including prolonged time spent sitting in a confined space, ability to sleep on long-haul flights, decreased physical activity, and a low 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 environment, may influence severity. </br>222 Objective Findings Objective laboratory testing usually is not indicated.</br>When performed, polysomnogra- phy or actigraphy shows disturbed sleep and a loss of a normal sleep-wake pattern or a mismatch between the timing of sleep and wakefulness with the desired sleep-wake pattern of the local time. </br>Differential Diagnosis A thorough history and physical examination should be performed to exclude other mental, physical, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Somatic complaints of gastrointestinal symptoms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may indicate an underlying medical condition.</br>When jet lag symptoms persist, increas- ing frustration, negative expectations, and poor sleep hygiene may predispose the indi- vidual to the development of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Unresolved Issues and Further Directions Understanding mechanisms of individual differences in vulnerability and tolerance to disturbed sleep and wakefulness during jet lag is necessary.</br>Development of effective and practical strategies to combat jet-lag symptoms and improve sleep, performance and safety are needed. </br>It is unknown how expression of the disorder varies across the life span. </br>Bibliography Auger RR, Morgenthaler TI.</br>Jet lag and other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 relevant to the traveler.</br>Travel Med Infect Dis 2009;7:60–8. </br>Burgess HJ, Crowley SJ, Gazda CJ, Fogg LF.</br>Eastman CI.</br>Preflight adjustment to eastward travel: 3 days of advancing sleep with and without morning bright light.</br>J Biol Rhythms 2003;18:318–28. </br>Daan S, Lewy AJ.</br>Scheduled exposure to daylight: a potential strategy to reduce “jet lag” following transmeridian flight.</br>Psychopharmacol Bull 1984;20:566–8. </br>Dawson D, Campbell SS.</br>Timed exposure to bright light improves sleep and alertness during simulated night shifts.</br>Sleep 1991;14:511–6. </br>Drake CL, Wright KP Jr. Shift work, shift work disorder, and jet lag.</br>In: Kryger MH, Roth T, Dement WC, eds.</br>Principles and practice of sleep medicine, 5th ed.</br>Philadelphia: Elsevier Saunders, 2011; 784–98. </br>Eastman CI, Gazda CJ, Burgess HJ, Crowley SJ, Fogg LF.</br>Advancing circadian rhythms before eastward flight: a strategy to prevent or reduce jet lag.</br>Sleep 2005;28:33–44. </br>Moline ML, Pollak CP, Monk TH, et al.</br>Age-related differences in recovery from simulated jet lag.</br>Sleep 1992;15:28–40. </br>Muhm, JM, Rock PB, McMullin DL, et al.</br>Effect of aircraft-cabin altitude on passenger discomfort.</br>N Engl J Med 2007;357:18–27. </br>Sack R, Auckley D, Auger RR, et al.</br>Circadian rhythm sleep disorders: part i, basic principles, shift work and jet lag: An American Academy of Sleep Medicine Review.</br>Sleep 2007;30:1456–79. </br>Suhner A, Schlagenhauf P, Höfer I, Johnson R, Tschopp A, Steffen R. Effectiveness and tolerability of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    zolpidem
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 for the alleviation of jet lag.</br>Aviat Space Environ Med 2001;72:638–46. </br>223 Circadian Rhythm Sleep-Wake Disorders Circadian Rhythm Sleep-Wake Disorders Tresguerres 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    JA, Ariznavarreta C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Granados B, et al.</br>Circadian urinary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    6-sulphatoxymelatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cortisol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 excretion and locomotor activity in airline pilots during transmeridian flights.</br>J Pineal Res 2001;31:16–22. </br>Waterhouse J, Edwards B, Nevill A, et al.</br>Identifying some determinants of “jet lag” and its symptoms: a study of athletes and other travellers.</br>Br J Sports Med 2002;36:54–60. </br>Circadian Sleep-Wake Disorder Not Otherwise 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Specified
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (NOS) ICD-9-CM code: 327.30 ICD-10-CM code: G47.20 Patients who meet all of the general diagnostic criteria for a CRSWD but do not meet criteria for one of the specific types of circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm sleep-wake disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are clas- sified here.</br>This diagnosis is intended primarily for patients with alterations in circa- dian sleep-wake patterns due to underlying medical, neurologic, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dis- orders.</br>The underlying 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological, psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or medical condition is typically the precipitating factor.</br>Patients may present with a variety of symptoms, including dis- turbed nocturnal sleep and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The sleep-wake pattern may range from alterations in the phase of the sleep-wake cycle to irregular sleep-wake pattern.</br>Recordings of sleep logs and actigraphy over a period of at least seven days, preferably for 14 days or longer, demonstrate sleep onsets and sleep offsets that may be delayed or advanced relative to conventional times, irregular or non-24-hour. </br>Sleep-wake disturbances are common in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodegenerative disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Huntington disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), as well as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodevelop- mental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep-wake disturbances associated with these disorders may exhibit some features of irregular sleep-wake patterns, but do not have a consistent pattern of at least three sleep periods per day.</br>The particular features of this disorder vary with the type of underlying medical, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or neurological condition.</br>The disruption of the sleep-wake cycle has been implicated in the etiology of sundowning and noc- turnal wandering in older adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may exhibit various types of circadian-rhythm alterations.</br>In addition, motor fluctuations can exhibit marked diurnal fluctuation in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>224 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 NREM-Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Disorders of Arousal (From NREM Sleep)..................................................228 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Confusional Arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
..................................................................................229 Sleepwalking ..............................................................................................229 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ..............................................................................................230 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Eating Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ...................................................................240 REM-Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias REM Sleep Behavior Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
....................................................................246 Recurrent Isolated Sleep Paralysis ............................................................254 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nightmare Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ....................................................................................</br>257 Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Head Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.........................................................................264 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
......................................................................267 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ...........................................................................................270 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder......................................................276 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance .........................................276 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Unspecified ...........................................................................278 Isolated Symptoms and Normal Variants Sleep Talking ..............................................................................................279 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are undesirable physical events or experiences that occur during entry into sleep, within sleep, or during arousal from sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur during non-rapid eye movement sleep (NREM), rapid eye movement sleep (REM), or during transitions to and from sleep. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 encompass abnormal sleep related complex movements, behaviors, emo- tions, perceptions, dreams, and autonomic nervous system activity.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are clinical disorders because of the resulting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    injuries
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep disruption, adverse health effects, and untoward psychosocial effects.</br>The clinical consequences of the parasom- nias can affect the patient, the bed partner, or both. </br>Human consciousness consists of three essential states: Wake, NREM sleep, and REM sleep.</br>The three states are modulated by a host of influences including the degree of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ami-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 nergic and cholinergic neurochemical bias, central nervous system (CNS) activation, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the degree of endogenous versus exogenous input.</br>Under normal physiologic conditions, which include homeostatic drive and circadian rhythmicity, the process of state declaration is maintained in a stable and predictable fashion throughout a 24-hour period.</br>However, as the sleep-wake cycle oscillates, the normally distinct states of con- sciousness may be rendered into a state that is not fully declared, resulting in a tempo- rary unstable state of dissociation.</br>Thus, sleep and wake can be viewed as occurring on a spectrum rather than being entirely dichotomous states. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are the result of such state dissociation.</br>Recent research has shown that com- binations of one or more of these states do occur and may result in unstable states of altered consciousness manifesting as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Disorders of arousal, such as sleepwalking, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are an admixture of wakefulness and NREM sleep.</br>Higher cognitive function is severely impaired, if not absent, while the potential for motor capacity has, for the most part, been retained.</br>REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is an admixture of REM sleep coupled with waking or NREM sleep levels of tonic EMG activity.</br>All three states may be present in the same individual as an overlap of disorders. </br>The comingling of basic states of consciousness is the result of different forms of pathophysiology.</br>In disorders of arousal, no identifiable 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuropathology
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present, but functional changes in cerebral activity during NREM sleep are present, essentially resulting in a brain in which certain areas are deactivated (asleep) and others remain activated (awake).</br>This CNS activation, with concomitant skeletal muscle and auto- nomic nervous system activation, is believed to reflect a functional disabling of, or damage to, brain areas usually responsible for the inhibition of these activities during sleep.</br>Additionally, sleep inertia, sleep state instability, and locomotor/central pattern generators are thought to contribute to the occurrence of NREM parasomnias. </br>NREM disorders of arousal frequently appear to involve the disinhibition of “basic drive states” such as feeding, sex, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aggression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Here, it has been postulated that central pattern generators elicit primal fixed action patterns that would otherwise have been inhibited by the prefrontal cortex during wake.</br>In this regard, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aggression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is typ- ically abrupt in onset and characterized by apparent instinctual defensive posturing as opposed to behaviors that are complex and procedural.</br>These can emerge in pathologic forms with the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as seen with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aggression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and locomotion, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (SRED), and abnormal sleep related sexual behaviors. </br>In contrast, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often results from serious neuropathology.</br>Initially, this 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuropathology
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 affects the area of the brain responsible for inhibiting muscle tone during REM sleep.</br>As a result, dreams may be enacted.</br>In the case of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    REM-related
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 behaviors, the experience and activity reflect the actual, often aggressive content of a dream.</br>It is frequently pos- sible to correlate observed movements with later descriptions of the dream.</br>The initial appearance of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms is often followed years later by the development of neu- rodegenerative disorders, particularly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and related synucleinopathies. </br>Abnormal sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 comprise a separate category of disorders, which is detailed in the sleep related movement disorders section.</br>Unlike the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which typ- ically entail more complex movements and behavior, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 encompass a broad range of predominantly simple motoric activities: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, repetitive, rocking, rhythmic, grinding, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramping
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, fragmentary, dystonic, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyskinetic movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which are not usually associated with dream mentation or experiential concomitants. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 involve 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep related behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and experiences over which there is no conscious deliberate control.</br>There are ten core categories of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 listed in the International Classification of Sleep Disorders, 3rd Edition.</br>Only one of the core cat- egories, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, requires video-polysomnographic documentation as one of the essen- tial diagnostic criteria.</br>However, for most of the other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, polysomnographic monitoring can provide corroborative documentation in support of the clinical diagnosis. </br>Considerable advances have taken place in understanding the neurophysiologic aspects of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from slow wave sleep associated with the disorders of arousal.</br>Advances in the clinical understanding of these NREM sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have occurred as well, particularly in regard to their prevalence and severity in adults.</br>In regard to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, long-term delayed emergence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodegeneration
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has frequently been found in middle-aged and older adults following onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>When combined with thorough clinical interviews, video-polysomnography a powerful discriminating tool for identifying the cause of sleep related injury in adults. </br>Bibliography Cramer Bornemann MA, Mahowald MW.</br>Sleep forensics.</br>In: Kryger MH, Roth T, Dement WC, eds.</br>Principles and practice of sleep medicine, 5th ed.</br>Philadelphia: Elsevier Saunders, 2010. </br>Hobson JA.</br>REM sleep and dreaming: towards a theory of protoconsciousness.</br>Nat Rev Neurosci 2009;10:803–13. </br>Ohayon M, Caulet M, Priest R. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Violent behavior
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>J Clin Psychiatry 1997;58:369–76. </br>Ohayon M, Mahowald M, Dauvilliers Y, Krystal A, Leger D. Prevalence and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbidity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of nocturnal wandering in the US adult general population.</br>Neurology 2012;78:1583–9. </br>Schenck C, Milner D, Hurwitz T, Bundlie S, Mahowald M. A polysomnographic and clinical report on sleep related injury in 100 adult patients.</br>Am J Psychiatry 1989;146:1166–73. </br>Siclari F, Khatami R, Urbaniok F, et al.</br>Violence in sleep.</br>Brain 2010;133:3494–509. </br>Tassinari C, Rubboli G, Gardella E, et al.</br>Central pattern generators for a common semiology in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fronto- limbic seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A neuroethologic approach.</br>Neurol Sci 2005;26:s225–32. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 NREM-Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Disorders of Arousal (From NREM Sleep) This group of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NREM-related disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which includes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep- walking, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, arise as a result of incomplete 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from deep sleep.</br>The conditions share: (1) similar genetic and familial patterns; (2) similar pathophysiology of partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from deep sleep; and (3) similar priming by sleep deprivation and biopsychosocial stressors.</br>Disorders of arousal are: (1) not secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; (2) not generally secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuropathology
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; (3) associated with absent or minimal cognitive functioning; (4) associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amnesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for the prior episode; and (5) may be triggered by sound, touch, or other stimuli. </br>General Diagnostic Criteria for Disorders of Arousal Criteria</br>A-E must be met A. Recurrent episodes of incomplete awakening from sleep.1 B. Inappropriate or absent responsiveness to efforts of others to intervene or redirect the person during the episode. </br>C. Limited (e.g., a single visual scene) or no associated cognition or dream imagery. </br>D. Partial or complete 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amnesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for the episode. </br>E.</br>The disturbance is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical condition, medication, or substance use. </br>Notes .</br>The events usually occur during the first third of the major sleep episode. </br>2. The individual may continue to appear confused and disoriented for several minutes or longer following the episode. </br>228 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Confusional Arousals ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.41 Alternate Names Elpenor syndrome. </br>Diagnostic Criteria Criteria A-C must be met ICD-10-CM code: G47.51 Sleepwalking ICD-9-CM code: 307.46 Alternate Names Somnambulism. </br>Diagnostic Criteria Criteria A and B must be met ICD-10-CM code:</br>F51.3 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 A.</br>The disorder meets general criteria for NREM disorders of arousal. </br>B. The episodes are characterized by mental 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or confused behavior that occurs while the patient is in bed. </br>C. There is an absence of terror or ambulation outside of the bed. </br>Notes .</br>There is typically a lack of autonomic arousal such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mydriasis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachypnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diaphoresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during an episode. </br>A. The disorder meets general criteria for NREM disorders of arousal. </br>B. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are associated with ambulation and other complex behaviors out of bed. </br>229 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Terrors ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 307.46 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Night terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pavor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 nocturnus. </br>Diagnostic Criteria Criteria A-C must be met ICD-10-CM code:</br>F51.4 A.</br>The disorder meets general criteria for NREM disorders of arousal. </br>B. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are characterized by episodes of abrupt terror, typically beginning with an alarming vocalization such as a frightening scream. </br>C. There is intense fear and signs of autonomic arousal, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mydriasis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachypnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diaphoresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during an episode. </br>Essential Features Disorders of arousal consist of complex behaviors that are usually initiated during partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from slow wave (N3) sleep.</br>Most episodes are brief, but they may last as long as 30 to 40 minutes in some children.</br>Sleep talking and shouting may accompany these events.</br>The eyes are usually open during an episode and, not uncom- monly, are wide open with a confused “glassy” stare.</br>The patient with a disorder of arousal may be very difficult to awaken and, when awakened, is often confused.</br>There is usually 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amnesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for these episodes, although adults may remember fragments of episodes.</br>Dream-like mentation is sometimes reported in adults.</br>Other high-level cog- nitive functions such as attention, planning, social interaction, and intent are absent.</br>Because disorders of arousal usually originate from slow wave sleep, they most often emerge in the first third or first half of the typical sleep period.</br>They may occur during other times of increased slow wave sleep, such as during recovery sleep following sleep deprivation.</br>They rarely arise from a daytime nap. </br>Disorders of arousal are encountered most commonly in children and typically resolve by puberty but may persist (or, infrequently, arise de novo) in adolescence or adulthood. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Confusional Arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, unlike sleepwalking, occur with the patient in bed.</br>When the patient leaves the bed, sleepwalking has been initiated.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often start with the individual sitting up in bed and looking about in a confused manner. </br>Sleepwalking: Sleepwalking episodes typically begin as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleepwalking episodes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can also begin with the individual immediately leaving the bed and walking or even “bolting” from the bed and running.</br>Highly inappropriate, agitated, resistive, belligerent, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    violent behavior
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can also occur.</br>Behaviors can be simple and non–goal-directed, or complex and protracted, and may involve inappro- priate sexual activity with oneself or an individual in close proximity such as a bed partner.</br>The ambulation may terminate spontaneously, at times in inappropriate places, or the sleepwalker may return to bed, lie down, and continue to sleep without reach- ing conscious awareness at any point.</br>The sleepwalking individual is disoriented in time and place, with slow speech, with severely diminished mentation, and blunted response to questions or requests.</br>There is often prominent anterograde and retrograde memory impairment.</br>Despite diminished external perception as a result of blockade of sensory input, the individual may appear to be awake during some or most of a disorder of arousal with reduced vigilance and impaired cognitive response. </br>Sleep Terrors: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 differ from other disorders of arousal in that the events are often accompanied by a cry or piercing scream, accompanied by autonomic nervous system and behavioral manifestations of intense fear.</br>There is often intense autonomic discharge, with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachypnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, flushing of the skin, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diaphoresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mydriasis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and increased muscle tone.</br>The person usually sits up in bed; is unresponsive to exter- nal stimuli; and, if awakened, is confused and disoriented.</br>However, bolting out of bed and running is not uncommon in adults and also can be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    violent behav- iors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly if attempts are made to block or restrain the individual.</br>The sleep terror episode may be accompanied by incoherent vocalizations.</br>Sometimes there is prolonged 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inconsolability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with a sleep terror in children or adults. </br>Associated Features Disorders of arousal are devoid of higher cognitive functions such as planning, memory from before an incident, formation of a memory during an incident, true social inter- action, or recognition of others.</br>Patients exhibiting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders of arousal
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not con- sciously aware and behaviors are often thought to be “automatic” in nature.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Self-injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur as well as injury to others in close proximity. </br>Disorders of arousal, in particular sleepwalking, can involve normal, routine behav- iors that are inappropriate only in regard to their timing.</br>More often, however, sleep- walking involves 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inappropriate behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as urinating in a wastebasket, moving furniture around haphazardly, or climbing out a window.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleepwalkers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are sometimes able to navigate in familiar surroundings, but are prone to bumping into objects or falling down.</br>A sudden arousal consistent with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may segue rapidly into agitated sleepwalking and panicky running and other potentially dangerous behav- iors.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Self-injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not unusual and when resulting in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been given the term of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 “
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 pseudosuicide.”</br>Cuts, bruises, and other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    injuries
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur—often to the surprise of the sleepwalker once awake.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleepwalkers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are reported to have a high tol- erance for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Knife cuts, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    burns
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    self-injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sustained during sleepwalking may not awaken them. </br>Violence to others also can occur with adult sleepwalking, especially in men.</br>The sleepwalker does not generally seek out the eventual victim of violence.</br>More typi-</br>cally, a person attempting to block, grab, restrain, redirect or awaken a sleepwalker during an episode may be violently attacked, even if they are family members or friends.</br>This may result in a form of primitive defensive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aggression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 including pushing, hitting, kicking, or throwing objects.</br>This pattern also has been reported in the sleep laboratory when technical personnel have attempted to return sleepwalking patients to bed.</br>In extreme cases, victims have been stabbed with knives or blunt objects.</br>Such inappropriate and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antisocial behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have legal and forensic implications, as sleep- walkers have been arrested and charged with assault and battery, attempted homicide, homicide, and sexual assault with indecency. </br>The child with calm sleepwalking may quietly walk toward a light or to the parents
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ’
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 bedroom.</br>Occasionally, children will walk toward a window or door or even go outside, with obvious attendant risk. </br>Clinical or Pathophysiological Subtypes Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal sexual behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are primarily classified as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arous-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 als in that they typically occur without any behaviors outside of the bed (or chosen sleep- ing accommodation), but have also been less commonly associated with sleepwalking.</br>Other terms for this condition include “atypical sexual behavior during sleep,” “sexsom- nia,” and “sleep sex.”</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal sexual behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often have major inter- personal, clinical, and occasional criminal consequences.</br>The set of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal sexual behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disordered arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 includes prolonged or violent masturbation, sexual molestation and assaults (of minors and adults), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    initiation of sexual intercourse irre- spective of the menstrual status of the bed partner (in contrast to waking intercourse for those
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 individuals), and loud (sexual) vocalizations during sleep—followed by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morning amnesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The preponderance of patients have also been diagnosed with a NREM sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, most often 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 alone but on occasion with sleepwalking, sleep related driving, or sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is another recognized precipitant of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal sexual behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>The presence of an overlap disorder, in which 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and a partial arousal disorder (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepwalking or sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) are 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in a patient, may complicate diagnosis of each condition.</br>Careful review of history and use of polysomnography may facilitate identification of this presentation. </br>Demographics There is no sex difference with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders of arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>They are especially prevalent among children and adults younger than 35 years.</br>The prevalence rate of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleepwalking are similar. </br>The prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children three to 13 years of age in a large population-based study was 17.3%.</br>Lifetime prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has recently been reported as 18.5% (16.1-20.9 confidence interval).</br>The prevalence among adults older than 15 years is 2.9% to 4.2%. </br>The lifetime prevalence of sleepwalking is as high as 18.3%.</br>A recent study of “noctur- nal wandering” that likely included a large percentage of sleepwalkers reported a life- time prevalence of 29.2%.</br>A Swedish study of children aged 6-16 years found the inci- dence of sleepwalking to be 40%.</br>Up to 4.3% of adults sleepwalk.</br>In one series, one third of 54 adult patients with injurious sleepwalking (with or without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    night terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) began sleepwalking after 16 years of age. </br>The prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has not been studied as thoroughly.</br>Prevalence rates of 1% to 6.5% in children and 2.2% in adults have been reported, with a virtually constant prevalence rate of 2.3% to 2.6% in the 15-year-old to 64-year-old age group, before falling to 1% in the older than 65 years age group.</br>Other studies have reported the intermittent appearance of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 25% of children younger than five years. </br>Predisposing and Precipitating Factors Disorders of arousal are most often evaluated in terms of predisposing, priming, and precipitating (triggering) factors.</br>Most often a simultaneous co-occurrence of these factors is thought necessary in order for a disorder of arousal occur.</br>However, the reason a disorder of arousal occurs on one night and not others is not fully understood. </br>A genetic predisposition has been hypothesized and several studies have identified dif- ferent genetic loci and modes of inheritance (see Familial Pattern, below).</br>In childhood, disorder of arousal can usually be considered an expected and normal developmental sleep phenomenon, apart from those cases with clinical consequences.</br>However, dis- orders of arousal that persist beyond adolescence or begin in adulthood can often be problematic and may require clinical attention. </br>233 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Many priming factors for disorders of arousal, in particular sleepwalking, have been identified.</br>Sleep deprivation and situational stress are the most potent factors.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hyperthyroidism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    encephalitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and other conditions have also been reported much more rarely as potential priming factors. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other sleep related respiratory events are increasingly recognized precipitants of disorders of arousal in both children and adults.</br>Treatment of these comorbid con- ditions may reduce or eliminate the occurrence of disorders of arousal.</br>Disorders of arousal may also be triggered by environmental stimuli such as telephone calls, pagers, messaging from electronic devices, and a host of other stimuli.</br>It is clinically important to note that first responders, physicians, and others on call may be vulnerable to such stimuli, increasing the potential for inappropriate responses and behavior. </br>Travel, sleeping in unfamiliar surroundings, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    febrile
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 states in children, physical or emo- tional stress in adults, the premenstrual period in women, as well as the use of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psycho-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 tropic medications such as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lithium carbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phenothiazines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, anticholinergic agents, and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sedative/hypnotic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 agents have been associated with the onset of sleepwalking, but a causal relationship has yet to be established.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 has been identified in previous reports as a potential sleepwalking trigger.</br>However, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amnesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with dis- orders of arousal makes these reports unreliable.</br>More recent evidence-based reviews have found no compelling relationship between 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and disorders of arousal.</br>Internal stimuli, such as a distended bladder, or external stimuli, such as noise or light, can also precipitate episodes. </br>There is no significant association between childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders of arousal and psycho- pathology
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In adult sleepwalking, although a considerable number of patients may have a past or current history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonpsychotic depressive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, it does not appear that the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleepwalking, in particular, are tightly linked.</br>In addition, when the two conditions emerge in close temporal proximity, control of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often does not control the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, for which separate treatment is required. </br>Familial Pattern Genetic factors appear to play an important role in all of the disorders of arousal.</br>However, published research data exist primarily for patients who sleepwalk.</br>Sleepwalking has a familial pattern.</br>The rate of childhood sleepwalking increases in relation to the number of affected parents: 22% when neither parent has the disor- der, 45% if one parent is affected, and 60% when both are affected.</br>Population-based studies of monozygotic and dizygotic twins suggest that genetic factors play a role in 65% of cases of sleepwalking.</br>Different models of modes of inheritance includ- ing multifactorial, recessive with incomplete penetrance, and autosomal dominant trait with reduced penetrance have been proposed, based primarily on analysis of family histories.</br>However, these finding are not sufficiently specific to be used for diagnostic testing.</br>Further, the mechanisms by which a genetic predisposition for confusional arousal or other related disorders contributes to their occurrence are not known. </br>Onset, Course, and Complications 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 most often appear in early childhood around the age of two years.</br>This childhood form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is typically benign, but may cause concern in parents.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of early childhood diminish in occurrence after the age of five years. </br>Sleepwalking can begin as soon as a child is able to walk but may begin at almost any time in the life cycle, including as late as the seventh decade.</br>Sleepwalking is often preceded by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Childhood sleepwalking usually disappears sponta- neously around puberty but may persist into adolescence.</br>Episodes can occur sporad- ically or with high frequency, such as multiple times nightly for several consecutive nights.</br>Sleepwalking may occur for the first time in adulthood or may recur in adult- hood during periods of sleep deprivation or stress. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 usually emerge in children aged four to 12 years (but can also emerge in adulthood) and tend to resolve spontaneously by early adolescence, as does sleep- walking.</br>Social embarrassment over the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can impair social relationships in children and adults.</br>Serious or even lethal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    injuries
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur. </br>Developmental Issues As noted above, disorders of arousal most often occur initially in childhood and decrease in occurrence steadily until young adulthood.</br>However, they may occur for the first time in adulthood or reappear after many asymptomatic years, often related to stress, sleep deprivation, or development of another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Pathology and Pathophysiology The overwhelming majority of individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders of arousal
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 do not have neuro- logical or psychological pathology.</br>There are rare reported cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arous-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 als associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brain lesions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in areas subserving arousal, such as the posterior hypothalamus, midbrain reticular area, and periventricular gray matter.</br>However, data from a single patient with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 suggest that they may be due to a func- tional abnormality in the brain that leaves some regions, such as hippocampus and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 frontal associative cortices, asleep, while other parts of the brain such as motor, cingu- late, insular, amygdala, and temporopolar cortices, are active or awake. </br>It is generally considered that disorders of arousal represent a dissociation of different regions of the brain in addition to activation of locomotor centers/central pattern</br>gen- erators, accompanied by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep inertia and sleep state instability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Objective Findings Although not routinely indicated for the evaluation of typical, uncomplicated, and non- injurious 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, polysomnographic studies demonstrate that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders of arousal typically
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 begin after an arousal from slow wave sleep, most commonly toward the end of the first or second episode of slow wave sleep.</br>Occasionally, disorders of arousal can emerge from stage N2 sleep.</br>Heart rate acceleration, increased muscle tone, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle twitching
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may rarely be observed before a slow wave sleep arousal. </br>Diagnostic polysomnography may note high-amplitude hypersynchronous delta waves and frequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from slow wave sleep.</br>However, these findings have a low spec- ificity and have been reported to occur in other disorders such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and in asymp- tomatic individuals.</br>On rare occasions, polysomnography can provide support for the clinical diagnosis by documenting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from slow wave sleep accompanied by behaviors typical of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Out-of-bed behaviors are very rare in the sleep laboratory.</br>Changes between the home and sleep laboratory environment, timing, habits, and other factors may serve to decrease the likelihood of sleepwalking in the laboratory.</br>Time-synchronized video-polysomnographic (vPSG) recording is essen- tial if polysomnography (PSG) is to be used as support for the diagnosis.</br>However, a normal PSG does not rule out the diagnosis of a disorder of arousal.</br>In adults in whom there are only one or two episodes per year, there is a very low likelihood of occurrence in the sleep laboratory.</br>However, the sleep study may assist in ruling out disorders with similar presentations, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>PSG may further be useful by identifying potential triggers, such as sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peri- odic leg movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that are currently present.</br>Provocative sleep studies using sleep deprivation and acoustic stimuli have been used for research purposes, with success.</br>However, the sensitivity and specificity of these techniques for clinical purposes are unknown. </br>Postarousal EEG recordings in children and adults with sleepwalking often 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    demon-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
</br>strate a partial or virtually complete persistence of sleep, with diffuse, rhythmic delta activity; diffuse delta and theta activity; mixed delta, theta, alpha, and beta activity; or at times alpha and beta activity. </br>236 PSG also may be helpful in excluding the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by demonstration of normal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in REM sleep (assuming adequate amounts of REM sleep are observed).</br>Although the “macrostructure” of sleep (i.e., the cycling of various NREM and REM sleep stages and the relative distributions of these sleep stages) is generally preserved with sleepwalking, the “microstructure” of sleep can be perturbed.</br>Power spectral analyses of slow wave activity in adult sleepwalkers have revealed several forms of slow wave sleep dysregulation, including high amounts of slow wave sleep fragmentation (particularly during the first NREM-REM sleep cycle), a significant increase in delta power just prior to an arousal, and increased slow wave activity across all NREM sleep cycles. </br>Differential Diagnosis Disorders of arousal should be carefully distinguished from other disorders with similar presentations, but different pathophysiologies, courses, and treatments.</br>Other disorders to be considered include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dissocia- tive disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drug related behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 typically presents as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dream-enacting behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the second half of the night and usually affects middle-aged men, but also can affect women and virtually any age group.</br>Because sleepwalking in adults can also present as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dream-enacting behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that emerge during any time of the night, vPSG may be necessary to distinguish sleep- walking from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In contrast to disorders of arousal, signs of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly tonic/phasic EMG activity during REM sleep, are almost always present during sleep studies.</br>If sleepwalking (or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) occurs with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the same patient, both should be diagnosed.</br>This has been referred to as a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 overlap disorder. </br>Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, can precipitate disorders of arousal.</br>Therefore, a careful history must be obtained to identify other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can manifest with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    wandering behavior
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or with frenzied walking or running.</br>In adults, a diagnosis of malingering also should be considered.</br>If a neurologic or medical disor- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    der
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is identified as the precipitant of a disorder of arousal, then the sleepwalking should be diagnosed as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder. </br>Disorders of arousal should not be diagnosed in the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol intoxication
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The behavior of the alcohol-intoxicated individual may superficially resemble that of the sleepwalker.</br>However, the sleepwalker is typically severely cognitively impaired, but with only limited motor impairment.</br>The alcohol-intoxicated individual’s level of cognitive functioning may be reduced, but not absent, whereas motor behavior is often severely impaired.</br>In 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcoholic blackouts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, where anterograde 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amnesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is, by definition, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 the cardinal manifestation, it is important to note that outward motor behavior and cog- nitive function may not be impaired and may be perceived as normal.</br>Thus, the impor- tance of appreciating the neuroscience of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcoholic blackouts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and its potential role in the explanation of unusual and bizarre 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cannot be understated because these can mimic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The former are exponentially more prevalent and thus should be given appropriate weight when attributing likely causation in cases with criminal allegations. </br>Unresolved Issues and Further Directions With the development of sophisticated genetic testing and neuroimaging, direct research into the causes and mechanisms of disorders or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is anticipated.</br>Further investigations that aid in the characterization of the pathophysiology are necessary.</br>Further development of sleep laboratory-based techniques for provoking episodes of sleepwalking would improve diagnostic accuracy. </br>Bibliography Achermann P, Werth E, Dijk DJ, Borbély AA.</br>Time course of sleep inertia after nighttime and daytime sleep episodes.</br>Arch Ital Biol 1995;134:109–19. </br>Broughton RJ.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: disorders of arousal?</br>Science 1968;159:1070–8. </br>Fisher C, Kahn E, Edwards A, Davis D, Fine J. A psychophysiological study of nightmares and night 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>III.</br>Mental content and recall of stage 4 night 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Nerv Ment Dis 1974;158:174–88. </br>Fisher C, Kahn E, Edwards D,</br>Davis D. A psychophysiological study of nightmares and night 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: physiological aspects of the stage 4 night terror.</br>J Nerv Ment Dis 1973;157:75–98. </br>Gastaut H, Broughton R. A clinical and polygraphic study of episodic phenomena during sleep.</br>In: Wortis J, ed.</br>Recent advances in biological psychiatry, Volume 7.</br>New York: Plenum Press, 1965:197–223. </br>Guilleminault C, Moscovitch A, Yuen 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Poyares D. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Atypical sexual behavior
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>Psychosom Med 2002;64:328–36. </br>Guilleminault C, Silvestri JM.</br>Disorders of arousal and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>In: Sterman M, Shouse M, Passouant P, eds.</br>Sleep and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>New York: Academic Press, 1983:513–31. </br>Hublin C, Kaprio J, Partinen M, Heikkila 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Koskenvuo M. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: co-occurrence and genetics.</br>Psychiatr Genet 2001;11:65–70. </br>Hublin C, Kaprio J, Partinen M, Heikkila 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Koskenvuo M. Prevalence and genetics of sleepwalking: a population-based twin study.</br>Neurology 1997;48:177–81. </br>Iranzo A, Santamaria J. Severe obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea/hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 mimicking REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2005;28:203–6. </br>Kales A, Soldatos C, Bixler E, et al.</br>Hereditary factors in sleepwalking and night 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Br J Psychiatry 1980;137:111–8. </br>Klackenberg G. Somnambulism in childhood—prevalence, course and behavioral correlations: a prospective longitudinal study (3-16 years).</br>Acta Paediatr Scand 1982;71:495–9. </br>Mahowald M, Schenck C, Goldner M, Bachelder V, Cramer Bornemann M. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 pseudo-suicide.</br>J Forensic Sci 2003;48:1158–62. </br>238 Nino-Murcia G, Dement W. Psychophysiological and pharmacological aspects of somnambulism and night 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children.</br>In: Meltzer H, ed.</br>Psychopharmacology: the third generation of progress.</br>New York: Raven Press, 1987:873–9. </br>Ohayon M, Guilleminault C, Priest R. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Night terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleepwalking, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the general population: their frequency and relationship to other sleep and mental disorders.</br>J Clin Psychiatry 1999;60:268–76. </br>Ohayon M, Priest R, Zulley J, Smirne S.</br>The place of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in sleep and mental disorders: findings in a general population sample of 13,057 subjects.</br>J Nerv Ment Dis 2000;188:340–8. </br>Pilon M, Zadra A, Joncas S, Montplaisir J. Hypersynchronous delta waves and somnambulism: brain topography and effect of sleep deprivation.</br>Sleep 2006;29:77–84. </br>Pressman M, Mahowald M, Schenck C, Cramer Bornemann M. Alcohol-induced sleepwalking or confusional arousal as a defense to criminal behavior: a review of scientific evidence, methods and forensic considerations.</br>J Sleep Rev 2007;16:198–212. </br>Pressman M. Factors that predispose, prime and precipitate NREM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in adults: clinical and forensic implications.</br>Sleep Med Rev 2007;11:5–30. </br>Pressman MR.</br>Hypersynchronous delta sleep EEG activity and sudden 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from slow wave sleep in adults without a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: clinical and forensic implications.</br>Sleep 2004; 27:706–10. </br>Schenck C, Arnulf I, Mahowald M. Sleep and sex: what can go wrong?</br>A review of the literature on sleep related disorders and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal sexual behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and experiences.</br>Sleep 2007;30:683–702. </br>Schenck C, Boyd J, Mahowald M. A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 overlap disorder involving 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepwalking, sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 33 polysomnographically confirmed cases.</br>Sleep 1997;20:972–81. </br>Schenck C, Mahowald M.</br>On the reported association of psychopathology with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in adults.</br>Sleep 2000;23:448–9. </br>Simonds J, Parraga H. Prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children and adolescents.</br>J Am Acad Child Adolesc Psychiatry 1982;21:383–8. </br>Zadra A, Desautels A, Petit D, Montplaisir J. Somnambulism: clinical aspects and pathophysiological hypotheses.</br>Lancet Neurol 2013;12:285–94. </br>239 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Eating Disorder ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.40 Alternate Names Sleep eating Diagnostic Criteria Criteria</br>A-D must be met ICD-10-CM code: G47.59 A. Recurrent episodes of dysfunctional eating that occur after an arousal during the main sleep period. </br>B. The presence of at least one of the following in association with the recurrent episodes of involuntary eating: .</br>Consumption of peculiar forms or combinations of food or inedible or toxic substances. </br>2. Sleep related injurious or potentially injurious behaviors performed while in pursuit of food or while cooking food. </br>3. Adverse health consequences from recurrent nocturnal eating. </br>C. There is partial or complete loss of conscious awareness during the eating episode, with subsequent impaired recall. </br>D.</br>The disturbance is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    medical disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication, or substance use. </br>Essential Features SRED consists of recurrent episodes of involuntary eating and drinking during arous- als from sleep, associated with diminished levels of consciousness and subsequent recall, with problematic consequences. </br>The episodes of eating always occur in an involuntary or “out of control” manner after an interval of sleep.</br>Typically, they occur during partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from sleep with subsequent partial recall.</br>On the one hand, some patients cannot be easily brought to full consciousness during an episode of eating, as is the case with sleepwalking, and may have no recall of having eaten during the night.</br>On the other hand, some patients seemingly have considerable 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alertness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during an episode and have substantial recall in the morning.</br>There may be variability of awareness and subsequent recall within one night, and across the evolution of the disorder in individual patients.</br>The recurrent episodes of involuntary eating and drinking during the main sleep period are typically associated with a feeling of lack of control over eating. </br>240 Problematic features of the recurrent sleep related eating include the following: con- sumption of peculiar forms or combinations of food, or of inedible or toxic substances (e.g., frozen pizzas, raw bacon, buttered cigarettes, cat food and salt sandwiches, coffee grounds, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ammonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 cleaning solutions); sleep related injury (e.g., lacerations from care- less manipulation of kitchen utensils; internal or external 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    burns
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from consuming or spilling hot foods or beverages; or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    poisoning
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and internal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    injuries
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from ingesting toxic substances); adverse health consequences (e.g., dental 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caries
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and tooth chipping from biting frozen foods); 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight gain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (including morbid 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 resulting in bar- iatric surgery); various metabolic problems, such as destabilization or precipitation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertriglyceridemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypercholesterolemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; nonrestorative sleep from sleep disruption; 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morning anorexia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abdominal distention
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>SRED carries the risk of consuming foods to which one is 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    allergic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Also, overnight fasting prior to next-day surgery or testing can be compromised.</br>Secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may emerge from longstanding personal dejection and a sense of failure over the inability to control the nocturnal eating.</br>Secondary food restriction, prompted by despair over not being able to stop the nocturnal eating, often occurs at some point during the course of the disorder.</br>Patients may engage in potentially hazardous (and expensive) weight-loss regimens.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can also be a complication. </br>Associated Features Nightly eating, including multiple episodes nightly, is reported by a majority of affected individuals.</br>The episodes of eating occur during any time in the sleep cycle.</br>High-caloric foods are typically preferred.</br>The foods preferentially consumed during sleep related eating are not typically consumed with preference during the daytime.</br>Paradoxically, to the extent that there is recall, hunger and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thirst
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are notably absent during episodes of compulsive eating with SRED.</br>The episodes of eating are some- times experienced as food-related enactment of a dream.</br>Simple foods or entire hot or cold meals may be prepared and consumed.</br>Careless food handling often occurs.</br>Alcoholic beverages are almost never consumed.</br>The usual response to interference during an eating episode is 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    agitation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Clinical or Pathophysiological Subtypes None known. </br>Demographics The following rates of SRED, as determined by self-administered questionnaire, have been reported: 16.7% in an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inpatient eating disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 group; 8.7% in an outpatient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eating disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 group; and 4.6% in an unselected university student group.</br>This study would indicate a high prevalence of SRED, although confirmatory studies across 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 different clinical and nonclinical population groups are needed.</br>Females comprise 60% to 83% of patients in reported series.</br>Mean age of onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRED
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is reported to be 22-39 years.</br>In the reported series, the mean duration of SRED prior to clinical presen- tation ranged from four to 15 years, suggesting that SRED often is a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Predisposing and Precipitating Factors SRED can be 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but it appears to be most commonly associated with a primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, another clinical condition, or use of a sedative-hypnotic medication.</br>Sleepwalking is the most common 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with sleep related eating, although once eating becomes part of the behavioral repertoire, it quickly becomes the predominant, if not the exclusive, nocturnal “sleepwalking” behavior.</br>This would indi- cate that SRED is most often a “
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepwalking variant disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.”</br>A history of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepwalk-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 ing during childhood appears to be a predisposing factor in many cases.</br>A recent retro- spective controlled study of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRED
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients, sleepwalking patients, and controls found that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRED
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients were mainly women with onset of the disturbance in adulthood.</br>They typically experienced nightly episodes and had more frequent eating problems in childhood and higher current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anorexia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 scores than sleepwalking patients or controls.</br>They also shared commonalities with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepwalking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients, including a high (66%) frequency of past or current sleepwalking, a similar timing of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes (in the first half of the night), and numerous 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from stage N3.</br>On video-polysom- nography, eating episodes occurred mostly within one minute after awakening from stage N2 or N3.</br>The frequencies of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, PLMs, and sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 were similar across the three groups. </br>Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that can be closely associated with SRED include: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm sleep-wake disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly irregular sleep/ wake pattern.</br>Multiple 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the same patient have been reported with SRED, including sexsomnia and a variant of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleepwalking.</br>Medication-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRED
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been reported with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    zolpidem
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, in particular, but also with a broad range of sedative hypnotics, including 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzodiazepines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzodiazepine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 receptor agonists, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mirtazapine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    risperidone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    quetiapine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lithium carbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, anticholin- ergics, and various other psychotropic agents.</br>Onset of SRED also has been reported with cessation of cigarette smoking, cessation of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, acute stress (usually involving major separation reactions), after daytime dieting, and with onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autoimmune hepatitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    encephalitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and other conditions.</br>SRED can also be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime eating disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal dissocia- tive disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In a controlled study of 65 patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy-cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 32% of patients had SRED vs. 2% of controls.</br>Nocturnal 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    smoking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 was present in 33% of SRED-narcolepsy-cataplexy patients and in 16% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy-cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients without SRED.</br>(A link between SRED and nocturnal 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    smoking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 had previously been identified when nocturnal 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    smoking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 was first reported in 2008).</br>A study of 88 patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 42 patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 who were systematically questioned for the presence of SRED or other nocturnal eating demonstrated that 36% of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 versus zero patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 had SRED, and the very significant difference was not related to arousal frequency.</br>In that study, patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 who were taking hypnotic medications were at additional risk for SRED. </br>Familial Pattern A familial basis for SRED is not uncommon, including co-occurrence in fraternal twins, although detailed genetic studies have not been carried out. </br>Onset, Course, and Complications The onset of SRED can be 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insidious and sporadic, or it
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be precipitous and fulmi- nant with rapid development of nightly episodes of eating, related or unrelated to the start of hypnotic medication therapy of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The course is usually unremitting.</br>Fires can occur when the individual with SRED begins to cook foods on the stove or in the oven, and then abandons them.</br>A variety of other complications have been described previously. </br>Developmental Issues SRED can emerge in childhood, either associated or unassociated with a family history of SRED. </br>Pathology and Pathophysiology The underlying pathophysiology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRED
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is unclear.</br>Despite the broad range of pre- disposing and precipitating factors in SRED, the relatively homogeneous set of clinical features suggests the presence of a “final common pathway” that can be accessed by a variety of factors.</br>Although SRED has prominent features of both a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, its relatively homogeneous presentation supports its classification as a separate diagnostic entity.</br>More than half of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRED
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have a history of another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that preceded the onset of nocturnal eating, suggesting that the presence of another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a major risk factor for SRED.</br>However, the female predominance in SRED is more consistent with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eating disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which are female pre- dominant, than with sleepwalking or movement disorders (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS/PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) which have slight to no female bias.</br>Thus it appears that two basic drive states—sleeping and eating—are pathologically intertwined in SRED. </br>243 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Objective Findings Although not routinely indicated in the assessment of SRED, vPSG evaluations have often reported positive findings.</br>The most common finding consists of multiple confu- sional 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, with or without eating, arising from slow wave sleep.</br>However, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnor- mal arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been documented from all stages of NREM sleep and also occasion- ally from REM sleep.</br>The level of consciousness has typically spanned the range from virtual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    unconsciousness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to various levels of partial consciousness despite a concurrent EEG pattern that is often predominantly awake, suggesting dissociation between the EEG and the level of consciousness.</br>This dissociation also can be found in adult sleep- walking without associated eating.</br>In contrast, classic sleepwalking in childhood is usually associated with the persistence of high-voltage delta waves or the admixture of delta, theta, and alpha activity.</br>A predominant wake pattern is rare in childhood sleep- walking.</br>PLMs and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be observed in polysomnographic monitoring of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRED
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients.</br>In one recent study that addressed the boundaries between SRED and fully conscious abnormal nocturnal eating, 22 of 35 patients had PLMs, 5 of 35 had 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 29 of 35 had recurring chewing and swallowing movements during sleep that were associated with nearly half of the total number of EEG 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Differential Diagnosis SRED must be distinguished primarily from night 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eating syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (NES), which is characterized by excessive eating between dinner and bedtime and during full awaken- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 during the sleep period.</br>In contrast to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime eating disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bulimia nervosa
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anorexia nervosa
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), inappropriate compensatory behavior, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    self-induced
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 vom- iting, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enemas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, misuse of laxatives, diuretics, or other medications, or other purging activity, are not present in SRED, although the two conditions may be comorbid.</br>A person with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also have a coexisting SRED that is asso- ciated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but not associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    purging behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the night or upon arising in the morning.</br>Patients with longstanding SRED and excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight gain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may eventually fast during the daytime and/or engage in excessive exer- cise to prevent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from the SRED.</br>Likewise, patients who otherwise fulfill crite- ria for SRED may consciously eat during the prebedtime period in a futile attempt to suppress the compulsion to eat after subsequently falling asleep. </br>SRED appears to be considerably more female predominant that NES (which has &lt; 60% female prevalence), and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are more common with NES than with SRED.</br>Nevertheless, SRED and NES share a considerable number of overlapping features and may exist along a common spectrum of pathophysiology.</br>SRED should also be distinguished from nocturnal (sleep related) extensions of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bulimia nervosa
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    binge-eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anorexia nervosa
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, binge/purge type. </br>244 The nocturnal eating (drinking) syndrome described in the original International Classification of Sleep Disorders is primarily a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorder of infancy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that is characterized by recurrent awakenings with the inability to resume sleep without eating or drinking.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (periodic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) can present with inappropriate noctur- nal eating, but its predominance in adolescent males and its hallmark symptom complex of periodic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersexuality
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperphagia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lasting days to weeks should easily distinguish it from SRED.</br>Medical and neurologic disorders that could be asso- ciated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal recurrent eating during the main sleep period (usually with full or almost full alertness) should also be excluded.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>These include: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoglycemic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 states, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peptic ulcer disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reflux esophagitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kluver-Bucy syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Unresolved Issues and Future Directions The extent of overlap and divergence between SRED and NES needs to be further elucidated. </br>Bibliography Brion A, Flamand M, Oudiette D, Voillery D, Golmard JL, Arnulf I. Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 versus sleepwalking: a controlled study.</br>Sleep Med 2012; 3:1094–101. </br>Howell MJ, Schenck CH, Crow SJ.</br>A review of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nighttime eating disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Med Rev 2009;13:23–-34. </br>Howell MJ, Schenck CH.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Restless nocturnal eating
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a common feature of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Willis-Ekbom syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>J Clin Sleep Med 2012;8:413–9. </br>Palaia V, Poli F, Pizz F, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal compulsive behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a case-control study.</br>Sleep 2011;34:1365–71. </br>Schenck CH, Hurwitz 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Bundlie SR, Mahowald MW.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep-related eating disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: polysomnographic correlates of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heterogeneous syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 distinct from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime eating disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 1991;14:419–31. </br>Schenck CH, Hurwitz 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, O’Connor 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    KA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Mahowald MW.</br>Additional categories of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-related eating disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the current status of treatment.</br>Sleep 1993;16:457–66. </br>Vetrugno R, Manconi M, Ferini-Strambi L, Provini F, Plazzi G, Montagna P. Nocturnal eating: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-related eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    night eating syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
?</br>A videopolysomnographic study.</br>Sleep 2006;29:949–54. </br>Vinai P, Ferri R, Ferini-Strambi L, et al.</br>Defining the borders between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-related eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    night eating syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Med 2012;13:686–90. </br>Winkelman JW.</br>Clinical and polysomnographic features of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-related eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Clin Psychiatry 1998;59:14–9. </br>Winkelman JW, Herzog DB, Fava M.</br>The prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-related eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and non-psychiatric populations.</br>Psychol Med 1999;29:1461–6. </br>Winkelman JW.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep-related eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    night eating syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eating disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or both?</br>Sleep 2006;29:876–7. </br>245 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 REM-Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias REM Sleep Behavior Disorder ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.42 Alternate Names None. </br>Diagnostic Criteria Criteria A-D must be met ICD-10-CM code: G47.52 A. Repeated episodes of sleep related vocalization and/or</br>complex motor behaviors.1,2 B. These behaviors are documented by polysomnography to occur during REM sleep or, based on clinical history of dream enactment, are presumed to occur during REM sleep. </br>C. Polysomnographic recording demonstrates REM sleep without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (RWA)3 D.</br>The disturbance is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication, or substance use. </br>Notes .</br>This criterion can be fulfilled by observation of repetitive episodes during a single night of video polysomnography. </br>2. The observed vocalizations or behaviors often correlate with simultaneously occurring dream mentation, leading to the frequent report of “acting out one’s dreams.” </br>3.</br>As defined by the guidelines for scoring PSG features of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the most recent version of the American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events. </br>4. Upon awakening, the individual is typically awake, alert, coherent, and oriented. </br>5.</br>On occasion, there may be patients with a typical clinical history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dream-enacting behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, who also exhibit typical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during vPSG, but do not demonstrate sufficient RWA, based on the current evidence-based data, to satisfy the PSG criteria for diagnosing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In such patients, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be provisionally diagnosed, based on clinical judgment.</br>The same rule applies when vPSG is not readily available. </br>246 .</br>Medications may unmask latent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with preexisting RWA, according to current expert opinion.</br>Therefore, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    medication-induced RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be diagnosed as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, using clinical judgment, pending future longitudinal studies. </br>Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 emerging during REM sleep that may cause 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    injury or sleep disruption
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is also associated with EMG abnormalities during REM sleep.</br>The EMG demonstrates an excess of muscle tone during REM sleep, and/or an excess of phasic EMG 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    twitch
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 activity during REM sleep. </br>A complaint of sleep related injury is common with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which usually manifests as an attempted enactment of unpleasant, action-filled, and violent dreams in which the individual is being confronted, attacked, or chased by unfamiliar people or animals.</br>Typically, at the end of an episode, the individual awakens quickly, becomes rapidly alert, and reports a dream with a coherent story.</br>The dream action corresponds closely to the observed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Sleep and dream-related behaviors reported by history and documented during vPSG include both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    violent
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and (less commonly) nonviolent behaviors: talking (including giving speeches), smiling, laughing, singing, whistling, shouting, swearing profan- ities, crying, chewing, gesturing, reaching, grabbing, arm flailing, clapping, slap- ping, punching, kicking, sitting up, leaping from bed, crawling, running, or dancing.</br>Walking, however, is quite uncommon with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and leaving the room is especially rare, because the eyes are usually closed, precluding attention to the environment.</br>There can be rare occurrences of smoking a fictive cigarette, masturbation-like behav- ior, pelvic thrusting, and mimics of eating, drinking, urinating, and defecating.</br>The eyes usually remain closed during an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episode, with the person attending to the dream action and not to the actual environment. </br>Medical attention is usually sought after sleep related injury has occurred to either the person or the bed partner, and rarely because of sleep disruption.</br>Because 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs during REM sleep, it usually appears at least 90 minutes after sleep onset, unless there is coexisting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, in which case 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can emerge shortly after sleep onset during a sleep onset rapid eye movement period (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>There is an acute form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that emerges during intense REM sleep rebound states, such as during withdrawal from 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and sedative-hypnotic agents, or in association with certain medication use, drug intoxication, or relapsing multiple sclerosis. </br>247 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Associated Features PLMs during NREM sleep are very common with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and may disturb the sleep of the bed partner.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime tiredness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is uncommon, unless 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is also present.</br>There is typically no history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritable
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, aggressive, or violent behav- ior during the day.</br>There may be a longstanding prodromal history of sleep talking, yelling, limb twitching, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep that may or may not be dream related. </br>Clinical or Pathophysiological Subtypes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 overlap disorder is a condition in which patients have both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and either a disorder of arousal, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sexsomnia, or rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>This condition is male predominant, but less so than isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Most cases begin during childhood or adolescence.</br>Virtually all age groups can be affected.</br>It can be 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or symptomatic of a broad set of disorders, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, mul- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tiple sclerosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brain tumor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (and therapy), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhombencephalitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (right 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pontine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 tegmen- tum/medulla lesion), brain 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congenital Moebius syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    agrypnia excitata
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Machado-Joseph disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, various 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and their pharmacotherapies, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance abuse disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and withdrawal states. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Status dissociatus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be classified as a subtype of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that manifests as an extreme form of state dissociation without identifiable sleep stages, but with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep and dream-related behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that closely resemble 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Status dissociatus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 represents a major breakdown of the polysomnographic markers for REM sleep, NREM sleep, and wakefulness, with admixtures of these states being present, but with conventional sleep stages not being identifiable during polysomnographic monitoring.</br>There is abnormal behavioral release that can be associated with disturbed dreaming, strongly suggestive of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dream-enacting behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that closely resemble 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Not uncommonly, the indi- vidual thinks he is awake when observers presume he is asleep and attempting to act out a dream, or vice versa.</br>An underlying neurologic or medical condition, spanning a broad range of pathology, is virtually always present. </br>Dream enactment (“oneirism”) that is REM sleep related or related to a dissociated REM sleep-wakefulness state can be a core feature of a pathologic condition called 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    agrypnia excitata
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that is characterized by generalized 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    motor overactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, impaired ability to initiate and maintain sleep (with “wakeful dreaming”), loss of slow wave sleep, and marked motor and autonomic sympathetic activation.</br>Agrypnia 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excitata
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is found with such diverse conditions as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    delirium tremens
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Morvan syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and fatal familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Thus, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    agrypnia excitata
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 manifests as both a severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and a severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>248 Demographics 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a male predominant disorder that usually emerges after age 50 years.</br>Cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from early childhood up to age 88 years have been reported.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 emerging in adults before age 50 years tends to have different demographics and associated features, including greater sex parity and increased rates of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and para- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    somnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 overlap disorder (POD), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbid narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 medication use, and possibly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autoimmune diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In addition, the clinical presentation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in younger adults differs from that in older adults in being less aggressive and violent, presumably due to greater female representation and higher rates of comorbid narco- lepsy (which manifests with milder 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other symptomatic forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are as male predominant as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, with the exception of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (as described below) and multiple system 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Of note, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may not be the presenting com- plaint to a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 center.</br>Therefore, systematic questioning for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be included for all newly evaluated patients at a sleep center.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children is virtually never 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and is usually associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (at times emerging months before the emergence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcoleptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brainstem tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 medications, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodevelopmental disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and various rare conditions. </br>The prevalence is not known with much certainty, although a prevalence of 0.38% to 0.5% is reported in the elderly and the general population.</br>A 2.1% prevalence of current sleep related violence has been reported; 38% of these events have associated dream enactment, suggesting a prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as high as 0.8%. </br>Predisposing and Precipitating Factors The major predisposing factors are male sex, age 50 years or older, and an under- lying 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, multiple system 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lewy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 bodies, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A recent multicenter case-control study of environmental risk factors of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 found that smoking, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, pesticide exposure, and farming were significant risk factors.</br>Medications, particularly the anti- depressants 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    venlafaxine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    serotonin-specific
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 reuptake inhibitors (
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SSRIs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
), 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mirtazapine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and other 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 agents (but not 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bupropion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
) are an increasingly recognized precipitating factor.</br>Beta-blockers (
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bisoprolol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atenolol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
), anticholinesterase inhibitors, and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    selegiline
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 can also trigger 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 involving 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (that require 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 pharmacotherapy) may comprise a predisposing factor, particu- larly in adults younger than 50 years.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic stress disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>249 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Familial Pattern A recent multicenter controlled study revealed a significantly increased positive family history of dream enactment, raising the possibility of a genetic contribution to RBD. </br>Onset, Course, and Complications Onset of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be gradual or rapid, and the course is often progressive.</br>Complications include sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    injuries
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to self and/or bed partner that at times are life threatening, and disruption of the bed partner’s sleep that can be severe.</br>Marital discord due to the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is uncommon but can be severe when present, due to repeated injury and/or disruption of the bed partner’s sleep. </br>Delayed emergence of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodegenerative disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, often more than a decade after the onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, is very common in men 50 years of age and older.</br>These dis- orders include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), multiple system 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
), and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lewy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 bodies (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DLB
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Two recently reported series found 81% and 82% eventual conversion rates from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parkinsonism/dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (and also mild cog- nitive impairment in the latter study).</br>Conversely, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present in &gt;90% of reported cases of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, in approximately 50% of reported cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DLB
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and in up to 46% of reported patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Developmental Issues As stated previously, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can emerge in children, usually in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narco- lepsy-cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brainstem tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 medications. </br>Pathology and Pathophysiology Current evidence suggests a selective association between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and neurodegenera- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tive disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    synucleinopathies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 comprise a set of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodegenerative disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that share a common pathologic lesion composed of aggregates of insoluble α-synu- clein protein in selectively vulnerable populations of neurons and glial cells.</br>These pathologic aggregates appear to be closely linked to the onset and progression of clin- ical symptoms and the degeneration of affected brain regions in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodegenerative disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    major synucleinopathies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DLB
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and MSA. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be strongly linked with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (almost always 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1), rep- resenting another form of REM sleep motor-behavioral dyscontrol.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be precipitated or worsened by the pharmacologic treatment of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associ- ated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is now considered to be a distinct phenotype of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, character- ized by lack of sex predominance, less complex and more elementary movements in REM sleep, less 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    violent behavior
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in REM sleep, earlier age of onset, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocretin deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (that is characteristic of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1).</br>The presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in pediat- ric patients may be an initial manifestation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1. </br>Other reported etiologic associations of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include isch- emic or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hemorrhagic cerebrovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multiple sclerosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, progressive supranu- clear 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    palsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Guillain-Barré syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, brainstem neoplasms (including cerebellopon- tine angle 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Machado-Joseph disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    spinocerebellar ataxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 3), mitochon- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drial encephalomyopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, normal pressure 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hydrocephalus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tourette syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, group A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    xeroderma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>The pathophysiology of human 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is presumed to correspond to the findings from an animal model of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with respect to interruption of the REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 pathway and/ or disinhibition of brainstem motor pattern generators. </br>Objective Findings Polysomnography demonstrates an excessive amount of sustained or intermittent loss of REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or excessive phasic muscle twitch activity of the submental and/or limb EMGs during REM sleep.</br>Some patients have almost exclusively arm and hand behaviors during REM sleep, indicating the need for both upper and lower extremity EMG monitoring in fully evaluating for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Some patients preserve most of their REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but have excessive EMG twitching during REM sleep.</br>The most current evidence-based data for detecting RWA in the evaluation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 indicate that any (tonic/phasic) chin EMG activity combined with bilateral phasic activity of the flexor digitorum superficialis muscles in &gt;27% of REM sleep (scored in 30-second epochs) reliably distinguishes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients from controls.</br>Autonomic nervous system activa- tion (such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is uncommon during REM sleep motor activation in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, in contrast to the disorders of arousal.</br>Approximately 75% of patients have PLMs during NREM sleep; a low percentage of these movements is associated with EEG signs of arousal.</br>Increased percentages of slow wave sleep and increased delta power in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been found in controlled and uncontrolled studies, but this can be a highly vari- able finding in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, depending on the clinical population.</br>Sleep architecture and the customary cycling among REM and NREM sleep stages are usually preserved in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, although some patients show a shift toward N1 sleep. </br>Validated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 screening questionnaires that can assist in the process of diagnosing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are currently available. </br>251 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Differential Diagnosis 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is one of several disorders that can manifest as complex, injurious, and violent sleep related and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dream-related behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in adults.</br>Other disorders that can mimic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in adults and/or children include sleepwalking, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal frontal lobe epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; nocturnal complex partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
); rhyth- mic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; sleep related dissociative disorders, frightening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnopom- pic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic stress disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; a diagnosis of malingering also should be considered. </br>In general, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 involves attempted enactment of unpleasant, aggressive dreams that usually occurs two or more hours after sleep onset, with rapid awakening from an episode.</br>In contrast, sleepwalking and sleep terror episodes often emerge within two hours after sleep onset, are not usually associated with rapid alertness, and are rarely associated with dreaming in children.</br>Adults can have dreams associated with disor- ders of arousal, but they are usually more fragmentary and limited than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dreams.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 usually present with repetitive, stereotypical behaviors. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 overlap disorder can be distinguished from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    status dissociatus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in several ways: if there is an awakening after an episode of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleepwalking, or sleep terror, there is the realization of having just been asleep; 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    status dissociatus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, however, is more likely to manifest with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 over whether one is asleep, awake, or dreaming.</br>vPSG in overlap conditions shows the typical findings for both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD and disorders of arousal, whereas with status dissociatus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, there is an inability to discern sleep stages.</br>Also, patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    status dissociatus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 do not walk far during an episode, and their behavioral repertoire more closely resembles that of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 than that of the disorders of arousal. </br>Unresolved Issues and Future Directions Numerous questions related to the vPSG evaluation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 remain unresolved.</br>These include issues of defining and quantifying RWA and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 activity such as: (1) What is the minimum REM sleep percentage of total sleep time (and minimum absolute REM sleep time) needed to diagnose RWA or rule out RWA?</br>(2) What is the minimum number of REM sleep epochs and minimum duration of REM sleep epochs necessary to diagnose RWA or rule out RWA?</br>(3) What guidelines can be developed for diag- nosing or ruling out RWA in the setting of disrupted REM sleep continuity associated with conditions such as obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and with medications?</br>(4) What are the minimal amounts of true 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 documented by vPSG needed to identify 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients without sufficient RWA? </br>252 It is unclear why there is a male predominance of this disorder in middle-aged and older adults.</br>It is unknown if 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subgroups other than men age 50 years or older 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    demon-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 strate increased risk for development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parkinsonism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>One such subgroup comprises patients with antidepressant-triggered 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for whom the potential risk for future 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parkinsonism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is unclear.</br>New 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 or other psychotro- pic agents being developed for clinical use should be assessed for their immediate and long-term effects on REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, REM phasic activity, REM sleep behavioral release, and proclivity to precipitate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dream-enacting
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 behaviors. </br>Bibliography Boeve BF.</br>REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: Updated review of the core features, the REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder-neurodegenerative disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 association, evolving concepts, controversies, and future directions.</br>Ann N Y Acad Sci 2010;1184:15–54. </br>Dauvilliers Y, Jennum P, Plazzi G. REM sleep behaviour disorder and REM sleep without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Med 2013;14:775–81. </br>Frauscher B, Gschliesser V, Brandauer E, et al.</br>REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    703 sleep-disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients: the importance of eliciting a comprehensive sleep history.</br>Sleep Med 2010;11:167–71. </br>Frauscher B, Iranzo A, Gaig C, et al.</br>Normative EMG values during REM sleep for the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    REM sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2012;35:835–47. </br>Iranzo A, Santamaria J. Severe obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea/hypopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 mimicking REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2005;28:203–6. </br>Iranzo A, Santamaria J, Tolosa E.</br>The clinical and pathophysiological relevance of REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodegenerative diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Med Rev 2009;13:385–401. </br>Iranzo A, Tolosa E, Gelpi E, et al.</br>Neurodegenerative disease status and post-mortem pathology in isolated rapid-eye-movement 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behaviour disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: an observational cohort study.</br>Lancet Neurol 2013;12:443–53. </br>Ju YE.</br>Rapid eye movement 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in adults younger than 50 years of age.</br>Sleep Med 2013;14:768–74. </br>Lloyd R, Tippman-Peikert M, Slocumb N, Kotagal S. Characteristics of REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in childhood.</br>J Clin Sleep Med 2012:15:127–31. </br>Olson E, Boeve B, Silber M. Rapid eye movement 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: demographic, clinical, and laboratory findings in 93 cases.</br>Brain 2000;123:331–9. </br>Oudiette D, De Cock VC, Lavault S, Leu S, Vidailhet M, Arnulf I. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Non-violent
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 elaborate behaviors may also occur in REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Neurology 2009;72:551–7. </br>Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodegenerative disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic REM sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Neurology 2009;72:1296–300. </br>Schenck CH, Mahowald MW.</br>REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP.</br>Sleep 2002;25:120–38. </br>Schenck CH, Boeve BF, Mahowald MW.</br>Delayed emergence of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parkinsonian disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 81% of older males initially diagnosed with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic REM sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
): 16 year update on a previously reported series.</br>Sleep Med 2013;14:744–8. </br>Schenck CH, Howell MJ.</br>Spectrum of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (overlap between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Sleep and Biological Rhythms 2013;11(Supplement 1):27–34. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Recurrent Isolated Sleep Paralysis ICD-9-CM code: 327.43 ICD-10-CM code: G47.53 Alternate Names Hypnagogic and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnopompic paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, predormital and postdormital 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, kanashibari (Japan). </br>Diagnostic Criteria Criteria A-D must be met 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    A. A recurrent inability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to move the trunk and all of the limbs at sleep onset or upon awakening from sleep. </br>B. Each episode lasts seconds to a few minutes. </br>C.</br>The episodes cause clinically significant distress including bedtime 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or fear of sleep. </br>D.</br>The disturbance is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (especially 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical condition, medication, or substance use. </br>Essential Features Recurrent isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by an inability to perform voluntary movements at sleep onset (hypnagogic or predormital form) or on waking from sleep (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnopompic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or postdormital form) in the absence of a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The event consists of an inability to speak or to move the limbs, trunk, and head.</br>Respiration is usually unaffected.</br>Consciousness is preserved, and full recall is present.</br>An episode of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lasts seconds to minutes.</br>It usually resolves spontaneously but can be aborted by sensory stimulation, such as being touched or spoken to, or by the patient making intense efforts to move. </br>Associated Features At least during the initial episodes, intense 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is usually present.</br>Hallucinatory experiences accompany the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in about 25% to 75% of patients.</br>These may include auditory, visual, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tactile hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or the sense of a presence in the room.</br>Some patients experience predormital or postdormital 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at separate times from episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Clinical or Pathophysiological Subtypes A familial form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been described (see below). </br>254 Demographics Estimates of the prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 vary widely due to differences in the definition used, the age of the population sampled, and possibly cultural and ethnic factors.</br>Most prevalence studies of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (usually of students younger than 30 years) have investigated the occurrence of one or more episodes without require- ment of recurrence or distress.</br>These suggest a 15% to 40% prevalence of at least one episode of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Two notable exceptions are a 1962 study of mostly college students that reported a prevalence of 5%, and a 1999 study of all adult ages that found a prevalence of 6%.</br>No consistent sex differences have emerged from multiple studies.</br>The mean age of onset is 14 to 17 years, although onset earlier and later in life has been reported. </br>Predisposing and Precipitating Factors Sleep deprivation and irregular sleep-wake schedules have been identified as predis- posing factors to episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Mental stress has been reported as a precipitating factor in some but not other studies.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 appears to be more common with sleep in the supine position.</br>Personality factors have not been shown to play a major role, although one study found a higher score on the paranoia scale of the Minnesota Multiphasic Personality Inventory in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 com- pared to controls.</br>Other factors that have been noted on regression analysis include an association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bipolar disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the use of anxiolytic medication, and sleep related leg cramps. </br>Familial Pattern Two families with apparent familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurring over three and four gen- erations have been reported.</br>A maternal form of transmission has been postulated. </br>Onset, Course, and Complications Onset is usually in adolescence.</br>Most events appear to occur in the second and third decades, but may continue later in life.</br>There are no known complications, apart from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 over the episodes. </br>Developmental Issues Though 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present as part of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tetrad in children, there is no information currently available about childhood presentation of recurrent isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>255 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Pathology and Pathophysiology Episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 elicited by awakening patients from nocturnal sleep appear to arise from REM sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is an example of state dissociation with ele- ments of REM sleep persisting into wakefulness.</br>Early-onset REM sleep after forced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    awakenings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been shown to predispose an individual to having 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It may be that subjects with less tolerance to sleep disruption are more likely to experi- ence the phenomenon. </br>Objective Findings Analysis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 after forced awakenings during PSG studies reveals the event to be a dissociated state with the persistence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    REM-related
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 electromyographic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 into conscious wakefulness.</br>Hallucinatory experiences may be present but are not essential for the diagnosis. </br>Differential Diagnosis 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 produces similar generalized 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of skeletal muscles but occurs during wakefulness and is precipitated by emotion.</br>Atonic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur during wakefulness.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal panic attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not usually associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Familial periodic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes, especially 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypokalemic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 periodic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, may occur at rest and on awakening.</br>However, the episodes usually last hours, may be associated with car- bohydrate intake, and are usually accompanied by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypokalemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>There are also hyper- kalemic and normokalemic periodic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes. </br>Unresolved Issues and Further Directions Not applicable or known. </br>Bibliography Fukuda 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K. Sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep-onset REM period in normal individuals.</br>In: Olgilvie R, Harsh J, eds.</br>Sleep onset: normal and abnormal processes.</br>Washington: American Psychological Association, 1994:161–81. </br>Goode G. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Arch Neurol 1962;6:228–34. </br>Hishikawa Y. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In: Guilleminault C, Dement W, Passouant P, eds.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>New York: Spectrum, 1976:97–124. </br>Ohayon M, Zulley J, Guilleminault C, Smirne S. Prevalence and pathologic associations of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the general population.</br>Neurology 1999;52:1194–200. </br>Takeuchi T, Fukuda 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Sasaki Y, Inugami M, Murphy T. Factors related to the occurrence of isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 elicited during a multi-phasic sleep-wake schedule.</br>Sleep 2002;25:89–96. </br>Takeuchi T, Miyasita A, Sasaki Y, Inugami M, Fukuda K. Isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 elicited by sleep interruption.</br>Sleep 1992;15:217–25. </br>256 Nightmare Disorder ICD-9-CM code: 307.47 ICD-10-CM code: F51.5 Alternate Names Nightmares, REM nightmares, recurrent nightmares, dream 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dreams. </br>Diagnostic Criteria Criteria A-C must be met A. Repeated occurrences of extended, extremely 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphoric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and well- remembered dreams that usually involve threats to survival, security, or physical integrity. </br>B. On awakening from the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphoric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dreams, the person rapidly becomes oriented and alert. </br>C. The dream experience, or the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 produced by awakening from it, causes clinically significant distress or impairment in social, occupational, or other important areas of functioning as indicated by the report of at least one of the following: </br>1.</br>Mood disturbance (e.g., persistence of nightmare affect, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphoria
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>2. Sleep resistance (e.g., bedtime 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, fear of sleep/subsequent nightmares). </br>3. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cognitive impairments
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., intrusive nightmare imagery, impaired concentration, or memory). </br>4. Negative impact on caregiver or family functioning (e.g., nighttime disruption). </br>5.</br>Behavioral problems (e.g., bedtime avoidance, fear of the dark). </br>6. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>7. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or low energy. </br>8.</br>Impaired occupational or educational function. </br>9. Impaired interpersonal/social function Notes .</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nightmare disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children is most likely to occur in those exposed to severe psychosocial stressors.</br>Because childhood nightmares often resolve spontaneously, the diagnosis should be given only if there is persistent distress or impairment. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nightmare disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by recurrent, highly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphoric dreams
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which are disturbing mental experiences that generally occur during REM sleep and that often result in awakening.</br>Given that these experiences are most often associated with REM sleep, the episodes have a greater tendency to occur during the second half of the major sleep episode when the REM pressure is most pronounced.</br>Nightmares involve an internally generated conscious experience or dream sequence that seems vivid and real.</br>They have a tendency to become increasingly more disturbing as they unfold.</br>Emotions are characteristically negative and most frequently involve 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, fear, or terror but may also involve 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anger
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, rage, embarrassment, and disgust.</br>Nightmare content most often focuses on imminent physical danger to the individual but may also involve other distressing themes.</br>Ability to detail the nightmare’s contents upon awakening is common in nightmare disorder.</br>Multiple nightmares within a single sleep episode may occur and may bear similar themes.</br>Because nightmares typically arise during REM sleep, they may occur at any moment that REM pressure is high. </br>Nightmares are very common in children.</br>They typically occur in the last third of the night and result in a complete awakening, after which the child can often provide a detailed description of the frightening scenario.</br>However, clear distinction from con- fusional 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in young children is often not possible. </br>Associated Features Postawakening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and difficulty returning to sleep may be present.</br>Nightmares are more common in those with higher levels of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Additionally, nightmares are commonly seen in those who have been physically or sexually abused and in those suf- fering from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic stress disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Nightmares arising either immediately following a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    acute stress disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 [ASD]) or one month or more after a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic stress disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 [
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTSD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
]) have been described during NREM sleep, especially N2, as well as during REM sleep and at sleep onset.</br>Posttraumatic nightmares may take the form of a realistic reliving of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    traumatic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 event or may depict only some of its elements or emotional content. </br>Clinical or Pathophysiological Subtypes None known. </br>Demographics Occasional nightmares are very common in children, occurring in 60% to 75% of chil- dren, beginning as young as 2.5 years of age.</br>The occurrence of occasional nightmares in children does not constitute a nightmare disorder.</br>However, frequent nightmares are uncommon, occurring in 1% to 5% of preadolescent children.</br>It is estimated that 10% to 50% of children aged three to five years have at least occasional nightmares severe enough to disturb their parents.</br>Nightmares appear to be a trait-like characteristic that persists over time during childhood.</br>The best predictor of recurrent nightmares at an older age is recurrent nightmares in childhood.</br>Approximately 2% to 8% of the general population has a current problem with nightmares, and this frequency is higher in clini- cal populations.</br>Trauma-related nightmares are the most consistent problem reported by patients with PTSD.</br>Nightmares beginning within three months of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are present in up to 80% of patients with PTSD.</br>Although approximately 50% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTSD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cases resolve within three months, posttraumatic nightmares may persist throughout life. </br>Predisposing and Precipitating Factors Frequent nightmares are associated with enduring personality characteristics and psy- chopathologies; they are inversely correlated with measures of well-being.</br>Associations with psychopathology have been identified for adults and adolescents, but research on children is largely absent other than for assessments of PTSD.</br>Measures of nightmare distress are much more robustly associated with psychopathology than are measures of nightmare frequency. </br>The clinical use of pharmacologic agents affecting the neurotransmitters 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    norepinephrine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    serotonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dopamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is associated with the complaint of night- mares.</br>A majority of these agents are 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, antihypertensives, and dopa- mine-receptor agonists.</br>Agents affecting the neurotransmitters 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gamma-aminobutyric acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GABA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
), 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    acetylcholine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    histamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and the withdrawal of REM sleep sup- pressive agents also can be associated with the complaint of nightmares.</br>Of note, nightmares are a common reaction in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    varenicline
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, which is an agent that blocks α-4-β-2 nicotinic 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    acetylcholine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 receptors. </br>Familial Pattern Twin-based studies have identified persistent genetic predisposition to nightmares in childhood (reported retrospectively by adults) and adulthood as well as genetic influ- ences on the co-occurrence of nightmares and some other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as sleep talking (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    somniloquy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Onset, Course, and Complications Nightmares usually start between ages three years and six years.</br>The proportion of children reporting nightmares reaches a peak between six and ten years of age and decreases thereafter.</br>A subgroup of children continue to have nightmares into 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias adolescence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or adulthood and may become lifelong nightmare sufferers.</br>Nightmares generally diminish in frequency and intensity over the course of decades, but some patients still describe frequent episodes at the age of 60 or 70 years.</br>Nightmare dis- order can lead to sleep avoidance and deprivation, and thereby to more intense night- mares, which can produce 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>ASD and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTSD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated nightmares can develop at any age after physical or emo- tional 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTSD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are at risk for developing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, social and employment consequences, self-destructive and impulsive behavior, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; it is not known to what extent the nightmares symp- tomatic of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTSD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 contribute to these complications. </br>Developmental Issues As stated above, nightmares are very common in children but the occurrence of occa- sional nightmares does not constitute nightmare disorder.</br>Population studies have revealed that the prevalence and frequency of nightmares increases through childhood into adolescence.</br>For example, preschoolers seldom report “bad dreams.”</br>Furthermore, in regard to the prevalence of nightmares, children appear to exhibit a sex divergence over time, with girls demonstrating higher prevalence by late adolescence. </br>Pathology and Pathophysiology Not applicable or known. </br>Objective Findings PSG recordings during actual nightmares are few in number and, in some instances, have shown abrupt awakenings from REM sleep preceded by accelerated heart and respiratory rates.</br>Highly disturbing dream content frequently contrasts strikingly with relatively minor autonomic changes.</br>Distinctive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anomalies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in nightly sleep architec- ture have not been demonstrated; brainstem and auditory-evoked potentials appear normal.</br>Recordings during 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic nightmares
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are few but have been recorded from both REM and NREM sleep.</br>PSG recordings of sleep in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTSD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have provided widely variable results. </br>PSG evaluation is not routinely performed but may be indicated in some circumstances to exclude other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders of arousal and sleep-associated sei- zures.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>A PSG is particularly appropriate if patients report nightmares in conjunction with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that are repetitive or stereotyped or are injurious to self or others. </br>260 Differential Diagnosis Nightmare disorder must be distinguished from dream disturbances associated with certain other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological and sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Rare cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 presenting only as “nightmares” have been reported and should be considered in the differential diagno- sis, particularly in those patients who present with a history of central nervous system disease.</br>PSG or continuous video EEG may be necessary to identify nightmares asso- ciated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Nightmares differ from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in having detailed recollection of dreaming in contrast to fragments of dreams or no dream recall, pre- senting no or minimal overt movement or autonomic activity, occurring late in the night, being followed by rapid awakening and difficulty returning to sleep, and most often arising from REM sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs more often in late middle-aged men and is more often associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    violent explosive movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal injuries
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The dream disturbance of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 usually involves being threatened or attacked by unfamiliar people or animals and is controlled in tandem with the sleep behavioral disturbance by appropriate medication.</br>Nightmares occur at any age and are not typ- ically associated with movements, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    overt behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    injuries
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may accom- pany episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurring either at sleep onset (hypnagogic) or offset (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnopompic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), when the individual feels conscious but unable to move, speak, and, at times, breathe properly.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be further worsened if disturbing hypnago- gic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or dream sequences accompany the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Nightmares, although they may involve some degree of movement inhibition or some degree of apparent wakefulness, are usually not accompanied by feelings of either total 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or com- plete waking consciousness. </br>Patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often report nightmares; these may occur at sleep onset.</br>However, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and nightmare disorder are clearly distinguishable by other clinical symptoms.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal panic attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur either during or immediately after nocturnal awakenings from NREM sleep, usually in the first four hours of the sleep episode.</br>Although frequency of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    panic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 attacks is correlated with frequency of night- mares and many patients report that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphoric dreams
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 precede their attacks, there may be no dream recall reported on awakening with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    panic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 attack. </br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dissociative disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 comprise a sleep related variant of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dissociative disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).</br>These include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dissociative identity disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (formerly called multi- ple personality disorder) and dissociative fugue, in which individuals meeting waking criteria for these diagnoses may at times experience the recall of actual physical or emotional 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a “dream” during periods of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EEG-documented
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 nocturnal waking. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias Nightmares
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that occur intermittently during the course of ASD or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTSD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are an expected symptom of those mental disorders and do not always require independent coding as nightmare disorder.</br>However, as is often the case, when the frequency and/or severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic nightmares
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is such that they require independent clinical attention, then a diagnosis of nightmare disorder should be applied.</br>In some cases, other symp- toms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTSD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may have largely resolved while the nightmares persist.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nightmare disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be coded in these cases as well.</br>It is clinically important to establish whether nightmares are associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTSD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or ASD because the evaluation, course, complications, and treatment differ significantly for these groups. </br>Unresolved Issues and Further Directions Basic pathophysiologic studies are still needed, especially studies contrasting “idio- pathic” nightmare disorder and nightmares associated with PTSD.</br>In particular, deter- mining whether 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic nightmares
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 arise from sleep or primarily from wakeful- ness would be an important distinguishing feature particularly when determining effec- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 clinical interventions.</br>The PSG correlates of nightmare disorder and posttraumatic nightmares as well as the variables affecting dream mentation and recall require further definition and delineation. </br>The distinction between nightmares and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is difficult when assessed only by questionnaires.</br>It still remains unclear to what degree and level of complexity sleep mentation is associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The topic of NREM sleep dream distur- bances (other than disturbed mentation that may occur with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) also needs formal investigation, including whether or not the term NREM sleep nightmare should be utilized. </br>The optimal methods for assessing nightmare frequency and nightmare distress are still unclear.</br>Standardized scales assessing nightmare distress should be developed and utilized.</br>Retrospective questionnaire-based evaluations of nightmares are problematic inasmuch as they underestimate nightmare frequencies relative to home logs, whereas home logs may selectively increase recall of nightmares. </br>Bibliography Germain A, Nielsen T. Sleep pathophysiology in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic stress disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 nightmare sufferers.</br>Biol Psychiatry 2003;54:1092–8. </br>Hobson J. REM sleep and dreaming: towards a theory of protoconsciousness.</br>Nat Rev Neurosci 2009;10:803–13. </br>Hublin C, Kaprio J, Partinen M, Koskenvuo M. Nightmares: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial aggregation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in a nationwide twin cohort.</br>Am J Med Genet 1999;88:329–36. </br>262 Lavie P. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the wake of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    traumatic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events.</br>N Engl J Med 2001;345:1825–32. </br>Levin R, Fireman G. Nightmare prevalence, nightmare distress, and self-reported psychological disturbance.</br>Sleep 2002;25:205–12. </br>Muzur A, Pace-Schott EF, Hobson J.</br>The prefrontal cortex in sleep.</br>Trends Cogn Sci 2002;6:475–81. </br>Nielsen T, Zadra 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    A. Idiopathic nightmares and dream disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with sleep-wake transitions.</br>In: Kryger MH, Roth T, Dement WC, eds.</br>Principles and practice of sleep medicine, 5th ed.</br>Philadelphia: Elsevier Saunders, 2010:1106–15. </br>Pagel J, Helfter 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Drug induced nightmares—an etiology based review.</br>Hum Psychopharmacol 2003;18:59–67. </br>Zadra A, Donderi D. Nightmares and bad dreams: their prevalence and relationship to well-being.</br>J Abnorm Psychol 2000;109:273–81. </br>263 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Head Syndrome ICD-9-CM code: 327.49 Alternate Names Sensory sleep starts, sensory sleep
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 shocks. </br>Diagnostic Criteria Criteria A-C must be met ICD-10-CM code: G47.59 A. There is a complaint of a sudden loud noise or sense of explosion in the head either at the wake-sleep transition or upon waking during the night. </br>B. The individual experiences abrupt arousal following the event, often with a sense of fright. </br>C. The experience is not associated with significant complaints of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Essential Features Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by a sudden, loud imagined noise or sense of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    violent explosion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the head occurring as the patient is falling asleep or waking during the night. </br>The event is variously described as a painless loud bang, an explosion, a clash of cymbals, or a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bomb
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 exploding, but occasionally may be a less alarming sound.</br>It is usually associated with a sense of fright, and many patients believe they are having a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In a minority of cases a flash of light or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerk
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may accompany the event.</br>The abnormal sensation lasts a few seconds and may recur during further attempts at sleeping.</br>The number of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 varies—from many on a single night to infrequent—with some patients reporting clustering of attacks over several nights fol- lowed by a gap of weeks to months.</br>A high level of clinical distress can be associated with recurrent attacks, with concern about their underlying cause. </br>Associated Features A flash of light may accompany the sound, and a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerk
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may sometimes occur.</br>Although the event is typically painless, a simultaneous stab of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the head has occasionally been reported.</br>An 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia complaint
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may develop as a result of the recurring 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 regarding the events. </br>264 Clinical or Pathophysiological Subtypes None known. </br>Demographics The prevalence is unknown.</br>Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is reported to be more common in women than in men.</br>The median age of onset is 58 years, but onset at all ages has been reported, including the first and eighth decades. </br>Predisposing and Precipitating Factors Most patients do not detect precipitating factors, but some report increased numbers of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 when under personal stress or overtired. </br>Familial Pattern Occasional cases of exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurring in the same family have been reported, although it is not clear whether this represents a true familial pattern. </br>Onset, Course, and Complication The course is benign with no reported 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic sequelae
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Frequent events on a single night can result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Clinical levels of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may result from patient concern about a serious medical basis for the exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The condition may also exacerbate a comorbid 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In many patients, the symptoms appear to remit spontaneously over some years. </br>Developmental Issues Not known or applicable. </br>Pathology and Pathophysiology The events occur most frequently during a period of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drowsiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 preceding sleep.</br>Some events are reported to occur upon waking during the night, but may actually be occur- ring during reinitiating sleep.</br>The condition appears to be a sensory variant of the better-known transient motor phenomenon of sleep starts or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurring at wake-sleep transition.</br>The neurophysiologic mechanisms underlying these hypnago- gic phenomena are unknown. </br>Objective Findings VPSG in a small sample of patients found that events arose from early 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drowsiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with predominant alpha rhythm interspersed with some theta activity.</br>In one patient, events arose during transition from N1 sleep, in another patient from N1 sleep to wakeful- ness, and in a third patient from N2 sleep to wakefulness.</br>Events occurring in the N1/ 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 N2 to wake transition have been recorded during both nocturnal vPSG and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MSLTs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Slow eye movements were present in the only tracing reproduced in the report of a patient with exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 emerging during wake to N1 sleep transition.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurred immediately following the episodes.</br>No epileptiform discharges accompany the event. </br>Differential Diagnosis Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be distinguished from sudden onset-headache 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    syn-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 dromes.</br>“
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Idiopathic stabbing headache” (ice-pick headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is a benign syndrome of brief stabs of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on the side of the head.</br>Although they can occur at sleep onset, they are more common during wakefulness.</br>“
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Thunderclap headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
” is a very severe sudden onset 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 characteristic of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    subarachnoid hemorrhage
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but also resulting from other causes and occasionally occurring as a benign symptom.</br>It does not usually occur at sleep onset.</br>“
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic headache syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
” affects older people who regularly awaken 4-6 hours after sleep onset, with a diffuse 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that lasts 30-60 minutes and is often associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nausea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but no autonomic symptoms.</br>Other conditions to be con- sidered include sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cluster headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal paroxysmal hemicrania
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In contrast to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes, exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is usually painless.</br>Simple partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can present with sensory phenomena but do not usually occur predominantly at sleep onset.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal panic attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can waken a person from sleep, but are not usually associated with a sense of noise or explosion.</br>Recurrent night- mares are characterized by recall of more complex and longer-lasting visual imagery.</br>Sleep starts occur at wake-sleep transition but are predominantly a motor phenomenon with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sudden myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 rather than an emphasis on sensory symptoms. </br>Unresolved Issues and Future Directions The neurophysiologic basis of these events requires further study. </br>Bibliography Chakravarty A. Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: report of two new cases.</br>Cephalalgia 2008;28:399–400. </br>Evans RW.</br>Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 followed by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a rare 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 aura.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 2006;46:682–3. </br>Kallweit U, Khatami R, Bassetti CL.</br>Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 - more than “snapping of the brain”?</br>Sleep Med 2008;9:589. </br>Palikh 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Vaughn BV.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Topiramate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 responsive exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Clin Sleep Med 2010;6:382–3. </br>Pearce JM.</br>Clinical features of the exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Neurol Neurosurg Psychiatry 1989;52:907–10. </br>Sachs C, Svanborg E.</br>The exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: polysomnographic recordings and therapeutic suggestions.</br>Sleep 1991;14:263–6. </br>266 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ICD-9-CM code: 368.16 ICD-10-CM code: H53.16 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnopompic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-C must be met A.</br>There is a complaint of recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that are experienced just prior to sleep onset or upon awakening during the night or in the morning. </br>B. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are predominantly visual. </br>C. The disturbance is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (especially 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    medical disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication, or substance use. </br>Essential Features Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinatory
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 experiences that occur at sleep onset or on awakening from sleep.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are predominantly visual but may include auditory, tactile, or kinetic phenomena.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at sleep onset (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) may be difficult to differentiate from sleep onset dream- ing.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on waking in the morning (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnopompic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) may arise out of a period of REM sleep, and patients also may be uncertain whether they rep- resent waking or dream-related experiences.</br>Complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may represent a distinct form of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>They typically occur 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fol-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lowing a sudden awakening, without recall of a preceding dream.</br>They usually take the form of complex, vivid, relatively immobile images of people or animals, sometimes distorted in shape or size.</br>These 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may remain present for many minutes but usually disappear if ambient illumination is increased.</br>Patients are clearly awake but often initially perceive the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as real and frightening. </br>Associated Features Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be associated with episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, either at the same time or on different nights.</br>Patients with complex nocturnal visual hal- lucinations may jump out of the bed in terror, sometimes injuring themselves.</br>Some patients may experience other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as sleep talking or sleepwalking, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sep-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 arate from the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; some patients may also experience similar complex hal- lucinations during the day, unassociated with sleep. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Clinical and Pathophysiological Subtypes Dream-like hypnagogic and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnopompic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 appear to differ in clini- cal features and pathogenesis from complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 arising in wakefulness after sudden 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the night.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are common in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and also occur as occasional phenomena in a high per- centage of the general population.</br>In contrast, complex nocturnal visual hallucina- tions appear to be rare and occur in the setting of a range of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic and visual disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see Differential Diagnosis) as well as in an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 form.</br>However, further work is needed to establish whether or not these forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 represent different entities. </br>Demographics In large European population studies, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been reported to occur with a prevalence of 25% to 37% for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, whereas the equivalent reported prevalence for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnopompic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is 7% to 13%.</br>Both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnagogic and hypnopompic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are more common in younger persons and occur slightly more frequently in women than in men. </br>Predisposing and Precipitating Factors Multivariate analyses in large population studies have suggested that sleep related hal- lucinations are associated with younger age, current drug use, past 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 use, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep onset 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and perceived insufficient sleep. </br>Familial Pattern Not applicable or known. </br>Onset, Course, and Complications Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 appear to be more common in adolescence and early 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adult-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 hood.</br>In many patients, the frequency appears to decrease with age.</br>The natural history of complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 depends on the underlying cause. </br>Developmental Issues Not known or applicable. </br>Pathology and Pathophysiology It is presumed that most sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are due to dream 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ideation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of REM sleep intruding into wakefulness, but this has not been firmly established.</br>Infrequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of this type may be within the limits of normal sleep-wake transition.</br>Complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may in some cases be release phenomena in which 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    loss of visual input or decreased reticular activating system activity results in the visual cortex generating aberrant images
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Objective Findings 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnagogic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 appear to arise predominantly from sleep onset REM periods.</br>However, the very few reports of polysomnography in complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 suggest an onset from NREM sleep.</br>MRI scans of the brain, PSG, EEG, and neuropsychological testing may help in the differential diagnosis and in identifying underlying disorders. </br>Differential Diagnosis Nightmares are frightening dreams awakening the patient from sleep.</br>They are clearly recognized as dreams and do not persist into wakefulness.</br>Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 consists of a sudden sensation of an explosion in the head, usually at sleep onset and sometimes accompanied by a noise or flash of light.</br>It does not involve complex visual imagery and lasts only seconds.</br>In 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the patient acts out dreams during REM sleep.</br>If not awakened by an observer, the person usually has little recollection of dream content.</br>Sleepwalking may occasionally be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dream ideation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but the patient recognizes that the dream occurred during sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but are usually brief, stereotyped, and fragmentary in such cases.</br>Occasionally, complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but are usually followed by a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be seen in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DLB
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    visual loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (Charles 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Bonnet hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), and midbrain and diencephalic pathology (peduncular 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), as well as with the use of β-adrenergic receptor- blocking medications.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Anxiety disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been noted in some patients. </br>Unresolved Issues and Further Directions </br>In contrast to the extensive study of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, little work has been reported on sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It is uncertain whether they represent normal variants or pathologic entities.</br>It is unclear whether they are always associated with REM sleep intruding into wakefulness.</br>It is uncertain how frequently complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are an independent entity, as opposed to representing a final common pathway of a range of other disorders.</br>Further work is needed to determine from which stages of sleep they arise. </br>269 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Bibliography Barnes J, David AS.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson’s disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a review and phenomenological survey.</br>J Neurol Neurosurg Psychiatry 2001;70:727–33. </br>Kavey N, Whyte J. Somnambulism associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Psychosomatics 1993;34:86–90. </br>Mahowald M, Woods S, Schenck C. Sleeping dreams, waking 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and the central nervous system.</br>Dreaming 1998;8:89–102. </br>Manford M, Andermann F. Complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Clinical and neurobiological insights.</br>Brain 1998;121:1819–40. </br>Ohayon M. Prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and their pathological associations in the general population.</br>Psychiatry 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Res
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 2000;97:153–64. </br>Ohayon M, Priest R, Caulet M, Guilleminault C. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnagogic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnopompic hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: pathological phenomena?</br>Br J Psychiatry 1996;169:459–67. </br>Silber 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MH
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Hansen M, Girish M. Complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Med 2005;6:363–6. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Enuresis ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 788.36 ICD-10-CM code: 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    N39.44
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Enuresis nocturna
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal bedwetting
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; primary, familial, functional, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monosymptomatic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or essential 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; night wetting; sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Primary Sleep Enuresis – Criteria A-D must be met A.</br>The patient is older than five years. </br>B. The patient exhibits recurrent involuntary voiding during sleep, occurring at least twice a week. </br>C. The condition has been present for at least three months. </br>D.</br>The patient has never been consistently dry during sleep. </br>Secondary Sleep Enuresis – Criteria A-D must be met A.</br>The patient is older than five years. </br>B. The patient exhibits recurrent involuntary voiding during sleep, occurring at least twice a week. </br>C. The condition has been present for at least three months. </br>D.</br>The patient has previously been consistently dry during sleep for at least six months.</br> Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is characterized by recurrent involuntary voiding that occurs during sleep.</br>In primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, recurrent involuntary voiding occurs at least twice a week during sleep after five years of age in a patient who has never been consistently dry during sleep for six consecutive months.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is considered secondary in a child or adult who had previously been dry for six consecutive months and then began wetting at least twice a week.</br>Both primary and secondary enuresis must be present for a period of at least three months.</br>Though primary and secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 share the common symptom of voiding during sleep, they are understood as distinct phenomena with different etiologies. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with difficulty arousing from sleep in response to an urge to urinate and may occur during any sleep stage.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that fragment sleep such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and treatment of these disorders may cure or reduce their incidence. </br>Associated Features Involuntary voiding during wakefulness may be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and, if present, generally points toward a physiological etiology.</br>Psychosocial problems are consid- ered a relatively rare cause in primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, though it does occur more commonly in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attention deficit hyperactivity disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and in children living in disorga- nized families.</br>Secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is seen more commonly in children who have recently experienced a significant psychosocial stress, such as parental divorce, physical or sexual abuse, or neglect.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chronic constipation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    encopresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (fecal soiling) often occur in children with secondary SE. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and urinary tract infection.</br>It may occur in individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Among older adults, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be associated with symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>SRBD is reported in 8% to 47% of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, compared to an overall prev- alence of 1% to 2%.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been reported in patients with refractory 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A large epidemiology study of children aged 6-10 years found that a current complaint of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was significantly associated with increased ORs (2.7-3.4) for subjectively high arousal threshold, night 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 when awakened from sleep.</br>Other studies have found mouth breathing, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nasal congestion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and restless sleep to be highly related to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children. </br>271 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Clinical and Pathophysiological Subtypes The most important distinction is between primary and secondary SE. </br>Demographics 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs in 15% to 20% of 5-year-olds.</br>It is three times more common in boys than in girls.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is reported by 2.1% of community-dwelling older adults and is more common among women than men. </br>Predisposing and Precipitating Factors The etiology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is complex.</br>The factors that precipitate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on a particular night and at a particular time remain unknown.</br>One popular model hypothesizes that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 consists of three interrelated factors: large nocturnal urine volume production, noc- turnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bladder overactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and difficulty arousing from sleep.</br>Several studies suggest difficulty arousing from sleep is most important in primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, whereas 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bladder instability/overactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is more important in secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are often described by their families as “deep sleepers” and very difficult to arouse.</br>A high arousal threshold has been objectively confirmed in these children. </br>It has been reported that fragmentation of sleep by disorders such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is highly correlated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep fragmenting disorders such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been previously reported to be proximal triggers for the occurrence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders of arousal—sleepwalking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and night 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Successful treatment of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in these disorders has been reported to result in reduction or elimination of disorders of arousal.</br>Similarly, surgical treatment of sleep apneas by adenotonsillec- tomy has been reported to cure 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 60% or more of patients, although this is not a consistent result.</br>Several studies have noted the presence of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in &gt; 40% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients studied.</br>However, not all sleep studies have noted SRBD in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Those without SRBD were still found to have high arousal threshold from sleep. </br>Primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a disorder that occurs when an individual fails to arouse from sleep in response to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bladder sensations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or fails to inhibit a bladder contraction.</br>These are devel- opmentally acquired skills, and, as such, there is a range in the ages of their acquisition.</br>A small proportion of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lack the normal increase in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vasopressin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 release during sleep, leading to a high urinary volume that exceeds the bladder capac- ity.</br>If these children do not arouse to the sensation of a full bladder, primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is the result.</br>Secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be caused by, or be associated with, any one of the following identifiable problems: (1) an inability to concentrate urine due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes insipidus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nephrogenic diabetes insipidus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or pharmacologic</br>[e.g., secondary to the use of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lithium carbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
]), or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sickle cell disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; (2) increased urine production secondary to the ingestion of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, diuretics, or other agents; (3) urinary tract pathology, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    urinary tract infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritable bladder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, malformations of the genitourinary tract (e.g., ectopic ureter); (4) chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    constipation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    encopresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; (5) neurologic pathology, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or neurogenic bladder; or (6) psychosocial stressors, such as parental divorce, neglect, physical or sexual abuse, and institution- alization.</br>The mechanisms by which secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with these problems are often not understood. </br>Familial Patterns Hereditary factors are suspected in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>There is often a high prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 among the parents, siblings, and other relatives of the child with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The reported prevalence is 77% when both parents were enuretic as children and 44% when one parent has a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Recent linkage studies support the hypothesis of genetic and phenotypic heterogeneity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A putative linkage of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to a region on chromosomes 22q, 13q, and 12q across different families has been reported. </br>Onset, Course, and Complications Voiding is a spinal reflex during wakefulness and sleep during infancy, until about 18 months of age.</br>Between 18 months and three years of age, the child is able to delay voiding with a full bladder, first during wakefulness and at a later age during sleep.</br>The primary determinant of the age at which this skill is acquired is developmental matura- tion.</br>Somewhat arbitrarily, primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is defined as a problem if it persists beyond five years of age.</br>The spontaneous cure rate is 15% per year.</br>The primary complication of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is to the child’s self-esteem.</br>How well the child’s family deals with the symptom is an important determinant of whether complications develop.</br>Secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur at any age.</br>Complications of secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are determined by the problem leading to the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Developmental Issues The developmental pattern of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is similar to NREM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, although its first occurrence in adulthood is uncommon. </br>Pathology and Pathophysiology 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heterogeneous disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with various underlying pathophysiological mecha- nisms, resulting in a mismatch between nocturnal bladder capacity and the amount of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 urine produced during sleep, in association with a simultaneous failure of arousal from sleep in response to the sensation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bladder fullness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be seen in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep fragmentation disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 including SRBD, which in children is most often secondary to adenotonsillar hypertrophy. </br>Objective Findings In primary and secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, enuretic episodes can occur in all sleep stages, during nocturnal wakefulness, and in association with transient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep stages have not been found to be different on nights when 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs versus nights on which it does not occur.</br>The results of polysomnographic studies of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 com- pared to normal controls have been inconsistent.</br>A computerized power analysis of sleep data suggested an increase in delta power, whereas the majority of other studies have reported no differences.</br>However, a recent study found those age 6-14 years had elevated light stage N1 sleep and reduced N3 sleep and REM sleep compared to normal controls.</br>The population with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 had a significantly elevated arousal index. </br>SRBD has been reported in 8% to 47% of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are highly correlated with an increasing prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as the respiratory distur- bance index (RDI) increases.</br>In addition to SRBD, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (range of 3.9 to 38.6 per hour of sleep) have been reported in a group of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    treatment-resistant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 SE. </br>Recent studies have demonstrated that patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are subjectively sleepier than normal controls.</br>This has been hypothesized to result from fragmented nocturnal sleep and is consistent with a large body of sleep research in other areas. </br>Differential Diagnosis 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be caused by a variety of medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes insipidus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sickle cell disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, bowel or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bladder dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, anatomical abnormalities or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the urinary tract, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological/
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 developmental disorders or other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, especially 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Organic pathology of the urinary tract is more prevalent in children who, in addition to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, also exhibit 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, abnormalities in the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    initiation of micturition
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or abnormal urinary flow. </br>Evaluation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should include complete 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 history, sleep history, physical examination and laboratory studies (as indicated) to exclude these etiol- ogies.</br>When signs and symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are present—mouth breathing, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adenotonsillar hypertrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
—a sleep study should be conducted. </br>274 Unresolved Issues and Further Directions Recent advances suggest that the terms primary and secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be overly simplistic.</br>Further work is necessary to understand the genetic and clinical aspects of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are common in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Though it may be possible that the apneas, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and snoring-related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children with SRBD could be the trigger of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, many children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 do not have a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In such cases, the underlying 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bladder overactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be the stimulus for arousal. </br>Studies of the relationship of sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and sleep fragmentation to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 performed to date have been inconsistent.</br>This is likely due to differing definitions of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and varying research methodologies.</br>Further sophisticated sleep laboratory studies are necessary to elucidate the relationship.</br>In particular, the proximal trigger for episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has not been determined.</br>Some studies suggest 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is sponta- neous, whereas others suggest a relationship to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that result in arousals— similar to findings in disorders of arousal. </br>Bibliography Burgio 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Locher J, Ives D, Hardin J, Newman A, Kuller L. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in community-dwelling older adults.</br>J Am Geriatr Soc 1996;44:139–43. </br>Brooks LJ, Topol HI.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Pediatr 2003;142:515–8. </br>Chandra M, Saharia R, Hill V, Shi QH.</br>Prevalence of diurnal voiding symptoms and difficult arousal from sleep in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Urol 2004;172:311–6. </br>Cohen-Zrubavel V, Kushnir B, Kushnir J, Sadeh A. Sleep and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2011;34:191–4. </br>Dhondt 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Raes A, Hoebeke P, Van Laecke E, Van Herzeele C, Vande Walle J. Abnormal sleep architecture and refractory 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Urol 2009;182:1961–5. </br>Jeyakumar A, Rahman SI, Armbrecht ES, Mitchell R. The association between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-disordered breathing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children.</br>Laryngoscope 2012 Aug;122:1873–7. </br>Neveus T. The role of sleep and arousal in nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Acta Paediatr 2003;92:1118–23. </br>Kalorin 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Mouzakes J, Gavin JP, et al.</br>Tonsillectomy does not improve bedwetting: results of a prospective controlled trial.</br>J Urol 2010;184:2527. </br>Neveus T, Stenberg A, Lackgren G, Tuvemo T, Hetta J. Sleep of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: A polysomnographic study.</br>Pediatrics 1999;103:1193–7. </br>Norgaard JP, Hansen JH, Nielsen JB, Petersen BS, Knudsen 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    N, Djurhuus JC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Simultaneous registration of sleep-stages and bladder activity in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Urology 1985;26:316–9. </br>Sakellaropoulou AV, Hatzistilianou MN, Emporiadou MN, et al.</br>Association between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary nocturnal enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    habitual snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnoea-hypopnoea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Arch Med Sci 2012;8:521–7. </br>Stone J, Malone PS, Atwill D, et al.</br>Symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-disordered
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 breathing in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Pediatr Urol 2008;4:197. </br>275 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Weissbach A, Leiberman A, Tarasiuk A, Goldbart A, Tal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    A. Adenotonsillectomy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 improves 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Int J Pediatr Otorhinolaryngol 2006;70:1351–6. </br>Wolfish N. Sleep arousal function in enuretic males.</br>Scand J Urol Nephrol Suppl 1999;202:24–6. </br>Wolfish NM, Pivik RT, Busby KA.</br>Elevated sleep arousal thresholds in enuretic boys: clinical implications.</br>Acta Paediatr 1997;86:381–4. </br>Yeung CK, Chiu HN, Sit 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    FK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bladder dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in enuretic children with treatment failure: fact or fiction?</br>Scand J Urol Nephrol Suppl 1999;202:20–3. </br>Yeung CK, Diao M, Sreedhar B. Cortical arousal in children with severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>N Engl J Med 2008;359;22–4. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder ICD-9-CM code: 327.44 ICD-10-CM code: G47.54 The essential feature of this diagnosis is the presence of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that is attrib- utable to an underlying neurological or medical condition.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 most commonly associated with an underlying neurological condition (“symptomatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
”).</br>However, when diagnostic criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are met, the more specific diagno- sis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    REM sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be made. </br>Complex nocturnal sleep related (hypnagogic and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnopompic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) visual hallucina- tions can occur with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DLB
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    visual loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (Charles 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Bonnet hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), and midbrain and diencephalic pathology (pedun- cular 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Dreaming and sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may or may not be associated with these 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance ICD-9-CM code: 292.85 (drug-induced); 291.82 (alcohol-induced) ICD-10-CM code: F11-F19 (see table in Appendix B for detailed coding instructions) </br>The essential feature of this diagnosis is the close temporal relationship between expo- sure to a drug, medication, or biological substance and the onset of the signs and symp- toms of that disorder.</br>A likely causal relationship can be inferred if signs and symp- toms of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 disappear when the drug or substance is withdrawn. </br>The emergent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be a de novo 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the aggravation of a chronic intermittent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or the reactivation of a previous 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>As discussed previously, a variety of medications and biological substances, including selective 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    serotonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 reuptake inhibitors, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    venlafaxine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, tricyclic 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mono- amine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 oxidase inhibitors, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mirtazapine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bisoprolol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    selegiline
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, or cholinergic treatment for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, have been reported to be associated with acute or chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Acute 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can also be seen during states of withdrawal from 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cocaine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amphetamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    barbiturate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    meprobamate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 abuse.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chocolate abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been implicated in causing or unmasking 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, when diagnostic criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are met, the more specific diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    REM sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be made. </br>The use of medications such as β-adrenergic receptor-blocking agents can be associ- ated with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>When the clinical presentation suggests a direct relationship between a drug or substance and sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance should be employed. </br>Sedative-hypnotics such as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    zolpidem
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    zopiclone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 have been associated with apparent NREM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 including SRED and sleep driving.</br>It has been suggested that sleep driving is an overlap behavior in which the sedative-hypnotic increases the arousal threshold during sleep at the beginning of the behavior, while later behavior is due to the CNS depressing effects of the drug while awake.</br>It has not been determined if drug-re- lated NREM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are associated with the same genetic predisposition, priming factors, and triggers observed in disorders of arousal.</br>When clinical presentation sug- gests a direct relationship between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders of arousal and use of a drug or substance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance should be employed. </br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 has often appeared on lists of potential sleepwalking triggers without a basis in reliable empirical scientific research.</br>Recent evidence-based reviews have found no relationship between 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and sleepwalking.</br>The behavior of the alcohol-in- toxicated individual may superficially resemble that of the sleepwalker.</br>However, the sleepwalker is typically severely cognitively impaired, but with only limited motor impairment.</br>The alcohol-intoxicated individual’s level of cognitive functioning may be reduced, but not absent, whereas motor behavior is severely impaired. </br>Proponents of the theory of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 related sleepwalking suggest that the effects of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 are similar to that of sleep deprivation—that is, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 increases deep sleep.</br>However, this claim in not substantiated by sleep laboratory-based studies in normal controls, and no empirical sleep studies of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepwalking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have ever been conducted. </br>There is no scientific evidence that complex behaviors occurring during the sleep period following 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 ingestion are anything other than the nocturnal wandering of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 an alcohol-intoxicated individual.</br>Unconsciousness, intoxication, and sleep are very different states of consciousness.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be easily distinguished from 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 intoxication by the presence of significant 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 ingestion prior to bedtime. </br>The association of therapeutic doses of sedative hypnotic drugs and apparent para- somnias should be carefully distinguished from the expected effects of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drug abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or misuse that result in CNS 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Investigations of drivers who had 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    accidents
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 attributed to drug-related sleep driving are reported to show that (1) blood levels of prescribed sedative hypnotics exceeded therapeutic ranges; (2) the individuals failed to take the medication at the correct time or remain in bed for sufficient time follow- ing ingestion; and/or (3) the individuals combined sedative-hypnotics with other CNS depressants and/or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Driving with a high blood level of a sedative-hypnotic can result in significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cognitive and motor impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Serious 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    accidents
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can result.</br>Sleep driving and other complex behaviors in this population are more likely to have resulted from drug misuse and abuse rather than true 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Unspecified ICD-9-CM code: 327.40 ICD-10-CM code: G47.50 This diagnosis is intended for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that cannot be classified elsewhere or for cases in which the physician has a clinical suspicion of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but is unable to establish a specific diagnosis.</br>In many cases, “
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, unspecified” will be a tem- porary diagnosis.</br>However, in other patients, an underlying condition may not ever be established, and in those patients, “
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, unspecified” should remain an ongoing diagnosis. </br>278 Isolated Symptoms and Normal Variants </br>Sleep Talking Alternate Names Somniloquy. </br>The essential feature is talking, with varying degrees of comprehensibility, during sleep.</br>Sleep talking may occur during REM or NREM sleep.</br>Sleep talking can be 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or disorders of arousal such as confusional arousal.</br>Sleep talking may follow 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from sleep or more rarely cause them.</br>Sleep talking is highly prevalent.</br>A recent cross-sectional epidemiologic study found the life- time prevalence of sleep talking to be 66% and current prevalence—in the past three months—to be 17%.</br>There is no apparent sex difference.</br>Onset and course are unknown. </br>Complications usually arise when sleep talking is very frequent or loud or if the content is objectionable to others.</br>Sleep talking is usually reported by the bed partner or someone sleeping in the same room or sleeping area as the affected individual.</br>Sleep talking can disrupt the sleep of a bed partner, roommate, or others in a group-sleeping situation (such as college dormitories, military barracks, fire stations, or a tent while camping).</br>The content of sleep talking has not been shown to reflect actual prior waking behavior or memories.</br>The sleep talker is rarely aware of his or her sleep talking. </br>Nocturnal vocalization, including frank sleep talking, is often seen in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and subclinical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A recent report notes that sleep talking may be a useful diagnostic marker for differentiating 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DLB
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other types of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The vocalizations of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be loud, emotional, profane, and associated with behav- iors that correlate with remembered dream mentation.</br>Nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be asso- ciated with vocalization that tends to be stereotypic.</br>The vocalizations associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are emotionally laden and associated with behaviors of intense arousal and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    agitation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In PTSD, increased vocalizations during sleep have been described. </br>Bibliography Arkin AM, Toth MF, Baker J, Hastey JM.</br>The frequency of sleep talking in the laboratory among chronic sleep talkers and good dream recallers.</br>J Nerv Ment Dis 1970;151:369–74. </br>Bjorvatn B, Grønli J, Pallesen S. Prevalence of different 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the general population.</br>Sleep Med 2010;11:1031–4. </br>279 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Honda 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hashimoto
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 M, Yatabe Y, et al.</br>The usefulness of monitoring sleep talking for the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lewy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 bodies.</br>Int Psychogeriatr 2013;25:851–8. </br>Hublin C, Kaprio J, Partinen M, Koskenvuo M. Sleeptalking in twins: epidemiology and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 comorbidity.</br>Behav Genet 1998;28:289–98. </br>Reimao RN, Lefevre AB.</br>Prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-talking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in childhood.</br>Brain Dev 1980;2:353–7. </br>280 Sleep Related Movement 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Disorders Restless Legs Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
............................................................................282 Periodic Limb 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 .............................................................292 Sleep Related Leg Cramps ........................................................................299 Sleep Related Bruxism...............................................................................303 Sleep Related Rhythmic Movement Disorder.............................................312 Benign 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Myoclonus of Infancy ...........................................................317 Propriospinal Myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at Sleep Onset....................................................321 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder..................325 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance .....326 Sleep Related Movement Disorder, Unspecified........................................327 Isolated Symptoms and Normal Variants Excessive Fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ...........................................................328 Hypnagogic Foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and Alternating Leg Muscle Activation ...............330 Sleep Starts (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Jerks)........................................................................335 Sleep related movement disorders are primarily characterized by relatively simple, usually stereotyped, movements that disturb sleep or its onset.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is an exception in that patients typically engage in walking or nonstereotypic limb movement to reduce leg discomfort.</br>However, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is closely associated with periodic limb movements (PLMs), which are usually simple and stereotyped within a series.</br>Nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or complaints of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are a prerequisite for a diagnosis of a sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>For example, many normal sleepers exhibit episodes of periodic limb movements of sleep (PLMS) but have no complaint of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, nor do they show a significant objective dis- turbance of their sleep as a result of the movements.</br>Such persons should not be classi- fied as having periodic limb 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), but instead, the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should simply be noted.</br>Similar considerations relate to the distinction between rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the presence of rhythmic movements. </br>Body movements that disturb sleep also are seen in many other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 categories (e.g., in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as sleepwalking, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and rapid eye movement (REM) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
)).</br>However, these 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 differ from the simple ste- reotyped movements categorized as sleep related movement disorders in that they involve complex behaviors during the sleep period.</br>Parasomnia-related movements may appear Sleep Related Movement Disorders purposeful and goal directed, but are outside the conscious awareness of the individual.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are listed in a separate section from the sleep related movement disorders. </br>Although the history may be diagnostic, polysomnography is sometimes necessary to make a firm diagnosis of sleep related movement disorders and distinguish them from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In these cases, it is necessary to add all-night video recording to the poly- somnographic recording and to correlate the documented movements with the techni- cian’s description of the patient’s behavior and level of consciousness in order to estab- lish a diagnosis.</br>There are some 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that may occur during both sleep and wakefulness.</br>If the presentation during sleep is significantly different from that during wakefulness, or if the movement is entirely confined to sleep, then the move- ment disorder is classified here (e.g., the occurrence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 exclusively in sleep). </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Restless Legs Syndrome ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 333.94 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Willis-Ekbom disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-C must be met ICD-10-CM code: G25.81 A. An urge to move the legs, usually accompanied by or thought to be caused by uncomfortable and unpleasant sensations in the legs.1,2</br>These symptoms must: . Begin or worsen during periods of rest or inactivity such as lying down or sitting; . Be partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues;3 and .</br>Occur exclusively or predominantly in the evening or night rather than during the day.4 B. The above features are not solely accounted for as symptoms of another medical or a behavioral condition (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, positional discomfort, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myalgia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    venous stasis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arthritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, habitual foot tapping). </br>C. The symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cause concern, distress, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or impairment in mental, physical, social, occupational, educational, behavioral, or other important areas of functioning.5 Notes .</br>Sometimes the urge to move the legs is present without the uncomfortable sensations, and sometimes the arms or other parts of the body are involved in addition to the legs. </br>2. For children, the description of these symptoms should be in the child’s own words. </br>3.</br>When symptoms are very severe, relief by activity may not be noticeable but must have been previously present. </br>4.</br>As a result of severity, treatment intervention, or treatment-induced augmentation, the worsening in the evening or night may not be noticeable but must have been previously present. </br>5.</br>For certain research applications, such as genetic or epidemiological studies, it may be appropriate to omit criterion C.</br>If so, this should be clearly stated in the research report. </br>Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a sensorimotor disorder characterized by a complaint of a strong, nearly irresist- ible urge to move the limbs.</br>This urge to move is often but not always accompanied by other uncomfortable sensations felt deep inside the limbs or by a feeling that is simply difficult or impossible to describe.</br>Although the legs are most prominently affected, “restless legs” is a misnomer, in that 21% to 57% of individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 describe some arm sensations.</br>The most common adult 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 descriptors in English are “rest- less,” “uncomfortable,” “twitchy,” “need to stretch,” “urge to move,” and “legs want to move on their own.”</br>About half express their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS sensations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as painful.</br>“Numb” and “cold” are very uncommon descriptors for RLS. Criteria A1-3 specify the necessary characteristics of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS sensations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: worse at rest, better with movement, and predominant occurrence in the evening or night.</br>The separation of worsening at rest (criterion A1) from worsening in the evening/ night (criterion A3) is based on circadian rhythm studies that show an increase at night, independent of activity level.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 must be differentiated from other condi- tions that can mimic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (criterion B).</br>Clinically significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is defined by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms causing substantial distress, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or impairment of function (criterion C). </br>Associated Features Disturbed sleep is a common, prominent, and distressing aspect of RLS.</br>Sleep onset and maintenance complaints in individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are notably higher than in con- trols, with odds ratios (OR) between 1.7 and 3.5.</br>In clinical populations, disturbed Sleep Related Movement Disorders Sleep Related Movement Disorders sleep is reported in 60% to 90% of individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, is typically the most trou- bling symptom, and is often the primary reason for seeking medical care.</br>The Medical Outcomes Study Sleep Questionnaire scores for sleep quantity, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep adequacy, and sleep problems are significantly worse for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients than con- trols.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Daytime fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are also common complaints; however, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not as severe as expected for the degree of sleep disruption, implying hyperarousal in RLS.</br>In contrast to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Epworth Sleepiness Scale scores in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are typically in the normal range, and either no different or marginally elevated when compared to normal controls.</br>Clinical sleep disturbance correlates with both severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and health impact of RLS.</br>Some individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may choose to work at night, thereby shifting quiet activities and their sleep schedule away from the circadian peak of their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms. PLMs, a family history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and response to dopaminergic therapy are supportive of the diagnosis.</br>Periodic limb movements can occur in sleep (PLMS) or wakeful- ness (PLMW).</br>PLMW occur during quiet rest and frequently at the transition between waking and sleep, disrupting sleep onset or the return to sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are frequently associated with arousal from sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sensory and motor features respond initially to treatment with dopaminergic therapy in almost all cases. </br>Multiple clinic-based and population-based studies have shown an increased preva- lence of mood and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Most controlled studies using validated assessments have shown significantly increased ORs for moderately or highly elevated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive symptoms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (OR 1.95 and 3.67), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    major depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (OR 2.6), major 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (OR 2.57 and 4.7), generalized 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (OR 3.5), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    panic disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (OR 4.7, 12.9, and 18.9), and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic stress disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (OR 3.76).</br>In addition, a positive correlation has been found between the severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression/anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms.</br>Relevant to the RLS-depression relationship is the emerging evidence that treatment of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 improves 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms. </br>Similarly, increased rates of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attention deficit hyperactivity disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ADHD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) have been found in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, both in pediatric and adult studies.</br>Emerging data indicate that about one fourth of individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ADHD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms, and conversely, that 12% to 35% of those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ADHD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 meet criteria for RLS.</br>Other medical condi- tions for which there is some evidence for greater-than-chance association include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multiple sclerosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral neuropathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes melli-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tus, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibromyalgia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rheumatoid arthritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, nocturnal eating, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thyroid disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>284 Clinical and Pathophysiological Subtypes Evidence in the literature is not sufficient to support well-defined subtypes of RLS.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Early-onset RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (prior to age 45 years) is more familial and associated with slower progression than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    late-onset RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In addition, the classification of “secondary” 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been suggested when the condition occurs in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    iron deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, preg- nancy, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but this construct has been challenged based on patho- physiological, family history, genetic, and clinical course data. </br>Demographics The overall prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been estimated at 5% to 10% in European and North American population-based studies.</br>However, in Asian countries, studies thus far indicate a lower prevalence.</br>Prevalence is about twice as high in women than in men.</br>In most studies, prevalence increases with age up to 60-70 years, except in Asian populations where an age-related increase has not been found.</br>Various measures of clinical significance such as frequency (1-2 times/week), severity (moderate to severe distress), differential diagnosis, and impact have been applied to population-based studies.</br>These analyses indicate the prevalence of clinically significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to be 2% to 3% in Europe and North America, but lower in Asia.</br>Annual incidence rates have been reported as 0.8% to 2.2%. </br>Pediatric prevalence rates are 2% to 4% in UK/US and Turkish studies, with moderate to severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in about 0.5% to 1%.</br>Adolescents are more likely to have moderate to severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms than younger children—one half of 12- to 17-year-olds com- pared to one fourth of 8- to 11-year-olds with RLS.</br>Boys are affected as often as girls, with the sex difference not emerging until the late teens or twenties. </br>Predisposing and Precipitating Factors A positive family history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the genetic variants noted below, and female sex confer increased risk for RLS.</br>The best characterized precipitating factors are 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    iron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 deficiency, certain medications, pregnancy, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and prolonged immo- bility.</br>Mild 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    iron deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, characterized by serum ferritin below 50 μg/L, has been associated with increased severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and repletion of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    iron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 stores from below 50-75 μg/L has been found to diminish 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms.</br>Medications that may precip- itate or aggravate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include sedating 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antihistamines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, some centrally active 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dopamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 receptor antagonists, and most 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>An exception is the 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant bupropion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, with its dopamine-promoting activity. </br>The prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during pregnancy is two to three times greater than in the general population.</br>There is a peak in the number of women affected by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the Sleep Related Movement Disorders Sleep Related Movement Disorders third trimester, with resolution of symptoms for most, but not all, by one month after delivery.</br>Independent predictors of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during pregnancy are a family history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (OR 8.43), a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in prior pregnancy (OR 53.74), a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the past (OR 12.91), and hemoglobin ≤11 g/dL (OR 2.05).</br>Parity, the number of previous pregnancies, appears to account for the 2:1 sex difference between women and men in the general population prevalence of RLS. </br>In 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients, the prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is two to five times greater than in the general population.</br>This represents prevalence rates of 11% to 58% in US and European 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 clinics.</br>Compared to patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have greater 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, report poorer quality of life, and more frequently discontinue dialysis prematurely.</br>Typically, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms improve dramatically within one month after kidney transplantation but become severe again with transplant failure. </br>There is limited or contradictory evidence for sleep deprivation, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral neuropathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    radiculopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, tobacco, or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 as exacerbating factors for RLS. </br>Familial Patterns Early-onset 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is highly familial, with 40% to 92% of cases reporting affected family members.</br>High concordance rates are observed in monozygotic twins.</br>The risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is two to six times greater for first-degree relatives of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 than for those from the general population.</br>Although an autosomal dominant model of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is sug- gested by many family studies, recent genomewide linkage and association studies suggest a more complex gene-environment pattern.</br>Linkage analyses have reported several different gene loci associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but, to date, no single causative gene.</br>However, genomewide association studies have identified single nucleotide poly- morphisms in RLS, four of which have been replicated: BTBD9, MEIS1, MAP2K5/ LBXCOR, and PTPRD.</br>Nonetheless, the relationship between familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and these findings remains to be determined. </br>Onset, Course, and Complications Onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms occurs at all ages, from childhood to late adult life.</br>Mean age of onset for familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is in the third or fourth decade, with onset prior to age 21 years in about one third of cases.</br>The clinical course of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 differs based on age of onset.</br>In early-onset 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (before age 45 years), slow progression of symptoms is found in about two thirds of cases.</br>Most of the remaining one third report stable symp- toms over time, although remission has been described.</br>In 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    late-onset RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, rapid pro- gression is typical and aggravating factors are common. </br>286 Significant impairment of health-related quality of life (HRQoL) has been found in moderate to severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Both physical health and mental health scores have consis- tently been found to be lower for individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, using standard QoL assess- ment tools.</br>The HRQoL impairments are strongly associated with severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and remain after controlling for age, sex, and disease comorbidity.</br>In addition, patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, type 2 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 who also have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been shown to have poorer quality of life than those without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Overall, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 accounts for a major disease burden on those who suffer from it, demonstrated to be similar to or worse than that associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    osteoarthritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Large population-based studies have found positive associations between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary heart disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Repetitive surges in heart rate and blood pressure associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are a potential mediator in the physiology of these relationships.</br>Only limited mortality data are available, suggesting increased risk of mortality in women and in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Developmental Issues The accurate diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children and adolescents requires understanding of developmental language and cognitive skills.</br>Adequate verbal skills are needed for children to communicate the sensory component of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and description must be in “the child’s own words,” rather than by a parent or caretaker.</br>For criterion A, children rarely use or understand the word “urge.”</br>Instead they describe that their legs “need to” “have to” or “got to” move.</br>Descriptors for the discomfort include: bugs, ants, weird/ funny feelings, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tingle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, wiggly, and shaky.</br>Younger children often use the word “kick” rather than “move,” e.g., “my legs want to kick.”</br>Similar to adults, children report arm involvement in almost half of cases.</br>Sitting in class, lying in bed, reading a book, and riding in a car are situations where children report onset or worsening of their symp- toms.</br>Relief is typically achieved by moving around, walking, rubbing, kicking, or distraction.</br>Perhaps as a result of prolonged periods of sitting in class, two thirds of children and adolescents with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 report 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime leg sensations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Because of this, for diagnostic criterion A3 (worse in the evening/night), it is important to compare equal duration of sitting or lying down in the day to sitting or lying down in the evening/ night.</br>However, even with such comparisons, a significant subset of children do not report worsening at evening/night, yet meet all other diagnostic criteria and have sup- portive features for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including a positive family history.</br>Children who are age six years or older and developmentally normal have been shown to report detailed, ade- quate descriptors for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms.</br>For children who are too young to adequately describe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS sensations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or are developmentally delayed, a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis may be Sleep Related Movement Disorders Sleep Related Movement Disorders the initial diagnosis, with full RLS symptomatology evident over time.</br>Diagnosis by observational techniques has been suggested but not yet validated. </br>The differential diagnosis of pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 includes positional discomfort, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sore
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 leg muscles, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    joint/tendon injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and bruises, all of which are common mimics.</br>In child- hood, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is frequently misdiagnosed as “growing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pains
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.”</br>Four specific domains that are affected in pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are sleep, daily activities, mood, and energy/vital- ity.</br>Difficulties with sleep onset, sleep maintenance, and sleep quality are common.</br>Negative influence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on waking activities includes academic impact due to dis- ruption of schoolwork, homework, and ability to concentrate.</br>Severity assessment of pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has thus far been limited to simple measures of self-reported frequency and intensity. </br>Because pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is highly familial, the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in a first-degree rela- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 helps to increase diagnostic certainty in childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Similarly, the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is quite helpful in supporting an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis in chil- dren.</br>As in adults, approximately 70% of children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 demonstrate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ≥ 5/ hour on a single night and nearly 90% when multiple nights are sampled.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ≥ 5/ hour are uncommon in pediatric normative samples.</br>As noted above, pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is comorbid with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ADHD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in about one fourth of cases, and, as in adults, higher rates of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depressive
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms are found.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is common in pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic kidney disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Prevalence rates of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 increase with age until late adulthood then stabilize or decrease slightly in the elderly.</br>However, strong associations with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and decreased QoL measures remain in the elderly.</br>Diagnostic criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the cog- nitive-impaired elderly have been suggested but not validated. </br>Pathology and Pathophysiology Brain 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    iron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 deficiency, central nervous system 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dopamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 regulation, and genetics appear to be primary factors in the pathophysiology of RLS.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Iron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is important in brain dopa- mine production and synaptic density, as well as in myelin synthesis and energy pro- duction.</br>A connection between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and low brain 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    iron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is supported by autopsy data, MRI, brain sonography, and cerebrospinal fluid analysis.</br>Evidence for central nervous system dopaminergic system involvement comes mainly from multiple randomized clinical trials that have clearly demonstrated the effect of dopaminergic drugs for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In addition, an altered dopaminergic profile in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is supported by func- tional MRI, positron emission tomography, and autopsy data.</br>Association of gene vari- ants BTBD9, MEIS1, MAP2K5/LBXCOR, and PTPRD with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been replicated, indicating a genetic substrate upon which environmental factors might act.</br>BTBD9 is estimated to confer a population attributable risk (PAR) of 50% for RLS.</br>Together, BTBD9, MEIS1, and MAP2K5/LBXCOR account for 70% of the PAR for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in indi- viduals with European ancestry.</br>Thus far, two of the variants, BTBD9 and MEIS1, appear to influence expression of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as well as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    iron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 homeostasis.</br>However, the full role of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 gene variants has not been adequately defined. </br>Objective Findings Although polysomnography is not routinely indicated in the evaluation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, poly- somnographic studies demonstrate significant objective 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, with increased latency to persistent sleep and higher arousal index as the most consis- tent differences in sleep architecture.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ≥5/hour occur in 70% to 80% of adults with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on single-night testing but in &gt;90% when multiple nights are sampled.</br>In adult 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are more prominent during the first half of the night and vary in frequency from night to night.</br>About one third of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cortical arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and most have associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autonomic arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not influenced by placebo effect.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 contribute to the primary RLS morbidity of sleep dis- turbance.</br>Furthermore, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sensory symptoms impair return to sleep, and thereby result in more prolonged awakening. </br>The Suggested Immobilization Test (SIT) evaluates PLMW and related sensory com- ponents of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during resting wakefulness.</br>A standard polysomnogram recording without respiratory measures is used for one hour before the usual bedtime while the subject sits comfortably awake and upright in bed with the legs outstretched.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis is supported by a finding of more than 40 PLMW/hour. </br>Activity monitors with high-frequency sampling and body-position monitoring may be attached to the ankle or foot to provide an alternate measure of PLMs.</br>Recordings assess the frequency and variability of PLMs from night to night, typically over three to five nights. </br>Differential Diagnosis The differentiation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from other conditions that may have characteristics of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is essential, because approximately 40% of individuals without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will report some urge or need to move the legs while at rest.</br>Fulfilling diagnostic criteria A2 (better with movement) and A3 (worse in the evening/night) improves specificity for an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis to only about 70%, based on studies that have used structured diagnostic interviews.</br>However, differentiating 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and positional discomfort improves specificity to 94%, emphasizing the importance of differential diagnosis.</br>The Sleep Related Movement Disorders Sleep Related Movement Disorders most important “mimics” of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, positional discomfort, arthralgias/ 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arthritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myalgias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral neuropathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    radiculopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and habitual foot tapping.</br>Not characteristic of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are: “knotting” of the muscle (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), relief with a single postural shift (positional discomfort), limitation to joints (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arthritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), sore- ness to palpation (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myalgias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), and other abnormalities on physical examination.</br>Less common conditions to be differentiated from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuroleptic-induced
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 akathi-</br>sia, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myelopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, symptomatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    venous insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eczema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, orthopedic problems, painful legs and moving toes, and anxiety-induced restlessness.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Neuroleptic-induced akathisia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 differs from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    akathisia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with the need to move the entire body and occurs in association with use of dopamine-receptor antagonists.</br>Painful legs and moving toes have neither a clear circadian pattern nor the sense of an urge to move. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 involving the legs occurs with numerous conditions, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arthritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, vascular problems, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sports/orthopedic injuries
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuropathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>These 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pains
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can have a nocturnal presentation and may be worse at rest, but improvement with movement either does not occur or entails more exercise than simple movement of the leg.</br>The urge to move, if present at all, usually stems from awareness that movement produces relief rather than the strong primary urgency of movement felt with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, however, does not exclude a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, because about 50% of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 report their 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms as painful. </br>Although it is important that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms not be attributable solely to another medical or behavioral condition, it should also be appreciated that any of these mimics can occur in an individual who also has RLS.</br>For example, some subjects may have both 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and leg cramps.</br>When the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not certain, evaluation for the supportive features such as the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or a family history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be helpful.</br>Diagnostic interviews that include differential diagnosis have been validated for RLS.</br>These demonstrate sensitivity and specificity of &gt; 90%. </br>Unresolved Issues and Further Directions The diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 relies on the subjective report of sensory symptoms that lie outside the range of common sensory experience.</br>Many patients have difficulty describing the sensations.</br>Further studies of the biological bases for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may lead to better classification of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and possibly to objective tests for diagnosis.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Iron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, dopa- mine, and genetic research hold particular promise.</br>Additional epidemiological and genetic studies outside the US and Europe are needed to explore apparent population differences.</br>The diagnostic standards and severity assessment for children and cogni- tively impaired adults require further development.</br>Clarification of the natural course and potential exacerbating factors is needed.</br>Better understanding of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comor- bidities such as
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attention deficit hyperactivity disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 might lead to improved outcomes in those disorders.</br>Further evaluation of long-term complica- tions is important, including clarification of associations with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, cardiovas- cular disease, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Bibliography Allen R, Picchietti D, Hening W, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: diagnostic criteria, special considerations, and epidemiology.</br>A report from the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis and epidemiology workshop at the National Institutes of Health.</br>Sleep Med 2003;4:101–19. </br>Allen RP, Stillman P, Myers AJ.</br>Physician-diagnosed 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in a large sample of primary medical care patients in western Europe: Prevalence and characteristics.</br>Sleep Med 2010;11:31–7. </br>Dauvilliers Y, Winkelmann J. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: update on pathogenesis.</br>Curr Opin Pulm med 2013;19:594-600. </br>Earley CJ, Silber MH.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: Understanding its consequences and the need for better treatment.</br>Sleep Med 2010;11:807–15. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Ekbom K. Restless legs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a clinical study.</br>Acta Med Scand 1945;158:1–122. </br>Ferini-Strambi L, Walters AS, Sica D.</br>The relationship among 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Willis-Ekbom
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Disease), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebrovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Neurol 2013</br>Aug 21.</br>[Epub ahead of print] Hening WA, Allen RP, Washburn M, Lesage SR, Earley CJ.</br>The four diagnostic criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Restless Legs Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are unable to exclude confounding conditions (“mimics”).</br>Sleep Med 2009;10:976–81. </br>Ohayon MM, O’Hara R, Vitiello MV.</br>Epidemiology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: A synthesis of the literature.</br>Sleep Med Rev 2012;16:283–95. </br>Picchietti DL, Arbuckle RA, Abetz L, et al.</br>Pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: analysis of symptom descriptions and drawings.</br>J Child Neurol 2011;26:1365–76. </br>Picchietti DL, Bruni O, de Weerd A, et al.</br>Pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnostic criteria: An update by the International Restless Legs Syndrome Study Group.</br>Sleep Med 2013;14:1253-9. Sleep Related Movement Disorders Sleep Related Movement Disorders Periodic Limb 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement Disorder ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.51 ICD-10-CM code: G47.61 Alternate Names Periodic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep myoclonus syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, nocturnal myoclo- nus syndrome. </br>Diagnostic Criteria Criteria A-D must be met A. Polysomnography demonstrates 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as defined in the most recent version of the American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events. </br>B. The frequency is &gt; 5/hour in children or &gt; 15/hour in adults.1 C.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cause clinically significant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or impairment in mental, physical, social, occupational, educational, behavioral, or other important areas of functioning.2,3 D. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the symptoms are not better explained by another current 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurring with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypopneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should not be scored).4,5 Notes .</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Index must be interpreted in the context of a patient’s sleep related complaint.</br>In adults, normative values greater than five per hour have been found in studies that did not exclude respiratory event-related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (using sensitive respiratory monitoring) and other causes for PLMS.</br>Data suggest a partial overlap of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Index values between symptomatic and asymptomatic individuals, emphasizing the importance of clinical context over an absolute cutoff value. </br>2.</br>If 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are present without clinical sleep disturbance or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be noted as a polysomnographic finding, but criteria are not met for a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>3. The presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not sufficient to establish the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Studies have shown that in most cases the cause of the accompanying 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is something other than the PLMS.</br>To establish the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, it is essential to establish a reasonable cause-and-effect relationship between the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the PLMS.</br>This requires that other causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or other causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are ruled out.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are common, but 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is thought to be rare in adults. </br>4. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cannot be diagnosed in the context of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur commonly in these conditions but the sleep complaint is more readily ascribed to the accompanying disorder.</br>The diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 takes precedence over that of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 when potentially sleep- disrupting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur in the context of RLS.</br>In such cases, the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is made and the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are noted. </br>5.</br>When it is reasonably certain that the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been induced by medication, and full criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are met, it is preferred that the more specific diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 be used, rather than “Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance.” </br>Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by periodic episodes of repetitive, highly stereotyped limb movements that occur during sleep (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), in conjunction with clinical sleep dis- turbance or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that cannot be accounted for by another primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or other etiology. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur most frequently in the lower extremities.</br>They typically involve exten- sion of the big toe, often in combination with partial flexion of the ankle, the knee, and sometimes, the hip.</br>Similar movements can occur in the upper limbs.</br>Individual movements may be associated with an autonomic arousal, a cortical arousal, or an awakening.</br>Typically, the patient is unaware of the limb movements or the frequent sleep disruption.</br>An arousal may precede, coincide with, or follow the limb movement, suggesting that a central generator may give rise to both the periodic movements and the related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>A clinical history of sleep onset problems, sleep maintenance problems, or unrefresh- ing sleep attributable to the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is needed for a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>These symp- toms have most consistently been associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and the presence of these clinical symptoms differentiates 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from asymptomatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although exces- sive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been reported with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the past, newer data do not find significantly elevated Epworth Sleepiness Scale scores or Multiple Sleep Latency Test (MSLT) values in subjects with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>If the only complaint is sleep disruption for the bed partner, then 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should not be diagnosed but the sleep disturbance of the bed partner can be noted. </br>293 Sleep Related Movement Disorders Sleep Related Movement Disorders The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 index should exceed five per hour in children and 15 per hour in adult cases for a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>This is based on substantial normative data in children.</br>In adults, there is a significant increase in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 &gt;15/hour. </br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or nonrestorative sleep should not be better explained by another etiology.</br>Most important in the differential diagnosis are 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Research studies indicate that five or more 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 per hour occur in 80% to 90% of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, in about 70% with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and in 45% to 65% with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are often present without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during nonrapid eye movement sleep (NREM) sleep but can also con- tinue into REM sleep, which is unusual in all other settings.</br>If significant daytime sleep- iness and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are present, a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be considered.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should not be diagnosed when criteria for one of these three disorders is met.</br>However, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 “with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
” can be specified (e.g., “
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
”). </br>A sensitive technique, such as pressure transducer airflow monitoring or esophageal manometry, should be used to monitor breathing during polysomnography to rea- sonably exclude sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRBDs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) as the direct cause of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>When independent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are present in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRBDs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a separate diag- nosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be considered if the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 persist despite adequate treatment of the SRBD and otherwise unexplained 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 remains.</br>Ideally, polysom- nography for the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be performed after the biologic effect of a medication or substance, such as an 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 known to induce or aggravate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, has ended. </br>Associated Features Higher rates of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attention deficits
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oppositional behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been reported in some studies of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a family history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is common.</br>A sustained clinical response to dopa- minergic therapy is supportive of the diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms may be responsive to 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzodiazepines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzodiazepine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 responsiveness is not support- ive of the diagnosis due to the nonspecific effect of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzodiazepines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 on sleep. </br>Clinical and Pathophysiological Subtypes Not applicable or known. </br>Demographics Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is thought to be rare, the exact prevalence is not known.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been reported in both children and adults.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 &gt;5/hour are very uncommon in children and adults younger than the age of 40 years, but then increase markedly with advancing age, occurring in over 45% of the elderly.</br>The population prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 &gt;15/hour has been estimated at 7.6% of 18- to 65-year-olds, with 4.5% of the total population also reporting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    medication-induced PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 were not exclusionary criteria in this popula- tion, suggesting much lower rates for PLMD.</br>The increase in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with age may occur as a partial expression of familial or genetic factors associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, based on data that show very little increase in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with age when individuals who have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or first-degree relatives with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are excluded.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are less common in black adults and children than in whites.</br>No sex difference has been described for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Predisposing and Precipitating Factors A positive family history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 confers increased risk for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The genetic variants noted below may be a mediator of this risk.</br>Precipitation or aggrava- tion of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been reported with the use of several medications.</br>Selective sero- tonin reuptake inhibitor 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, tricyclic 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lithium
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and dopa- mine receptor antagonists have most often been associated with this effect. </br>Low brain 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    iron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, as reflected by serum ferritin level, may worsen 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 via the role of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    iron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dopamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 function.</br>Less evidence is available for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and sleep deprivation as factors that worsen 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Familial Patterns The familial pattern of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has not been studied in detail.</br>Families with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been found to include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    first-degree relatives
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but with increased rates of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, raising the possibility that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is an attenuated manifestation or a precursor to RLS.</br>The gene variants BTBD9 and MEIS1, which were found in genome- wide studies of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, appear to influence the expression of PLMS. </br>Onset, Course, and Complications Although the typical age of onset is not known, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs in both children and adults, with onset as early as infancy.</br>The natural history has not been described in detail, but some pediatric cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 progress to RLS.</br>Incidence and remission rates are unknown.</br>Impaired performance in a simulated driving task has been found in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Increased 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been associated with a higher risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and mortality in some studies.</br>PLMS-related overac- tivity of the sympathetic nervous system is postulated to be a potential mechanism for these associations. </br>295 Sleep Related Movement Disorders Sleep Related Movement Disorders Developmental Issues Given the low background rates of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has emerged as a useful diagnostic category in pediatric sleep medicine.</br>Pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has important</br>clini-</br>cal</br>and polysomnographic correlates that are comparable in severity to pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 normative data remain sparse for children younger than two years. </br>In the elderly, frequent occurrence of other conditions that can account for sleep dis- turbance and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 makes application of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 criteria difficult, even though 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are common. </br>Pathology and Pathophysiology Dopaminergic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been implicated in the pathophysiology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The study of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and in children also suggests genetic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diathesis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    iron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 status as factors.</br>Cyclic alternating pattern, a marker of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonrestorative
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sleep, is increased in individuals with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and may influence the periodicity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cortical arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can precede, coincide with, or follow 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, indicating that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 do not cause the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In addition, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be dissociated from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 pharma- cologically, suggesting an indirect relation, possibly mediated by a central generator.</br>The autonomic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are characterized by significant heart rate and blood pressure surges, a mechanism for possible increased 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular and cerebrovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 risk. </br>Objective Findings 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can appear immediately with the onset of stage N1 sleep, are frequent during stage N2 sleep, decrease in frequency in stage N3, and are usually absent during stage R sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 typically occur in discrete episodes that last from a few minutes to an hour.</br>Both lower limbs should be monitored for the presence of limb movements.</br>Movements of the upper limbs may be sampled if clinically indicated.</br>The anterior tibialis electro- myogram (EMG) shows repetitive contractions, each lasting 0.5 to 10 seconds.</br>The movements may affect one or, more typically, both of the lower limbs, but not neces- sarily in a symmetric or simultaneous pattern.</br>Specific scoring criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are described in the AASM Manual for the Scoring of Sleep and Associated Events. </br>Self-reports, bed partner observations, or parental reports for children have not been found to have sufficient specificity or sensitivity to replace objective testing for PLMS. </br>Care must be taken to discriminate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from other movements such as a simple change in body position, stretching of a limb, or a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle cramp
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are longer in duration than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which, by definition, are typically 50 to 150 millisec- onds long.</br>Movements associated with respiratory events, hypnagogic foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or alternating leg muscle activation during sleep (ALMA) should not be included in the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 index. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be associated with electroencephalographic (cortical) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or with awakenings.</br>Autonomic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
—measured by a change in heart rate, blood pressure, or pulse transit time—have been shown to be more frequent than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cortical arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In some cases, periodic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may persist even though the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have subsided.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are typically more difficult to measure than are the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and their clinical significance is a topic of ongoing debate.</br>As with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the associated cortical arousal index has not proven more useful than the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 index in making clini- cal decisions.</br>Although a subjective report of excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is present in some patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, mean sleep latency measured by MSLT has not been found to be consistently abnormal or to correlate with the PLMS cortical arousal index. </br>The movements should be reported as an index of total sleep time, called the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 index.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 index is the number of periodic limb movements per hour of total sleep time, as determined by polysomnography.</br>The PLMS arousal index is the number of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with a cortical arousal, expressed per hour of total sleep time.</br>Other parameters for the description of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include periodicity index, intermove- ment interval distribution, and time of night distribution.</br>These features have been shown to help differentiate 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patterns in different conditions (e.g., a finding of the highest periodicity indices in adult 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Leg actigraphy has been validated against PSG for the measurement of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and provides a methodology to assess 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in large populations, as well as night-to-night variability. </br>Differential Diagnosis As described in the essential features section, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a diagnosis of exclusion and it is important to differentiate it from other conditions in which 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur, particularly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRBDs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Increased rates of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have also been reported in multiple system 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dopa-responsive dystonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, spinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cord injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    end-stage renal disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sickle cell disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posttraumatic stress disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Asperger syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Williams syn- drome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and multiple sclerosis.</br>Dopaminergic impairment and/or diminished inhibition of the central pattern generator for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been proposed as common factors linking various disorders and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>297 Sleep Related Movement Disorders Sleep Related Movement Disorders Sleep starts (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) need to be differentiated from PLMS.</br>Sleep starts typically are limited to the transition from wakefulness to sleep, are not periodic, and are briefer (20 to 100 milliseconds) than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Normal phasic REM activity is limited to REM sleep, typically occurs in 5- to 15-second clusters, and is usually associated with bursts of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    REMs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Phasic REM EMG twitches are more variable in duration and do not have the periodicity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by EMG activity that is briefer (75 to 150 milliseconds), more variable in duration, less periodic than 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and has little or no associated visible movement.</br>Also, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 must be differentiated from movements associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal epileptic seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and from a number of forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 seen while awake, such as in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Creutzfeldt-Jakob disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and other neuropathologic conditions.</br>However, in these disorders, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    involuntary movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are prominent during the daytime, often do not disappear with activity, are prominent in the arms and other body parts in addition to the legs, and do not display the periodicity seen with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Unresolved Issues and Further Directions </br>There has been controversy over the clinical significance of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>To date, the inter- pretation of most studies has been confounded by multiple factors that include: impre- cise diagnostic criteria; 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; inadequate monitoring for subtle 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRBDs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; a lack of consideration of medications known to induce, worsen, or suppress 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; and inadequate measurement of the known night-to-night vari- ability of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Newer respiratory monitoring techniques for polysomnography and the use of actigraphy monitors over several nights should help address a number of these issues.</br>The role of associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in relation to clinical symptoms is yet to be determined, but the appreciation of autonomic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as well as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cortical arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 might be critical.</br>It is possible that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are a measurable marker of unstable sleep, related to genetic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diathesis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and dopaminergic impairment. </br>Bibliography Ferri R. The time structure of leg movement activity during sleep: The theory behind the practice.</br>Sleep Med 2012;13:433–41. </br>Gingras JL, Gaultney JF, Picchietti DL.</br>Pediatric periodic limb movement disorder: sleep symptom and polysomnographic correlates compared to obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Clin Sleep Med 2011;7:603–9. </br>Hornyak M, Feige B, Riemann D, Voderholzer U. Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment.</br>Sleep Med Rev 2006;10:169–77. </br>Koo BB, Blackwell T, Ancoli-Israel S, Stone KL, Stefanick ML, Redline S. Association of incident 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with periodic limb movements during sleep in older men: Outcomes of Sleep Disorders in Older Men (MrOS) Study.</br>Circulation 2011;124:1223–31. </br>Pennestri 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MH
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Whittom S, Adam B, Petit D, Carrier J, Montplaisir J. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and PLMW in healthy subjects as a function of age: prevalence and interval distribution.</br>Sleep 2006;29:1183–7. </br>298 Picchietti DL, Rajendran RR, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Wilson MP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, Picchietti MA.</br>Pediatric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and periodic limb movement disorder: parent-child pairs.</br>Sleep Med 2009;10:925–31. </br>Picchietti D. Periodic limb movements in sleep: irrelevant epiphenomenon, marker for a potential problem, or a disorder?</br>J Clin Sleep Med 2006;2:446–7. </br>Scofield H, Roth T, Drake C. Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences.</br>Sleep 2008;31:1221–7. </br>Stefansson H, Rye DB, Hicks A, et al.</br>A genetic risk factor for periodic limb movements in sleep.</br>N Engl J Med 2007;357:639–47. </br>Walters AS, Rye DB.</br>Review of the relationship of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and periodic limb movements in sleep to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2009;32:589–97. </br>Sleep Related Leg Cramps ICD-9-CM code: 327.52 Alternate names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, “charley horse,” 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-C must be met ICD-10-CM code: G47.62 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement Disorders A. A painful sensation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the leg or foot associated with sudden, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    involuntary muscle hardness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tightness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, indicating a strong muscle contraction. </br>B. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    painful muscle contractions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur during the time in bed, although they may arise from either wakefulness or sleep. </br>C. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is relieved by forceful stretching of the affected muscles, thus releasing the contraction. </br>Essential Features Sleep related leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    painful sensations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 caused by sudden and intense involun- tary contractions of muscles or muscle groups during which there is 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle spasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hardness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for several seconds.</br>These 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    painful sensations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are usually in the calf or small muscle of the foot.</br>Occurring during the time in bed, sleep related leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may arise from either wakefulness or sleep. </br>Sleep related leg cramps usually start abruptly but may in some cases be preceded by a less 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    painful warning sensation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The muscle contractions last for a few seconds up to several minutes and then remit spontaneously.</br>The frequency of sleep related leg cramps varies considerably from less than yearly to multiple episodes every night. </br>299 Sleep Related Movement Disorders The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be relieved by strongly stretching the affected muscle and sometimes also by local massage, application of heat, or movement of the affected limb.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be present primarily during the daytime. </br>Associated Features The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle cramp
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 affects sleep.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramp
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 itself and from the activities used to relieve it commonly disturb sleep onset or cause an awakening from sleep.</br>Often the presenting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaint
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, at times severe. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tenderness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and discomfort in the muscle may persist for several hours after the cramp- ing.</br>Persisting discomfort after the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramping
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episode often delays subsequent return to sleep. </br>Clinical and Pathophysiological Subtypes Sleep related leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are known to be either 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or secondary to other medical conditions, but there have been no indications of significant differences in the clinical features of the disorder related to the cause. </br>Demographics Sleep related leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are common.</br>It has been suggested that nearly every adult older than 50 years has experienced sleep related leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at least once.</br>Both the prevalence and the frequency of the events increase with age.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been reported to occur at least occasionally in about 7% of children and adoles- cents, 33% in adults older than 60 years, and 50% in adults older than 80 years, with both older groups reporting a symptom frequency of at least once every two months.</br>Nightly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been reported in 6% of adults older than 60 years.</br>No defin- itive sex information has been reported, though a single study reported a higher prev- alence in women. </br>Predisposing and Precipitating Factors </br>Predisposing factors include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amyotrophic lateral sclerosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramp fasciculation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral vascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypokalemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypocalcemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypomagnesemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and metabolic disorders.</br>The disorder can be associated with prior vigorous exercise, prolonged standing at work, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dehydration
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, fluid and electrolyte distur- bances, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endocrine disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuromuscular disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders of reduced mobility
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cirrhosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and hemodialysis.</br>Medications that have been associated with sleep related leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oral contraceptives
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, intravenous 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    iron sucrose
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    teriparatide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    raloxifene
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, diuretics, long-acting β-agonists, and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    statins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Sleep related leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur in about 40% of pregnant women and generally resolve after delivery. </br>300 Familial Pattern Not known. </br>Onset, Course and Complications Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have not been reported in infancy, nor in children younger than eight years.</br>The peak onset is usually in adulthood, but the condition may be seen for the first time in old age.</br>The natural history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not well under- stood.</br>Many patients describe a waxing and waning course of many years
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ’
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 duration.</br>Complications include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle tenderness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and occasional 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to interrupted sleep.</br>No marked mental or social dysfunction has been described due to sleep related leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 alone. </br>Pathology and Pathophysiology Many sleep related leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 appear to be 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 involve 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal muscle tone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, they are generally considered not to involve agonist-antagonist co-contractions and, thus, are not classified as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dystonias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Some 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly those in the feet, may resemble 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dystonias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 but, unlike classic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dystonias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related leg and foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are relieved by stretching the affected muscle or muscles. </br>Electrophysiologic recordings show that the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 typically start with spontaneous firing of anterior horn cells followed by motor unit discharges for contractions at rates up to 300 Hz (considerably more than with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    voluntary muscle contractions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may result from local metabolite accumulations or from local 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Muscle and tendon shortening due to age or lack of stretching exercise is thought to contribute to the development of sleep related leg cramps.</br>Exercise involving stretch- ing the affected muscles is thought to help prevent or reduce the occurrence of sleep related leg cramps. </br>Objective Findings Polysomnographic studies of patients with chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep related leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 reveal non- periodic bursts of gastrocnemius EMG activity.</br>Episodes arise from sleep without any specific preceding physiologic changes during sleep. </br>Differential Diagnosis Sleep related leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are common in chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myelopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral neuropathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscular pain fasciculation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and disorders of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    calcium
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 metabolism.</br>These causes should be differentiated by clinical history and physical examination.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is Sleep Related Movement Disorders Sleep Related Movement Disorders sometimes confused with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep related leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 because both can present with leg discomfort during the sleep period and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients sometimes complain of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramping
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sensation.</br>However, if patients meet the diagnostic criteria for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and do not describe an actual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramp
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or hardening of the muscle, the diagnosis should be RLS.</br>Because 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can mimic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and meet all the criteria for RLS, the description of an actual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    spasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or hardening of the muscle is a critical differentiating factor.</br>A leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramp
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is also a much briefer event than the typical symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which can persist for hours.</br>However, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may sometimes be seen in the same individual. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Dystonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is ongoing daily 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    spasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of muscles and is distinguished electrophysiologi- cally from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by ongoing co-contraction of agonist and antagonist muscles.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Dystonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be focal, as in the case of muscles of the neck (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    torticollis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) or hand (writer’s 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramp
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), or generalized as in the case of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    torsion dystonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Unresolved Issues and Further Directions Sleep related leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are common and can affect sleep.</br>Their association with other disorders and different medications hinder accurate epidemiological data and under- estimate their effect on sleep and on quality of life.</br>Instruments to quantify the sever- ity of the disorder and its impact are needed to adequately address clinical relevance, treatment, and the potential occupational hazards.</br>Effective treatments for sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have yet to be developed.</br>The prophylactic benefits of stretching exercises remain to be adequately validated. </br>Bibliography Allen RE, Kirby KA.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am Fam Physician 2012;86:350–5. </br>Bahk JW, Kim H, Jung-Choi 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Jung MC, Lee I. Relationship between prolonged standing and symptoms of varicose veins and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 among women and men.</br>Ergonomics 2012;55:133–9. </br>Butler J, Mulkerrin E, O’Keeffe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S. Nocturnal leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in older people.</br>Postgrad Med J 2002;78:596–8. </br>Garrison SR, Dormuth CR, Morrow RL, Carney GA, Khan KM.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and prescription use that precedes them: a sequence symmetry analysis.</br>Arch Intern Med 2012;172:120–6. </br>Hawke F, Chuter V, Burns J. Factors associated with night-time calf 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; a case control study.</br>Muscle Nerve 2013;47:339–43. </br>Hawke F, Chuter V, Burns J. Impact of nocturnal calf 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cramping
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on quality of sleep and health-related quality of life.</br>Qual Life Res 2013;22:1281–6. </br>Heimisdottir F, Guddnason V, Sigurdsson G, Benediktsson R. [Foot disease in Icelandic patients with established type 2 diabetes].</br>Laeknabladid 2008;94:109–14. </br>Hudson AJ, Brown WF, Gilbert JJ.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscular pain-fasciculation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Neurology 1978;28:1105–9. </br>Jacobsen J, Rosenberg R, Huttenlocher P, Spire J. Familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal cramping
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 1986;9:54–60. </br>Kleopa KA, Zamba-Papanicolaou E, Kyriakides T. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Compressive lumbar myelopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 presenting as segmental motor neuron disease.</br>Muscle Nerve 2003;28:69–73. </br>302 Leung 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Wong 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Chan 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PY
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Cho HY.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children: incidence and clinical characteristics.</br>J Natl Med Assoc 1999;91:329–32. </br>Matsumoto M, Watanabe 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Tsuji T, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a common complaint in patients with lumbar spinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    canal stenosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Spine (Phila Pa 1976) 2009;34:E189–94. </br>Norris FJ, Gasteiger E, Chatfield P.</br>An electromyographic study of induced and spontaneous 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Electroencephalogr Clin Neurophysiol 1957;9:139–47. </br>Parisi L, Serrao M, Rossi P, et al.</br>Afterdischarge activity in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuropathic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients with frequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Acta Neurol Scand 2000;102:359–62. </br>Pitkin RM.</br>Endocrine regulation of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    calcium
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 homeostasis during pregnancy.</br>Clin Perinatol 1983;10:575–92.</br>Saskin P, Whelton C, Moldofsky H, Akin F. Sleep and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 1988;11:307–8.</br>Weiner I, Weiner H. Nocturnal leg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>JAMA 1980;244:2332–3. </br>Sleep Related Bruxism ICD-9-CM code: 327.53 ICD-10-CM code: G47.63 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, nocturnal tooth grinding, tooth clenching. </br>Diagnostic Criteria Criteria A and B must be met A.</br>The presence of regular or frequent tooth grinding sounds occurring during sleep. </br>B. The presence of one or more of the following clinical signs: .</br>Abnormal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth wear
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 consistent with above reports of tooth grinding during sleep. </br>2. Transient morning jaw 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; and/or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    temporal headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; and/or jaw locking upon awakening consistent with above reports of tooth grinding during sleep. Notes .</br>Although polysomnography is not required for the diagnosis, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as described in the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events, is ideally recorded with masseter muscle activity with audio-video signal to increase diagnostic reliability. </br>Essential Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is defined as a repetitive jaw-muscle activity characterized by clenching or grinding of the teeth and/or by bracing or thrusting of the mandible.</br>Bruxism Sleep Related Movement Disorders Sleep Related Movement Disorders has been divided into its two distinct circadian manifestations: sleep bruxism and awake bruxism. </br>In sleep, jaw 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle contractions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are frequently repeated over time and are termed rhythmic masticatory muscle activity (RMMA).</br>These contractions can take two forms on electromyographic traces: a series of repetitive activity (phasic muscle contractions) or isolated sustained jaw clenching (tonic contractions).</br>These contractions during sleep produce 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth-grinding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sounds and are referred to as sleep related bruxism. </br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can lead to abnormal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth wear
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, jaw 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    temporal headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Severe sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also result in sleep dis- ruption.</br>This may involve not only the individual affected, but also the bed partner, because the sounds made by the friction of the teeth are usually perceived as being unpleasant and can be quite loud and disturbing to those nearby. </br>The disorder is typically brought to dental or medical attention because of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth damage
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or disturbing sounds.</br>Less commonly, it may present as a cause of dis- turbed sleep.</br>Young and otherwise healthy individuals with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 appear to have normal sleep structure and homeostasis.</br>The majority of RMMA epi- sodes during sleep occur in association with sleep arousal. </br>Jaw 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tenderness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the masseter and temporalis muscle regions, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morning headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can arise due to sleep related bruxism. </br>Associated Features Additional symptoms include a variety of unpleasant muscle and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth sensations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, lim- itation of jaw movements, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orofacial pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    temporal/tension headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tooth wear
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, fractured teeth, and buccal lacerations also can occur.</br>These symptoms may be induced by sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but the connection may not be apparent to the affected indi- vidual and diagnostic discrimination is weak. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are frequently reported by both adults and children with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 usually involves the temporal regions and it has the charac- teristics of a tension 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It is reported either in the morning (more frequently) or during the day (with wake bruxism).</br>The estimated OR for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in individuals with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is &gt; 4 compared to controls. </br>There is high individual variability in the intensity and duration of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but in the most severe cases, hundreds of events can occur during a night of sleep.</br>However, no direct relationship has been observed between the severity of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the appearance of clinical signs and symptoms.</br>Indeed, indi- viduals with a mild to moderate index of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (2 to 4 RMMA 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    episodes/hour of sleep
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) have a higher risk of reporting painful jaw upon awakening (OR 3.9), and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    masticatory muscle fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (OR 5.1) compared to individuals with severe sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (&gt; 4 RMMA 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    episodes/hour of sleep
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Psychosocial components may also be linked to sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The psycholog- ical assessment of otherwise healthy adults with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 suggests a cor- relation (not yet proven as a causality) between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stress/anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Moreover, both children and adults with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 seem to have higher scores in stress, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 scales compared to control individuals. </br>Clinical and Pathophysiological Subtypes Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without clear cause is termed primary or idiopathic. </br>Forms of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with the use of psychoactive medications, recreational drugs, or a variety of medical disorders (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Down syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) are defined as secondary sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Treatment-induced sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is also termed iatrogenic. </br>Although the primary form of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is most often reported in healthy children and adults, secondary sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is observed in children with cere- bral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    palsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental retardation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and in adult patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oromandibular
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 myoclonus/facio-mandibular 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 commonly co-occur. </br>Tooth grinding and clenching also can occur during wakefulness, as an oral parafunc- tional activity known as awake bruxism.</br>Awake 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is considered a different dis- order, probably with different diagnostic criteria and pathophysiology; its association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is still under debate.</br>However, the two oral activities may coexist in the same individual. </br>Demographics The prevalence of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, based on reports from parents or sleep partner, is highest in childhood (approximately 14% to 17%) and then decreases over the life span.</br>In teenagers to young adults, prevalence is in the 12% range.</br>In young to middle-aged adults, it is approximately 8% but as little as 3% in older persons.</br>The reported reduction in tooth grinding in the elderly probably overestimates the actual Sleep Related Movement Disorders Sleep Related Movement Disorders reduction, because edentulism, use of dentures, and changes in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleeping behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (i.e., in isolation) may influence reporting.</br>There is no reported sex difference for the prev- alence of sleep related bruxism. </br>Predisposing and Precipitating Factors </br>Predisposing factors include personality types; for example, individuals who are highly motivated or characteristically maintain high vigilance may have an increased preva- lence of sleep related bruxism. </br>Genetic predisposition is plausible but still under investigation.</br>As described below, there is some 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial predisposition
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to environmental or shared genetic factors.</br>Recently, a 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    serotonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 gene was described in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients but the absence of distinction between the wake and sleep forms in this report preclude firm conclusions. </br>Precipitating factors can include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to current life events, tasks requir- ing high levels of performance, and repetitive tasks with short deadlines.</br>The use of cigarettes or 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 in the hours before sleep also can contribute to the occur- rence of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (probably due to the increased 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep instability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>The role of dental morphologic “defects” (occlusal interferences) remains controver- sial in the etiology of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Tooth contacts do not usually set in motion a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episode; they are usually late in the series of events occurring during sleep related bruxism/</br>tooth grinding.</br>Hence, the causality link between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth contact and sleep related bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not supported by the temporal sequence. </br>Familial Patterns Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tends to occur in families; approximately 20% to 50% of affected individuals have at least one direct family member with a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 grinding, and childhood sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 appears to persist into adulthood in two thirds of reported cases.</br>However, no genetic variants or genetic inheritance patterns so far have been associated with sleep related bruxism. </br>Onset, Course, and Complications The onset of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur during childhood, adolescence, or adulthood.</br>It is difficult to establish the time of onset with precision because it is mainly based on the awareness of the individual or</br>his/her family members who report the disorder. </br>306 Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in childhood has been reported by parents to begin as soon as both upper and lower teeth have erupted.</br>Secondary sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur at any age, but is more common in younger and middle-aged adults. </br>Even without a tooth grinding history or complaints, RMMA may be observed in most normal sleepers (on average, one episode per hour of sleep) across the life span.</br>However, in individuals with sleep related bruxism, jaw-muscle contractions are more frequent and more intense.</br>This may explain the secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth damage
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the occurrence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other symptoms. </br>The night-to-night variability in episodes of audible tooth grinding sounds is large (greater than 50% coefficient of variation).</br>In-laboratory polysomnographic record- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 indicate that the corresponding variability in frequency of RMMA is smaller (approximately 25%), although ambulatory recording has suggested somewhat higher RMMA variability.</br>First-night effect on RMMA index is minimal. </br>Dental damage and abnormal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth wear
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are the most frequent signs of the disorder.</br>However, they are not a direct proof of current sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and many contrib- uting factors have to be ruled out (e.g., type of diet in the occurrence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal tooth wear
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
).</br>Diagnostic discriminative strength of these dental findings is weak; severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    wear
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 cannot account for the index (i.e., frequency of RMMA).</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 could lead to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    temporomandibular joint disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, joint sound [click], or jaw movement limitations), although recent evidence does not support this association.</br>Transient morning 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orofacial pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including temporal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, is not uncommon, as described above.</br>Hypertrophy of the masseter and temporalis muscles can occur, but the diagnostic specificity of this finding for sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is also weak. </br>The natural course of this 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is usually benign.</br>Many individuals with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 remain asymptomatic for most of their lives.</br>Others can experi- ence associated symptoms (i.e., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) that may interfere with their quality of life and/ or sleep and may require treatments.</br>Further diagnostic investigations and assessment are recommended if sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with other more severe sleep or medical disorders (e.g., SRBD, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>Developmental Issues Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is frequently reported in childhood but decreases with age.</br>However, some individuals may experience it every night for most of their lives. </br>307 Sleep Related Movement Disorders Sleep Related Movement Disorders Conceptualizations of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children vary.</br>Some consider this a physiological oral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parafunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 while teeth are erupting or exfoliating, whereas others view this as a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with many associated signs and symptoms.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, especially in children, has been associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attention deficit hyperactivity disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, SRBD, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and many psychological and medical conditions. </br>In the elderly, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been observed in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or oral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tardive dyskinesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 persisting during sleep), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Pathology and Pathophysiology The majority of RMMA episodes during sleep (up to 80%) occur in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes typically follow a clear arousal sequence, starting with increased sympathetic-cardiac activity and fast electroenceph- alographic (EEG) waves in the minutes to seconds preceding the onset of an RMMA episode.</br>The jaw muscle contractions are then followed by, or are concomitant with, an increase in blood pressure and ventilation.</br>RMMA episodes sometimes conclude with swallowing.</br>Other causes of sleep bruxism onset are unknown, although potential candidates include airway resistance and oropharyngeal dryness. </br>In the majority of individuals with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the frequency of sleep arous- als is within the normal range.</br>However, they may have an exaggerated responsiveness to ongoing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or an increased magnitude of arousal.</br>Individuals with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 show more 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CAP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 phase A3 (as described by the scoring and analysis of cyclic alternating pattern (CAP) during sleep) than controls, an expression of increased arousal pressure and increased sleep instability.</br>This increased 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep instability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 seems to be the “permissive window” for occurrence of RMMA during sleep. </br>Objective Findings Polysomnographic (PSG) monitoring of individuals with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 demonstrates increased masseter and temporalis muscle activity during sleep, along with grinding sounds.</br>RMMA episodes can occur during all sleep stages, but are most common in sleep stages N1 and N2 (more than 80% of episodes), whereas fewer than 10% of RMMA episodes occur during REM sleep.</br>However, in some individuals, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs predominantly in REM sleep. </br>As described above, the majority of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes are temporally associated with sleep arousal and are preceded by signs of autonomic/cardiac activa- tion (e.g., increased heart rate and blood pressure). </br>308 Three subtypes of the EMG pattern of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been described: phasic activity at 1 Hz frequency with EMG bursts lasting 0.25 to 2 seconds; sustained tonic activity lasting longer than 2 seconds; or a mixed pattern.</br>An episode begins after at least a three-second interval with no muscle activity. </br>Polysomnography is not usually performed in otherwise healthy individuals with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in routine clinical settings.</br>However, PSG may be indicated to 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    demon-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 strate the disorder and to rule out associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, gastroesophageal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, night 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, faciomandibular 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The sensitivity of polysomnographic study in detecting sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in severe cases is moderate to high; in milder cases, however, it may be low due to the night-to-night variability in RMMA and tooth grinding. </br>Ambulatory home monitoring may be used for screening, diagnosis, and treatment outcome assessment by studying the individual in his/her usual environment, but it is characterized by lower diagnostic specificity due to the absence of audiovisual record- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (i.e., 20% overestimation in RMMA frequency is expected due to poor capacity to exclude concomitant nonspecific activities). </br>To record and score sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 activity (i.e., RMMA)</br>, there must be a minimum of one masseter muscle monitor, ideally with audiovisual recording, to associate muscular activity with grinding sound production.</br>Video monitoring helps distinguish 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orofacial and masticatory movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that normally occur during sleep (e.g., swallowing, coughing) and from specific 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tapping, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oromandibular myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>For the best level of diagnostic specificity and sensitivity, bilateral masseter and tem- poralis muscle EMG recordings, referenced to ear, mastoid, or zygomatic bone, are advisable. </br>Differential Diagnosis The disorder seldom poses diagnostic problems.</br>Evaluation for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    temporomandibular disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and damage to dentition is indicated. </br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 needs to be differentiated from other faciomandibular activities occurring during sleep, such as faciomandibular 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, SRBD, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, abnormal swallowing, gastro-esophageal reflux, night 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, dyskinetic jaw movements persisting in sleep (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dystonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chorea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyskinesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), and, rarely, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>309 Sleep Related Movement Disorders Sleep Related Movement Disorders 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Oromandibular
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or faciomandibular 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been observed in approximately 10% of individuals with severe sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but it can also occur in indi- viduals without abnormally increased RMMA events.</br>As opposed to sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, faciomandibular 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 consists of EMG bursts of brief duration (less than 250 milliseconds in length) in the facial muscles; these can occur either as isolated bursts or as a cluster of regularly or irregularly occurring brief bursts.</br>A high index of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oromandibular myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in sleep has been observed in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients. </br>Rhythmic jaw movements also have been observed in association with partial complex or generalized 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizure disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 needs to be considered in the differential diagnosis, although the presentation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as relatively isolated sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is very rare. </br>Unresolved Issues and Further Directions An expert 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 international group has proposed a diagnostic grading system of “possible,” “probable,” and “definite” for both sleep and awake bruxism.</br>Such a clinical tool will help to discriminate sleep bruxism from awake bruxism, although further validation is required for clinical and research purposes in all relevant dental and medical domains.</br>In summary, this group suggests that a rating of: (1) “possible” is given if based on self-report, by means of questionnaires, and/or the anamnestic part of a clinical examination; (2) “probable” sleep or awake 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is given if based on self-report and supportive physical findings; (3) “definite” sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 if based on self-report, physical findings, and a polysomnographic recording, preferably with audiovisual recordings. </br>The clinical relevance of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    comorbidity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with other medical problems such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attention deficit hyperactivity disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orofacial pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 needs to be assessed in order to distinguish primary benign forms of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from those that rep- resent an epiphenomenon of other more severe sleep and medical disorders. </br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be concomitant to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including any level of severity of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; further research is in progress to assess the specificity and validity of this association. </br>There is currently no evidence supporting the possibility that patients with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, in its primary form, are at increased risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; such a risk factor assessment needs long- term study before any conclusion can be drawn. </br>310 Investigation of genetic associations to sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 require large sample sizes, using valid tools to assess the specificity of RMMA versus other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oromandibular
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 activities and to discriminate gene candidates specific for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from those related to its comorbidities such as stress or other related triggers of RMMA. </br>Bibliography Abe S, Yamaguchi T, Rompré PH, De Grandmont P, Chen YJ, Lavigne GJ.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tooth wear
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in young subjects: a discriminator between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep bruxers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and controls?</br>Int J Prosthodont 2009;22:342–50. </br>Carra MC, Macaluso 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Rompre PH, et al.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Clonidine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 has a paradoxical effect on cyclic arousal and sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during NREM sleep.</br>Sleep 2010;33:1711–6. </br>Hublin C, Kaprio J, Partinen M, Koskenvuo M. Sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 based on self-report in a nationwide twin cohort.</br>J Sleep Res 1998;7:61–7. </br>Lavigne G, Guitard F, Rompre P, Montplaisir J. Variability in sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 activity over time.</br>J Sleep Res 2001;10:237–44. </br>Lavigne G, Manzini C, Huynh NT.</br>Sleep bruxism.</br>In: Kryger MH, Roth T, Dement WC, eds.</br>Principles and practice of sleep medicine, 5th ed.</br>St. Louis: Elsevier Saunders, 2011:1129–39. </br>Lobbezoo F, Ahlberg J, Glaros AG, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 defined and graded: An international consensus.</br>J Oral Rehab 2013;40:2–4. </br>Ohayon M, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Li K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Guilleminault C. Risk factors for sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the general population.</br>Chest 2001;119:53–61. </br>Rompre PH, Daigle-Landry D, Guitard F, Montplaisir JY, Lavigne GJ.</br>Identification of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subgroup with a higher risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Dent 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Res
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 2007;86:837–42. </br>Vetrugno R, Provini F, Plazzi G, et al.</br>Familial nocturnal facio-mandibular 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 mimicking sleep bruxism.</br>Neurology 2002;58:644–7. </br>311 Sleep Related Movement Disorders Sleep Related Movement Disorders Sleep Related Rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement Disorder ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.59 ICD-10-CM code: G47.69 Alternate Names Body rocking, head banging, head rolling, body rolling, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jactatio capitis nocturna
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, jac- tatio 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    corporis nocturna
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, rhythmie du sommeil. </br>Diagnostic Criteria Criteria A-D must be met A.</br>The patient exhibits repetitive, stereotyped, and rhythmic motor behaviors involving large muscle groups. </br>B. The movements are predominantly sleep related, occurring near nap or bedtime, or when the individual appears drowsy or asleep. </br>C. The behaviors result in a significant complaint as manifest by at least one of the following:1 .</br>Interference with normal sleep. </br>2. Significant impairment in daytime function. </br>3. Self-inflicted bodily injury or likelihood of injury if preventive measures are not used. </br>D.</br>The rhythmic movements are not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Notes .</br>When there are no clinical consequences of the rhythmic movements, the rhythmic movements are simply noted but the term rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not employed. </br>Essential Features Sleep related rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (RMD) is characterized by repetitive, ste- reotyped, and rhythmic motor behaviors (not 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) that occur predominantly during 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drowsiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or sleep and involve large muscle groups.</br>The occurrence of significant clinical consequences differentiates RMD from developmentally normal sleep related movements. </br>Typically seen in infants and children, but also in adults, RMD comprises several sub- types.</br>Body rocking may involve the entire body, with the individual on hands and knees, or it may be limited to the torso, with the individual sitting.</br>Head banging often occurs with the person prone, repeatedly lifting the head or entire upper torso, and forc- ibly banging the head back down into the pillow or mattress.</br>Alternately, the individual may sit with the back of the head against the headboard or wall, repeatedly banging the occiput.</br>Combining head banging and body rocking, they may rock on hands and knees, banging the vertex or frontal region of the head into the headboard or wall.</br>Head rolling consists of side-to-side head movements, usually with the child (or adult) in the supine position.</br>Less common rhythmic movement forms include body rolling, leg banging, or leg rolling.</br>Rhythmic humming or inarticulate sounds often accompany the body, head, or limb movements and may be quite loud. </br>Episodes often occur near sleep onset, although they also may occur at any time during the night and even during quiet wakeful activities, such as listening to music or trav- eling in vehicles.</br>The movement frequency can vary, but the rate is usually between 0.5 per second and two per second.</br>Duration of the individual movement clusters also varies but generally is less than 15 minutes.</br>Cessation of movements may occur 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fol-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lowing environmental disturbance or being spoken to.</br>Children who have sufficient language development to be asked about event recall in the morning are typically 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amnestic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for the episodes.</br>Rarely, adults will report a volitional component. </br>Sleep related rhythmic movements are common in normal infants and children.</br>Without evidence for significant consequences, the movements alone should not be considered a disorder.</br>Sleep related rhythmic movements should be considered a disorder only if the behaviors significantly interfere with normal sleep, cause significant impairment in daytime function, or result in self-inflicted 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bodily injury
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (or would result in injury if preventive measures are not used). </br>Associated Features The vast majority of infants and children with sleep related rhythmic movements are otherwise developmentally and intellectually normal, as are most adolescents and adults. </br>Clinical and Pathophysiological Subtypes Body Rocking: The whole body is rocked while on the hands and knees. </br>Head Banging: The head is forcibly moved, striking an object. </br>Head Rolling: The head is moved laterally, typically while in a supine position.</br>Other: Includes body rolling, leg rolling, and leg banging. </br>Combined: Involves two or more of the individual types. </br>313 Sleep Related Movement Disorders Sleep Related Movement Disorders Demographics At nine months of age, 59% of all infants have been reported to exhibit one or more of the following sleep related rhythmic movements: body rocking (43%), head banging (22%), or head rolling (24%).</br>At 18 months, the overall prevalence has been reported to decline to 33%, and by five years, to only 5%.</br>Most pediatric studies have found no sex difference. </br>Over 50 cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been reported in adolescents and adults, with a male pre- ponderance found in adults. </br>Predisposing and Precipitating Factors The soothing effect of vestibular stimulation has been proposed as the initiating factor in infants and toddlers.</br>Environmental stress and lack of environmental stimulation have also been proposed as factors.</br>One study found higher 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 scores in children with body rocking than in controls.</br>Self-stimulation has been suggested as a factor, particularly in intellectually disabled, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autistic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and emotionally disturbed children.</br>Rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been postulated to be a calming technique employed by children to combat 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been reported in association with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ADHD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Rhythmic movements may be used as a conscious strategy to relieve the urge to move or the uncomfortable 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sensations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. OSA-</br>associated RMD often improves with positive airway pressure.</br>Individuals with narco- lepsy may initiate rhythmic movements to terminate episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>In older children or adults, stereotypic movements may be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intellectual disability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism spectrum disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, in most of these cases, the movements are not predominantly sleep related, and an additional diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not indicated. </br>Familial Patterns A familial pattern has been reported rarely, as has occurrence in identical twins. </br>Onset, Course, and Complications The onset of sleep related rhythmic movements is typically in early childhood.</br>Body rocking has a mean age of onset of six months, head banging of nine months, and head rolling of ten months.</br>The condition may rarely present at an older age following central nervous system 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep related rhythmic movements commonly resolve in the second or third year of life.</br>Persistence at five years of age occurs in about 5% of children.</br>Sleep related movements rarely continue into adolescence and adulthood. </br>314 Worsening or spontaneous onset in adults is very rare.</br>In some adult cases the chief concern is disturbance of the bed partner’s sleep.</br>Most adolescents and adults have one form of RMD, although some have two or more. </br>Head banging is the most disturbing form of the problem.</br>Typical cases in infants and toddlers pose little risk of serious injury.</br>Vigorous rhythmic movements can produce loud noises when the patient hits the bed frame or when the bed bangs against the wall or floor.</br>The noises can be very disturbing to other family members.</br>Parental concern is common, and psychosocial consequences in the older individual can be distressing.</br>It is important to discuss appropriate safety precautions with the patient’s caretak- ers.</br>Under extraordinary circumstances, particularly in the developmentally disabled, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    injury to soft tissues or bone has been reported.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 </br>Developmental Issues Because age-related factors are a critical dimension for RMD, developmental issues are discussed under Essential Features and other sections. </br>Pathology and Pathophysiology In infants and young children, rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been hypothesized to promote motor development by stimulation of the vestibular system.</br>More recently, the role of inhibitory control on the central motor pattern generator has been sug- gested as a physiologic mechanism to explain both pediatric and adult forms of sleep related rhythmic movements. </br>Objective Findings Polysomnographic scoring rules for RMD are defined in the AASM Manual for the Scoring of Sleep and Associated Events.</br>Video-polysomnographic studies have shown rhythmic movements to occur most often in association with stages N1 and N2 sleep; 46% occur while falling asleep or during NREM sleep; 30% during both NREM and REM sleep; and 24% only during REM sleep.</br>The exclusively REM-related rhythmic movements occur more frequently in adults.</br>Although an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 etiology has been reported in one individual, most EEG studies have shown normal activity between epi- sodes of rhythmic behavior. </br>Differential Diagnosis RMD must be distinguished from other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    repetitive movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 involving restricted small muscle groups, such as sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, thumb sucking, and rhythmic sucking of a pacifier or the lips, as well as other specifically defined rhythmic movements of sleep, such as hypnagogic foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>315 Sleep Related Movement Disorders Sleep Related Movement Disorders In adults, RMD can be misdiagnosed as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or be comorbid with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Video poly- somnography is particularly helpful in these cases.</br>Rhythmic movements may occur as a conscious or unconscious strategy to relieve 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms.</br>If the rhythmic move- ments are clearly in response to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS sensations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, then a separate diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not needed.</br>However, RMD may be diagnosed if RMD criteria are met and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 does not adequately explain the presence or extent of rhythmic movements. </br>Children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism spectrum disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often exhibit 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    repetitive behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but these movements typically occur during wakefulness and are not predominantly sleep related.</br>Stereotypic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnosis that is typically seen with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intellectual disability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and is not predominantly sleep related.</br>In children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism spectrum disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intellectual disability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, an additional diagnosis of RMD should be made only if the movements are predominantly sleep related.</br>Akathisia is seen as a complication of neuroleptic medi- cation and is not predominantly sleep related. </br>Autoerotic or masturbatory behaviors may involve body rocking or other repetitive body movements, but the primary focus is genital stimulation as is evident by direct genital contact.</br>Rarely, RMD needs to be differentiated from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tic disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    involuntary movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with other neurological conditions. </br>Unresolved Issues and Further Directions </br>There is controversy about the classification of hypnagogic foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a separate entity or as a subtype of sleep related rhythmic movements.</br>Many aspects of sleep related rhythmic movements deserve further study, including the relationship of the typical form seen in otherwise normal infants and young children to the rhythmic movements seen in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intellectual disability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism spectrum disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The pathophysiology of persistent RMD is poorly understood, as is the association with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in adults. </br>Bibliography Dyken M, Lin-Dyken D, Yamada T. Diagnosing rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with video-polysomnography.</br>Pediatr Neurol 1997;16:37–41. </br>Kohyama J, Matsukura F, Kimura 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Tachibana N. Rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: polysomnographic study and summary of reported cases.</br>Brain Dev 2002;24:33–8. </br>Laberge L, Tremblay R, Vitaro F, Montplaisir J. Development of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from childhood to early adolescence.</br>Pediatrics 2000;106:67–74. Manni R, Terzaghi M. Rhythmic movements during sleep: a physiological and pathological profile.</br>Neurol Sci 2005;26:s181–5. </br>Mayer G, Wilde-Frenz J, Kurella B. Sleep related rhythmic movement disorder revisited.</br>J Sleep Res 2007;16:110–6. </br>316 Benign 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Myoclonus of Infancy ICD-9-CM code: 327.59 Alternate Names Benign neonatal sleep myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-E must be met ICD-10-CM code: G47.69 Sleep Related Movement Disorders A. Observation of repetitive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that involve the limbs, trunk, or whole body. </br>B. The movements occur in early infancy, typically from birth to six months of age. </br>C. The movements occur only during sleep. </br>D.</br>The movements stop abruptly and consistently when the infant is aroused. </br>E.</br>The disorder is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or medication use. </br>Essential Features Benign sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of infancy (BSMI) is characterized by repetitive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that occur during sleep in neonates and infants.</br>Although BSMI is benign and relatively rare, it is included in the sleep related movement disorders section because it is commonly confused with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, unlike the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the jerks of BSMI occur exclusively during sleep.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are often bilateral and massive, typically involving large muscle groups.</br>The movements can occur in the whole body or exclusively in the limbs, the trunk, or rarely, the face. </br>Associated Features Not applicable or known. </br>Clinical and Pathophysiological Subtypes Most infants with BSMI are neurologically normal, born to mothers with no history of illicit drug use.</br>However, BSMI has been described in more than half of infants with neonatal opioid 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    withdrawal syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, suggesting a subtype with this specific etiology.</br>It must be stressed, however, that some cases of neonatal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abstinence syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 do not follow a benign clinical course.</br>Whether such cases should be included with those of BSMI is an unresolved matter. </br>317 Sleep Related Movement Disorders Demographics The prevalence is unknown.</br>The incidence has been estimated at 3.7 per 10,000 live births.</br>More than 200 cases have been described in the literature.</br>Males are affected more than females by a ratio of about 2:1.</br>The typical age range is birth to six months of age. </br>Predisposing and Precipitating Factors </br>Predisposing factors have not been delineated.</br>Rocking or repetitive noises may pre- cipitate individual episodes of BSMI. </br>Familial Patterns Familial occurrence has been described. </br>Onset, Course, and Complications Onset is usually noted between birth and one month of age in a neurologically normal infant.</br>The course is self-limited and benign.</br>The disorder may be present for only a few days or may last for several months.</br>Maximum expression is typically between 15 and 35 days of age.</br>BSMI resolves by three months of age in 64% of affected infants, by six months in 95%, and by 12 months in 97% with persistence rarely into the second year of life or later.</br>There are no known complications.</br>Long-term follow-up in a limited number of children has shown normal psychomotor development and normal cognitive function at five to 10 years of age.</br>There is no evidence for an increased risk of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Developmental Issues Because age-related factors are a critical dimension for BSMI, developmental issues are discussed throughout this section. </br>Pathology and Pathophysiology The presence of a generator in the cervical spinal cord that is not adequately inhibited due to immature myelination of descending pathways has been hypothesized. </br>Objective Findings Video-polysomnographic EEG and EMG monitoring has demonstrated paroxysmal muscle activity, without ictal or interictal EEG abnormalities.</br>BSMI occurs predom- inantly during quiet sleep but also may be present during active sleep.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are usually seen in clusters of four or five jerks per second, each jerk lasting 40 to 300 milliseconds.</br>BSMI clusters typically repeat in irregular series for one to 15 minutes, but, in some cases, the clusters may recur for up to 60 minutes or longer and be mistaken for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    status epilepticus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>One study showed 30% of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to involve the whole body, 20% to involve the abdominal or proximal muscles, and 50% to involve only the arms or the legs.</br>The arms are usually more involved than the legs.</br>Activity is symmetrical in over 90% of cases but can be lateralized.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not associ- ated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, awakenings, or sleep stage transitions. </br>Spontaneous or provoked awakening of the infant leads to prompt, abrupt, and consis- tent cessation of the movements.</br>Gentle rocking of the infant or the infant’s crib has been shown to provoke the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>This may be a useful maneuver during EEG monitoring when differentiation from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is of concern.</br>In contrast to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jitteriness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other nonepileptic etiologies, BSMI will often increase rather than be suppressed by gentle restraint.</br>Neuroimaging studies are normal. </br>Differential Diagnosis BSMI should be distinguished from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; misdiagnosis may lead to unnecessary diagnostic testing or medication use.</br>The absence of episodes while awake in infants with BSMI is the single most helpful clinical feature.</br>In addition, BSMI will stop abruptly and consistently when the infant is aroused.</br>Neonatal sei- zures are often seen in the context of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    perinatal disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxic-ischemic encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, whereas BSMI is typically present in neurologically normal infants.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Infantile spasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (West syndrome) are most often seen after the first month of life but sometimes occur earlier.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Infantile spasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are usually manifest by sudden head flexion with arm extension and lower extremity flexion.</br>They are usually associated with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypsarrhythmic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 EEG pattern.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pyridoxine- dependency seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are responsive to treatment with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vitamin B6
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>In cases that are dif- ficult to differentiate, an EEG obtained during sleep will show normal patterns when BSMI is elicited by gentle rocking.</br>Anticonvulsant medications are ineffective and unnecessary in BSMI. </br>BSMI also should be distinguished from other disorders that occur during wakeful- ness, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic encephalopathies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperekplexia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (startle disease), drug withdrawal, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jitteriness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Benign 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of early infancy usually occurs after the third month of life and only occurs during wakefulness. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur in infants but typically has a distinctly different duration and fre- quency.</br>The muscle activity is of longer duration (0.5 to 10 seconds) and recurs at a more regular and longer interval (typically 20 to 40 seconds).</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be associated with EEG 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, whereas BSMI is not.</br>BSMI is more often seen in the arms than the legs, whereas 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 predominantly occurs in the lower limbs. </br>319 Sleep Related Movement Disorders Sleep Related Movement Disorders Phasic-REM muscle activity typically involves smaller muscle groups and can be linked to observable eye movements.</br>Sleep starts occur at the wake-sleep transition and typ- ically are not repetitive.</br>Propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at sleep onset is a rare disorder that has not been reported in children and is characterized by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 involving the abdominal and truncal muscles at the transition from wakefulness to sleep.</br>Fragmentary myoclo- nus has been described in adults and is primarily a nonspecific EMG finding with little or no visible movement. </br>Unresolved Issues and Further Directions The prevalence, incidence, and pathophysiology of BSMI warrant further study. </br>Bibliography Alfonso I, Papazian O, Aicardi J, Jeffries HE.</br>A simple maneuver to provoke benign neonatal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Pediatrics 1995;96:1161–3. </br>Di Capua M, Fusco L, Ricci S, Vigevano F. Benign neonatal sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: clinical features and video- polygraphic recordings.</br>Mov Disord 1993;8:191–4. Held-Egli 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Rüegger C, Das-Kundu S, Schmitt B, Bucher HU.</br>Benign neonatal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in newborn infants of opioid dependent mothers.</br>Acta Paediatrica 2009;98:69–73. </br>Hrastovec A, Hostnik T, Neubauer D. Benign 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    convulsions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in newborns and infants: Occurrence, clinical course and prognosis.</br>Eur J Paediatr Neurol 2012;16:64–73. </br>Maurer VO, Rizzi M, Bianchetti MG, Ramelli GP.</br>Benign neonatal sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a review of the literature.</br>Pediatrics 2010;125:e919–24. Propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at Sleep Onset ICD-9-CM code: 327.59 ICD-10-CM code: G47.69 Alternate Names Spinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, plurisegmental 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, intersegmental 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, axial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Diagnostic Criteria Criteria A-E must be met A.</br>The patient complains of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sudden jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, mainly of the abdomen, trunk, and neck. </br>B. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 appear during relaxed wakefulness and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drowsiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as the patient attempts to fall asleep. </br>C. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 disappear upon mental activation and with onset of a stable sleep stage. </br>D. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 result in difficulty initiating sleep. </br>E.</br>The disorder is not better explained by another 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medication use, or substance use disorder. </br>Notes .</br>Although there is no current definitive evidence that propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 confined to sleep onset is associated with significant structural lesions of the spinal cord, propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that is persistent during the day has been linked to structural spinal cord pathology in 16% to 20% of cases. </br>Essential Features Propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at sleep onset (PSM) consists of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sudden myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurring in the transition from wakefulness to sleep and, rarely, during intrasleep wakefulness and upon awakening in the morning.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 arise mainly in the axial muscles and spread rostrally and caudally according to propriospinal propagation.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be of variable intensity; they are isolated, recurring in quasi-periodic fashion for variable durations, or may be repeated in brief clusters of a few movements, sepa- rated by longer intervals.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 involve the abdominal and truncal muscles first and are then propagated to proximal muscles of the limbs and the neck.</br>The pattern of move- ment is usually flexor but may be an extension of the trunk.</br>Vocalization rarely occurs.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are most often spontaneous but, in some cases, can be evoked by external stimulations.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 appear to be related to the recumbent position and a state of Sleep Related Movement Disorders Sleep Related Movement Disorders relaxed wakefulness, particularly when the patient tries to fall asleep.</br>Any mental acti- vation makes the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 disappear.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 eventually disappear at sleep onset and remain absent throughout all stages of sleep, even though they sometimes reappear during intrasleep wakefulness. </br>Associated Features PSM often is associated with severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-onset insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to the inability of the patient to fall asleep because of the recurrent disturbing muscular activity. </br>Clinical and Pathophysiological Subtypes PSM may be considered a variant of the more generally described propriospinal myoc- lonus seen during the daytime.</br>In daytime PSM, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 involve the thoracoab- dominal/paraspinal or cervical muscles and spread caudally or rostrally to the other myotomes.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are provoked or worsened by the recumbent position and cannot be voluntarily suppressed.</br>They are often preceded by premonitory sensations, are stable over time, and respond unpredictably to drug treatment.</br>The frequent presleep worsening of daytime PSM (around 50% of the cases) suggests that patients with PSM may have a milder or variant form of a single clinical and neurophysiologic entity. </br>Demographics Epidemiologic data are lacking.</br>PSM is probably a rare condition.</br>A higher prevalence in men is reported.</br>The disorder affects adults and has not been reported in children. </br>Predisposing and Precipitating Factors Not applicable or known. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications PSM arises in adulthood and is usually a chronic, unremitting condition.</br>Patients may develop a fear of falling asleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Intense 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may cause 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    injury to the patient or the bed partner.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 </br>Pathology and Pathophysiology The pathophysiology of PSM is unknown.</br>PSM is thought to originate from a focal spinal pattern generator, set into motion by supraspinal dysfacilitatory influences typical of the state of relaxed wakefulness and drowsiness.</br>PSM is presumed to propagate up and down the spinal cord via slowly conducting, long propriospinal (intersegmental) pathways.</br>A focal spinal generator thus is able to recruit muscles from multiple segments. </br>Objective Findings Polysomnography demonstrates brief 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 EMG bursts recurring nonperiodi- cally with alpha activity present on the EEG and, in particular, when alpha activity spreads from the posterior to the anterior brain regions.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epileptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 EEG discharges are not observed in PSM.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 disappear either with EEG desynchronization, due to mental activation, or with appearance of sleep spindles and K-complexes.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 remain absent throughout sleep but may occasionally reappear upon awakening and during intrasleep wakefulness.</br>Polysomnography with extended EMG recording demonstrates that the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 arise first in spinal innervated muscles and then propagate to more caudal and rostral muscles according to a propriospinal pattern of propagation.</br>Detailed analysis of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 shows that the EMG activity originates in muscles innervated by thoracic or cervical spinal segments (sternocleidomastoid, paraspinalis, rectus abdominis) and then spreads to more rostrally and caudally innervated muscles at a slow velocity (2 to 16 milliseconds; around 5 milliseconds on average).</br>Back-averaging of the EEG does not show any jerk-locked cortical activity.</br>MRI of the brain is normal.</br>In a recent review of PSM, only one patient with exacerbation at sleep onset had a hypersignal at T10-T11 and a nonspecific medullary cone lesion.</br>The remaining patients had no signs on spinal cord MRI at sleep onset. </br>MRI of the spine is usually normal but demonstrates a focal lesion in around 20% of the cases.</br>The causal relationship of PSM with these spinal lesions is unclear, although magnetic resonance diffusion tensor imaging with fiber tracking may demonstrate spinal tract disorganization. </br>Differential Diagnosis PSM shows features similar to those of the syndrome of intensified sleep starts.</br>However, sleep starts (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) usually appear during the transition between wakefulness and sleep and during light NREM sleep, whereas PSM may sometimes be present during relaxed wakefulness.</br>Unlike PSM, sleep starts (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) some- times affect only one or a few body segments; propriospinal propagation is not present in neurophysiological studies of sleep starts.</br>Phasic REM twitches, which are a normal phenomenon during REM sleep, involve the distal muscles of the hands and face, often without displacement of the body segment.</br>Fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 resembles physiological 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but in an enhanced form, and persists throughout all stages of NREM and REM sleep.</br>Both physiological 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and frag- mentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are EMG findings not associated with overt muscular activity and Sleep Related Movement Disorders Sleep Related Movement Disorders do not involve muscles acting across large joints.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epileptic myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not confined to relaxed wakefulness and may be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 discharges on the EEG.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are longer in duration, involve mainly the lower limbs, and usually spare truncal and abdominal muscles.</br>PLMs may begin during presleep wakefulness but generally occur during NREM sleep.</br>Some patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may have prominent PLMs in wakefulness while sitting or lying down.</br>However, prominent leg discomfort is usually present in these patients.</br>Occasionally PSM may be present in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS/PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients in wake before sleep, but the EMG morphology is different.</br>In addition, when 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 involving leg muscles appear, the PSM disappears.</br>Psychogenic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may simulate PSM but the muscle recruitment pattern, the spread velocity, and the record- ing of cortical premovement activity observed before voluntary movements may be useful to differentiate the two types of jerks. </br>Unresolved Issues and Further Directions Future studies are needed to better define the distinctions between PSM and related conditions such as sleep starts (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) and, in particular, the syndrome of inten- sified sleep starts.</br>Also, neuroimaging and possibly postmortem studies may detect the neural structures responsible for the initiation of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Bibliography Montagna P, Provini F, Plazzi G, Liguori R, Lugaresi E. Propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 upon relaxation and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drowsiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a cause of severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Mov Disord 1997;12:66–72. </br>Montagna P, Provini F, Vetrugno R. Propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at sleep onset.</br>Neurophysiologique clinique 2006;36:351–5. Roze E, Bounolleau P, Ducreux D, et al.</br>Propriospinal myclonusmyoclonus revisited.</br>Clinical, neurophysiologic, and neuroradiologic findings.</br>Neurology 2009;72:1301–9. </br>Tison F, Arne P, Dousset V, Paty J, Henry P. Propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 induced by relaxation and drowsiness.</br>Rev Neurol (Paris) 1998;154:423–5. </br>Vetrugno R, Provini F, Meletti S, et al.</br>Propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at the sleep-wake transition: a new type of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep 2001;24:835–43. </br>324 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medical Disorder ICD-9-CM code: 327.59 ICD-10-CM code: G47.69 Diagnostic Criteria Criteria</br>A-C must be met A.</br>The patient manifests sleep related movements that disturb sleep or its onset. </br>B. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs as a consequence of a significant underlying medical or neurological condition. </br>C. The symptoms are not better explained by another sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, other untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, substance use, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>This diagnosis is intended for sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to an underlying medical or neurologic condition that do not meet criteria for another specific 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Many neurological conditions may be associated with movement abnormali- ties that are evident in wake and sleep.</br>In some cases, the nocturnal manifestations of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be apparent before establishment of a firm neurolog- ical diagnosis.</br>Thus, in some cases, “sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder” is a temporary diagnosis, given when a sleep diagnosis is required before the underlying medical or neurological condition can be fully diagnosed.</br>Once the pres- ence of a medical or neurological condition is clearly established, that becomes the sole diagnosis unless the sleep complaint is the focus of independent clinical attention. </br>When a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that is listed elsewhere in the sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 section of the International Classification of Sleep Disorders, 3rd Edition is caused or exacerbated by a medical or neurological condition (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless legs syn- drome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), it is preferred that the more specific diagnosis (e.g., RLS) be used rather than “sleep related movement due to a medical disorder,” with annotation of the relation- ship to the medical or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Sleep Related Movement Disorders Sleep Related Movement Disorders Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Due to a Medication or Substance ICD-9-CM code: 292.85 (drug-induced); 291.82 (alcohol-induced) ICD-10-CM code: F11-F19 (see table in Appendix B for detailed coding instructions) </br>Diagnostic Criteria Criteria</br>A-C must be met A.</br>The patient manifests sleep related movements that disturb sleep or its onset. </br>B. The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs as a consequence of current medication or substance use or withdrawal from a wake-promoting medication or substance. </br>C. The symptoms are not better explained by another sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, other untreated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or medical, neurological, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>This diagnosis is intended for sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance (toxin or other bioactive substance) that do not meet criteria for another spe- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cific movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Many substances may be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement abnor- malities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that are evident in wake and sleep.</br>To the extent that the movement abnormal- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is an expected complication of the substance(s) involved (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tardive dyskinesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    akathisia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with neuroleptic usage), this diagnosis is unnecessary unless the sleep related aspects of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement abnormality
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or its sequelae, are the focus of independent clinical attention. </br>When a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that is listed elsewhere in the sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 section of the International Classification of Sleep Disorders, 3rd Edition is caused or exacerbated by drugs or substances (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), it is pre- ferred that the more specific diagnosis (e.g., RLS) be used rather than “Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance,” with annotation of the relation- ship to drug or substance.</br> Sleep Related Movement Disorder, Unspecified ICD-9-CM code: 327.59 ICD-10-CM code:</br>G47.69 This diagnosis is assigned when patients have a sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that cannot be classified elsewhere or is suspected to be associated with an underlying psy- chiatric condition.</br>In some cases, “sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, unspecified” is a temporary diagnosis prior to establishment of an underlying 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 condition that may explain the sleep related movement (e.g., movements associated with posttrau- matic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stress disorder nightmares
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 prior to firm establishment of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric diag-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 nosis).</br>Once the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 diagnosis is established, that becomes the sole diagnosis unless the sleep complaint is the focus of independent clinical attention. </br>327 Sleep Related Movement Disorders Sleep Related Movement Disorders Isolated Symptoms and Normal Variants Excessive Fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Excessive fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (EFM) is a largely incidental polysomnographic finding on EMG, characterized by small movements of the corners of the mouth, fingers, or toes, or by no visible movement at all.</br>The finding is associated with no known clinical consequence.</br>Large limb movements across large joint spaces are not characteristic of EFM and, if present, should exclude the diagnosis of EFM.</br>Scoring of EFM is described in the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events.</br>The condition is a NREM phenomenon and the move- ments resemble the phasic twitches seen in normal REM sleep except that they are more universally dispersed throughout a sleep epoch than phasic REM twitches, which are generally clustered within small groups in a sleep epoch.</br>Its importance lies in that it is within the differential diagnosis of other sleep related movement disorders. </br>Patients usually are not aware of the twitch-like movements.</br>Patients may have other coexistent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but EFM does not appear to contribute to the symptoms of these 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>EFM, a NREM phenomenon, is less common than phasic REM twitches, which occur in REM sleep in normal individuals without sleep complaints.</br>Most cases have been reported in adults.</br>EFM is predominantly found in males.</br>A recent study found EFM in 100% of 62 patients with a variety of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, bringing into question the specificity of EFM. </br>Numerous causes of chronic sleep fragmentation may be associated with EFM.</br>The condition has been described with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and primary central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related hypoxemic/hypoventilation syndromes, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and various causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients, the twitching intensifies during periods of increased 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>One report has found excessive fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to be very common in children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Niemann-Pick disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, type C. No specific precipitating factors have been reported.</br>The contribution of EFM to the symptomatology of any of these disorders is unknown. </br>The course is not well studied but appears to be benign and non-progressive.</br>The dis- order may be the sole abnormality in some cases of excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but causality is questionable.</br>No other serious consequences of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been described when it occurs in isolation. </br>328 In some cases, EFM is present in normal individuals.</br>Its relatively benign course sug- gests that it is not associated with a neurodegenerative process.</br>In most reported cases, there have been associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep disruption, suggesting that EFM may be due to disruptions of normal motor-control mechanisms during sleep.</br>Whether there is a genetic or other basis predisposing individuals to develop the condi- tion is unknown.</br>In any case, it would appear to result from intensification of an other- wise normal motor phenomenon.</br>The predominant topographic distribution of EFM in distal and facial muscles suggests that cortical motor centers participate in its generation. </br>EFM is detected as isolated, very brief (usually 75 to 150 milliseconds), asymmetrical, asynchronous EMG potentials in various muscles of the face, trunk, arms, and legs.</br>The amplitude varies from approximately 50 to several hundred microvolts; the taller amplitudes are often associated with visible movement of the fingers, toes, or corners of the mouth, whereas the smaller ones may resemble 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fasciculation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 potentials and be without overt movement.</br>Large movements across large joint spaces preclude a diag- nosis of EFM.</br>Small twitch-like movements may be observed on video recording.</br>Episodes of these 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 potentials typically last from 10 minutes to several hours.</br>They often appear at sleep onset and continue through the NREM sleep stages, includ- ing slow wave sleep.</br>The presence of EFM in REM is difficult to determine because it is superimposed on the normal phasic clusters of physiological phasic REM twitches.</br>EFM is electromyographically similar to the latter.</br>Occasionally, the EMG activity also persists during EEG periods of wakefulness within the sleep period or is present in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drowsiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 prior to sleep onset.</br>The EEG usually shows no changes at the time of the movements, although high-amplitude EMG potentials may be associated with a 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 complex or even with transient EEG arousal.</br>There are no ocular or autonomic accom- paniments.</br>It seems possible that, depending on the digitalization rates, digital systems may record less fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 than earlier paper records.</br>No laboratory tests other than polysomnography (optimally with multiple EMG leads) have been reported to be helpful in assessing EFM. </br>EFM generally has a maximum burst duration of only 150 milliseconds and does not recur periodically.</br>It can be distinguished from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 because 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are character- ized by a longer burst duration (typically 0.5 to 10 seconds) and a long period between bursts (5-90 seconds).</br>EFM, which occurs in NREM, must also be differentiated from normal physiological phasic REM twitches, which have a similar burst duration but are limited to the REM state and tend to occur in clusters within an epoch, as opposed to EFM in which bursts tend not to cluster within a particular epoch.</br>Larger body move-</br>ments across the large joints are not a feature of excessive fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The presence of such movements suggests other disorders. </br>329 Sleep Related Movement Disorders Sleep Related Movement Disorders Further investigation is necessary to determine whether EFM occurs as a consequence of sleep disruption or whether it is an independent cause of sleep disruption and daytime symptoms in its own right.</br>It must also be determined whether there are any physiolog- ical differences that distinguish fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 seen in many normal individu- als from EFM.</br>It is not known whether some additional pathophysiological element is required to increase fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 into an abnormal range.</br>The current thresh- old for the diagnosis of EFM should be further investigated because the scoring criteria lack specificity.</br>The apparent strong predominance in males also remains unexplained. </br>Bibliography Broughton R. Pathological fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, intensified sleep starts and hypnagogic foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: three unusual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-related disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In: Koella WP, Schulz OF, Visser P, eds.</br>Sleep 1986.</br>Stuttgart:</br>Fischer-Verlag, 1988:240–3. </br>Broughton R, Tolentino MA.</br>Fragmentary pathological 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in NREM sleep.</br>Electroencephalogr Clin Neurophysiol 1984;57:303–9. </br>Broughton R, Tolentino MA, Krelina M. Excessive fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in NREM sleep: a report of 38 cases.</br>Electroencephalogr Clin Neurophysiol 1985;61:123–33. </br>Frauscher B, Kunz A, Brandauer E, Ulmer H, Poewe W, Hogl B. Fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in sleep revisited: A polysomnographic study in 62 patients.</br>Sleep Med 2011;12:410–5. </br>Goyal MK, Kumar G, Sivaraman M. Sahota P. Teaching neuroimages: excessive fragmentary hypnic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Neurology 2011;77:e59–e60. </br>Lins O, Castonguay M, Dunham W, Nevsimalova S, Broughton R. Excessive fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: time of night and sleep stage distributions.</br>Can J Neurol Sci 1993;20:142–6. </br>Vankova J, Stepanova I, Jech R, et al.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and hypocretin deficiency in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Niemann-Pick disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type C. Sleep 2003;26:427–30. </br>Vetrugno R, Plazzi G, Provini F, Liguori R, Lugaresi E, Montagna P. Excessive fragmentary hypnic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: clinical and neurophysiological findings.</br>Sleep Med 2002;3:73–6. </br>Montagna P, Liguori R</br>et al.</br>Physiological 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Electroencephalogr Clin Neurophysiol 1988;70:172–6. </br>Hypnagogic Foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and Alternating Leg Muscle Activation Hypnagogic foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (HFT) is rhythmic movement of the feet or toes that occurs at the transition between wake and sleep or during light NREM sleep (stages N1 and N2).</br>Alternating leg muscle activation (ALMA) consists of brief activation of the ante- rior tibialis in one leg in alternation with similar activation in the other leg during sleep or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from sleep.</br>HFT may be a relatively common and normal finding.</br>Affected individuals move the feet or the toes rhythmically for seconds to minutes during drowsy wakefulness or lighter stages of sleep.</br>It can be pathologically exagger- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ated
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 in some patients.</br>ALMA is defined by a polysomnographic pattern with unknown clinical manifestations, but frequency of muscle activations, length of activations, and occurrence primarily with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 suggest that ALMA may be similar to HFT or rep- resent an EMG manifestation of some episodes of HFT.</br>The original case series that described ALMA did not link it with movement of the lower extremity, but a subse- quent report did.</br>HFT and ALMA are considered together because the relationship between them remains to be clarified, and the similarity in a number of their features suggests they may not be fully independent entities. </br>Associated features of HFT and ALMA are similar.</br>Most cases of HFT have been reported in persons with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SRBDs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>ALMA has been identified mainly in patients with SRBD or PLMs.</br>Seventy-five percent of patients with ALMA in the original series used 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 medication.</br>In that study, patients with ALMA complained of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    restless of the legs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but only one reported patient had more specific 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of sudden nocturnal muscle contractions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in his legs and a sensation that his legs were vibrating.</br>A separately reported case of a patient with ALMA documented absence of any SRBD, PLMs, or use of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 medication.</br>This patient complained of frequent and easily provoked awakenings, as well as excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The ALMA and symptoms responded to treat- ment with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pramipexole
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
. </br>The single series in which HFT was studied found that it occurs in 7.5% of patients in whom a polysomnogram was performed for other reasons.</br>Affected individuals range in age from 14 to 72 years, with a majority in the middle-age range (40 to 65 years).</br>Men and women are equally affected.</br>It is possible that the frequency of these move- ments may be increased in individuals with disorders such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or SRBD, but it can occur in individuals with otherwise normal sleep.</br>The prevalence of the condition in the general population and its frequency in affected individuals remains uncertain.</br>The initial series reporting ALMA found that it occurs in 1.1% of unselected studies from a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 center.</br>Patients with ALMA were mostly male (11:5) and ranged in age from 12 to 70 years, with most aged 35 to 55 years (mean age 41 years).</br>Therefore, the age ranges of both conditions are similar, with both males and females affected.</br>These distributions may be due to the incidental discovery of both entities during routine sleep studies for other sleep complaints. </br>No predisposing factors are known for HFT.</br>The use of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 medication may increase risk for ALMA. </br>No longitudinal studies have been performed for either entity.</br>In some individuals, HFT is an occasional finding, but others appear to manifest the rhythmic movements Sleep Related Movement Disorders Sleep Related Movement Disorders on many nights and over a span of at least months.</br>ALMA showed some tendency to persist between two different recordings in the originally reported series.</br>Because most individuals are unaware of the presence of the HFT movements, and patients with ALMA may have no associated complaint or awareness of the phenomenon, the evo- lution of HFT and ALMA may be difficult to follow except in the sleep laboratory or with home monitoring.</br>Although usually an incidental and benign finding, HFT may cause sleep disruption and sleep-onset 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 if sufficiently prolonged or severe. </br>In HFT, the patient typically reports foot movements (directly experienced or observed by others) that occur at the transition between wake and sleep or during light sleep.</br>On occasion, movement has not been observed but HFT is seen as an incidental finding on sleep study conducted for other indications.</br>Polysomnography demonstrates a pattern of brief, repeated activation of the anterior tibialis in one leg.</br>The minimum frequency is 0.3 Hz; the maximum 4.0 Hz.</br>Multiple leg activations in a single leg occur in a train of at least four movements.</br>EMG recordings of the foot or leg muscles or video record- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 of movement may show trains of recurrent 1-Hz to 2-Hz EMG potentials or move- ments.</br>Typical associated EMG bursts are 300 to 700 milliseconds in duration, and the typical duration of trains is 10 to 15 seconds, although longer bursts and trains have been reported.</br>In morbid conditions, trains may persist much longer.</br>Events are recorded at the transition into sleep and during stages N1 and N2 sleep.</br>Distribution over the night has not been fully investigated.</br>Persistent HFT has been found in about half of the indi- viduals who have had multiple studies.</br>Alternation between legs has not been described, but its potential occurrence is suggested in two published studies of HFT. </br>In ALMA, polysomnography demonstrates a pattern of brief, repeated activation of the anterior tibialis in one leg alternating with similar activation in the other leg.</br>At a minimum, a single leg muscle activation in one leg is followed sequentially by a similar single activation in the other leg, reactivation in the original leg, and then reactivation in the alternate leg, with some continued alternation beyond this minimal sequence in most instances.</br>The minimum frequency of alternating EMG bursts is 0.5 Hz, and the maximum frequency is 3.0 Hz.</br>The patient may report foot movements (directly experi- enced or observed by others) that occur at the transition between wake and sleep or during light sleep.</br>As noted above, there is frequently no observation of movement reported but alternating leg muscle activation is recorded as an incidental finding on polysomnography. </br>ALMA can be demonstrated by polysomnography if the surface EMG is recorded inde- pendently from both right and left anterior tibialis muscles.</br>A sequence of ALMA may begin with one to several lengthy activations (one to two seconds) in one or both legs.</br>Some patients show unilateral activity at times.</br>ALMA usually closely precedes or follows an arousal or awakening and gradually diminishes as sleep returns.</br>However, ALMA can also emerge without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from any sleep stage.</br>Proclivity for any spe- cific portion of the nocturnal sleep cycle has not been identified.</br>Leg muscle activa- tions during REM sleep, in comparison to NREM sleep, are often briefer and some-</br>what less regular.</br>Sequences of ALMA sometimes recur at intervals similar to those of PLMs.</br>Extensor forearm EMG study may suggest alternating muscle activity in the upper extremities, though it is less prominent than activation in the legs.</br>ALMA shows some night-to-night consistency.</br>Repeat studies are likely to show persistent ALMA.</br>The number of sequences recorded, on average, and the timing of ALMA with respect to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tends to remain constant. </br>The specific polysomnographic criteria for HFT during sleep and ALMA are defined in the most recent version of the AASM Manual for the Scoring of Sleep and Associated Events. </br>Presentation of HFT or ALMA with other concurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is common. </br>Because of the similar frequency, duration, and body part involvement of the move- ments, HFT and ALMA may represent variants of the same disorder.</br>Insufficient sci-</br>entific evidence has accumulated to make this a certainty.</br>Thus, these entities are listed sequentially but separately. </br>Of note, some have questioned whether HFT and ALMA might represent a variant of rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in which movements are confined to the legs and an older population is affected. </br>HFT and ALMA should be distinguished from other sleep-onset movements: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (especially the polyclonic form), PSM, and sleep related RMD.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that should be distinguished from HFT and ALMA include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyskinetic movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the foot, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    painful legs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and moving toes; 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or rhythmic movements of other cause (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, clonus); and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuroleptic-induced akathisia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>None of these conditions involves regular alternation between sides, as seen in ALMA, or an associ- ation with the use of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 medication. </br>Whether HFT should be distinguished from ALMA is not known.</br>Potential differences based on existing reports include the presence of clear movement in HFT as opposed to some uncertainty whether ALMA must involve movement.</br>ALMA, in contrast to HFT, alternates between sides, occurs in any sleep stage, can occur without arousal, and is associated with the use of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
. </br>333 Sleep Related Movement Disorders Sleep Related Movement Disorders High-frequency leg movements (HFLM) also have been described as a repetitive ante- rior tibialis, polysomnographic activation phenomenon, possibly showing some asso- ciation with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and with potential overlap with HFT and ALMA.</br>In contrast to HFT, however, HFLM occur in all sleep stages, and are mostly unilateral rather than bilateral.</br>In contrast to ALMA, HFLM are mostly unilateral rather than alternating, and often show sequences that last longer than those reported for ALMA.</br>The reported HFLM may be more common than ALMA, and the possibility exists that ALMA rep- resents a subtype of HFLM in which leg alternation occurs. </br>The degree to which these movements are quasi-voluntary remains to be determined because some are suppressible.</br>Whether HFT and ALMA are merely alternate forms of the same underlying motor mechanism is also unclear.</br>As reports of these move- ments have arisen from reviews of sleep center records, nothing is known about their manifestation in the general population.</br>The associations noted may be due to biased sampling caused by a skewing of the population toward those with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, especially 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The degree to which HFT and ALMA have clinical significance remains uncertain. </br>Bibliography Berry RB.</br>A woman with rhythmic foot movements.</br>J Clin Sleep Med 2007;3:749–51. </br>Broughton R. Pathological fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, intensified sleep starts and hypnagogic foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: three unusual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-related disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In: Koella WP, Schulz OF, Visser P, eds.</br>Sleep 1986.</br>Stuttgart:</br>Fischer-Verlag, 1988:240–3. </br>Chervin RD, Consens FB, Kutluay E. Alternating leg muscle activation during sleep and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a new 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-related motor phenomenon
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
?</br>Mov Disord 2003;18:551–9. </br>Consentino FI, Iero I, Lanuzza B, Tripodi M, Ferri R. The neurophysiology of the alternating leg muscle activation (ALMA) during sleep: Study of one patient before and after treatment with 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pramipexole
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Sleep Med 2006;7:63–71. </br>Cunningham SL, Winkelman JW, Dorsey 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, et al.</br>An electromyographic marker for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuroleptic-induced akathisia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: preliminary measures of sensitivity and specificity.</br>Clin Neuropharmacol 1996;19:321–32. </br>Wichniak A, Tracik F, Geisler P, Ebersbach G, Morrissey SP, Zulley J. Rhythmic feet movements while falling asleep.</br>Mov Disord 2001;16:1164–70. </br>Yang C, Winkelman JW, White DP.</br>The effects of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 on 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leg movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (abstract) Sleep 2004;27(Abst Suppl):A311–2. </br>Yang C, Winkelman JW.</br>Clinical and polysomnographic characteristics of high frequency leg movements.</br>J Clin Sleep Med 2010;6:431–8. </br>334 Sleep Starts (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic Jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) Sleep starts, also known as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, are sudden, brief, simultaneous contractions of the body or one or more body segments occurring at sleep onset.</br>Sleep starts (or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) usually consist of a single contraction that often affects the body asymmetrically.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be either spontaneous or induced by stimuli.</br>The motor activity is often associated with a sensory component, which may be somesthetic, often an impression of falling or less commonly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or tingling; auditory, such as banging, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snapping
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or crackling noises; or visual, including flashing lights, hypnagogic dreams, or hallucina- tions.</br>A sharp cry may occur.</br>The patient may not recall a jerk that was noted by a bed partner if the sleep start does not cause awakening.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Multiple jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occasionally occur in succession, usually early in the sleep period.</br>When sleep starts or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are frequent, intense, or repetitive, they may lead to sleep-onset 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Purely sensory sleep starts are subjective, localized, sensory impressions that occur at sleep onset and are not associated with motor activity.</br>The term “Intensified sleep starts” has been applied to both the motor and purely sensory forms when a complaint of difficulty falling asleep as a result of the starts is present. </br>A prevalence of 60% to 70% has been reported, but with a highly sporadic occurrence.</br>Sleep starts affect all ages and both sexes. </br>Excessive 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 or other stimulant intake, prior intense physical work or exercise, sleep deprivation, and emotional stress can increase the frequency and severity of sleep starts. </br>Sleep starts are an essentially universal component of the sleep-onset process, although they are often not recalled.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur at any age, as a subjective com- plaint; however, they are usually encountered in adulthood.</br>The course is usually benign.</br>Intensified sleep starts may lead to avoidance/delay of sleep, a fear of falling asleep and chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>As a result, acute and chronic sleep deprivation may occur.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep-onset insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may result either from repeated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    awakenings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 induced by the starts or from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 about falling asleep.</br>Injury, such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruising
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 a foot against a bedstead or kicking a sleeping companion, may occasionally occur. </br>The physiological mechanisms underlying sleep starts are uncertain.</br>No pathologic finding has been described except for a single case of auditory sleep starts associated with a brainstem lesion.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are hypothetically caused by sudden descending volleys originating in the brainstem reticular formation activated by the system insta- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bility
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at the transition between wake and sleep.</br>However, the similarity between sleep starts and the startle response has led some to postulate that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormalities of sensory Sleep Related Movement Disorders Sleep Related Movement Disorders processing are primary
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, with secondary motor manifestations involving the reticulo- spinal tract.</br>Sleep starts are a prominent symptom in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hereditary hyperekplexia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, some cases of which are caused by mutations in the 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glycine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 receptor.</br>It has also been postu- lated that sleep starts are a response to hypnagogic imagery. </br>Polysomnographic monitoring shows that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur during transitions from wakefulness to sleep, mainly at the beginning of the sleep episode.</br>Superficial EMG recordings of the involved muscles show brief (generally 75-millisecond to 250-mil- lisecond) high-amplitude potentials, either singly or in succession.</br>The EEG typically shows 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drowsiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or stage N1 sleep patterns, sometimes with a negative-vertex sharp wave occurring at the time of the jerk.</br>Autonomic activation, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachypnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or irregular breathing, and sudomotor activation may follow an intense jerk.</br>After the jerk, a brief arousal or a return to sustained wakefulness may occur.</br>Physical and neurological examinations and routine laboratory tests are otherwise normal.</br>Although polysomnography is not necessary for diagnosis in most individuals, it may be indicated in occasional cases with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and frequent movements. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 must be differentiated from a number of physiological or pathologic movements that occur at sleep onset or during sleep.</br>Physiological partial hypnic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 consists of small, isolated contractions of a muscle or part thereof, occur- ring sporadically in distal muscles and resembling 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fasciculation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 potentials.</br>The con- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tractions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are particularly evident during stage N1 and REM sleep. </br>Fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 consists of profuse, brief, small-amplitude muscle twitches that occur in an asynchronous, symmetrical, and bilateral manner, especially in distal muscles.</br>Fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs at sleep onset as well as within all sleep stages.</br>Contrary to the massive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks of the sleep
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 starts or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the small muscle twitches of physiological partial hypnic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and of fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often represent only an EMG finding and are not associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    overt movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at the joints.</br>Normal body movements are complex, with body postural shifts usually at the transition between one sleep stage and another.</br>Benign sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of infancy consists of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at the elbow, fingers, toes, and face during sleep in infants. </br>PSM is characterized by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, usually spontaneous, but sometimes also evoked, arising first in spinal innervated axial muscles of the trunk, neck, or abdomen and then 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prop-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 agated at slow velocity to more rostral and caudal muscles.</br>PSM is present during relaxed wakefulness, characterized by diffuse EEG alpha activity, and disappears with sleep onset or mental activation.</br>PSM is usually a chronic condition associated with sleep-onset 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>336 Excessive startling and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur as part of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperekplexia syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, in which generalized 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is readily elicited by stimuli during either wakeful- ness or sleep.</br>The major form of this condition is also characterized by stiffness and falls.</br>Brief 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can be differentiated by coexistent EEG discharge, the presence of other features of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and the occurrence of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in both wakefulness and during sleep rather than only at sleep onset. </br>The muscle contractions of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are much longer in duration, involve mainly the feet and lower legs, show periodicity, and occur within sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 consists of slower and repetitive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    semivoluntary movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at sleep onset that are associated with deep, unpleasant, and sometimes unbearable sensations, which are temporarily relieved by getting up and exercising. </br>Bibliography Broughton R. Pathological fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, intensified sleep starts and hypnagogic foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: three unusual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-related disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In: Koella WP, Schulz OF, Visser P, eds.</br>Sleep 1986.</br>Stuttgart: Fisher Verlag; 1988:240–3. </br>Kennard MA, Schwartzman AE, Millar TP.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep, consciousness, and the alpha electroencephalographic rhythm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Arch Neurol Psychiatry 1958;79:328–35. </br>Montagna P, Liguori R, Zucconi M, et al.</br>Physiological 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Electroencephalgr Clin Neurophysiol 1988;70:172–6. </br>Oswald I. Sudden bodily 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on falling asleep.</br>Brain 1959;82:92–103. </br>Salih F, Klingebiel R, Zschenderlein R, et al.</br>Acoustic sleep starts with sleep-onset 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to a brainstem lesion.</br>Neurology 2008;70:1935–7. </br>Sander HW, Geisse H, Quinto C, Sachdeo R, Chokroverty S. Sensory sleep starts.</br>J Neurol Neurosurg Psychiatry 1998;64:690. </br>Vetrugno R, Montagna P. Sleep-to-wake transition movement disorders.</br>Sleep Med 2011;12:S11–6. </br>337 Sleep Related Movement Disorders Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Disorder ICD-9-CM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 code: 327.8 ICD-10-CM code: G47.8 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that cannot be classified elsewhere in the International Classification of Sleep Disorders, 3rd Edition are listed here.</br>This may be due to the fact that the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 overlaps more than one category or, more often, when insufficient data have been collected to firmly establish another diagnosis.</br>It is also possible that new 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that do not fall within any of the current major categories will be dis- covered during the lifetime of the International Classification of Sleep Disorders, 3rd Edition.</br>When a specific diagnosis cannot yet be determined but the presenting problem clearly falls into a specific category (e.g., a circadian rhythm sleep-wake dis- order), the “unspecified” diagnosis within that category (e.g., circadian rhythm sleep- wake disorder, unspecified) is preferred. </br>The International Classification of Sleep Disorders, 2nd Edition included a specific diagnosis of environmental 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 within this section.</br>This diagnosis is infre- quently employed in the clinical setting and significant controversy exists regarding whether environmentally induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 represents a clinical disorder per se.</br>The condition is typically characterized by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complaints of sleep initiation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or maintenance that are the direct result of an environmental factor.</br>Associated daytime symptoms such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cognitive or emotional disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present.</br>The environmental disturbance may be a physical stimulus such as noise (e.g., vehicular traffic, aircraft, bed partner 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), light, temperature, movement (e.g., bed partner 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), an emotional stimulus such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    environ- mental danger
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., combat setting or disaster area), or an environmental requirement (such as caring for an infant or elderly family member).</br>Hospitalization is often cited as a precipitant of environmental 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 although many additional factors (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) may also contribute to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in this setting.</br>If the clinician determines that an environmental factor is the primary cause of a sleep distur- bance, a diagnosis of Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be employed. </br>It is the physical aspects of the environment, rather than their psychological meaning, which account for the sleep complaint.</br>Unlike 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is dependent on the presence of the environmental factor.</br>In the absence of the stimu- lus, sleep is normal. </br>The prevalence of environmentally induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not known although, as noted, the diagnosis is not commonly reported in sleep centers.</br>Some individuals Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be more susceptible to environmental disturbances but little is known about spe- cific characteristics that might predispose to this condition. </br>Although environmental factors may play a contributing role in some cases of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, multiple other factors account for that condition, which is typically evident even in the absence of the offending environmental stimulus.</br>Distinguishing an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from an environmentally induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may pose a challenge in certain clinical encounters and providers must use clinical judgment in establishing the diagnosis. </br>In behavioral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of childhood, the child may require certain environmental cir- cumstances in order to sleep (e.g., a pacifier, music, lights, television, or a parent).</br>It is the absence of these circumstances that results in sleep initiation or maintenance prob- lems.</br>In such cases, a diagnosis of chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (behavioral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of childhood – sleep-onset association type) is indicated. </br>Bibliography Basner M, Griefahn B, Berg MV.</br>Aircraft noise effects on sleep: mechanisms, mitigation and research needs.</br>Noise Health 2010;12:95–109. </br>Hume KI, Brink M, Basner M. Effects of environmental noise on sleep.</br>Noise Health.</br>2012;14:297–302. </br>Thiessen G, Lapointe A. Effect of continuous traffic noise on percentage of deep sleep, waking, and sleep latency.</br>J Acoust Soc Amer 1983;73:225–9. </br>Yilmaz M, Sayin Y, Gurler H. Sleep quality of hospitalized patients in surgical units.</br>Nurs Forum 2012;47:183–92. </br>340 Appendix A: Sleep Related Medical and Neurological Disorders Fatal Familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
...............................................................................342 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ..............................................................................345 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
..........................................................................350 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ....................................................................355 Sleep Related Gastroesophageal Reflux ...................................................358 Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Myocardial Ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 ...........................................................363 The disorders presented in this section may have a unique presentation during the sleep period or may present exclusively in association with sleep.</br>Some of these disorders (e.g., sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) may be encountered during evaluation for other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In addition, some of these disorders are in the dif- ferential diagnosis of other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-wake disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 must be con- sidered in the differential diagnosis of certain movement disorders and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be a clue to the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep related gastroesophageal reflux may either be a precipitant of a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episode or be trig- gered by sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with aspiration 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as its most serious consequence.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is an important consideration because myocardial infarc- tion has a predilection for the early morning hours during the latter phase of the sleep period and may be precipitated by episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>It is important to be aware of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as a potentially life-threatening consequence of neurode- generative diseases such as multiple system 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Fatal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, although rare, presents with severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and has a well-understood neuropathology. </br>341 Appendix A: Sleep Related Medical and Neurological Disorders Fatal Familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Alternate Names Fatal progressive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysautonomia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, familial thalamic degeneration of the anterior and dorsomedial thalamic nuclei, thalamic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Essential Features Fatal familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a very rare, progressive disorder characterized by initial dif- ficulties in falling asleep and maintaining sleep, spontaneous lapses from quiet wake- fulness into a sleep state with enacted dreams (oneiric stupor), and loss of slow wave sleep features.</br>In later stages of the disease, it may not be possible to identify any dis- tinct sleep stages. </br>Although loss of temporal and spatial orientation develops, cognitive function is retained until impaired alertness makes testing impossible.</br>The disorder progresses to unarousable 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and finally, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Associated Features 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Bronchopulmonary
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also be present.</br>There is a loss of the circadian rhythmicity of endocrine rhythms.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Autonomic hyperactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pyrexia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, salivation, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperhidrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachypnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is present.</br>The disor- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    der
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 includes somatomotor disturbances, with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysarthria
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphagia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sponta- neous and reflex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dystonic posturing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ataxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and a positive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Babinski
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sign.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present. </br>Clinical and Pathologic Subtypes None. </br>Demographics Age of onset is usually in adulthood, between 36 and 62 years of age.</br>The disorder is rare.</br>There are no sex differences. </br>Predisposing and Precipitating Factors Not known or applicable. </br>Familial Patterns Fatal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (FFI) is transmitted according to an autosomal dominant pattern.</br>Patients harbor a missense GAC to AAC mutation at codon 178 of the prion protein gene PRNP located on chromosome 20, cosegregating with the 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methionine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 Appendix A: Sleep Related Medical and Neurological Disorders polymorphism at codon 129 of the same gene on the mutated allele (D178N 129M).</br>The clinical syndrome varies by the M129V genotype.</br>Patients who are 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methionine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 homozygous at the 129 codon are younger and display a shorter disease course than do patients who are 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methionine-valine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 heterozygous at codon 129. </br>Onset, Course, and Complications </br>The disorder is always fatal, usually within eight to 72 months.</br>The course is one of relentless worsening of symptoms.</br>Patients may die after a short (less than 12 months) or long (12 to 72 months) disease course.</br>The younger age at disease onset and, conse- quently, a lower rate of comorbidity, may explain the generally more prolonged disease course in FFI in comparison to other prion diseases.</br>Complications include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (in particular of the lungs and bladder) that develop during the course of the disease, especially in the late stages, and represent the usual cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other frequent com- plications include skin 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ulcers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 when patients become bedridden and aspiration of food due to the severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphagia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; the latter may require nasogastric or gastrostomy feeding. </br>Pathology and Pathophysiology Severe bilateral loss of neurons, with reactive gliosis of the anterior and dorsomedial thalamic nuclei and severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuronal loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and reactive astrogliosis in the inferior olives, are found.</br>Spongiform changes in cortical layers in cases with a prolonged course have been described.</br>Deposition of proteinase K-resistant prion protein type 2 in the grey matter but not the white matter occurs in both familial and sporadic fatal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Both familial and sporadic fatal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been transmitted to transgenic animals by intracerebral inoculum of brain homogenates. </br>Objective Findings In early stages of FFI, periods of relaxed wakefulness alternate with episodes of elec- troencephalographic (EEG) desynchronization, rapid eye movement (REM) bursts, loss of antigravity muscle tone, and irregular 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and tremor-like limb-muscle activities associated with vivid dreams (oneiric stupor).</br>Sleep spindles and features of slow wave sleep are absent or progressively lost throughout the course of the illness.</br>In the final stages of the disorder, the EEG becomes unreactive and progressively flattens until 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs; it may display periodic spike discharges. </br>Positron emission tomography (PET) with (18F)-2-fluorodeoxy-d-glucose shows tha- lamic hypometabolism.</br>Magnetic resonance spectroscopy with multisequences can detect prion-induced gliosis in vivo.</br>Circadian rhythms of body temperature, systemic blood pressure, and heart and respiratory rate and endocrine rhythms of growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and adrenocorticotropic Appendix A: Sleep Related Medical and Neurological Disorders hormone may be lost.</br>Serum 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catecholamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cortisol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 values are elevated, with low or undetectable adrenocorticotropic hormone levels.</br>Pathologic examination 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    demon-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 strates degeneration of the anterior and dorsomedial thalamic nuclei and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the inferior olivary nucleus.</br>Deposition of proteinase K-resistant prion protein type 2 is found in the brain. </br>Differential Diagnosis This disorder must be differentiated from REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), which is not associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autonomic hyperactivity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or a familial pattern.</br>The differential diagnosis includes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial Creutzfeldt-Jakob disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with the 178 codon mutation in the PRNP cosegregating with the 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    valine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 polymorphism at codon 129 on the mutated allele, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Morvan fibrillary chorea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    delirium tremens
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or even 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    schizophrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A sporadic form of fatal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has also been reported. </br>Unresolved Issues and Future Directions Not applicable or known. </br>Bibliography Cortelli P, Perani D, Parchi P, et al.</br>Cerebral metabolism in fatal familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: relation to duration, neuropathology, and distribution of protease-resistant prion protein.</br>Neurology 1997;49:126–33. Goldfarb L, Petersen R, Tabaton M, et al.</br>Fatal familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial Creutzfeldt-Jakob disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: disease phenotype determined by a DNA polymorphism.</br>Science 1992;258:806–8. </br>Haik S, Galanaud D, Linguraru MG, et al.</br>In vivo detection of thalamic gliosis.</br>A pathoradiologic demonstration in familial fatal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Arch Neurol 2008;65:545–9. </br>Krasnianski A, Bartl M, Sanchez Juan PJ, et al.</br>Fatal familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: clinical features and early identification.</br>Ann Neurol 2008;63:658–61. </br>Lugaresi E, Medori R, Montagna P, et al.</br>Fatal familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysautonomia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with selective degeneration of thalamic nuclei.</br>N Engl J Med 1986;315:997–1003. </br>Monari L, Chen S, Brown P, et al.</br>Fatal familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial Creutzfeldt-Jakob disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: different prion proteins determined by a DNA polymorphism.</br>Proc Natl Acad Sci U S A 1994;91:2839–42. </br>Montagna P, Cortelli P, Gambetti P, Lugaresi E. Fatal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: sleep, neuroendocrine and vegetative alterations.</br>Adv Neuroimmunol 1995;5:13–21. </br>Montagna P, Gambetti P, Cortelli P, Lugaresi E. Familial and sporadic fatal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Lancet Neurol 2003;2:167–76. </br>Sforza E, Montagna P, Tinuper P, et al.</br>Sleep-wake cycle abnormalities in fatal familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Evidence of the role of the thalamus in sleep regulation.</br>Electroencephalogr Clin Neurophysiol 1995;94:398–405. </br>Telling G, Parchi P, DeArmond S, et al.</br>Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity.</br>Science 1996;274:2079–82. Appendix A: Sleep Related Medical and Neurological Disorders Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal seizure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Essential Features A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a paroxysmal event resulting from a sudden excessive discharge of the neurons of the cerebral cortex, whereas 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a condition of recurrent unpro- voked 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep facilitates 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 activity and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The characteristics of specific subtypes of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are discussed in the Clinical and Pathologic Subtypes section below. </br>Associated Features The different types of nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    frontal lobe epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) may cause severe sleep disruption, affecting both macrostructure and microstructure of sleep, resulting in poor sleep quality, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in some patients.</br>The movements also may be so severe that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    injuries
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur.</br>From one third to one half of patients with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also have occasional 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the day, although these are not necessarily of the same type as those occurring at night. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Neurocognitive impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is typically diagnosed in almost all cases of continuous spike waves during NREM sleep (CSWS).</br>Motor impairment in the form of a unilat- eral deficit is sometimes seen as an associated feature of CSWS. </br>Clinical and Pathologic Subtypes Clinical and EEG criteria are used to define a variety of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 subtypes. </br>Several types of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic syndromes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have a marked tendency to manifest only or pre- dominantly during sleep, or after arousal from sleep.</br>These include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, benign 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of childhood with centrotemporal spikes (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BECT
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benign epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with occip- ital 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paroxysms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BEOP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    early-onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    late-onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 childhood 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    occipital epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    juvenile myoclonic epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    JME
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), generalized tonic-clonic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on awakening, certain forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    temporal lobe epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, tonic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (as a component of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lennox-Gastaut syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Landau-Kleffner syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and continuous spike waves during NREM sleep (CSWS). </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may present in three distinct ways: (1) nocturnal paroxysmal arousal, (2) noc- turnal paroxysmal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dystonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or (3) episodic nocturnal wanderings. </br>345 Appendix A: Sleep Related Medical and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Neurological Disorders BECT
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can present with focal clonic facial twitching that is often preceded by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    perioral numbness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>These 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are more often seen in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drowsiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep than wakeful- ness.</br>The clinical course is often benign with disappearance of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in adulthood. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BEOP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by focal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 marked by deviation of the eyes and vom- iting.</br>Sleep is the main precipitating factor, with most of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurring soon after sleep onset or in the early hours of the morning.</br>There is frequent evolution to secondary generalized attacks.</br>The clinical evolution of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    early-onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type is benign, whereas in the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    late-onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    visual seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the prognosis is uncertain. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    JME
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by massive bilaterally synchronous 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which are most frequently noted on awakening. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSWS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (formerly known as electrical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    status epilepticus of sleep [ESES
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
]) is charac- terized by continuous and diffuse slow spike-and-wave complexes persisting through NREM sleep (at least 85% of the duration), as well as neuropsychological and motor impairment.</br>Despite the continuous presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 spike-wave activity on EEG in sleep, there may be no associated visible sleep related movement.</br>However, clinical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are sometimes seen in the daytime. </br>Demographics There is no significant sex predominance. </br>Predisposing and Participating Factors Stress, sleep deprivation, irregularities of the sleep-wake rhythm, other sleep patholo- gies, and the use of stimulant drugs or other drugs that modify sleep architecture may predispose an individual to having 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Perinatal or prenatal problems, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congenital hemiparesis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and prior 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be considered antecedents of the syndrome of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSWS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may exacerbate sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and complicate their treatment. </br>Familial Patterns The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic generalized epilepsies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 form the largest category of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that appear to be heritable but show no clear mendelian mode of transmission.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Juvenile myoclonic epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic generalized epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with adolescent onset appear to be genet- ically heterogeneous.</br>Among the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    partial epilepsies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BECT
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 shows a familial pattern.</br>A form of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autosomal dominant NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 70% to 80% penetrance has been reported in many countries, and a genetic heterogeneity also has been reported.</br>Genetic factors have not been established in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSWS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and seem to play a minor role.</br>Familial anteced- ents of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    febrile convulsions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) have been found in 15% of cases. </br>346 Appendix A: Sleep Related Medical and Neurological Disorders Onset, Course, and Complications 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Idiopathic generalized epilepsies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    partial epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may start at any age.</br>The onset of benign 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of childhood with centrotemporal or occipital spikes is between 4 and 12 years of age.</br>The onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is generally from age 10 to 16 years, mostly before the age of 20 years.</br>The average age of recognition of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSWS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is between 4 and 14 years, but the appearance of the first 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is early, typically between two months and 12 years of age.</br>Most patients with recurrent sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 continue to have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 restricted to sleep.</br>In some cases, they may have 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during both sleep and wakefulness.</br>For focal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (excluding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BECT
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the early-onset type of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BEOP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), the prognosis is less favorable compared to generalized 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>At least 35% of the focal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 confined to sleep are resistant to antiepileptic drugs. </br>Definitive data on the natural history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not available, although a high prev- alence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been documented in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSWS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 resolves in many cases within three years after onset, and in almost all cases by the mid-teen years.</br>Despite normalization of the EEG and elimination of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, neuropsychological impairment may persist.</br>Interictal paroxysmal activity may induce prolonged 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cognitive and motor impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hyperkinesias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aggressiveness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and psy- chotic states may appear.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may exacerbate sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and complicate their treatment. </br>Pathology and Pathophysiology In 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic generalized epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, genetic factors are contributory.</br>Pathogenic markers, associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurologic deficits
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or characteristic brain imaging findings have not been identified.</br>However, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    microdysgenesis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been described in some forms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic generalized epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>EEG recordings with sphenoidal or zygomatic leads may show 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 activity over the mesiotemporal regions in partial complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Video-polysomnographic (vPSG) analysis confirms that the motor pattern of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 resembles that noted in orbital and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mesial frontal seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Nocturnal frontal lobe sei-</br>zures involve a large neuronal network, and some of their clinical expressions are pos- sible consequences of disinhibition of innate motor patterns produced by the central pattern generator.</br>Recent reports derived from stereo-EEG studies seem to show that in some cases, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (in particular nocturnal wanderings) may arise from temporal or insular regions (rather than frontal regions) with a secondary spread to the cingulate regions.</br>They may sometimes mimic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>347 Appendix A: Sleep Related Medical and Neurological Disorders Secondary bilateral synchrony is the mechanism generating CSWS.</br>This hypothesis is supported by EEG, intracranial recordings, EEG with coherence computer-assisted analysis, and metabolic (positron emission tomography</br>[PET] and single-photon emis- sion computed tomography [SPECT]) studies.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSWS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Landau-Kleffner syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (an acquired 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic aphasia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) is probably secondary to an alteration of function over the temporal area. </br>Objective Findings Patients with suspected sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 often need to be evaluated in the sleep laboratory with video and full-head EEG monitoring in order to obtain the correct diagnosis.</br>The characteristic interictal epileptiform activity in idiopathic general- ized 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 usually increases during NREM sleep, whereas it decreases during REM sleep and wakefulness.</br>Interictal epileptiform activity may be associated with phasic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>In partial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsies
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the interictal epileptiform activity occurs in a localized distribu- tion with an increase in spike frequency in stages N2 and N3 compared to REM sleep.</br>Most of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are activated in stage N2 sleep.</br>Monitoring may also detect tran- sient autonomic alterations in cardiac rhythm, blood pressure, and respiration during 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>If 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is suspected, a standard daytime 16-channel to 20-channel EEG (with partial or total sleep deprivation the night before, as indicated) should be per- formed.</br>Ambulatory 24-hour EEG recordings may be useful to detect distribution of interictal epileptiform activity during the sleep-wake cycle. </br>Nocturnal vPSG is the gold standard test for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Most of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 appear during NREM sleep, with preponderance in NREM stages N1 and N2 (greater than 60%).</br>Rarely do they emerge from REM sleep.</br>In some cases, particularly in paroxysmal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the motor attacks may show a periodicity (every 20 seconds to two minutes).</br>Due to the fact that the discharges originate deep in the frontal lobe and are not visible using scalp EEG, the EEG during the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is uninformative in almost half of the cases.</br>In a few cases, recording using intracranial or depth electrodes confirms the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paroxysms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during or preceding the motor components.</br>The interictal sleep EEG is generally normal, but in 30% to 40% of subjects, focal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic abnormalities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are seen, predominantly in the anterior regions.</br>The video recording of the different types of attacks in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 permits categorization of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and characterization of the main features. </br>During 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CSWS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, diffuse spike waves at two to 2.5 Hz occur in bursts, with or without clinical manifestations.</br>The discharges are continuous and occupy from 85% to 100% </br>348 Appendix A: Sleep Related Medical and Neurological Disorders of NREM sleep stages.</br>Abnormalities arise as soon as the patients fall asleep and dis- appear abruptly on awakening.</br>REM sleep is typically preserved, and the frequency of spike-wave discharges significantly decreases but the frontal predominance of the infrequent bursts may become more prominent.</br>In general, EEG patterns during REM sleep are similar to those in the awake records.</br>The sleep structure is normal, but the presence of almost continuous spike-wave discharges makes the recognition of normal NREM sleep EEG elements (such as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 complexes, spindles, or vertex sharp transients) difficult. </br>Differential Diagnosis 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be mistaken for a disorder of arousal from NREM such as sleepwalking, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusional
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 arousal, or sleep terror.</br>Ictal and interictal EEGs are often normal because the focus for the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 discharge may be deep in the brain.</br>Disorders of arousal show a different pattern of episodes in that they occur out of stage N3 sleep, are not ste- reotyped, often have a sustained autonomic component, and are frequently seen during the first part of the night.</br>Partial arousal disorders tend to disappear or decrease in fre- quency after adolescence.</br>VPSG is often useful.</br>Sleep talking, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and rhythmic movement disorders can be differentiated from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by history and vPSG recordings.</br>Benign neonatal sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be confused with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    clonic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or myoc- lonic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>In the elderly (older than 60 years), the main differentiation from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is by vPSG recording.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLMD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep starts, and propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at sleep onset do not show EEG epileptiform activity and belong in the category of move- ment disorders during sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyskinesias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or arousal on resumption of breathing in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also enter into the differential diagnosis of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Rare cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anoxic syncope
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with some 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    clonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at the end of a prolonged (longer than two minutes) obstructive event have been described. </br>Unresolved Issues and Further Directions Not applicable or known. </br>Bilbliography Bazil C, Malow B, Sammaritano M. Sleep and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: the clinical spectrum.</br>Amsterdam: Elsevier Science; 2002. </br>Dinner D, Luders H. Relationship of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep: an overview.</br>In: Dinner D, Luders H, eds.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep: physiological and clinical relationships.</br>San Diego: Academic Press, 2001:2–18. </br>Malow B. Paroxysmal events in sleep.</br>J Clin Neurophysiol 2002;19:522–34. </br>Nobili L, Cossu M, Mai R. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep-related hyperkinetic seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of temporal lobe origin.</br>Neurology 2004;62:482–5. </br>Oldani A, Zucconi M, Ferini-Strambi L, Bizzozero D, Smirne 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S. Autosomal dominant nocturnal frontal lobe epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: electroclinical picture.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epilepsia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 1996;37:964–76. </br>349 Appendix A: Sleep Related Medical and Neurological Disorders Provini F, Plazzi G, Tinuper P, Vandi S, Lugaresi E, Montagna P. Nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    frontal lobe epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A clinical and polygraphic overview of 100 consecutive cases.</br>Brain 1999;122:1017–31. </br>Scheffer I, Bhatia 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Lopes-Cendes I, et al.</br>Autosomal dominant nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    frontal lobe epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A distinctive clinical disorder.</br>Brain 1995;118:61–73. </br>Shouse M, Martins da Silva A, Sammaritano M. Circadian rhythm, sleep, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Clin Neurophysiol 1996;13:32–50. </br>Tassinari C, Dravet C, Roger J. CSWS:</br>Encephalography related to electrical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    status epilepticus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during slow sleep.</br>Electroencephalogr Clin Neurophysiol 1977;43:529–30. </br>Tinuper P, Provini F, Bisulli F, et al.</br>Movements disorders in sleep: guideline for differentiating 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epileptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    non-epileptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 motor phenomena arising from sleep.</br>Sleep Med Rev 2007;11:255–67. </br>Zucconi M. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep-related epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Handb Clin Neurol 2011;99:1109–37. </br>Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Alternate Names Various (see Clinical and Pathologic Subtypes). </br>Essential Features Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are a group of unilateral or bilateral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cephalalgias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of varying severity and duration that occur during sleep or upon awakening from sleep.</br>It is a heterogenous group of different 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 entities with the common feature of occur- rence during sleep or upon awakening.</br>The characteristics of specific subtypes of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are discussed in the Clinical and Pathologic Subtypes section below. </br>Associated Features Individual features associated with specific sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 types are discussed in the following section. </br>Clinical and Pathologic Subtypes Most sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 conditions that also may occur during sleep.</br>These include the primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cluster head- ache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and chronic paroxysmal hemicrania.</br>There are other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that occur solely with sleep; for example, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In addition, secondary head- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to medical, neurological, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can cause sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Migraines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are common recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of moderate to severe intensity that last between four and 72 hours.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is typically unilateral and pulsating, aggra- vated by routine physical activity and associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nausea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and/or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    photophobia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Appendix A: Sleep Related Medical and Neurological Disorders or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phonophobia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>They occur during the day or during sleep; approximately 50% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 attacks occur between 4:00 a.m. and 9:00 a.m.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Migraine headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 do not have a fixed association with a particular sleep stage.</br>The patient may awaken with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 out of REM sleep, or the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur in relationship to stage N3 sleep.</br>A “classic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
” 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is preceded by an aura (if the patient is awake), which usually lasts four to 60 minutes and typically consists of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    homonymous visual field defects
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and scintillating scotomas.</br>In some patients, the aura may continue or even begin during the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 phase.</br>In contrast, “common 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
” does not start with an aura.</br>Other signs of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may include unilateral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paresthesias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aphasia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Features of brainstem involvement may include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vertigo
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, tinni- tus, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysarthria
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    decreased hearing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diplopia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ataxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, bilateral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paresthesias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and impaired level of consciousness.</br>A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    familial syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hemiplegia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is well described.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hemiplegia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is ipsilateral or contralateral to the side of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cluster headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are severe, unilateral, periorbital or temporal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that start quickly and peak within 10 to 15 minutes.</br>They have a relatively shorter duration, usually lasting 15 minutes to three hours (mean, 60 minutes).</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur daily during cluster periods—usually one to three attacks per day over a period of one to two months.</br>Most patients have one cluster period per year, though this can vary from patient to patient.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tend to occur at the same hour each day, with 75% of cluster episodes reported to occur between 9:00 p.m. and 10:00 a.m.</br>One or more cranial autonomic features (e.g., ipsilateral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    conjunctival injection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, lacrimation, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nasal congestion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhinorrhea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, forehead and facial sweating, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    miosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ptosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eyelid edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) invariably accompany attacks of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cluster headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A strong predilection for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to occur during sleep is well recognized, and these attacks are strongly related to REM sleep. </br>Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paroxysmal hemicrania
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 closely resembles cluster 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and consists of severe unilateral orbital, supraorbital, or temporal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with one or more cranial autonomic features.</br>However, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are usually of shorter duration (lasting two to 30 minutes) and occur more frequently, most often at a frequency of more than five per day.</br>In contrast to cluster 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic paroxysmal hemicrania
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is exqui- sitely sensitive to 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    indomethacin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>Attacks are also strongly associated with REM sleep. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are an uncommon type of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that awakens the patient from sleep with a generalized or lateralized 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that lasts at least 15 minutes (range, one to 180 minutes) with a frequency of at least 15 times per month.</br>Onset is typically after the age of 50, although similar 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are described rarely in younger indi- viduals, including children.</br>In comparison to cluster 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are Appendix A: Sleep Related Medical and Neurological Disorders less severe, often bilateral and not associated with cranial autonomic features.</br>Isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nausea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    photophobia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phonophobia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present.</br>They may occur one to three times during the night, with many patients reporting that the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occur at the same time of the night.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tend to occur during REM sleep.</br>However, they also have been reported to occur during stage N3 sleep.</br>A positive therapeutic response to 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lithium
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    indomethacin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 has been reported in many patients. </br>Other medical (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), neurologic (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brain tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arteriovenous mal-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 formations, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebral venous thrombosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) also can give rise to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that may occur during sleep or upon awakening from sleep.</br>Patients with increased intracranial pressure (due, for example, to brain 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hematoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arteriovenous malformations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebral venous thrombosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) may complain of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the morning or head- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that starts after recumbence and improves after the patient is up for 30 to 60 minutes.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nausea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vomiting
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, signs of focal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological deficits
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    papilledema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be present.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may worsen with bending down or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sneezing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or with other activities that may cause further increase in intracranial pressure. </br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can disrupt nocturnal sleep, although the exact prevalence of this complication is unknown. </br>Demographics The exact prevalence of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not known.</br>One study from a head- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 clinic suggested that 17% of all 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 patients complain of nocturnal or early 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morning headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and roughly half of these were related to an identifiable 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, many 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary headache disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can occur during sleep as well.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been reported to increase in frequency with age. </br>Predisposing and Precipitating Factors 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Migraine headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have several predisposing factors that vary from patient to patient.</br>However, stress, relaxation, changes in weather and barometric pressure, changes in sleep pattern, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoglycemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and specific foods (e.g., chocolate, Chinese food, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
) have been known to trigger 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 can also predispose an indi- vidual to having 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cluster headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic paroxysmal hemicrania
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and atten- dant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 have been reported to be a trigger for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cluster headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may also predispose a person to having other types of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and may inde- pendently lead to morning 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Change of sleep pattern and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can pre- dispose the patient to developing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>352 Appendix A: Sleep Related Medical and Neurological Disorders Familial Patterns There is a positive family history for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in up to 80% of patients with this disor- der.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Familial hemiplegic migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is inherited in an autosomal dominant pattern with a variety of genetic mutations identified on chromosomes 1 and 19.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cluster headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 does not have as strong of a familial disposition as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but first-degree relatives of probands with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cluster headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are seven times more likely to develop cluster 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and the concordance rates in monozygotic twins is 100%.</br>The inheritance patterns of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are not known. </br>Onset, Course, and Complications 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Migraine headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 usually starts in the second or third decade of life, with a slightly earlier onset in men than in women.</br>The mean age of onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cluster headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is 28 years.</br>Chronic paroxysmal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hemicrania
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has a wide range of onset, from childhood to old age.</br>Most patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are elderly, with the age of onset from 40 to 82 years.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Brain tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are more prevalent in the elderly, most occurring from the fifth decade to late life. </br>Most sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are benign and tend to decrease in frequency with age.</br>There may be spontaneous remissions that last from months to years.</br>Pregnancy has a variable effect on these 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Migraines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 tend to decrease with age and, in women, may stop after menopause.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cluster headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, as the name suggests, occur in clusters and are accompanied by pain-free intervals lasting months to a couple of years.</br>They also tend to decrease with age.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs infrequently.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    brain tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are related to an increase in intracranial pressure and tend to improve with treatment of the primary lesion and a decrease in intracranial pres- sure.</br>Some patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 report improvement of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 after treatment of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>The sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can cause sleep disruption and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with decreased sleep efficiency.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cluster headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurring regularly in sleep can also lead to tran- sient situational 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that may resolve after the remission or the treatment of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cluster headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Depending on the etiology of the sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g., brain 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), other complications may occur. </br>Developmental Issues Not applicable or known. </br>353 Appendix A: Sleep Related Medical and Neurological Disorders Pathology and Pathophysiology Several anatomic areas are common to the physiology of both sleep and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; these include the brainstem and diencephalon, specifically the ventrolateral periaque- ductal gray and the posterior hypothalamus.</br>From a neurochemical perspective, ade- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nosine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and orexin also are involved in both the regulation of sleep and the evolution of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Dysfunction of REM sleep and arousal mechanisms are common to many 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Data from transgenic models indicate that dis- ruption of sleep occurs in two forms of familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, current mechanis- tic explanations of the relationship between sleep and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are speculative. </br>Objective Findings Polysomnographic aspects of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 need to be better defined.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Migraine headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is reported to occur in association with REM sleep or stage N3 sleep.</br>An excess of stage N3 sleep also has been reported in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, large controlled studies are not available.</br>Fifty percent of cluster 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and a majority of chronic paroxysmal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hemicrania
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are associated with REM sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep may aggravate other sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or may be an independent cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs during sleep, with recent reports of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during REM sleep and uncommonly during stage N3 sleep.</br>Thus, the majority of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 seem to have some relationship with REM sleep, but there are no defining or pathognomonic polysomnographic aspects of indi- vidual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndromes. </br>Neuroimaging studies (computed tomography or magnetic resonance imaging head scans or angiography) may be performed to rule out structural, vascular, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infectious disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 processes that may cause 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Differential Diagnosis Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are a heterogeneous group of different 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 entities with a common expression of occurrence during sleep.</br>They need to be differentiated from other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 conditions that are not sleep related.</br>These include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tension-type
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 head- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paranasal sinus inflammation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tooth infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, ear 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    febrile illness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, benign 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intracranial hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, intracranial hypoten- sion, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vasculitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol intoxication
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although the initial presentation may be one of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, detailed history and examination will identify one of these contributing conditions. </br>Tension-type 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are bilateral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with a feeling of a band-like tighten- ing sensation around the head.</br>In patients older than 50 years, giant cell 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arteritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may Appendix A: Sleep Related Medical and Neurological Disorders present with lateralized or bilateral 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tenderness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 over the temporal area, accompanied by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polymyalgia rheumatica and visual problems
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    loss of vision
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is in the differential diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 because it may occur in association with the sleep period.</br>Patients report hearing an explosion in the head which is unaccompanied by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Unresolved Issues and Further Directions Not applicable or known. </br>Bibliography Brennan KC, Charles A. Sleep and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Semin Neurol 2009;29:406–17. </br>Sleep Related Laryngospasm Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Stridor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngeal dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Essential Features Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a disorder in which 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tracheal muscle dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or para- tracheal soft-tissue 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    swelling
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 causes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stridor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or interruption of airflow, with associated awakening from sleep.</br>Patients may have total or near-total cessation of airflow while asleep, and suddenly arouse.</br>This brief 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory blockage
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (lasting an estimated five to 45 seconds) is often followed by a period of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stridor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that lasts several minutes and gradually evolves to normal breathing.</br>Episodes are associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    panic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and fear of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    suffocation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cyanosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be observed.</br>In some cases of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep, patients may have frequent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngeal stridor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (which may be difficult for families to dif- ferentiate from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), associated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachypnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and intermittent upper airway blockage. </br>Associated Features Fear and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    panic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 upon awakening often accompany events and may, at times, lead to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In some cases of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, gastroesophageal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been identified.</br>Less commonly, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has been related to underlying 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Clinical and Pathophysiological Subtypes Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multisystem atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a neurode- generative disorder. </br>355 Appendix A: Sleep Related Medical and Neurological Disorders Demographics Prevalence data do not exist.</br>Typical age of onset is unknown, although when the con- dition is due to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multisystem atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, affected individuals are typically older. </br>Predisposing and Precipitating Factors Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Laryngeal dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 seen in other disorders, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngeal tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multisystem atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, may cause 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep related stridor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and intermittent laryngospasm.</br>Precipitating factors include use of hypnotic or other central nervous system depressant medications.</br>Tonic-clonic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be a rare cause of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in children. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a common cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in multiple system 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Developmental Issues Not known. </br>Pathology and Pathophysiology When not associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurodegenerative disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of known pathology (e.g., mul- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tisystem atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
), the pathology and pathophysiology is uncertain.</br>Sleep related laryn- gospasm can be related to tracheal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    postnasal
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 drip, or reflux of gas- troesophageal contents causing irritation of soft tissue in the upper airway.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Laryngeal tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multisystem atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can cause 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngeal dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, resulting in sleep related laryngospasm. </br>Objective Findings Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be observed on PSG with accompanying audio record- ing.</br>It is seen in all stages of sleep but is most severe in REM sleep.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can appear to be similar to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on the polysomnographic snoring channel, but the audio recording will confirm the high-pitched inspiratory sound as laryngospasm.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has also been detected in some cases.</br>Patients or family members may mistake 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>PSG evaluation may be necessary to distin- guish these disorders.</br>In children, PSG or sleep-deprived EEG may demonstrate sei- zures that manifest solely as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Endoscopy of the upper airway is necessary to examine vocal cord function and to exclude upper airway pathology.</br>Gastroesophageal studies may reveal evidence of reflux. </br>356 Appendix A: Sleep Related Medical and Neurological Disorders Differential Diagnosis 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may cause awakenings, with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    choking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or gasping for air, excessive daytime som- nolence, restlessness, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>If 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a diagnostic consideration, sleep study is warranted.</br>Sleep related gastroesophageal reflux may result in coughing or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    choking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes during the night without true laryngospasm.</br>However, these episodes usually are described in the setting of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or “
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.”</br>One possible cause of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    occult acid reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 into the upper airway, causing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    swelling
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be associated with sensations of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    impaired breathing or choking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, rapid heartbeat, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    agitation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>However, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are most common in children, and most patients do not focus on upper airway choking.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Panic disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can involve abrupt awakening with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory distress
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, signs of sympathetic activity, and fear of dying.</br>However, most patients also have daytime episodes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    panic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal asthma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 can result in sleep related coughing, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    wheezing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    shortness of breath
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>REM 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) may be in the differential diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but is generally recognizable by polysomnographic features of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RBD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and a history of dream enactment. </br>Unresolved Issues and Further Directions Published reports generally have been limited to case series.</br>Clarification of the rela- tionship between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and gastroesopha- geal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is needed. </br>Bibliography 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Aloe F
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, Thorpy M. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep-related laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Arq Neuropsiquiatr 1995;53:46–52. </br>Campbell A, Pierce R. Brief upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airway dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Respir Med 1994;88:125–9. </br>Guilleminault C, Eldridge F, Phillips J, Dement 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    W.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Two occult causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and their therapeutic problems.</br>Arch Gen Psychiatry 1976;33:1241–5. </br>Iriarte J, Urrestarazu E, Alegre M, Goni C, Viteri C, Artieda J. Sleep-related laryngospasm: A video polysomnographic recording.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epileptic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Disord 2006;8:70–2. </br>Kavey N, Whyte J, Blitzer A, Gidro-Frank 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S. Sleep-related laryngeal obstruction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 presenting as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Laryngoscope 1989;99:851–4. </br>Roland MM, Baran AS, Richert AC.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 caused by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep Med 2008;9:451–3. </br>Thorpy M, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Aloe
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 F. Choking during sleep.</br>Sleep Res 1989;18:314. </br>Thorpy M, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Aloe
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 F. Sleep related laryngospasm.</br>Sleep 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Res
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 1989;18:313. </br>Thurnheer R, Henz S, Knoblauch A. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep-related laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Eur Respir J 1997;10:2084–6. </br>357 Appendix A: Sleep Related Medical and Neurological Disorders Sleep Related Gastroesophageal Reflux Alternative Names Gastroesophageal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal gastroesophageal reflux, supine gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reflux esophagitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophagitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Essential Features Sleep related gastroesophageal reflux (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) occurs when gastric contents cross the lower esophageal sphincter (LES) into the esophagus and, potentially, into more prox- imal sites during sleep time.</br>Symptoms are usually noticed during 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or awak- enings.</br>Symptoms may include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substernal burning
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, chest discomfort, a sour or bitter taste in the mouth, regurgitation, water brash, coughing, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    choking
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or unex- plained excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, even in the absence of typical reflux symptoms.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with sleep onset and sleep maintenance 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, early 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morning awakenings
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, unrefreshing sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime functioning difficulties
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a potential 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    asthma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 trigger, predisposes to aspiration, and is a cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cough
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 commonly coexists in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, cystic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic pulmo-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 nary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bronchiolitis obliterans syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in lung transplant recipients.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and is prevalent in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Associated Features Associated features of this disorder include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphagia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    odynophagia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngopharyn-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 gitis, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, epigastric burning, chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cough
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    wheezing
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that may mimic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other associated features of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include sleep onset and sleep maintenance 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, excessive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, poor daytime functioning, and reduced work productivity.</br>Patients with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 also have a decrease in health-related quality of life and more health care visits. </br>Clinical and Pathological Subtypes Not applicable or known. </br>Demographics GER symptoms affect up to 44% of adults in the United States monthly, and 20% weekly.</br>Among patients with weekly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 79% report 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms during sleep time, 57% report waking up during sleep, and 40% report that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep time affected their ability to work the next day.</br>Among the 15,315 subjects of the Sleep Heart Health Study, 25% reported 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>In a review of 5 large Appendix A: Sleep Related Medical and Neurological Disorders population studies, the mean prevalence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep time was 54% ± 22% (standard deviation).</br>In patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related reflux symptoms are present in up to 62%.</br>Furthermore, in a trial examining consecutive asthmatics, 50% had awakenings from sleep because of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Thus, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms during sleep time are common.</br>There is no known predilection for men or women.</br>However, men are more likely than women to develop 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Barrett esophagus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Predisposing and Precipitating Factors Predisposing factors for sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include eating within two hours of bedtime, an elevated body mass index, erosive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophagitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and hiatal hernia.</br>Predictors of heart- burn during sleep include consumption of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 or carbonated beverages, or the use of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzodiazepines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 before sleep time.</br>Other predictors of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep include the presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    asthma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    snoring
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The relationship between 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is bidirectional.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is associated with short sleep duration, difficulty falling asleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, poor sleep quality, and early morning awakenings.</br>Conversely, sleep deprivation induces a state of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophageal hyperalgesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to acid, thus worsening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 symptoms. </br>Familial Patterns Not applicable or known. </br>Onset, Course, and Complications 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs in all age groups, including infants and children.</br>Sleep disruption occurs more frequently in infants and children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, compared to infants and children without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The incidence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 increases with age.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be more severe and is associated with more complications in older adults. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is a chronic disease which is rarely cured, but it may be controlled with lifestyle, and medical and/or surgical therapies.</br>In patients with sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, medical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 therapy improved 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and daytime functioning in placebo-con- trolled trials.</br>Long-term outcome data are currently lacking.</br>If 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is left untreated, the disease generally progresses and can be associated with many complications.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Esophageal complications
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophagitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophageal erosions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, esophageal stric- ture, ulcerations with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stricture
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Barrett esophagus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which is thought to be a precur- sor to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophageal adenocarcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Reflux can also result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphagia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and upper 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastrointestinal bleeding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is more commonly associated with erosive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophagitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stricture
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Barrett esophagitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and esophageal adenocarci- 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    noma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, compared to diurnal reflux.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Extraesophageal complications
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary complications
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 previously discussed in the Essential Features section. </br>359 Appendix A: Sleep Related Medical and Neurological Disorders Pathology and Pathophysiology Two major pathophysiologic mechanisms cause individual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes.</br>Transient LES relaxations (LES relaxations occurring without esophageal contractions) account for 53% to 74% of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes.</br>Transient LES relaxations decrease the LES pres- sure to the gastric pressure gradient, facilitating the retrograde flow of gastric contents.</br>An LES pressure of 10 mm Hg or less is the second mechanism by which intra-abdom- inal pressure overcomes the LES pressure, resulting in the retrograde flow of gastric contents into the esophagus. </br>Pathophysiology of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is similar to diurnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (i.e., transient LES relaxations and a low LES pressure).</br>However, sleep impacts esophageal physiology through the impairment of esophageal acid clearance mechanisms when 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events occur.</br>With sleep onset, the upper esophageal sphincter (UES) pressure decreases and is lowest during N3 sleep, thus predisposing to aspiration.</br>The UES contractile reflex remains intact during sleep, including REM sleep.</br>Lower esophageal sphincter (LES) pressure remains unchanged during sleep.</br>Sleep increases the vagal threshold for trig- gering transient LES relaxations, so they usually do not occur during stable sleep and are usually confined to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>When 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events occur during sleep, esophageal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    refluxate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 clearance is prolonged and an arousal is required.</br>Sleep facilitates proxi- mal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    refluxate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 migration toward the UES.</br>Saliva secretion, with its acid-neutralizing 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, ceases during sleep.</br>Swallowing, required for esophageal peristalsis and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    refluxate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 clearance, does not occur during sleep and is dependent on an arousal.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep also delays gastric emptying
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 by disrupting gastromyoelectric function.</br>Events causing 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including periodic limb movements and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apneas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, could trigger transient LES relaxations and thus 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events.</br>Because 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    refluxate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 clearance requires an arousal, medications decreasing the arousal response (including 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzodiazepines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and zolp- idem) may prolong 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    refluxate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 clearance and increase the risk of aspiration during sleep. </br>The pathology of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 includes abnormal esophageal manometry, endoscopy, and esophageal biopsy findings.</br>Esophageal manometry findings include an increased frequency of transient LES relaxations, altered or decreased esophageal peristaltic contraction amplitude, and a decrease in LES pressure.</br>Endoscopic findings include changes ranging from mild 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erosions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ulcerations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 to severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erosions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stricture
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Barrett esophagus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is identified when columnar tissue replaces the normal squamous epithelium of the distal esophagus. </br>Objective Findings Diagnostic testing is not required for sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The diagnosis can be made if typical symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and/or regurgitation are present during sleep time. </br>360 Appendix A: Sleep Related Medical and Neurological Disorders PSG is not indicated.</br>Esophageal pH monitoring, which may be combined with esophageal impedance, objectively measures individual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events.</br>Esophageal monitoring is recommended in difficult, refractory cases, or when symptoms continue despite therapy. </br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is more likely to occur during the first two hours of sleep time.</br>Furthermore, in studies using combined esophageal pH monitoring with actigraphy, acid reflux events occurred primarily during the recumbent-awake period, versus the recumbent-asleep period.</br>Reflux events are more likely to occur in the right side down and supine positions than in the left side down position. </br>PSG without esophageal pH or impedance monitoring reveals 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that are often associated with swallows and a notable increase in chin EMG tone.</br>Esophageal pH monitoring detects acid reflux events and can be integrated with PSG.</br>Esophageal pH monitoring should be performed over a 24-hour period to improve the test’s sensitiv- ity and specificity, which approximate 90%.</br>The distal pH probe is placed 5 cm above the LES.</br>A proximal pH probe is often placed near the UES.</br>An acid reflux event is defined when the pH 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    drops
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 to less than 4.0, and this variable is reported as time (%) where pH is less than 4.0.</br>The percent time where pH is less than 4 is reported over the total recording time, upright time and supine time.</br>Note that supine (in this testing) is defined as the period of time that the patient is in bed.</br>Symptom correlation is also helpful using the event marker on the device or diaries.</br>Normal esophageal pH times during the “supine” or sleep period are: 1) distal pH &lt; 4 - less than 3.5% of the time; and 2) proximal pH &lt; 4 - less than 0.6% of the time.</br>If esophageal pH monitoring is integrated with polysomnography, esophageal acid events can be cor- related with sleep events, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arousals
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, apneas, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and increased chin EMG tone.</br>Esophageal pH monitoring also can be performed simultaneously with actigraphy to correlate acid reflux events with sleep and wake periods.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Catheter-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 free wireless pH systems are also available and are deployed into the esophagus, usually by endoscopy. </br>Esophageal impedance monitoring can be combined with pH probes detecting liquid, gas, or liquid gas in the esophagus, and can assess both acid and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonacid reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 events.</br>Use of esophageal impedance monitoring is often performed in esophageal centers, and this technique would be difficult to integrate with polysomnography. </br>Other objective measures include esophageal endoscopy with or without biopsy in order to evaluate for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophagitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophageal complications
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A histologic evaluation is required to establish a diagnosis of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Barrett esophagus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>361 Appendix A: Sleep Related Medical and Neurological Disorders Differential Diagnosis The differential diagnosis is primarily with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peptic ulcer disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is sometimes indistinguishable from that of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Duodenal ulcer disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is commonly associated with a burning epigastric 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and this can sometimes be similar to the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 experienced by patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other conditions that may be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, sleep related abnormal swallowing, and sleep related laryngospasm.</br>PSG evaluation with respiratory and pH monitoring can differentiate these disorders. </br>Unresolved Issues and Further Directions Not applicable or known. </br>Bibliography Allen L, Poh CH, Gasiorowska A, et al.</br>Increased oesophageal acid exposure at the beginning of the recumbent period is primarily a recumbent-awake phenomenon.</br>Aliment Pharmacol Ther 2010;32:787–94. </br>Bajaj JS, Bajaj S, Dua KS, et al.</br>Influence of sleep stages on esophago-upper esophageal sphincter contractile reflex and secondary esophageal peristalsis.</br>Gastroenterology 2006;130:17–25. </br>Fass R, Johnson DA, Orr WC, et al.</br>The effect of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dexlansoprazole
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 MR on 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GERD-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with symptomatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GERD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Am J Gastroenterol 2011;106:421–31. </br>Fass R, Quan SF, O’Connor GT, et al.</br>Predictors of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep in a large prospective cohort study.</br>Chest 2005;127:1654–66. </br>Fujiwara Y, Arakawa T, Fass R. Gastroesophageal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reflux disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep disturbances.</br>J Gastroenterol 2012;47:760–9. </br>Gagliardi GS, Shah AP, Goldstein M, et al.</br>Effect of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    zolpidem
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 on the sleep arousal response to nocturnal esophageal acid exposure.</br>Clin Gastroenterol Hepatol 2009;7:948–52. </br>Gerson LB, Fass R. A systematic review of definitions, prevalence, and response to treatment of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal gastroesophageal reflux disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Clin Gastroenterol Hepatol 2009;7:372–8. </br>Ghaem M, Armstrong KL, Trocki O, et al.</br>The sleep patterns of infants and young children with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastro- oesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Paediatr Child Health 1998;34:160–3. </br>Green BT, Broughton WA, O’Connor JB.</br>Marked improvement in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in a large cohort of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 treated with continuous positive airway pressure.</br>Arch Intern Med 2003;163:41–5. </br>Harding SM, Richter JE, Guzzo MR, et al.</br>Asthma and gastroesophageal reflux: acid suppressive therapy improves 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    asthma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 outcome.</br>Am J Med 1996;100:395–405. </br>Harding SM.</br>Gastroesophageal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during sleep.</br>Sleep Med Clin 2007;2:41–50. </br>Locke 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 3rd, Talley NJ, Fett SL, et al.</br>Prevalence and clinical spectrum of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: a population-based study in Olmstead County, Minnesota.</br>Gastroenterology 1997;112:1448–56. </br>Mainie I, Tutuian R, Shay S, et al.</br>Acid and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    non-acid reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance pH monitoring.</br>Gut 2006;55:1398–402. </br>362 Appendix A: Sleep Related Medical and Neurological Disorders Schey R, Dickman R, Parthasarathy S, et al.</br>Sleep deprivation is 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperalgesic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Gastroenterology 2007;133:1787–95. Shaheen NJ, Weinberg DS, Denberg 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, et al.</br>Upper endoscopy for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: Best Practice Advice from the Clinical Guidelines Committee of the American College of Physicians.</br>Ann Intern Med 2012;157:808–16. Shaker R. Castell DO, Schoenfeld PS, et al.</br>Nighttime 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heartburn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association.</br>Am J Gastroenterol 2003;98:1487–93. </br>Sontag SJ, O’Connell S, Miller 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TQ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, et al.</br>Asthmatics have more nocturnal gasping and reflux symptoms than nonasthmatics, and they are related to bedtime eating.</br>Am J Gastroenterol 2004;99:789–96. </br>Sleep Related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Myocardial Ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Alternate Names 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Unstable angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, coronary insufficiency-acute, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 decubitus, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    variant angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prinzmetal angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vasospastic angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    angina pectoris
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atherosclerotic heart disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, asymptomatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, silent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Essential Features Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is characterized by nocturnal reduction of blood flow to the myocardium, typically during sleep.</br>The symptoms of sleep related 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myo-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 cardial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are very similar to those that characterize episodes of cardiac isch- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    emia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 during the daytime.</br>Classically, there is a feeling of chest pressure or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that awakens the patient from sleep and may be described as a “viselike” discomfort.</br>The discomfort may radiate to the chin and jaw and to the arm, especially the left arm. </br>Associated Features Acute episodes of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 sometimes elicit atrial or ventric- ular 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other associated presentations include acute onset of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    shortness of breath
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that wakes the patient from sleep and that may be secondary to left ventricular diastolic dysfunction or ischemic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mitral regurgitation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Other related features depend on the trigger for the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Ischemic events related to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may present during those times of sleep when nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desaturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is most severe.</br>Cardiac isch- 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    emia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 related to hemodynamic changes or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vasospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurring during REM sleep may present in the early hours of the morning, around the time of waking, when REM sleep is most likely to occur.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal hypotension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is most likely to occur during slow wave (N3) sleep, when blood pressure is lowest. </br>Clinical and Pathophysiologic Subtypes None known. </br>363 Appendix A: Sleep Related Medical and Neurological Disorders Demographics The specifics of prevalence, sex ratios, and age ranges have not been comprehensively evaluated.</br>Some insights into demographics can be extrapolated, depending on the cause of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>For sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 triggered by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the preponderance of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in men suggests that middle-aged men with severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are more likely to experience 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly if they have more severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Variant angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (also referred to as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vasospastic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prinzmetal angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) more commonly affects younger populations, particularly women and those of Asian descent.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cardiac ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 secondary to nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypotension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is more com- monly manifested in older individuals, particularly those with severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vasculopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 who are taking multiple antihypertensive medications, and especially those in whom 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autonomic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (related to either age or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) may impair blood pressure homeostatic mechanisms. </br>Predisposing and Precipitating Factors </br>Predisposing factors include established 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    valvular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aortic stenosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Because coronary filling occurs during diastole, conditions associated with reduced diastolic blood pressure, such as severe aortic regurgita- tion, may elicit 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly in the presence of preexisting coro-</br>nary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Similarly, any predisposition to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypotension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which is most likely to occur during slow wave (N3) sleep, may heighten risk.</br>Usual risk factors for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that predispose an individual to the development of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, cigarette smoking, and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperlipidemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Retrospective and prospective studies suggest that 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be a trigger for 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myo-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardial infarction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sudden 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that occurs at night.</br>Deeper oxyhemoglobin desaturations, which may be encountered in REM, particularly with coexisting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    truncal-abdominal obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, are more likely to trigger 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vasospastic angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, use of nonselective β-adrenergic receptor-blocking agents may theoretically increase the likelihood of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vasospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 secondary to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypotension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, an excess of antihy- pertensive medications, as well as long-acting 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nitroglycerin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 administered prior to sleep, may contribute.</br>Finally, in the proper clinical context, abuse of drugs such as 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amphetamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cocaine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, and other stimulants, needs to be considered in the evaluation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Familial Patterns Familial patterns reflect those of the underlying disease process. </br>364 Appendix A: Sleep Related Medical and Neurological Disorders Onset, Course, and Complications For 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the first presentation of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may occur only when the severity of both the sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the coronary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are suffi- cient to elicit sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>This is likely to be most common in middle-aged to older men, particularly those who are overweight, although several studies have documented life-threatening 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in women.</br>It is notable that several studies have reported 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 even in the absence of severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery stenosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>ST segment changes occur- ring as a result of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 would be expected to resolve with treatment of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Regardless of the underlying etiology, potential complications of sleep related 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myo-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 cardial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 include acute left 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventricular dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, ischemic mitral regur- gitation and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and even progression to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial infarction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Pathology and Pathophysiology For sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea-related hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and surges in blood pressure and heart rate at termination of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may all result in rel- ative 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial oxygen deficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>A substrate of preexisting severe 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is expected to exacerbate this problem.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Variant angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be more likely to occur during sleep because of the significant and abrupt fluctuations in cardiovascular neural control during REM sleep.</br>For 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypotension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, perfu- sion of the coronary arteries during diastole makes maintenance of diastolic pressures during sleep important for adequate myocardial perfusion.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Autonomic insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to old age, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and medication effects blunts the ability of the cardiovascular system to maintain adequate blood pressure. </br>Objective Findings Electrocardiographic monitoring during sleep reveals horizontal or downsloping ST segment 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of greater than or equal to 1 mm, or ST segment elevation of 1 mm or more.</br>The electrocardiographic evidence of sleep related coronary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    artery ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is sometimes unaccompanied by chest discomfort or other symptoms (silent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) and may be incidentally noted on either Holter monitoring or telemetry. </br>In general, ST segment abnormalities indicative of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 are 1 mm or more horizontal or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    down-sloping depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or ST segment elevation, which may be detected on the single lead electrocardiogram (ECG) employed in most sleep labo- ratories.</br>However, because the sensitivity of single-lead ECG in detecting ischemic changes is poor, the patient with symptoms compatible with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with a normal-ap- pearing single ECG channel should be further evaluated with multichannel ECG. </br>365 Appendix A: Sleep Related Medical and Neurological Disorders Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in patients without sleep related breathing disor- ders may be associated with REM sleep.</br>Slow wave sleep with a fall in blood pressure and heart rate can be associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, par- ticularly 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    OSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, may elicit 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 desaturation and consequent sleep related myocar- dial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>The presence of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should prompt an evaluation for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Differential Diagnosis Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 must be differentiated from 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gastroesophageal reflux
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which may also be associated with chest discomfort.</br>The nature of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, associated symptoms and prior history are helpful in making a distinction, although 12-lead ECG may be necessary in some cases.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal panic attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be asso- ciated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest wall pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory distress
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Although the majority of patients with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal panic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 will have a history of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    daytime panic attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, a small percentage have only nocturnal events.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal panic attacks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 typically occur during transition from N2 to N3 sleep. </br>Other causes of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal respiratory distress
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and pulmonary disease, may be confused with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 episodes, although typical anginal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is not evident in these cases. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chest pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to thoracic mass, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pleuritic pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aortic aneurysm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thoracic disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 should be considered in the differential diagnosis.</br>Chest wall 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 may be 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sec-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 ondary to a variety of causes such as 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    muscle spasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, or immobility. </br>Unresolved Issues and Further Directions More comprehensive data are needed to identify the prevalence and demographics of the various causes of sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Further information is also needed to explore the relationship between sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the circadian variation in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial infarction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sudden 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, particularly the role of treatment on outcomes. </br>Bibliography Caples S, Rosen C, Shen W, et al.</br>The scoring of cardiac events during sleep.</br>J Clin Sleep Med 2007;15:147–54. </br>Franklin K, Nilsson J, Sahlin C, Naslund U. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep apnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Lancet 1995;345:1085–7. </br>Gami A, Howard D, Olson E, Somers V. Day-night pattern of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sudden death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>New Engl J Med 2005;352:1206–14. </br>366 Appendix A: Sleep Related Medical and Neurological Disorders Muller J, Ludmer P, Willich S, et al.</br>Circadian variation and the frequency of sudden 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>Circulation 1987;75:131–8. </br>Nowlin J, Troyer WJ, Collins W, et al.</br>The association of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal angina pectoris
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with dreaming.</br>Ann Intern Med 1965;63:1040–6. </br>Schroeder J, Motta J, Guilleminault C. Hemodynamic studies in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>In: Guilleminault C, Dement W, eds.</br>Sleep Apnea Syndromes.</br>New York:</br>Alan R. Liss, 1978:177–96. </br>Sert Kuniyoshi F, Garcia-Touchard A, Gami A, et al.</br>Day-night variation of acute 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial infarction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>J Amer Coll Cardiol 2008;52:343–6. </br>Verrier R, Muller J, Hobson J. Sleep, dreams, and sudden 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: the case for sleep as an autonomic stress test for the heart.</br>Cardiovasc Res 1996;31:181-211. </br>367 Appendix B: ICD-10-CM Coding for Substance- Induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Disorders ICD-10-CM coding for substance-induced disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 is more complex than ICD-9-CM coding.</br>The series 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    F10.xxx-F19.xxx
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (which is the general section for substance-in- duced mental and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    behavioral disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in ICD-10-CM) contains the pertinent codes for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance-induced sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.</br>There are specific codes for 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 induced by 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, opioids, sedatives, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cocaine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, other 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stimulants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and other psychoactive sub- stances.</br>However, in the case of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cannabis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, hallucinogens, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nicotine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and inhalants, there are no sleep-specific codes.</br>In these instances, the coder must use an “unspecified” or “other” code.</br>A detailed list of the appropriate codes for substance-induced sleep dis- orders is included in the table below. </br>Substance Relevant ICD-10-CM Codes 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 F10.182 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alcohol abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol-induced sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F10.282 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 dependence with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol-induced sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F10.982 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 use, unspecified with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol-induced sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Opioid F11.182 Opioid abuse with opioid-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F11.282 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Opioid dependence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with opioid-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F11.982 Opioid use, unspecified with opioid-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Cannabis F12.188 Cannabis abuse with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cannabis-induced disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F12.288 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cannabis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 dependence with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cannabis-induced disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F12.988 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cannabis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 use, unspecified with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cannabis-induced disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Sedative, Hypnotic or Anxiolytic F13.182 Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F13.282 Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F13.982</br>Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Appendix B: ICD-10-CM Coding for Substance-Induced Sleep Disorders Substance Relevant ICD-10-CM Codes 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cocaine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 F14.182 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cocaine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 abuse with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cocaine-induced sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F14.282 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cocaine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 dependence with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cocaine-induced sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F14.982 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cocaine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 use, unspecified with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cocaine-induced sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Other Stimulant (includes 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amphetamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
) F15.182 Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stimulant abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with stimulant-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F15.282 Other stimulant dependence with stimulant-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F15.982 Other stimulant use, unspecified with stimulant-induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Hallucinogen (includes 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ecstasy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PCP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phencyclidine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
) 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    F16.188 Hallucinogen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 abuse with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinogen-induced disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F16.288 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hallucinogen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dependence with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinogen-induced disorder F16.988 Hallucinogen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 use, unspecified with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hallucinogen- induced disorder Nicotine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F17.208 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nicotine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 dependence, unspecified, with other nicotine- induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders F17.218 Nicotine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dependence, cigarettes, with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nicotine-induced disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F17.228 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nicotine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 dependence, chewing tobacco, with other nicotine- induced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disorders F17.298 Nicotine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 dependence, other tobacco product, with other nicotine-induced disorders Inhalant (includes volatile solvents) F18.188 Inhalant abuse with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inhalant-induced disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F18.288 Inhalant dependence with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inhalant-induced disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F18.988 Inhalant use, unspecified with other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inhalant-induced disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Other Psychoactive Substance (includes polysubstance drug use) F19.182 Other psychoactive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance abuse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychoactive substance-induced sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F19.282 Other psychoactive 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance dependence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychoactive substance-induced sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 F19.982 Other psychoactive substance use, unspecified with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychoactive substance-induced sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Glossary Actigraphy: A measurement of physical activity, typically via a wrist-worn movement sensor, employed to estimate sleep and wakefulness based on relative levels of physical inactivity and activity. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alveolar Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: A condition in which ventilation of the lung gas exchanging units is decreased relative to the 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carbon dioxide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 production (excretion) such that the arterial partial pressure of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carbon dioxide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is increased.</br>Alveolar ventilation is equal to the minute ventilation (tidal volume × respiratory rate) minus the dead space ventilation. </br>Apneic Threshold:</br>The value of PaCO2 below which central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurs during NREM sleep. </br>Ataxic Breathing: A breathing pattern consisting of irregular variation in tidal volume and respiratory rate, characteristic of the effects of opioids on breathing. </br>Autonomic Arousal: An abrupt shift in autonomic nervous system activity during sleep characterized by an increase in sympathetic activity, including heart rate and blood pressure. </br>Biological Day/Night: In humans, biological day refers to the internal circadian time when wakefulness and associated functions are promoted (e.g., when endogenous 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels are low).</br>Biological night refers to the internal circadian time when sleep and associated functions are promoted (e.g., when endogenous 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels are high). </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
:</br>More than one episode of generally brief (&lt; 2 minutes), usually bilaterally symmetrical sudden loss of muscle tone with retained consciousness.</br>The episodes are precipitated by strong emotions, usually positive, with almost all patients reporting some episodes precipitated by emotions associated with laughter. </br>Chemosensitivity: The sensitivity of the chemoreceptors to increases in PCO2 or decreases in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PO2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
.</br>In humans this is measured by increases in ventilation associated with these stimuli. </br>Chronotype: Individual timing preference for various physical and mental activities, and sleep and wakefulness, over the course of a day.</br>“Morningness” refers to preference for earlier timing of activities and sleep initiation; “eveningness” refers to preference for later timing of activities and sleep initiation. </br>371 Glossary Circadian Misalignment: Incorrect or inappropriate timing of sleep and wakefulness with respect to internal circadian timing (e.g., the wake episode occurring entirely or partially during the biological night and/or the major sleep episode occurring entirely or partially during the biological day). </br>Circadian Period (tau): The time it takes to complete one circadian cycle (e.g., time from one circadian phase on day 1 to the same circadian phase on day 2). </br>Circadian Phase: The time at which a particular event occurs within the circadian cycle (e.g., onset, offset, trough, peak). </br>Circadian Rhythm: Biological oscillation, with a periodicity near 24 hours, which is clock- driven (i.e., not caused by external or non-circadian clock factors). </br>Comorbid 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: An 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 thought to have partial or total independence from a co-occurring 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or sleep-disruptive medical, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    substance dependence/abuse disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Conditioned Arousal: An arousal response developed by the repeated association of a specific setting such as the bedroom with unsuccessful sleep attempts. </br>Cortical Arousal: An abrupt shift of EEG frequency to a faster frequency lasting at least 3 seconds, indicating cortical activation. </br>Cyclic Alternating Pattern (CAP): The occurrence in NREM sleep of transient EEG events (phase A, subtypes A1, A2 and A3) interrupting the background activity (phase B). </br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CAP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 is a sensitive marker of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep instability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, usually increased in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that adversely affect sleep continuity. </br>Dim Light 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 Onset (DLMO): A marker of internal circadian phase designated by the rise in 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 above low daytime levels, typically assessed via blood or salivary 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels.</br>
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 levels are reduced by exposure to light and thus need to be assessed in dim light to be accurate. </br>Dopaminergic:</br>Related to the neurotransmitter 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dopamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Dystonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: Involuntary muscle contractions that result in slow 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    repetitive movements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or abnormal postures. </br>372 Early Morning Awakening: The termination of sleep at least 30 minutes before the desired rising time with a concomitant reduced total sleep time compared to the usual premorbid sleep pattern. </br>Electromyogram (EMG): Physiological recording of muscle activity, based on electrical activity that accompanies muscle contraction.</br>For sleep monitoring purposes, EMG is typically recorded from skin surface rather than intramuscular electrodes. </br>Entrained/Entrainment: The successful end result (entrained) or process of (entrainment) synchronization of an internal circadian clock to the environment (e.g., light dark cycle), producing a stable phase relationship between the circadian clock and environmental time. </br>Fatigue: A lack of energy, accompanied by a desire to reduce or limit activity levels.</br>This symptom should be differentiated from reports of subjective 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 as well as from unintended sleep episodes. </br>Homeostasis:</br>The tendency of a living organism to maintain internal equilibrium by adjusting and regulating its physiological processes. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypercapnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: Elevation of the arterial partial pressure of 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carbon dioxide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (PaCO2) to a level &gt; 45</br>mm</br>Hg during wakefulness. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnolence
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during the normal wake period.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: A disorder characterized by 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    excessive sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (e.g. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
). </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnagogic Hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
:</br>Vivid dreamlike experiences occurring at the transition from wake to sleep. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnopompic Hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
:</br>Vivid dreamlike experiences occurring at the transition from sleep to wake. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Myalgia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Muscle pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Nonrestorative Sleep: Sleep that is perceived to be poor in quality and unrefreshing, resulting in a sense of feeling unrested upon awakening. </br>373 Glossary Glossary Odds Ratio: A statistical term that provides a measure of the strength of relationship between two variables; the odds of an event occurring in one group compared to the odds of it occurring in another group. </br>Oneirism: Acting-out of dreams, usually from REM sleep. </br>Out of Center Sleep Testing: A sleep study performed outside of the sleep center, usually at a patient’s home and with limited (typically respiratory related) channels (parameters) recorded. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Pseudo-Suicide: A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, erroneously attributed by authorities to suicide, which results from complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, usually from NREM sleep. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson Disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
: A neurodegenerative 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 which may result in 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bradykinesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rigidity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and/or postural instability, and eventually cognitive decline. </br>Phase Advance/Delay: A shift in the timing of the internal circadian clock in which circadian phase is moved earlier (advance, such as required for eastward jet travel or to assume an earlier sleep schedule) or later (delay, such as required for westward jet travel or to assume a later sleep schedule). </br>Phase Response Curve: Graphic representation that describes the circadian phase shifting response to a time cue (e.g., light) as a function of the internal circadian time at which the cue is presented. </br>Phase Tolerance:</br>The ability to be awake or asleep at an inappropriate internal circadian time. </br>Physiological Hyperarousal: A state of chronic physiologic arousal as reflected by measures such as increased mean latency on MSLT, increased metabolic rate and 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucose
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 metabolism in the CNS (
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PET
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 scan), decreased heart rate variability and increased heart rate. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PHOX2B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
:</br>A paired-like homobox gene, mutation of which is the defining abnormality of Congenital Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Prevalence: The proportion of the population affected by a disease or condition at a given time; prevalence indicates how widespread a disease or condition is, thereby serving as a measure of its burden on society. </br>374 REM Sleep without Atonia, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    REM-without
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Atonia: The intermittent or continuous loss of the normal muscle 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of REM sleep. </br>Reverse First Night Effect: A propensity to sleep better than usual on the first night in the sleep laboratory. </br>Sleep Attacks: Inappropriate falling asleep with few or no prodromal symptoms of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleepiness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Sleep Diary (sleep log): An instrument used by individuals to keep records of their nightly sleep duration and quality over a period of days to weeks. </br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Drunkenness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (prolonged sleep inertia): Prolonged difficulty waking up after a night’s sleep or a nap with repeated returns to sleep, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    irritability
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, automatic behavior and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
. </br>Sleep Homeostasis: A process which describes the propensity for sleep driven by duration of prior time awake and sleep history. </br>Sleep Hygiene: A set of rules/instructions about lifestyle (
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    caffeine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 intake, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 and tobacco use, diet, etc.)</br>and environmental factors (light, noise, temperature) that affect overall sleep duration and quality. </br>Sleep Onset REM Period (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SOREMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
): REM sleep occurring within 15 minutes of sleep onset on a multiple sleep latency test or overnight polysomnogram. </br>Sleep Related Abnormal Sexual Behaviors: Any of a spectrum of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sexualized behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 which arise from sleep, typically NREM sleep. </br>Sleep Related Violence: 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Violent behavior
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 which is associated with a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NREM parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 when the affected individual is accidentally provoked by another person in close proximity – usually a family member. </br>Suggested Immobilization Test: A procedure for evaluation of periodic leg movements and related sensory components of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RLS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 during resting wakefulness.</br>A standard polysomnogram recording without respiratory measures is used for one hour while the subject sits quietly awake and upright in bed with the legs outstretched. </br>375 Glossary Index A Actigraphy 35, 144, 152, 159, 161–163, 165, 182, 185, 187, 189, 191, 196, 199, 204, 207, 209, 213, 215, 218, 223, 224, 297, 298, 361 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Adenotonsillar hypertrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 65, 66, 139, 274 Advanced 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep-wake phase disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 198–203 Agrypnia excitata 248 Akathisia 290, 316, 326, 333 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alcohol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 27, 31, 43, 54, 57, 110, 122, 125, , 139, 167, 168, 175, 176, 192, 194, 200, 212, 217, 219, 220, 221, 234, 237, 238, 241, 242, 247, 268, 276–278, 286, 295, 326, 352, 354, 359, 369 Alpha-1 antitrypsin 129, 130, 136 Alternating leg muscle activation 330–334 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 204, 205, 224, 277, 279, Amyotrophic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lateral sclerosis 300 Angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 61, 358, 362–366 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Antidepressant
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 148, 153, 176, 249, 250, , 259, 277, 285, 294, 295, 331, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    333 Anxiety disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 26, 28, 31, 38, 148, 192, , 257, 269, 284 Anxiolytic 110, 122, 130, 255, 369 Apneic threshold 72, 73, 82, 91, 92 Apparent life-threatening event (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ALTE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 94, , 97, 114, 117 Arrhythmia 58, 65, 101, 110, 122, 126, , 136, 363, 365, 366 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Asperger syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 206, 297 Asthma 61, 357–359 Ataxic breathing 74, 76, 85, 87, 88, 105, , 125, 127, 128 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Atrial fibrillation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 53, 55, 58, 69, 71, 139 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Attention deficit hyperactivity disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 66, 192, 193, 195, 271, 284, 288, 291, 308, 310, 314 Augmentation 59, 283 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Autism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see also pervasive developmental disorder) 119, 195, 200, 206, 211, 251, 314, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    316 B Barrett esophagus 359–361 Behavioral insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of childhood (see also limit-setting 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and sleep- onset association disorder) 21, 27, 29, 340 Benign 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of childhood with centrotemporal spikes (BECT) 345–347 Benign 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    occipital paroxysms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BEOP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 345–347 Benign sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of infancy 317–320 Biot breathing 87 Blindness 202, 209–213 Body rocking 312–314, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    316 Breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see sleep related bruxism) C 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cataplexy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 141, 145–162, 171, 242, 250, 256 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Catathrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 141 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Central disorders of hypersomnolence –188 Central sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 breathing 75–79 Index Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance 85–89 Central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea syndromes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>69–107 Central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cheyne-Stokes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 breathing 69–75 Cerebrovascular accident (see also 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) , 78, 93 Charley horse 299 Chemoresponsiveness 80, 81, 91, 92, 121, , 129 Chemosensitivity 111, 123, 126, 130, 131, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chiari malformation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 76–78, 93, 116 Children’s Chronotype Questionnaire 196 Choking (see also sleep related laryngospasm) 53, 54, 96, 357, 358 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chronic bronchitis 129
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 39, 154, 160, , 181, 206 Chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 21–41 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chronic obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see also lower airway) 55, 56, 129, 131, , 138, 284, 358 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chronic pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 22, 31, 86, 87 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chronic renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 285, 286, 287 Chronotype 184, 189–193, 195–197, 199, , 219 Circadian period 195, 197, 201, 209, 212, , 222 Circadian phase 191–196, 199, 200 Circadian 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm sleep-wake disorders –224 Circadian sleep-wake disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 not otherwise specified 224 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cluster headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 266, 350–354 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Comorbid insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 21 Complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocturnal visual hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 –269 Complex 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see also treatment- emergent central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
)</br>102 Conditioned arousal 20, 23, 26, 28 Confusional arousal 228–239 Congenital central alveolar hypoventilation syndrome 113–117 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 50, 53, 55, 58, 61, , 71, 72, 93, 271, 287, 297 Continuous spike and wave in sleep (CSWS) , 346, 347, 348 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    also angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) , 55, 58, 61, 139, 364, 365 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cor pulmonale
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 55, 66, 77, 91, 109, 110, , 115, 117, 119, 122, 125, 129, 135 Cyclic alternating pattern 296, 308 Cystic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 129, 130, 136, 358 D Delayed sleep-wake phase disorder 191–198 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Dementia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lewy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 bodies 249, 250 Diabetes 53, 55, 58, 62, 118, 119, 187, 241, , 273, 274, 284, 287, 300, 364, 365 Diagnostic and statistical manual 26, 28, , 261, 316 Dim-light 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 onset 196, 199, 209 Disorders of arousal (from NREM sleep) –239 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Dopamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 172, 176, 259, 284, 285, 288, , 294–298 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Down syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 57, 65, 305 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Dystonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 297, 301, 302, 309, 345 E Early morning awakening 24, 33, 37, 45, 195, 202, 221, 358, 359 Electromyogram (EMG) 60, 226, 237, 247, 251, 296, 298, 301, 309, 310, 318, 320, 323, 324, 328, 329, 331–333, 336, 361 Emphysema (see also chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 129, 130,</br>136 Entrainment 189, 197, 206, 210–213 Environmental 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 339 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see also sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 68, 236, 237, 252, 271, 274, 298, 307, 309, 310, 312, 316, 317, 341, 345–349 Epworth Sleepiness Scale 55, 86, 144, 163, 173, 181, 196, 284, 293 Esophageal manometry 60, 294, 360 Esophageal pH 361 Excessive fragmentary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 328–330 Excessive time in bed 47 </br>Exploding 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    head syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 264–266 F Fatal familial 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 342–344 Ferritin 285, 295 Fibromyalgia 39, 284 Free-running (see non-24-hour sleep-wake rhythm disorder)</br>G Gastroesophageal reflux (see also sleep related gastroesophageal reflux) 22, 23, 31, 33, 38, 55, 61, 99, 101, 117, 309, 341, 355–358, 362, 363, 366 H Hcrt 149, 156–160, 171 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) Head banging 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    312–315
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 Head 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trauma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 149, 156, 157, 168, 170, 172, High-altitude periodic breathing 79–84 hPer2 (clock gene) 201 hPer3 (clock gene) 193, 194 Human leukocyte antigen 149, 150, 152, 153, 157–160, 164, 168, 169, 194 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Huntington disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 205, 224 Hypernychthemeral 209 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    psychiatric disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 179–182 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder –175 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance 175–178 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 32, 53, 55, 56, 58, 60, 61, 66, , 91, 110, 112, 116, 120, 122–126, 128–132, 134–137, 139, 140, 291, 352, 354, 359, 364 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hyperthyroidism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 234 Hypnagogic foot 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tremor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 330–334 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnagogic hallucination
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 148, 150, 151, , 158, 163, 171, 183, 261, 267–269, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 266, 350, 351, 353, 354 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see also sleep starts)</br>335–337 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypnopompic hallucination
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 148, 252, 267, , 276 Hypnotic 22, 33, 110, 122, 130, 176, 178, , 194, 212, 234, 242, 243, 247, 277, , 356, 369 Hypocretin 145, 146, 149–156, 158–160, , 169, 172, 250 Hypothyroidism 57, 112, 118, 123, 127, 173 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) </br>I Idiopathic central alveolar hypoventilation 121–124 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Idiopathic hypersomnia 161–166
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Idiopathic insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 20, 27 Inadequate sleep hygiene 20, 27, 197 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 19–48 Index Index 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to (a) medical condition 28 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to (another) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mental disorder Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to drug or substance 28 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with objectively short sleep duration 29 Insufficient 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 182–186 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Iron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 deficiency 285, 288 Irregular sleep-wake 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 –208 J Jet lag disorder 220–224 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Juvenile myoclonic epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    JME
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 345, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>166–170 L 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Laryngospasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see sleep related laryngospasm) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Late-onset
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 central 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypothalamic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 118–120 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Leg cramps
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see sleep related leg cramps)</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Limit-setting sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 21 Long sleeper 187–188 Lower airway (lung disease) (see also chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    emphysema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and chronic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bronchitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 52, 129, 135 M 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Major depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see also 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mood disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
)</br>180, 193, 284 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (see also dim-light 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melatonin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 onset)</br>173, 176, 189, 191, 195, 196, 200, 201, 206, 207, 209, 213, 218, 354 Menopause 57, 353 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Menstrual-related Kleine-Levin syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 167 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 (see also opioid) 86, 87, 105, 126 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Migraine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 170, 234, 265, 266, 269, 284, 350–354 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Mood disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see also major 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 28, 53, 168, 179, 192, 193, 212, 244, 260, 268, 288, 291, 294 Morningness-eveningness questionnaire 189, 190, 196 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Movement disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see sleep related movement disorders) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Multiple sclerosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 34, 156, 170, 247, 248, 251, 284, 297 Multiple sleep latency test 35, 55, 61, 144, 146, 151–165, 169, 171–174, 177, 179, 181, 185, 188, 218, 266, 293, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    297 Multisystem atrophy 355, 356 Munich Chronotype Questionnaire 190, 196 Muscular dystrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 67, 117 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Myotonic dystrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 57, 156, 172, 175 N 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 1 146–155 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Narcolepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 type 2 155–161 Negative expectations 23, 219, 223 Neuromuscular (disease/disorder) 52, 64, , 66, 67, 93, 112, 121, 123, 126–131, –137, 153, 300 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Night eating syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 244, 245 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nightmare disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 257–263 Nocturnal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    frontal lobe epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NFLE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) , 345–349 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nocturnal paroxysmal hemicrania 266 Non-24-hour sleep-wake rhythm disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 –214 Nonrestorative sleep 23, 33, 39, 43, 53, 69, 75, 79, 85, 89, 241, 294, 296 O Obesity 51, 53, 55, 57, 58, 61, 65, 66, 68, 108–111, 116, 118–121, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    123, 124
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 126, 128, 139, 148, 151, 173, 241, 244, 284, 364 Obesity 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 108–113 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obstructive sleep apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, adult 53–62 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Obstructive sleep apnea disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 53–68 Obstructive sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
,</br>pediatric 63–68 Oneirism 248 Opioid (see also 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methadone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
) 51, 69, 74, 85–88, 93, 103, 126, 176, 317, 369 Opioid withdrawal 88, 317 Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 46 Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 264–278 Other 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 339–340 Out-of-center sleep testing (OCST) 50, 53, , 60, 61, 134, 137, 139 P Paradoxical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 20, 27, 35 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder 276 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance –278 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 overlap disorder 237, 248, 249, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 225–280 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parasomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, unspecified 278 Parenchymal (lung disease) 52, 93, 109, , 121, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    123, 124
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 127–131, 134–137 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 156, 172, 205, 224, 227, 249, 250, 284, 287, 297, 305, 308, 333 Performance 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anxiety
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 26 Periodic breathing 50, 74, 78–83, 87, 92, , 95, 98, 101 Periodic limb movement disorder 292–299 Periodic limb movements of sleep 148, 271, 272, 274, 281, 284, 285, 287–290, 292–298, 324, 329 Periodic limb movements of wake 284, 289 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pervasive developmental disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see also 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    autism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 206 Phase response curve 193, 201 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PHOX2B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 113, 114, 116, 118–120, 123 Physiological hyperarousal 33, 35 Posttraumatic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stress disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 249, 252, 258, , 260, 262, 279, 284, 297, 327 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prader-Willi syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 120, 156, 172 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pramipexole
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">CHEMICAL</span>
</mark>
 176, 331 Pregnancy 139, 140, 285, 286, 353 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 91, 98–101 Primary central sleep apnea 89–94 Primary central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea of infancy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 –98 Primary central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prematurity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 –102 Primary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 20, 21, 26, 28, 29 Prion protein 342–344 Propriospinal 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 at sleep onset –324 Psychophysiological 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 20, 26 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 55, 56, 66, 77, 91, 110, 112, 113, 116, 120, 122–124, 126, 128, 130–132, 134, 136, 137 R Recurrent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 145, 166 Recurrent isolated 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 254–256 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    REM-related parasomnias 246–263 REM sleep behavior disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 246–253</br>REM sleep without 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 151, 152, 159, , 247, 251, 252 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 70–74, 285–287 Residual 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 173 Index Index Respiratory depressant 51, 85, 121, 125–127 Respiratory effort related arousal (RERA) 53, 54, 56, 60, 61, 65, 102, 139, 164 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Restless legs syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 282–291 Reverse first-night effect 34 Rhythmic masticatory muscle activity 304, , 307–311 S Secondary 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 20, 21, 28, 29 Sedating medication 54, 57, 165, 176, 177 Sedative 86, 125, 175–178, 192, 194, 200, , 234, 242, 247, 277, 278, 369 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see also 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 55, 66, 68, , 101, 115, 153, 170, 176, 252, 256, 260, 261, 266, 269, 273, 279, 298, 310, 317–319, 337, 345–349, 356 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sexsomnia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 232, 242, 248 Shift work disorder 215–219 Short sleeper 47–48 Short-term 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insomnia disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 41–45 Sleep attack 143, 147 Sleep drunkenness 154, 160, 162, 163 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep enuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 270–276 Sleep inertia 162, 192, 197, 226, 236 Sleep log 144, 152, 159, 162, 182, 187, 189, , 196, 199, 204, 207, 209, 213, 215, , 224 Sleep-onset association disorder 21</br>Sleep onset REM period 144, 146, 152, –162, 164, 165, 169, 171, 174, 177, , 247, 269 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep paralysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 148, 150, 151, 153, 156, , 163, 171, 183, 254–256, 261, 266, , 269, 276, 314 Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abnormal sexual behaviors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    breathing disorders 49–141 Sleep related Sleep related Sleep related Sleep related –363 Sleep related Sleep related Sleep
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 related –133 Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bruxism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 303–311 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    eating disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 240–245 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy 345–350 gastroesophageal reflux hallucinations
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 267–270 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headaches 350–355 hypoventilation disorders hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder 128–133 Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoventilation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance 124–128 Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>134–138 Sleep related injury 227, 241, 247, 250 Sleep related laryngospasm 355–357 Sleep related leg cramps 299–303 Sleep related medical and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neurological disorders
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 341–367 Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medical disorder 325 Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to a medication or substance 326 Sleep related movement disorders 281–337 Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, unspecified 327 Sleep related 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 363–367 Sleep related rhythmic 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    movement disorder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 –316 Sleep starts (see also 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypnic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
)</br>335–337 Sleep talking 279–280 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep terrors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
</br>228–239 Sleepwalking 228–239 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Smith-Magenis syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 173, 200, 206 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Snoring 139–140 Status cataplecticus 148 Status dissociatus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 248, 252 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Stroke
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (see also cerebrovascular accident) 34, 50, 53, 55, 58, 61, 70–74, 76, 140, 172, 173, 234, 249, 264, 287, 291, 295 Sudden infant 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    death
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 syndrome (
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SIDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 94, 97, 98 Suggested immobilization test 289 Synucleinopathies (see also 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Parkinson disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multisystem atrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) 227, 250 T Treatment-emergent central sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 102–107 V Ventilatory drive 50, 59, 66, 72, 74, 87, 90, 92, 122, 124, 125 Violence (in sleep) 232, 249 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    W Willis-Ekbom disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 282 Index </br></div>